{"meta":{"query_hash":"35fb7377424e","filters":{"venue":"HemaSphere"},"cohort_total":321,"direct_labels_cover":0,"predictions_cover":321,"exported":321,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/35fb7377424e","api":"https://metacan.xera.ac/api/v1/cohort?venue=HemaSphere"},"results":[{"id":"W2793129204","doi":"10.1097/hs9.0000000000000033","title":"Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Medical education","score_opus":0.048800714674720316,"score_gpt":0.3674418180071542,"score_spread":0.3186411033324339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793129204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860621,0.0011451015,0.00065126905,0.008045805,0.000063268795,0.00010136846,0.00004170863,0.000004380932,0.0038850238],"genre_scores_gemma":[0.9966702,0.00069763995,0.00114373,0.00091847975,0.000011553752,0.00015905916,0.000030230603,0.0000028452305,0.00036633827],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.97841054,0.013325785,0.0015946936,0.0007787233,0.0027416956,0.003148587],"domain_scores_gemma":[0.9610443,0.023396922,0.004308828,0.00071834837,0.006509861,0.0040217773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030408265,0.0002548103,0.00046598306,0.0017268125,0.0031177357,0.0031875006,0.0010521886,0.0018702353,0.0011980816],"category_scores_gemma":[0.065293096,0.00052720046,0.00035452863,0.0012517388,0.001868295,0.0052040257,0.005955497,0.0013754175,0.0001670029],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017806796,0.0006610525,0.15722103,0.0012900911,0.00005765164,0.0012328621,0.71883976,0.0003325287,0.0006487115,0.0035348109,0.0018304861,0.11417288],"study_design_scores_gemma":[0.000019460345,0.00020235895,0.06863555,0.0012854255,0.000016970409,0.00059009244,0.9171791,0.0005275811,0.00025161385,0.0017404177,0.0095088715,0.000042621145],"about_ca_topic_score_codex":0.006421494,"about_ca_topic_score_gemma":0.01053847,"teacher_disagreement_score":0.030408265,"about_ca_system_score_codex":0.004850015,"about_ca_system_score_gemma":0.0151165025,"threshold_uncertainty_score":0.1608162},"labels":[],"label_agreement":null},{"id":"W2802748326","doi":"10.1097/hs9.0000000000000044","title":"Clinical Utility of Next‐generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single‐Center Experience","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"European Hematology Association; Bristol-Myers Squibb","keywords":"Medicine; Myeloid; Oncology; Internal medicine; Myelofibrosis; DNA sequencing; Bioinformatics; Gene; Biology; Genetics; Bone marrow","score_opus":0.1708202741207578,"score_gpt":0.36932847587103346,"score_spread":0.19850820175027567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802748326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9226653,0.016008642,0.04292406,0.0030009022,0.00047743847,0.0006721913,0.0012307037,0.0004561636,0.012564663],"genre_scores_gemma":[0.9744343,0.0041848444,0.015894819,0.002255556,0.00021280776,0.00016661646,0.0011270684,0.00014657383,0.0015773937],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99928856,0.00035617867,0.000051041283,0.00014226067,0.00009449692,0.00006747783],"domain_scores_gemma":[0.9986284,0.00065465877,0.000130733,0.00013513319,0.00019592825,0.00025517042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029111789,0.00035563624,0.00043122517,0.00022724693,0.00040941135,0.0007705442,0.00025681243,0.0004941989,0.0025254234],"category_scores_gemma":[0.002887746,0.00013568965,0.0004081581,0.00024737976,0.0002794951,0.0005251767,0.0004132245,0.00079854653,0.0010136309],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026559131,0.0018935096,0.16096437,0.0004907392,0.0006103525,0.0053238003,0.0012654767,0.00391257,0.048663773,0.00077304937,0.013449216,0.7599972],"study_design_scores_gemma":[0.0020674176,0.033946127,0.5075617,0.0014985974,0.002320409,0.08848887,0.0026220274,0.038867537,0.11085962,0.0059062126,0.20555094,0.0003105677],"about_ca_topic_score_codex":0.0004614642,"about_ca_topic_score_gemma":0.0010915893,"teacher_disagreement_score":0.0029111789,"about_ca_system_score_codex":0.0002754813,"about_ca_system_score_gemma":0.00050711475,"threshold_uncertainty_score":0.015395999},"labels":[],"label_agreement":null},{"id":"W2903296906","doi":"10.1097/hs9.0000000000000159","title":"Maintenance Therapy With Interleukin‐2 for Childhood AML","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Assistance publique-Hôpitaux de Paris; Institut National Du Cancer; Fondation ARC pour la Recherche sur le Cancer; CNIB; Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent; Association Laurette Fugain","keywords":"Medicine; Cytarabine; Internal medicine; Mitoxantrone; Maintenance therapy; Acute myeloblastic leukemia; Population; Randomized controlled trial; Leukemia; Chemotherapy; Surgery; Oncology","score_opus":0.019421724370781965,"score_gpt":0.2944160902014198,"score_spread":0.2749943658306378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903296906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637214,0.016110536,0.001609303,0.00063942844,0.0003747159,0.00020617267,0.0007903904,0.00021727031,0.016330691],"genre_scores_gemma":[0.99414116,0.0010237807,0.0007523625,0.00023656069,0.00012759521,0.00009536392,0.0006883958,0.000011905658,0.0029228108],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99970204,0.00012489113,0.000014832964,0.000031526088,0.000052268082,0.0000744252],"domain_scores_gemma":[0.9995291,0.00018722769,0.00007507531,0.000059641014,0.000026468013,0.00012253657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058867945,0.00018669068,0.000278285,0.0001964125,0.00014304365,0.0002228139,0.0002425321,0.00015923938,0.0076963934],"category_scores_gemma":[0.0008497804,0.00005967028,0.00028318458,0.00015956999,0.000097151154,0.00023369578,0.0002670117,0.0005070038,0.0007828779],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.083870836,0.0028664365,0.1612168,0.0006415262,0.0021712799,0.0015416294,0.00017866227,0.0010085215,0.064727716,0.0011233052,0.015010556,0.66564274],"study_design_scores_gemma":[0.010383848,0.08305956,0.6732265,0.00026862594,0.0019030756,0.013791335,0.00015560331,0.0046042595,0.033777334,0.0010499489,0.1777385,0.000041385156],"about_ca_topic_score_codex":0.00027568647,"about_ca_topic_score_gemma":0.00059344113,"teacher_disagreement_score":0.0076963934,"about_ca_system_score_codex":0.00022695637,"about_ca_system_score_gemma":0.00040547096,"threshold_uncertainty_score":0.025747001},"labels":[],"label_agreement":null},{"id":"W2924768710","doi":"10.1097/hs9.0000000000000233","title":"AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"Blood Cancer UK; Medical Research Council; Bloodwise; Cancer Research UK","keywords":"Myeloproliferative neoplasm; Essential thrombocythemia; Polycythemia vera; Myeloid leukemia; Cancer research; Thrombopoietin receptor; Janus kinase 2; Myeloproliferative Disorders; Myelofibrosis; Tyrosine kinase; Stem cell; Haematopoiesis; Myeloid; Medicine; Polycythaemia; Biology; Immunology; Internal medicine; Receptor; Bone marrow; Thrombopoietin; Genetics","score_opus":0.0072144557509660635,"score_gpt":0.23445714613808136,"score_spread":0.22724269038711528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924768710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941713,0.0014115885,0.0013747636,0.00012055656,0.00003494012,0.00003662262,0.000492896,0.000097154414,0.0022600305],"genre_scores_gemma":[0.9946254,0.0009507811,0.0012358435,0.00007189889,0.0000092527,0.000027909255,0.0006799675,0.000007212493,0.0023917195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999954,0.000004566194,0.0000028652582,0.000007877263,0.000019842873,0.000010941462],"domain_scores_gemma":[0.99998116,0.0000036919373,0.000004070173,0.0000016376499,0.0000023103246,0.000007165578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044254895,0.0001726137,0.000112164234,0.00013816486,0.00008910922,0.00015130833,0.000111903246,0.0001294295,0.0014631274],"category_scores_gemma":[0.00003146726,0.000042960426,0.000080055324,0.00008913548,0.00007350788,0.00012055959,0.000097216864,0.00039542778,0.0002472581],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014795431,0.00010008799,0.0001410911,0.000040010098,0.0000048611696,0.000059312955,0.000010571413,0.00010261612,0.99432135,0.0001307756,0.0001528636,0.0047885072],"study_design_scores_gemma":[0.000032250533,0.00082407735,0.00437741,0.0000040804957,0.000008795129,0.00026039346,0.000013531128,0.000996062,0.9885346,0.000060664468,0.004885007,0.000002987841],"about_ca_topic_score_codex":0.00018975956,"about_ca_topic_score_gemma":0.00050759787,"teacher_disagreement_score":0.0014631274,"about_ca_system_score_codex":0.00014059295,"about_ca_system_score_gemma":0.000120133605,"threshold_uncertainty_score":0.004894614},"labels":[],"label_agreement":null},{"id":"W2926447864","doi":"10.1097/hs9.0000000000000185","title":"CAR‐T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Therakos; Celgene; Mallinckrodt Pharmaceuticals; Gilead Sciences; Sanofi; AOP Orphan; GlaxoSmithKline; Amgen","keywords":"Medicine; Chimeric antigen receptor; Cytokine release syndrome; Lymphoma; Hematopoietic stem cell transplantation; Cell therapy; Clinical trial; Oncology; Transplantation; Immunotherapy; Adverse effect; Blinatumomab; Immunology; Internal medicine; Stem cell; CD19; Antigen; Immune system; Biology","score_opus":0.05290399143292113,"score_gpt":0.3387629218292847,"score_spread":0.28585893039636356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2926447864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054494804,0.99716455,0.00019519565,0.0009317731,0.00037243636,0.000008053875,0.000024561748,0.000009031231,0.0007494072],"genre_scores_gemma":[0.0033741947,0.99228644,0.00037058862,0.0017882236,0.0010188578,0.000021749356,0.000072158626,0.000005498396,0.0010622666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977726,0.00006647305,0.000036527083,0.000028422646,0.00006678141,0.00002464706],"domain_scores_gemma":[0.99959606,0.00021816322,0.00006142728,0.000012497313,0.00007483287,0.000037114016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009646487,0.00045804447,0.0007584846,0.0008357821,0.00014585533,0.0007922639,0.00045754464,0.0009757585,0.0021012393],"category_scores_gemma":[0.00077812007,0.00012849811,0.0005470763,0.00070965046,0.00030396,0.0012517984,0.0003676786,0.0015012245,0.0009123477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032279638,0.000118544,0.00020988662,0.008602524,0.00011516017,0.0002415285,0.000064091706,0.0004683675,0.0025748168,0.0020668518,0.030550335,0.9546651],"study_design_scores_gemma":[0.00022705585,0.0012767045,0.0017900325,0.005510658,0.00039573078,0.0021182117,0.00009336259,0.00036239123,0.0012406236,0.0032493959,0.98370117,0.0000346627],"about_ca_topic_score_codex":0.00027624692,"about_ca_topic_score_gemma":0.0006772778,"teacher_disagreement_score":0.0021012393,"about_ca_system_score_codex":0.00026361027,"about_ca_system_score_gemma":0.00041819387,"threshold_uncertainty_score":0.0070293546},"labels":[],"label_agreement":null},{"id":"W2947040488","doi":"10.1097/hs9.0000000000000250","title":"A Simple RNA Target Capture NGS Strategy for Fusion Genes Assessment in the Diagnostics of Pediatric B‐cell Acute Lymphoblastic Leukemia","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Associazione Italiana per la Ricerca sul Cancro; Canadian Thoracic Society","keywords":"Fusion gene; Computational biology; Gold standard (test); Gene; Fusion transcript; Fluorescence in situ hybridization; Molecular diagnostics; Biology; Bioinformatics; Medicine; Genetics; Internal medicine","score_opus":0.015764705861514582,"score_gpt":0.2963564559634752,"score_spread":0.28059175010196064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947040488","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71123713,0.008601214,0.25309008,0.0009094764,0.0004521158,0.0012698561,0.0030701216,0.0012607777,0.020109292],"genre_scores_gemma":[0.83147347,0.002682676,0.14996767,0.0010095361,0.0001276626,0.0006932603,0.0023097736,0.00011034336,0.011625526],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907863,0.00018622106,0.00005272682,0.00023656069,0.0003654233,0.000080458165],"domain_scores_gemma":[0.99977404,0.00009479417,0.00003266755,0.000031726948,0.000046836605,0.000019925461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009283021,0.0006060665,0.0002336684,0.0007992108,0.00027375793,0.0004899143,0.00031264682,0.00075973396,0.0022109088],"category_scores_gemma":[0.0007275011,0.0002331554,0.00030424993,0.00037960886,0.0004716797,0.00025849591,0.00051563414,0.0005076189,0.00085839053],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014180086,0.000063610845,0.0054669622,0.00018832808,0.000051572082,0.00033831605,0.00009069431,0.00049770466,0.92626196,0.00066794857,0.0009033427,0.0653279],"study_design_scores_gemma":[0.000056737,0.000611132,0.029746544,0.000058213125,0.0001740811,0.0030560303,0.00010064554,0.010050624,0.9323145,0.00081625703,0.022973426,0.000041832765],"about_ca_topic_score_codex":0.0008342897,"about_ca_topic_score_gemma":0.003536471,"teacher_disagreement_score":0.0022109088,"about_ca_system_score_codex":0.00030810034,"about_ca_system_score_gemma":0.0005817932,"threshold_uncertainty_score":0.007396221},"labels":[],"label_agreement":null},{"id":"W2949123848","doi":"10.1097/01.hs9.0000562148.00155.2f","title":"PS961 PATIENTS WITH RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA HAVE SHORT REMISSION DURATION WITH RE‐INDUCTION: A SINGLE CENTER EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Single Center; Immunophenotyping; Chemotherapy; Induction chemotherapy; Oncology; Gastroenterology; Immunology; Antigen","score_opus":0.014677957396985113,"score_gpt":0.2547064270067543,"score_spread":0.24002846960976917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949123848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987902,0.00034027113,0.00014232389,0.000057285437,0.000006918822,0.000017731298,0.000049380025,0.00001136938,0.00058462244],"genre_scores_gemma":[0.9989957,0.00028880744,0.00013914434,0.000063074694,0.000025191732,0.0000149147645,0.00015515034,0.000008838282,0.0003091987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99971896,0.00006315486,0.000028067005,0.00006577571,0.000046889043,0.0000771264],"domain_scores_gemma":[0.999426,0.00010734909,0.00014998038,0.00008083985,0.000039833427,0.00019605501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032491406,0.00036873514,0.00039241512,0.00034534174,0.00061367016,0.00060738984,0.0004068866,0.00044220185,0.0022383737],"category_scores_gemma":[0.0013512083,0.00020072953,0.00042906572,0.00059451535,0.00030770936,0.00049276045,0.00042396315,0.00052579504,0.0007919326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014069116,0.0010103612,0.9057586,0.00009156717,0.00010900939,0.031040564,0.0017413248,0.0002879815,0.0041051237,0.00013456421,0.0011846559,0.053129308],"study_design_scores_gemma":[0.00039435463,0.007651395,0.85403776,0.00006544949,0.00014837191,0.12776363,0.0016782823,0.0010348625,0.002228038,0.00019745516,0.0047477814,0.00005259506],"about_ca_topic_score_codex":0.0011223706,"about_ca_topic_score_gemma":0.0012203709,"teacher_disagreement_score":0.0022383737,"about_ca_system_score_codex":0.00050167326,"about_ca_system_score_gemma":0.00043419257,"threshold_uncertainty_score":0.007488072},"labels":[],"label_agreement":null},{"id":"W2949128311","doi":"10.1097/01.hs9.0000567464.22478.55","title":"PB2247 ADJUSTED INDIRECT COMPARISON OF ELTROMBOPAG RELATIVE TO RITUXIMAB OR SPLENECTOMY IN SECOND LINE TREATMENT FOR CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Eltrombopag; Splenectomy; Medicine; Romiplostim; Rituximab; Thrombocytopenic purpura; Internal medicine; Thrombopoietin; Immune thrombocytopenia; Surgery; Gastroenterology; Platelet; Lymphoma; Spleen","score_opus":0.048526908402695745,"score_gpt":0.3407681379589744,"score_spread":0.2922412295562787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949128311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9157788,0.043647982,0.01288248,0.0015044564,0.003934362,0.0029375989,0.00830654,0.00032957754,0.010678149],"genre_scores_gemma":[0.9826701,0.0028494247,0.0059230034,0.0011401057,0.00035469743,0.002409108,0.0017611356,0.00006398125,0.0028283761],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97805035,0.01826652,0.0009545271,0.0012588564,0.0010208082,0.00044896998],"domain_scores_gemma":[0.98371845,0.01222267,0.0021302172,0.0010395919,0.00046793927,0.00042115076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0138389105,0.0021811852,0.0042311316,0.0010069228,0.0002684396,0.001624005,0.0013800885,0.0018952173,0.012482221],"category_scores_gemma":[0.02691539,0.0006890935,0.011229367,0.0007954782,0.0008587848,0.0012138353,0.0017643084,0.0033728164,0.0007331846],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85383856,0.0007626395,0.00997555,0.005085029,0.0928642,0.00010709737,0.00012611922,0.0031280476,0.0010069569,0.001217535,0.0016027871,0.030285474],"study_design_scores_gemma":[0.49026984,0.15031211,0.07794386,0.0019609581,0.23668261,0.00047041682,0.00038601816,0.019416684,0.0048007234,0.008260295,0.009245067,0.00025147825],"about_ca_topic_score_codex":0.0020081995,"about_ca_topic_score_gemma":0.0013817081,"teacher_disagreement_score":0.0138389105,"about_ca_system_score_codex":0.0011063794,"about_ca_system_score_gemma":0.0007823812,"threshold_uncertainty_score":0.07318807},"labels":[],"label_agreement":null},{"id":"W2949134677","doi":"10.1097/01.hs9.0000562560.17744.f0","title":"PS1066 AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES IN PATIENTS ≥ OR < 65 YEARS OF AGE IN THE PIVOTAL PHASE 1/2 ZUMA‐1 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Leukapheresis; Lymphoma; Adverse effect; Gastroenterology; Phases of clinical research; Clinical endpoint; Oncology; Surgery; Chemotherapy; Clinical trial; Stem cell; CD34","score_opus":0.01893548555659678,"score_gpt":0.31333592288334955,"score_spread":0.29440043732675275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949134677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955901,0.0026428413,0.000098745215,0.00014994842,0.0000290494,0.00012497908,0.0003184587,0.000013646419,0.0010323083],"genre_scores_gemma":[0.9965681,0.0012238104,0.00017859427,0.00027040715,0.00005387783,0.00013750918,0.0009097205,0.0000046049768,0.00065324706],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99981207,0.000082044164,0.000010035656,0.000025267776,0.00002742794,0.000043280357],"domain_scores_gemma":[0.9997731,0.000030368015,0.00006669368,0.000010479573,0.000012399169,0.00010690714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008942866,0.00039766167,0.00059317704,0.00021130573,0.00015743476,0.0005074121,0.00019480013,0.0003015622,0.0011677319],"category_scores_gemma":[0.00036851256,0.00012208679,0.0005803613,0.000276618,0.00022726644,0.00032670135,0.00019568663,0.00063842465,0.000253337],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5450056,0.016016984,0.13322096,0.0012026745,0.0026413372,0.0007578623,0.00037700968,0.0048897704,0.048503045,0.00051730825,0.009992136,0.2368753],"study_design_scores_gemma":[0.24595807,0.38211814,0.34471646,0.00018533491,0.0025339553,0.0013056092,0.00022150324,0.0032286781,0.0071287532,0.00045205926,0.012100608,0.00005086996],"about_ca_topic_score_codex":0.0005103693,"about_ca_topic_score_gemma":0.0016282278,"teacher_disagreement_score":0.0011677319,"about_ca_system_score_codex":0.0004649145,"about_ca_system_score_gemma":0.0004970244,"threshold_uncertainty_score":0.0047295094},"labels":[],"label_agreement":null},{"id":"W2949201926","doi":"10.1097/01.hs9.0000561740.44478.b8","title":"S865 CHANGE IN CLONE SIZE DOES NOT PREDICT RISK OF MAJOR ADVERSE VASCULAR EVENTS: RESULTS FROM THE INTERNATIONAL PNH REGISTRY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Medicine; Logistic regression; Paroxysmal nocturnal hemoglobinuria; Lactate dehydrogenase; Poisson regression; Internal medicine; Biology; Population; Environmental health; Genetics","score_opus":0.012555608972821776,"score_gpt":0.2373896514976666,"score_spread":0.22483404252484485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949201926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880565,0.00024347902,0.00028703097,0.00008469906,0.00001147222,0.000034492215,0.008942843,0.00002021574,0.0015702596],"genre_scores_gemma":[0.99006385,0.00014190178,0.00018358779,0.00006541687,0.00002215984,0.000047828977,0.009200477,0.0000128011325,0.0002620323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836165,0.00051916164,0.00023268806,0.00041581795,0.00032083003,0.00014984893],"domain_scores_gemma":[0.9879842,0.0028389674,0.0056994017,0.001778211,0.0010271459,0.0006720233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002391896,0.0002193017,0.0004771811,0.0008767738,0.0002889145,0.0008559544,0.0006508243,0.00038986304,0.0019891965],"category_scores_gemma":[0.0114675,0.00019648553,0.0007175089,0.0018593533,0.00022223213,0.0007570256,0.00082791,0.00048031876,0.0004681482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031034937,0.000022057544,0.9975381,0.000015718853,0.00007597311,0.000034804398,0.000036890076,0.00011403229,0.000041184245,0.000027486527,0.0005189874,0.0012644653],"study_design_scores_gemma":[0.000044644832,0.00012302594,0.9979463,0.000015923859,0.00009612157,0.000221479,0.0000861004,0.0007129086,0.00007947827,0.00004430864,0.00062292727,0.0000068088902],"about_ca_topic_score_codex":0.004251417,"about_ca_topic_score_gemma":0.0045357803,"teacher_disagreement_score":0.004251417,"about_ca_system_score_codex":0.00034899515,"about_ca_system_score_gemma":0.00064296636,"threshold_uncertainty_score":0.012649655},"labels":[],"label_agreement":null},{"id":"W2949220394","doi":"10.1097/01.hs9.0000561568.20578.1a","title":"S822 NIVOLUMAB AND BRENTUXIMAB VEDOTIN‐BASED, RESPONSE‐ADAPTED TREATMENT IN PRIMARY REFRACTORY AND IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN CHECKMATE 744","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Nivolumab; Refractory (planetary science); Cohort; Oncology; Salvage therapy; Regimen; Bendamustine; Surgery; Lymphoma; Chemotherapy; Rituximab; Cancer; Hodgkin lymphoma; Immunotherapy","score_opus":0.007223904925934763,"score_gpt":0.21527984959316313,"score_spread":0.20805594466722838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949220394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615943,0.0018149957,0.00014420792,0.00010240316,0.000015392126,0.00010196054,0.00042110562,0.000020186273,0.0012202393],"genre_scores_gemma":[0.997079,0.00064835756,0.00047487335,0.00020967716,0.000021282975,0.00009774132,0.0009832929,0.0000043667433,0.0004814209],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99990404,0.000031055675,0.000006845116,0.000019566965,0.000014688392,0.000023828681],"domain_scores_gemma":[0.9998266,0.000025978314,0.00004968857,0.000010461451,0.000011473559,0.00007579543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030964988,0.00016571551,0.00033326002,0.00013221017,0.00016303679,0.00029927888,0.00024708817,0.00020478868,0.00179131],"category_scores_gemma":[0.00045919273,0.00008862847,0.00030353921,0.00014973342,0.00012719273,0.00019969714,0.00021107074,0.00045142014,0.0002149607],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13004707,0.005381925,0.3622881,0.0012988882,0.0010904823,0.0031278273,0.000685285,0.0050388877,0.04750546,0.0007152356,0.013353539,0.42946732],"study_design_scores_gemma":[0.025824541,0.1103648,0.8075046,0.0003507004,0.0012342063,0.007728377,0.00033020272,0.004328412,0.01019923,0.00028830676,0.031803593,0.00004306033],"about_ca_topic_score_codex":0.0014736545,"about_ca_topic_score_gemma":0.0049756765,"teacher_disagreement_score":0.00179131,"about_ca_system_score_codex":0.00072431273,"about_ca_system_score_gemma":0.0006134745,"threshold_uncertainty_score":0.005992472},"labels":[],"label_agreement":null},{"id":"W2949266517","doi":"10.1097/01.hs9.0000560668.77636.9b","title":"PF595 POMALIDOMIDE + BORTEZOMIB + LOW‐DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE‐PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont; Centre Hospitalier Universitaire de Sherbrooke; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Dexamethasone; Bortezomib; Internal medicine; Population; Refractory (planetary science); Multiple myeloma; Phases of clinical research; Oncology; Surgery; Clinical trial","score_opus":0.018447104509424005,"score_gpt":0.2828985369928948,"score_spread":0.2644514324834708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949266517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96112305,0.028606655,0.00069199887,0.0017587153,0.0005255601,0.0015417914,0.0032811332,0.00007756608,0.0023935765],"genre_scores_gemma":[0.9919241,0.0023225583,0.0006262967,0.000769717,0.00034223153,0.0009703239,0.0025349564,0.000024152256,0.0004858157],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983228,0.0009120905,0.00018517628,0.000259751,0.00012245604,0.0001977118],"domain_scores_gemma":[0.9988121,0.00033943527,0.00036995413,0.00015700275,0.000068879875,0.0002526928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004165957,0.0014279921,0.003091615,0.0006088252,0.00035946153,0.0014704837,0.0007344049,0.0010389636,0.0035250578],"category_scores_gemma":[0.003821905,0.0003508914,0.0078017805,0.0008387767,0.00042122422,0.000772582,0.0007281236,0.001656734,0.0003617533],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8947922,0.0009771893,0.029162746,0.001412348,0.030377889,0.00015122608,0.000105582185,0.0015100861,0.0022343493,0.00021893646,0.0033993179,0.035658095],"study_design_scores_gemma":[0.7306121,0.05185303,0.12859632,0.00068809924,0.07123368,0.000676034,0.0003142687,0.004325308,0.0013059523,0.0033081204,0.006927244,0.0001598737],"about_ca_topic_score_codex":0.00086003816,"about_ca_topic_score_gemma":0.0026451803,"teacher_disagreement_score":0.004165957,"about_ca_system_score_codex":0.0009072211,"about_ca_system_score_gemma":0.0011690106,"threshold_uncertainty_score":0.022031963},"labels":[],"label_agreement":null},{"id":"W2949279564","doi":"10.1097/01.hs9.0000561604.66251.2e","title":"S831 CPI‐0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO‐INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Myeloproliferative neoplasm; Ruxolitinib; Bone marrow; Anemia; Internal medicine; Cancer research","score_opus":0.0057436719220246395,"score_gpt":0.22666235977413904,"score_spread":0.2209186878521144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949279564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847654,0.0063901884,0.00040950338,0.0006277689,0.00013344167,0.00027310406,0.001051464,0.00026861575,0.0060805],"genre_scores_gemma":[0.98995894,0.00231081,0.00080885313,0.0007720228,0.00005831178,0.00021505733,0.0013890131,0.000020279158,0.004466711],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998934,0.000031022282,0.000008641195,0.000015681286,0.000022453472,0.000028924302],"domain_scores_gemma":[0.999843,0.000020545349,0.00004085829,0.000009088973,0.00001337021,0.00007312404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003226373,0.00036932933,0.00072657585,0.00024586546,0.00013530192,0.0003671656,0.0003880783,0.0006236768,0.007447414],"category_scores_gemma":[0.0003002397,0.0001864411,0.0005462101,0.00020779789,0.00021002642,0.00028772702,0.00016886726,0.001603283,0.0011307515],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2473956,0.019042188,0.005285319,0.0020910231,0.0010673653,0.00054251205,0.00021431052,0.003638947,0.21224475,0.00096374226,0.020889647,0.48662466],"study_design_scores_gemma":[0.22304256,0.5097724,0.08974534,0.00071905984,0.0016961107,0.0046301195,0.00032669373,0.008996275,0.10931977,0.0011269542,0.050478864,0.00014589999],"about_ca_topic_score_codex":0.0005641693,"about_ca_topic_score_gemma":0.0013631021,"teacher_disagreement_score":0.007447414,"about_ca_system_score_codex":0.00030067138,"about_ca_system_score_gemma":0.00043043462,"threshold_uncertainty_score":0.024914086},"labels":[],"label_agreement":null},{"id":"W2949283805","doi":"10.1097/01.hs9.0000564528.96696.2c","title":"PS1570 PENTRAXIN-3 LEVEL AS A NOVEL VASCULAR ENDOTHELIAL MARKER IN NEWLY DIAGNOSED AND MULTI-TRANSFUSED PATIENTS WITH B-THALASSEMIA MAJOR: RELATION TO OXIDATIVE STRESS AND SUB-CLINICAL ATHEROSCLEROSIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Biomarkers in Disease Mechanisms","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Internal medicine; Oxidative stress; Gastroenterology; Endothelial dysfunction; Coronary artery disease; Thalassemia; Ferritin; Disease; Inflammation; Lipid profile; Biomarker; Cardiology; Immunology; Cholesterol","score_opus":0.01603195702708122,"score_gpt":0.24188225008250025,"score_spread":0.22585029305541904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949283805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99971694,0.0001324983,0.000033800163,0.00000800365,0.0000014720748,0.0000023164596,0.000026147505,0.0000010048428,0.000077766446],"genre_scores_gemma":[0.9997377,0.00005994316,0.00005306296,0.0000079323045,0.00000344927,0.0000023497537,0.000052336432,3.485696e-7,0.00008295373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999316,0.000015166811,0.000010820805,0.000016946216,0.0000152329685,0.00001019782],"domain_scores_gemma":[0.9997229,0.000040638573,0.00014040493,0.000011910075,0.00002613375,0.000057994745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011648989,0.00019566088,0.00021753117,0.0004235897,0.00018469825,0.00026512917,0.0000800354,0.00021664938,0.0009126411],"category_scores_gemma":[0.0005252781,0.0001316324,0.00014959586,0.00029150205,0.00010336358,0.00012858391,0.0001269958,0.0002770683,0.00009033275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005935446,0.0000884362,0.9904179,0.000021897013,0.0000416237,0.0005110006,0.0001996517,0.000035549612,0.0058566565,0.000015380429,0.000042621265,0.002175745],"study_design_scores_gemma":[0.00001115111,0.0006275031,0.9966936,0.000004956739,0.00003539141,0.0017668034,0.00014922595,0.00015137932,0.00044234097,0.000017954064,0.00009700665,0.0000026914313],"about_ca_topic_score_codex":0.00060692977,"about_ca_topic_score_gemma":0.0005399365,"teacher_disagreement_score":0.0009126411,"about_ca_system_score_codex":0.0001025984,"about_ca_system_score_gemma":0.000070237125,"threshold_uncertainty_score":0.003053069},"labels":[],"label_agreement":null},{"id":"W2949315927","doi":"10.1097/01.hs9.0000563256.18006.bf","title":"PS1244 REAL‐WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) OF PATIENTS DIAGNOSED WITH CLASSICAL HODGKIN LYMPHOMA (CHL) TREATED WITH ANTI‐PD1 CHECKPOINT INHIBITORS IN THE UNITED STATES (US)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Pediatrics; Internal medicine; Retrospective cohort study; Cancer; Immunotherapy","score_opus":0.01748511497946377,"score_gpt":0.25687475519915653,"score_spread":0.23938964021969278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949315927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97074395,0.00074214,0.00011738721,0.0001642627,0.000015351987,0.00003157238,0.027132843,0.000016338723,0.0010360087],"genre_scores_gemma":[0.98919684,0.00031233692,0.0001094278,0.000090742884,0.000020395908,0.000049546103,0.010064349,0.0000045272805,0.00015175833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999218,0.00018620497,0.00018048791,0.00018102731,0.00013305807,0.000101294856],"domain_scores_gemma":[0.9969079,0.00033557514,0.0021723793,0.000110177694,0.00019007247,0.00028392868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000571396,0.00020241544,0.00029365966,0.0017193403,0.00028667747,0.00067883066,0.00041235445,0.000364218,0.0020916515],"category_scores_gemma":[0.0020267044,0.00025078238,0.00052760716,0.003517811,0.00020520108,0.0006170751,0.0005925086,0.0006030429,0.0003265662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005844189,0.000020495438,0.9981439,0.00002431847,0.00007416202,0.000027191223,0.000027442198,0.0000933611,0.000030317893,0.000021905385,0.00073724776,0.00074124406],"study_design_scores_gemma":[0.000008977523,0.000047897138,0.99843746,0.000025532085,0.000029206507,0.00015347618,0.00017477323,0.0004270198,0.00003267759,0.000022956368,0.0006350647,0.0000049948385],"about_ca_topic_score_codex":0.018593801,"about_ca_topic_score_gemma":0.018055018,"teacher_disagreement_score":0.018593801,"about_ca_system_score_codex":0.00079064124,"about_ca_system_score_gemma":0.00073887163,"threshold_uncertainty_score":0.036971092},"labels":[],"label_agreement":null},{"id":"W2949392892","doi":"10.1097/01.hs9.0000559456.76601.13","title":"PF311 ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) ‐ AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Adrenal gland; Malignancy; Retrospective cohort study; Pathological; Internal medicine; Pathology","score_opus":0.012245290450787902,"score_gpt":0.26510805859907816,"score_spread":0.25286276814829023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949392892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986707,0.00051586604,0.00009837643,0.000019840856,0.0000033676085,0.000021185924,0.00030235827,0.0000024855542,0.00036586347],"genre_scores_gemma":[0.9992756,0.0001670437,0.0000609539,0.000020468233,0.000010177601,0.000018503362,0.00041026023,0.0000021799365,0.00003480701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986085,0.00044556023,0.00020138534,0.00035356704,0.00021669154,0.0001742712],"domain_scores_gemma":[0.9960388,0.00092857966,0.0016210052,0.0004396558,0.0005805419,0.00039144373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019587772,0.00031381773,0.00042962766,0.0011864693,0.00042169628,0.0008190489,0.0003541052,0.00040840506,0.0018550555],"category_scores_gemma":[0.0038455436,0.00024143666,0.00040424307,0.0018428075,0.00043013436,0.0007597814,0.0006132167,0.00026434494,0.00041840386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013318274,0.000020993877,0.99797136,0.000014604255,0.00003565475,0.0003590064,0.00008207959,0.000014552841,0.00016078421,0.000010745492,0.000052990174,0.0011440181],"study_design_scores_gemma":[0.000027572856,0.00022288895,0.9948573,0.000023736444,0.00008969486,0.0033991907,0.00057209824,0.00012515917,0.00009870859,0.000016109876,0.00056174624,0.000005766966],"about_ca_topic_score_codex":0.0018051269,"about_ca_topic_score_gemma":0.0014754295,"teacher_disagreement_score":0.0019587772,"about_ca_system_score_codex":0.00037457523,"about_ca_system_score_gemma":0.00037694126,"threshold_uncertainty_score":0.010359108},"labels":[],"label_agreement":null},{"id":"W2949420727","doi":"10.1097/01.hs9.0000564700.06449.e7","title":"S1613 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION CAN ABROGATE INCREASING RISK OF RELAPSE FROM PERSISTENT MUTATIONS MEASURED BY TARGETED SEQUENCING AT REMISSION IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Oncology; Cumulative incidence; Medicine; Internal medicine; Hazard ratio; Minimal residual disease; Myeloid leukemia; Proportional hazards model; Hematopoietic stem cell transplantation; Transplantation; Myeloid; Leukemia; Immunology; Confidence interval","score_opus":0.011044685027055674,"score_gpt":0.2357432481250833,"score_spread":0.22469856309802763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949420727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99903405,0.00033960395,0.00021795947,0.000019397876,0.000008049306,0.0000123447,0.000072301096,0.000025107001,0.00027115046],"genre_scores_gemma":[0.99921155,0.0001497127,0.00015961369,0.000018630242,0.000004775101,0.000015371292,0.00020471634,0.000008449161,0.00022713518],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99987006,0.000031626372,0.000011867743,0.000024603669,0.00003471517,0.00002714171],"domain_scores_gemma":[0.99974793,0.000044210687,0.00010843242,0.000022376078,0.000010143682,0.000066904206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032120434,0.0001894627,0.00037249082,0.00021602355,0.000075284595,0.0002107952,0.00022652873,0.00016280207,0.0019055696],"category_scores_gemma":[0.0004046423,0.000077291166,0.00021881257,0.0002125754,0.00022074586,0.00011200178,0.00020268737,0.00037599987,0.0002843284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027340218,0.003517917,0.0942563,0.00034911343,0.0002943575,0.00056139537,0.00013925711,0.0049407906,0.7060318,0.0006064724,0.0013919157,0.16057047],"study_design_scores_gemma":[0.0023978194,0.061251234,0.6415684,0.000098668585,0.0006338096,0.004566623,0.0001908892,0.01630251,0.26399314,0.0012163749,0.0077353525,0.000045128003],"about_ca_topic_score_codex":0.00027432124,"about_ca_topic_score_gemma":0.00034282674,"teacher_disagreement_score":0.0019055696,"about_ca_system_score_codex":0.00016713161,"about_ca_system_score_gemma":0.00026881273,"threshold_uncertainty_score":0.0063747168},"labels":[],"label_agreement":null},{"id":"W2949444368","doi":"10.1097/01.hs9.0000561592.51072.9b","title":"S828 A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM‐151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Essential thrombocythemia; Internal medicine; Randomization; Bone marrow; Polycythemia vera; Gastroenterology; Randomized controlled trial; Anemia","score_opus":0.031235462883460782,"score_gpt":0.3296657506900283,"score_spread":0.2984302878065675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949444368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987365,0.0010830576,0.00057176634,0.00046043468,0.00024159989,0.0051385364,0.0010204874,0.00013105715,0.0014794919],"genre_scores_gemma":[0.98484194,0.00080403866,0.0017730896,0.0012104902,0.00032051757,0.0071387645,0.001354693,0.000025585992,0.0025308814],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994228,0.00029048804,0.00003364215,0.000112772184,0.00003488765,0.00010547241],"domain_scores_gemma":[0.99922717,0.00015965347,0.0001399707,0.00008431653,0.000058973677,0.00032994983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015705192,0.0017453642,0.0030082348,0.0005097334,0.00046063287,0.0009571794,0.00094891014,0.001861845,0.006899923],"category_scores_gemma":[0.001225181,0.00096250913,0.0016232537,0.00036252956,0.0012484258,0.0011613707,0.00035658816,0.0025815377,0.0011916097],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9515601,0.023455534,0.0008619227,0.00030258743,0.00038917223,0.00006606379,0.00006832489,0.00043762778,0.009153022,0.000120018245,0.0008467349,0.012738872],"study_design_scores_gemma":[0.8812168,0.116400115,0.0012595614,0.000009096157,0.000105298575,0.000031653264,0.0000102421745,0.00021626377,0.00033344215,0.000059739363,0.0003450116,0.0000127888425],"about_ca_topic_score_codex":0.0005090269,"about_ca_topic_score_gemma":0.0013945651,"teacher_disagreement_score":0.006899923,"about_ca_system_score_codex":0.00063763256,"about_ca_system_score_gemma":0.0013893686,"threshold_uncertainty_score":0.023082554},"labels":[],"label_agreement":null},{"id":"W2949456808","doi":"10.1097/01.hs9.0000566328.51622.ab","title":"PB1958 SUDDEN ONSET HEARING AND VISUAL LOSS: AN UNUSUAL PRESENTATION OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Hearing loss; Sensorineural hearing loss; Tinnitus; Vertigo; Chronic myelogenous leukemia; Pediatrics; Audiology; Surgery; Leukemia; Internal medicine","score_opus":0.01761472004695952,"score_gpt":0.3226365060866205,"score_spread":0.30502178603966096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949456808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350774,0.0013458531,0.0007032863,0.00034009272,0.000045094508,0.00006458936,0.00010914294,0.000040480365,0.003843651],"genre_scores_gemma":[0.99877685,0.000286431,0.00021000755,0.00013474403,0.00011598781,0.000010641025,0.00006768651,0.0000052938376,0.00039242097],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997298,0.0000325471,0.000028727865,0.000041844105,0.000040701223,0.00012629946],"domain_scores_gemma":[0.9994191,0.00012567337,0.00019205236,0.000043001528,0.000035772635,0.00018446875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017760825,0.0008851447,0.00042772503,0.0015026311,0.0008911514,0.0005829417,0.00041359893,0.0012629373,0.0024613766],"category_scores_gemma":[0.0011815694,0.0004113082,0.0002259065,0.0007812469,0.0006046388,0.0006627353,0.0007678808,0.00067611603,0.0006068028],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006796082,0.000037034853,0.055103876,0.000035298148,0.0000071298673,0.9394878,0.00018440274,0.000050079154,0.0022463375,0.000118827054,0.0003607352,0.0023004182],"study_design_scores_gemma":[0.000017805405,0.00009264093,0.023107994,0.000009831166,0.0000065975373,0.9753921,0.00012714983,0.00012946723,0.00032992585,0.00009330486,0.000687854,0.0000052991777],"about_ca_topic_score_codex":0.00081262714,"about_ca_topic_score_gemma":0.0010991462,"teacher_disagreement_score":0.0024613766,"about_ca_system_score_codex":0.00036745166,"about_ca_system_score_gemma":0.00034839494,"threshold_uncertainty_score":0.008234143},"labels":[],"label_agreement":null},{"id":"W2949508612","doi":"10.1097/01.hs9.0000567684.54373.e5","title":"PB2304 CRIZANLIZUMAB DOSE CONFIRMATION IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE: SOLACE‐KIDS TRIAL DESIGN","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation","funders":"","keywords":"Medicine; Acute chest syndrome; Dosing; Placebo; Sickle cell anemia; Inflammation; Disease; Adverse effect; Internal medicine; Immunology; Gastroenterology; Pathology","score_opus":0.006921737993898245,"score_gpt":0.2106317121253292,"score_spread":0.20370997413143094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949508612","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95028764,0.016987355,0.0017092611,0.0022349313,0.0006632579,0.01140053,0.007004061,0.0002691835,0.009443826],"genre_scores_gemma":[0.9570005,0.005246355,0.0046683485,0.002507104,0.00057453866,0.017938292,0.0046969065,0.000059645594,0.0073083527],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99949694,0.00026861444,0.000029466391,0.00009015554,0.00003773696,0.00007708589],"domain_scores_gemma":[0.9994898,0.00011747835,0.00014177624,0.000037583228,0.000048733673,0.00016458724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014399552,0.001190525,0.0015802139,0.00026751214,0.00025132645,0.0009081513,0.00067692,0.00093523564,0.008038083],"category_scores_gemma":[0.0012414864,0.00038032533,0.0012729501,0.0003169783,0.00051916874,0.0006696308,0.00036893907,0.0019496758,0.00070508703],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9363518,0.00507756,0.0044972384,0.0022704832,0.0019221447,0.00017922957,0.00010023021,0.0015909022,0.0032937645,0.0009308479,0.0066410573,0.037144832],"study_design_scores_gemma":[0.9108948,0.075128965,0.00447563,0.00016488477,0.0009137375,0.00022261728,0.0000392429,0.0011151528,0.0006420332,0.00040817977,0.005972534,0.00002208624],"about_ca_topic_score_codex":0.00077523437,"about_ca_topic_score_gemma":0.002187377,"teacher_disagreement_score":0.008038083,"about_ca_system_score_codex":0.00083278894,"about_ca_system_score_gemma":0.0015667239,"threshold_uncertainty_score":0.02689004},"labels":[],"label_agreement":null},{"id":"W2949512078","doi":"10.1097/01.hs9.0000563628.38037.c3","title":"PS1337 IVOSIDENIB (AG‐120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1‐MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Isocitrate dehydrogenase; Medicine; IDH1; Internal medicine; Myelodysplastic syndromes; Refractory (planetary science); Myeloid leukemia; Bone marrow; Gastroenterology; Oncology; Pharmacodynamics; Pharmacokinetics; International Prognostic Scoring System; Mutant; Chemistry; Biology; Gene","score_opus":0.011476636537717237,"score_gpt":0.26962185674816475,"score_spread":0.2581452202104475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949512078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968726,0.00073068845,0.00028859245,0.00018405051,0.00003309298,0.0004658543,0.00033948445,0.00009883754,0.0009869846],"genre_scores_gemma":[0.99571913,0.000616631,0.0008000967,0.0002948724,0.00004803992,0.00037807485,0.0010519461,0.000020421738,0.0010707334],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99978465,0.000085382526,0.00001248347,0.000035709385,0.000028358714,0.000053420117],"domain_scores_gemma":[0.9996948,0.000049545142,0.000055991964,0.000031692383,0.000019916552,0.00014802947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008221239,0.0010127791,0.0010405589,0.00039776633,0.00028019524,0.00064362213,0.00057554815,0.0005528358,0.0021258793],"category_scores_gemma":[0.00040674445,0.00034849875,0.00054498436,0.0002939409,0.000548139,0.0005050681,0.00026307674,0.0025359266,0.00044875554],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28858018,0.11630896,0.01284873,0.001006054,0.0015298605,0.00056810456,0.0007849737,0.006381274,0.2610751,0.0007473308,0.011898606,0.29827082],"study_design_scores_gemma":[0.2609325,0.65810966,0.035374578,0.0000741502,0.0007273408,0.00085237616,0.00013007884,0.004260095,0.03130585,0.00044831153,0.007730793,0.0000543183],"about_ca_topic_score_codex":0.00054619473,"about_ca_topic_score_gemma":0.0016098998,"teacher_disagreement_score":0.0021258793,"about_ca_system_score_codex":0.00069381204,"about_ca_system_score_gemma":0.0010002723,"threshold_uncertainty_score":0.007111788},"labels":[],"label_agreement":null},{"id":"W2949669015","doi":"10.1097/01.hs9.0000562584.48238.c8","title":"PS1073 PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC CIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoma; Mycosis fungoides; Internal medicine; Refractory (planetary science); Adverse effect; Peripheral T-cell lymphoma; Cutaneous T-cell lymphoma; Brentuximab vedotin; Oncology; Gastroenterology; T cell; Immunology; Hodgkin lymphoma; Immune system","score_opus":0.010926125519944384,"score_gpt":0.2491841757747903,"score_spread":0.23825805025484592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949669015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99217623,0.0025936684,0.00055025064,0.00035524176,0.000045658704,0.00033133177,0.0008194439,0.00012847538,0.002999776],"genre_scores_gemma":[0.99401337,0.0013974565,0.0004375358,0.000328511,0.000043814915,0.00019556422,0.0016279086,0.000027884422,0.0019279283],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997795,0.0000965584,0.000017427092,0.000025101428,0.000034098728,0.000047342754],"domain_scores_gemma":[0.99975437,0.00006565195,0.00004187416,0.000027471722,0.00002243693,0.00008824802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005692388,0.000681816,0.00077856367,0.00024836574,0.00024024765,0.0005147549,0.00043117424,0.0005371942,0.0031938155],"category_scores_gemma":[0.0003892046,0.00019619499,0.0006159821,0.00024524273,0.00034981474,0.0004083704,0.00021340375,0.0019059622,0.0008079696],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15082107,0.03384028,0.0070021194,0.0016830844,0.0011167729,0.0020029137,0.00082983525,0.007481488,0.5258268,0.0004716585,0.009499411,0.25942463],"study_design_scores_gemma":[0.08429776,0.7341218,0.044955153,0.00009066195,0.0010543216,0.0030298147,0.0002649533,0.0048983754,0.1128092,0.00041602727,0.0140049495,0.000056955658],"about_ca_topic_score_codex":0.00091375574,"about_ca_topic_score_gemma":0.0018383091,"teacher_disagreement_score":0.0031938155,"about_ca_system_score_codex":0.0005152595,"about_ca_system_score_gemma":0.00047212187,"threshold_uncertainty_score":0.010684431},"labels":[],"label_agreement":null},{"id":"W2949673037","doi":"10.1097/01.hs9.0000558628.70462.93","title":"S102 POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) AND LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Regimen; Follicular lymphoma; Interim analysis; Gastroenterology; Rituximab; Adverse effect; Lymphoma; Clinical trial","score_opus":0.01006676472665592,"score_gpt":0.25852921532171413,"score_spread":0.24846245059505823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949673037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938936,0.002692029,0.00038004428,0.0006772302,0.000110493136,0.0013894265,0.0013977229,0.000107513384,0.0038561388],"genre_scores_gemma":[0.99042386,0.0010312786,0.0012214719,0.0007657982,0.000113684175,0.0010510989,0.0029181147,0.000028110911,0.0024465916],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99962425,0.0002046176,0.000028146313,0.00004464434,0.000033725875,0.00006460191],"domain_scores_gemma":[0.9994942,0.00009873032,0.000114966475,0.000041297917,0.000035186196,0.00021562814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014590229,0.00064755225,0.0010164498,0.00022542107,0.00024500012,0.0011538925,0.0006603578,0.0007881994,0.0035683655],"category_scores_gemma":[0.0006457631,0.00031521835,0.001168267,0.00032491688,0.00041686115,0.0005950604,0.00032000832,0.0019858067,0.0008221548],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7519876,0.01712739,0.015107994,0.00068280817,0.0018007202,0.00029440373,0.00023228099,0.0036841962,0.03513399,0.0004322299,0.007238879,0.16627768],"study_design_scores_gemma":[0.5350845,0.41525814,0.025619725,0.00010582866,0.0011861984,0.0006860421,0.00009032981,0.0025610905,0.008260583,0.00039030463,0.010723199,0.000033993612],"about_ca_topic_score_codex":0.00068954716,"about_ca_topic_score_gemma":0.0020910972,"teacher_disagreement_score":0.0035683655,"about_ca_system_score_codex":0.00086554297,"about_ca_system_score_gemma":0.0014944695,"threshold_uncertainty_score":0.01193732},"labels":[],"label_agreement":null},{"id":"W2949689749","doi":"10.1097/01.hs9.0000566416.30505.81","title":"PB1980 IMPROVING HEALTHCARE PROVIDERS’ KNOWLEDGE REGARDING THE PRINCIPLES OF GENE THERAPY FOR HEMOPHILIA THROUGH ONLINE EDUCATION","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Biomedical and Engineering Education","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Hemophilia Society","funders":"","keywords":"Haemophilia; Medicine; Curriculum; Continuing medical education; Certification; Test (biology); Health care; Family medicine; Multiple choice; Medical education; Continuing education; Internal medicine; Pediatrics; Psychology; Significant difference","score_opus":0.02563213125077249,"score_gpt":0.2677342574249516,"score_spread":0.24210212617417912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949689749","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563808,0.0007540444,0.0028935566,0.0021794976,0.00012521657,0.0013634955,0.001081039,0.00026979926,0.034952518],"genre_scores_gemma":[0.9688315,0.0008964811,0.013226735,0.0009142942,0.00015272426,0.0018003169,0.0010052845,0.000027920787,0.013144747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994785,0.00029385998,0.000018437955,0.000033875804,0.00011579311,0.000059503636],"domain_scores_gemma":[0.99602216,0.0026016037,0.0003617,0.00007340592,0.00039897035,0.00054227066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001743406,0.00012458599,0.00013041327,0.00026535374,0.00023781683,0.0003616216,0.00018818065,0.00027204282,0.0315456],"category_scores_gemma":[0.0058750445,0.00006351801,0.00009949749,0.00024849648,0.00013607656,0.00026536259,0.0004880127,0.00040351023,0.0020053412],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023985405,0.009276877,0.055599112,0.0013635461,0.000040915846,0.0001167963,0.0016634262,0.00041589257,0.0066002533,0.0004657281,0.02500161,0.8970573],"study_design_scores_gemma":[0.0021386344,0.022775358,0.84269786,0.0013088871,0.00017203677,0.0004444181,0.0038378064,0.0035940087,0.013768305,0.0009820675,0.10824832,0.00003236306],"about_ca_topic_score_codex":0.0013276936,"about_ca_topic_score_gemma":0.0019235398,"teacher_disagreement_score":0.0315456,"about_ca_system_score_codex":0.00038883043,"about_ca_system_score_gemma":0.0014012568,"threshold_uncertainty_score":0.10553056},"labels":[],"label_agreement":null},{"id":"W2949734536","doi":"10.1097/01.hs9.0000560652.54765.fe","title":"PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D‐RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research; Leukemia & Lymphoma Society of Canada; University of British Columbia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Internal medicine; Medicine; Lenalidomide; Tolerability; Oncology; Multiple myeloma; Gastroenterology; Adverse effect","score_opus":0.01260982214245829,"score_gpt":0.25760121233349176,"score_spread":0.24499139019103347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949734536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952766,0.00326592,0.00021010164,0.00009204679,0.000019352361,0.00011256694,0.0005871361,0.000012241915,0.00042414997],"genre_scores_gemma":[0.99748504,0.0005467265,0.00026099893,0.000101356985,0.000038368475,0.000099349556,0.0011594091,0.0000051470915,0.00030357882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922895,0.00032766012,0.00011221824,0.00012636677,0.00011685343,0.00008801662],"domain_scores_gemma":[0.9993685,0.00019326629,0.00022600462,0.00008740002,0.00004034364,0.00008453701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020506606,0.0005422296,0.0014518857,0.0007270111,0.00018176768,0.00074929325,0.00047564093,0.0003981683,0.0012790541],"category_scores_gemma":[0.0016575515,0.00023313385,0.0028538122,0.0005672027,0.000217824,0.00043361352,0.00054852705,0.00038942543,0.00015523484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35572317,0.0010294025,0.42939398,0.0018670306,0.029830206,0.00077654375,0.00043566324,0.003812858,0.016540617,0.00025555218,0.0032957753,0.15703923],"study_design_scores_gemma":[0.04180761,0.05001188,0.8504044,0.00024997248,0.035412923,0.0032553873,0.00038423153,0.0056260307,0.004956541,0.0005913498,0.007173555,0.00012614125],"about_ca_topic_score_codex":0.00059478346,"about_ca_topic_score_gemma":0.001489804,"teacher_disagreement_score":0.0020506606,"about_ca_system_score_codex":0.0004895089,"about_ca_system_score_gemma":0.00040046065,"threshold_uncertainty_score":0.0108450055},"labels":[],"label_agreement":null},{"id":"W2949752825","doi":"10.1097/01.hs9.0000561220.73976.40","title":"PF734 PATIENT PREFERENCES FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS OF A PATIENT SURVEY OF RAVULIZUMAB (ALXN1210) AND ECULIZUMAB","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Eculizumab; Paroxysmal nocturnal hemoglobinuria; Medicine; Dosing; Clinical trial; Pediatrics; Internal medicine; Immunology; Antibody","score_opus":0.023483692159303005,"score_gpt":0.25275744604142786,"score_spread":0.22927375388212484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949752825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99865925,0.00015850109,0.000047229223,0.00009727678,0.0000055318565,0.000029572913,0.00038980815,0.0000031271686,0.00060975034],"genre_scores_gemma":[0.99940443,0.00006448959,0.00007008917,0.00009300399,0.0000073881265,0.000028153141,0.00020164083,8.8254154e-7,0.0001298371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881834,0.00058690977,0.00013694214,0.00011550527,0.00020813783,0.00013420176],"domain_scores_gemma":[0.996167,0.001039822,0.0019172148,0.00011807175,0.00027282778,0.00048500148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015959645,0.0001731458,0.00035406215,0.0003128263,0.00037771786,0.00039967004,0.00013734978,0.000500583,0.0021493195],"category_scores_gemma":[0.0051064906,0.000102896454,0.00077696313,0.00043475252,0.00016255573,0.00046337373,0.00031736444,0.00050993747,0.00029157905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00328706,0.00061856513,0.97910166,0.00006567392,0.00030654474,0.00012086968,0.0004827591,0.00025741966,0.00046374756,0.00004764511,0.0011632835,0.014084735],"study_design_scores_gemma":[0.00019272306,0.0020282103,0.99492717,0.000018679386,0.0000846496,0.00037916627,0.00055576145,0.00078961684,0.00015294754,0.000032899818,0.00082032534,0.000017909959],"about_ca_topic_score_codex":0.0027607516,"about_ca_topic_score_gemma":0.0023014664,"teacher_disagreement_score":0.0027607516,"about_ca_system_score_codex":0.0003841895,"about_ca_system_score_gemma":0.00027481155,"threshold_uncertainty_score":0.008440316},"labels":[],"label_agreement":null},{"id":"W2949761811","doi":"10.1097/01.hs9.0000559724.11537.93","title":"PF378 TREATMENT EMERGENT ADVERSE EVENTS VARY WITH DIFFERENT PI3K INHIBITORS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cardiac pacing and defibrillation studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Medicine; Adverse effect; Idelalisib; Incidence (geometry); Internal medicine; Leukemia","score_opus":0.013331003188037302,"score_gpt":0.2542559222531651,"score_spread":0.2409249190651278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949761811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8929783,0.059822377,0.0072271107,0.0022075416,0.00023040302,0.0009349049,0.0071476717,0.00032602597,0.029125733],"genre_scores_gemma":[0.9896612,0.004465819,0.0015935713,0.0007629853,0.000117392075,0.00025600469,0.0020484822,0.000041269293,0.0010533284],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99569315,0.0015723861,0.00069045153,0.00042866002,0.0012514015,0.00036400306],"domain_scores_gemma":[0.9900941,0.004846545,0.00358145,0.00030066262,0.0009046571,0.00027259713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043414976,0.00038428564,0.00078352465,0.00054124836,0.00031280812,0.00068155874,0.00022165845,0.000320764,0.004251122],"category_scores_gemma":[0.011789358,0.00009927269,0.0015936998,0.0009939247,0.00024902992,0.0006872447,0.000353551,0.00074813666,0.00076735823],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020730037,0.0006182421,0.44576156,0.0019271502,0.0027229527,0.0009288275,0.00029132905,0.0030968417,0.0076710535,0.00061931106,0.012018399,0.5036143],"study_design_scores_gemma":[0.0022352461,0.0100030145,0.9238079,0.0007517781,0.0024310176,0.010868135,0.00030435357,0.0036353369,0.008234417,0.002188589,0.035452507,0.000087711436],"about_ca_topic_score_codex":0.0006357469,"about_ca_topic_score_gemma":0.0012847559,"teacher_disagreement_score":0.0043414976,"about_ca_system_score_codex":0.00118588,"about_ca_system_score_gemma":0.0005803353,"threshold_uncertainty_score":0.022960305},"labels":[],"label_agreement":null},{"id":"W2949764170","doi":"10.1097/01.hs9.0000564104.83392.dc","title":"PS1460 LONG-TERM FOLLOW UP OF JAK INHIBITOR (JAKI) TREATED PATIENTS WITH MYELOFIBROSIS: IMPACT OF MOLECULAR ENHANCED INTEGRATED SCORING SYSTEMS AND TYPE OF JAKI THERAPY FAILURE ON SURVIVAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Term (time); Medicine; Ruxolitinib; Internal medicine; Oncology; Physics","score_opus":0.014467297131724972,"score_gpt":0.26835723356450547,"score_spread":0.2538899364327805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949764170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990183,0.0002877843,0.00009676372,0.000019693325,0.0000040200534,0.000006389177,0.00029003227,0.0000021411902,0.00027486563],"genre_scores_gemma":[0.9992066,0.00006756785,0.00004990458,0.000011703812,0.000010807989,0.000007970847,0.0005274255,0.00000100392,0.00011692897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99969935,0.00006315338,0.00003447094,0.00008314952,0.00006110251,0.000058735102],"domain_scores_gemma":[0.998811,0.0002623923,0.0004670957,0.000054114258,0.00010513198,0.0003002707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007507134,0.00017409539,0.000411603,0.0005195524,0.0003008635,0.00051079004,0.00026757107,0.00035166886,0.001044473],"category_scores_gemma":[0.0014306204,0.00009606411,0.0005176105,0.000593261,0.00016400959,0.00054038,0.00034606617,0.00045651215,0.00022653068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00155295,0.000058734506,0.9939275,0.000015620893,0.00007619869,0.00019266368,0.00004038627,0.00022021482,0.0004979761,0.000017308521,0.000089018286,0.0033114152],"study_design_scores_gemma":[0.000027336213,0.0009267282,0.9972994,0.000007902535,0.00010491211,0.0004000254,0.000046732,0.00076661486,0.00014765577,0.000051055627,0.00021545649,0.000006357821],"about_ca_topic_score_codex":0.00080333307,"about_ca_topic_score_gemma":0.0012790243,"teacher_disagreement_score":0.001044473,"about_ca_system_score_codex":0.0002755157,"about_ca_system_score_gemma":0.00029959777,"threshold_uncertainty_score":0.0039702654},"labels":[],"label_agreement":null},{"id":"W2949825634","doi":"10.1097/01.hs9.0000567788.99221.f8","title":"PB2331 IMPACT OF PRETRANSPLANT CHEMOTHERAPY, GRAFT VERSUS HOST DISEASE PROPHYLAXIS, GENDER AND RISK GROUP ON ALLOGENEIC REDUCED INTENSITY CONDITIONING TRANSPLANTS FOR ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Busulfan; Internal medicine; Fludarabine; Population; Transplantation; Myeloid leukemia; Chemotherapy; Surgery; Graft-versus-host disease; Regimen; Oncology; Hematopoietic stem cell transplantation; Cyclophosphamide","score_opus":0.01376130337854467,"score_gpt":0.27589634943856917,"score_spread":0.26213504606002447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949825634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993604,0.000356145,0.000016777754,0.000017954795,0.000004780456,0.000003731949,0.000037287773,6.811464e-7,0.00020227832],"genre_scores_gemma":[0.99971575,0.00008899518,0.000019165875,0.000027433538,0.000008487918,0.0000031488285,0.00006578491,4.952317e-7,0.000070622824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998691,0.000053584597,0.0000105111685,0.00001837381,0.000022806033,0.000025714191],"domain_scores_gemma":[0.99949276,0.00013740048,0.0001662752,0.000014931581,0.0000272234,0.00016139909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040080835,0.0001043641,0.0002212868,0.00011962093,0.00011478846,0.00026202737,0.00007466886,0.000118626434,0.0012686484],"category_scores_gemma":[0.0007644402,0.00003801466,0.00023586332,0.00013201265,0.00009701766,0.0001248487,0.00011616322,0.00018131988,0.0001098487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020895647,0.0005008388,0.9440786,0.000052459356,0.000198283,0.0002408555,0.000063498584,0.00026842914,0.0044378145,0.00004394444,0.0003197523,0.028899884],"study_design_scores_gemma":[0.00038461146,0.010077811,0.98667485,0.00002030491,0.00021335456,0.000504724,0.00008859834,0.00028505677,0.0008580238,0.000048396676,0.0008404253,0.0000039047895],"about_ca_topic_score_codex":0.00040256252,"about_ca_topic_score_gemma":0.00088090455,"teacher_disagreement_score":0.0012686484,"about_ca_system_score_codex":0.00015927583,"about_ca_system_score_gemma":0.00023181234,"threshold_uncertainty_score":0.004244089},"labels":[],"label_agreement":null},{"id":"W2949973349","doi":"10.1097/01.hs9.0000562776.32990.9f","title":"PS1123 IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"IGHV@; Venetoclax; Rituximab; Chronic lymphocytic leukemia; Chemoimmunotherapy; Neuroblastoma RAS viral oncogene homolog; Bendamustine; Oncology; KRAS; Internal medicine; Medicine; Lenalidomide; Somatic evolution in cancer; CDKN2A; Lymphocytosis; Leukemia; Lymphoma; Multiple myeloma; Cancer","score_opus":0.02167245289051603,"score_gpt":0.33282394885288435,"score_spread":0.31115149596236835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949973349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986927,0.0005807272,0.000036290072,0.000042749143,0.0000051585944,0.000025502784,0.00021506232,0.0000041037,0.00039772264],"genre_scores_gemma":[0.999091,0.00012054623,0.00005258757,0.000048031303,0.0000127926305,0.000026262896,0.00051549263,0.000001931406,0.00013135343],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99972445,0.00014652284,0.00001544341,0.000049207796,0.000034086643,0.000030228253],"domain_scores_gemma":[0.9995958,0.00011430644,0.0001656878,0.00003185562,0.000021672886,0.000070702496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009750532,0.00020712,0.00046464865,0.00012647241,0.0001488382,0.00037987257,0.00020770816,0.00020556085,0.0010803862],"category_scores_gemma":[0.00073775684,0.00008688804,0.00040277292,0.00019524289,0.0001556543,0.00018575722,0.00023223532,0.0003498049,0.00011817844],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15425578,0.0014309662,0.72286433,0.00037271713,0.0023224028,0.000353453,0.00028438936,0.0019194307,0.02615521,0.00014261685,0.0023527192,0.08754596],"study_design_scores_gemma":[0.00852385,0.022440612,0.96233636,0.000032931486,0.0009130034,0.00043598746,0.000051783998,0.0011388967,0.0014690697,0.0001104169,0.0025332887,0.000013934577],"about_ca_topic_score_codex":0.00064119213,"about_ca_topic_score_gemma":0.0019816123,"teacher_disagreement_score":0.0010803862,"about_ca_system_score_codex":0.0003820145,"about_ca_system_score_gemma":0.00031903444,"threshold_uncertainty_score":0.0051566362},"labels":[],"label_agreement":null},{"id":"W2949991172","doi":"10.1097/01.hs9.0000567032.31064.27","title":"PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Leukemia & Lymphoma Society of Canada; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Multiple myeloma; Internal medicine; Melphalan; Prednisone; Progression-free survival; Surgery; Gastroenterology; Chemotherapy","score_opus":0.014403361998694684,"score_gpt":0.26546221435834677,"score_spread":0.2510588523596521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949991172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659919,0.01877171,0.000429669,0.0008474348,0.00022187308,0.00050776114,0.009470034,0.000031203672,0.0037283576],"genre_scores_gemma":[0.9911032,0.0015839842,0.00021588693,0.00064714963,0.00008949191,0.00025552974,0.0051936996,0.000027814081,0.0008833436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974712,0.0007437809,0.00028590194,0.00043206685,0.00042668244,0.00064046145],"domain_scores_gemma":[0.9971409,0.0007610008,0.00072089734,0.00043736162,0.0004950793,0.00044473697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030020345,0.0009921929,0.0026274307,0.0009194529,0.0009834274,0.0014466068,0.0009723161,0.0010109113,0.00401228],"category_scores_gemma":[0.005236926,0.0003176087,0.006356977,0.0018707899,0.00040716885,0.00039821933,0.00081679993,0.0011107943,0.0002872186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17513162,0.00029241404,0.71544343,0.0014403292,0.056436565,0.00063214375,0.000427696,0.0017578021,0.0019548943,0.00051975524,0.011911236,0.034052048],"study_design_scores_gemma":[0.0197999,0.0035668435,0.9170955,0.0005629034,0.04272618,0.0007162847,0.000843576,0.0022719495,0.0006857544,0.00077862496,0.010815674,0.00013687465],"about_ca_topic_score_codex":0.26754713,"about_ca_topic_score_gemma":0.50272846,"teacher_disagreement_score":0.26754713,"about_ca_system_score_codex":0.003885661,"about_ca_system_score_gemma":0.008528958,"threshold_uncertainty_score":0.5319797},"labels":[],"label_agreement":null},{"id":"W2949995351","doi":"10.1097/01.hs9.0000562472.96992.e6","title":"PS1044 THE PROGNOSTIC SIGNIFICANCE OF BCR‐1 AND BCR‐3 ISOFORM OF PML‐RARA AND FLT3‐ITD IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group; University of Calgary","funders":"","keywords":"Medicine; Acute promyelocytic leukemia; breakpoint cluster region; Internal medicine; Regimen; Oncology; Gastroenterology; Biology; Gene","score_opus":0.005892820207575328,"score_gpt":0.2284704105657468,"score_spread":0.22257759035817146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949995351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993899,0.00018594861,0.000019110063,0.000032943648,0.0000026995438,0.0000022714407,0.000076086275,0.0000016901403,0.00028926463],"genre_scores_gemma":[0.9997222,0.000042314343,0.000017380036,0.000009764344,0.0000069796865,0.0000017561653,0.00012760326,6.2816093e-7,0.000071294715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998591,0.00003213644,0.000016551325,0.000027511098,0.000028515386,0.00003620679],"domain_scores_gemma":[0.99945337,0.00010922919,0.00022790562,0.000019895379,0.000049144048,0.00014047192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024334488,0.00016684341,0.00018098822,0.0004731087,0.00019987622,0.00035187392,0.00019494543,0.00024246414,0.0012326844],"category_scores_gemma":[0.0011510641,0.00010269551,0.00014186636,0.0005087109,0.00019707864,0.0002649058,0.00023018979,0.00029123173,0.00022044466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026081092,0.000012773668,0.99665904,0.000006266799,0.000015078729,0.00030037566,0.00003558967,0.00007642501,0.00041215034,0.000011501416,0.00009040924,0.0021195346],"study_design_scores_gemma":[0.000019073945,0.00017498303,0.99720985,0.000005181807,0.00002902887,0.0016500457,0.00011756659,0.0002906764,0.00015303172,0.000047775557,0.0002999238,0.0000028606073],"about_ca_topic_score_codex":0.001195298,"about_ca_topic_score_gemma":0.0019186301,"teacher_disagreement_score":0.0012326844,"about_ca_system_score_codex":0.00034241812,"about_ca_system_score_gemma":0.00032368265,"threshold_uncertainty_score":0.0041237473},"labels":[],"label_agreement":null},{"id":"W2950158180","doi":"10.1097/01.hs9.0000563624.30413.c3","title":"PS1336 DISCREPANCE OF ALLELIC BURDEN CHANGES AND CLINICAL RESPONSE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME TREATED WITH HYPOMETHYLATING AGENTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Decitabine; Azacitidine; Medicine; Internal medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Hypomethylating agent; Allele; Gastroenterology; Myeloid; Oncology; Bone marrow; Gene; Genetics; DNA methylation; Biology","score_opus":0.015556206433921428,"score_gpt":0.2852610328947903,"score_spread":0.2697048264608689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950158180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996855,0.00008776608,0.000040466315,0.000008938899,9.392965e-7,0.000001934377,0.00004136641,0.0000021979226,0.0001308594],"genre_scores_gemma":[0.9997749,0.000022637409,0.00004645661,0.000006894143,0.0000020777263,0.0000020554442,0.00008869253,8.464343e-7,0.000055554214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998522,0.000035758047,0.000018760915,0.000040386578,0.000031971853,0.000020992102],"domain_scores_gemma":[0.9996239,0.000089275156,0.00017167832,0.000023556935,0.000037714308,0.000053864027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024775296,0.00012974559,0.00021235722,0.00038390962,0.00016945857,0.00024288941,0.00011180459,0.00016769975,0.0008543444],"category_scores_gemma":[0.0007745,0.00007729832,0.00012494861,0.0002980451,0.00015702457,0.00014662312,0.00016725261,0.00020012469,0.00012702754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001139535,0.00004277619,0.9796221,0.00001301584,0.000044660086,0.0005101463,0.0001236687,0.0002340713,0.009046613,0.000023485378,0.00010247041,0.00909749],"study_design_scores_gemma":[0.000025402956,0.0004416025,0.995125,0.000002961635,0.000038861424,0.0017554078,0.00006373659,0.00040162125,0.001764335,0.000048053676,0.00032962853,0.0000033428819],"about_ca_topic_score_codex":0.00052010093,"about_ca_topic_score_gemma":0.00050168566,"teacher_disagreement_score":0.0008543444,"about_ca_system_score_codex":0.0002105407,"about_ca_system_score_gemma":0.000109980974,"threshold_uncertainty_score":0.0028580427},"labels":[],"label_agreement":null},{"id":"W2950165149","doi":"10.1097/01.hs9.0000566236.65976.7d","title":"PB1935 REAL LIFE EXPERIENCE IN CML PATIENTS IN CANARY ISLAND","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Utilities Corporation","funders":"","keywords":"Medicine; Imatinib; Internal medicine; Cumulative incidence; Myeloid leukemia; Incidence (geometry); Dasatinib; Gastroenterology; Cohort","score_opus":0.013506230120531003,"score_gpt":0.2677709842224399,"score_spread":0.2542647541019089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950165149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745184,0.0003868429,0.00005635838,0.00014331505,0.000012633253,0.000024698973,0.00036762745,0.0000039618126,0.0015527095],"genre_scores_gemma":[0.9975314,0.0005447375,0.00010500069,0.00012696035,0.00003247906,0.000031592805,0.0008090694,0.000003675931,0.00081499404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999746,0.000063621206,0.000014849057,0.000036794663,0.00004982383,0.00008887277],"domain_scores_gemma":[0.9994954,0.000090639645,0.000109352404,0.000040451247,0.00005165954,0.00021235971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028806351,0.00020785179,0.00021269724,0.0005485346,0.00076132506,0.00052983843,0.0003908346,0.0004186891,0.0039531724],"category_scores_gemma":[0.0009143009,0.00012578699,0.0001771075,0.0011452395,0.00038419355,0.0002483449,0.000934175,0.0003974341,0.000528915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008947969,0.00040673284,0.95367044,0.00019298687,0.000068425616,0.008970821,0.003990786,0.00037654146,0.0012545901,0.0002249754,0.0025831405,0.027365828],"study_design_scores_gemma":[0.00006849323,0.0011145027,0.97133386,0.000043307286,0.000053197185,0.008868525,0.004105211,0.0003160207,0.00051591254,0.000113563445,0.013442907,0.000024610741],"about_ca_topic_score_codex":0.023489324,"about_ca_topic_score_gemma":0.022046547,"teacher_disagreement_score":0.023489324,"about_ca_system_score_codex":0.0012044251,"about_ca_system_score_gemma":0.0010731054,"threshold_uncertainty_score":0.046705186},"labels":[],"label_agreement":null},{"id":"W2950218799","doi":"10.1097/01.hs9.0000558992.23463.e7","title":"PF194 EVALUATION OF TELOMERE LENGTH AND TELOMERASE ACTIVITY AS PROGNOSTIC MARKERS IN A PEDIATRIC PATIENT COHORT WITH ACUTE LYMPHOBLASTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Telomerase; Telomere; Medicine; clone (Java method); Cohort; Oncology; Cancer; Pediatric cancer; Internal medicine; Stem cell; Acute lymphocytic leukemia; Immunology; Leukemia; Cancer research; Biology; Lymphoblastic Leukemia; Genetics; Gene","score_opus":0.008302490414296315,"score_gpt":0.2426752915722549,"score_spread":0.23437280115795858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950218799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988912,0.00018432068,0.000121651006,0.000021298894,0.0000023197306,0.000009496357,0.0004723107,0.0000066983653,0.0002908249],"genre_scores_gemma":[0.99881065,0.00016384028,0.00018160198,0.000012122493,0.00000771917,0.000016973034,0.00071372266,0.000003553804,0.00008994426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998319,0.000035121368,0.00001719611,0.000042285665,0.000035672103,0.000037903],"domain_scores_gemma":[0.9994825,0.000116652234,0.00020009854,0.00003995122,0.00007093476,0.000089890156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038064452,0.0002651815,0.0003083551,0.0007317725,0.00028860397,0.00043759317,0.00020739825,0.00021672003,0.0014033968],"category_scores_gemma":[0.0013354219,0.00014665318,0.00016581318,0.00097409444,0.00017028188,0.0003247317,0.0003178474,0.00034143566,0.00033502965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019702784,0.00001399364,0.9964026,0.0000059291806,0.000009526885,0.0002663807,0.000048658683,0.00005651945,0.00070048525,0.000012423445,0.00012034047,0.0021660822],"study_design_scores_gemma":[0.000012151915,0.00031854512,0.9949175,0.000005972402,0.000031074742,0.0031177304,0.00016847653,0.00025012266,0.0004931319,0.000030767093,0.0006513562,0.0000031467184],"about_ca_topic_score_codex":0.0014674028,"about_ca_topic_score_gemma":0.0009771936,"teacher_disagreement_score":0.0014674028,"about_ca_system_score_codex":0.00028352335,"about_ca_system_score_gemma":0.00033128465,"threshold_uncertainty_score":0.0046948195},"labels":[],"label_agreement":null},{"id":"W2950269753","doi":"10.1097/01.hs9.0000560680.23378.f5","title":"PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D‐VTD): PHASE 3 CASSIOPEIA STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Plerixafor; Multiple myeloma; Autologous stem-cell transplantation; Internal medicine; Daratumumab; Transplantation; Surgery; Bortezomib; Oncology; CXCR4","score_opus":0.024670295667957722,"score_gpt":0.2923307548691387,"score_spread":0.267660459201181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950269753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993655,0.0002990008,0.00004409749,0.00004495373,0.000010508981,0.00004778828,0.00008145287,0.000004416156,0.00010235028],"genre_scores_gemma":[0.99911946,0.00013156077,0.00011840713,0.00011682547,0.000036968824,0.00007444308,0.0002717914,0.0000022719787,0.00012830352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99956805,0.00020623581,0.000028003204,0.000076907345,0.000057210385,0.00006359253],"domain_scores_gemma":[0.9990387,0.00019174597,0.00026218718,0.000055940167,0.00003465873,0.0004167554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017672864,0.0005569933,0.0010335817,0.0002368847,0.00030378296,0.00059340807,0.00036317646,0.0006465498,0.0013373386],"category_scores_gemma":[0.0010035641,0.00026099218,0.00081043015,0.00026733725,0.00048644756,0.0004231722,0.000369531,0.0012845082,0.00026396263],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6638306,0.01841793,0.22246626,0.00021710955,0.001588459,0.00026611626,0.0002948172,0.0020153797,0.027984306,0.00015225649,0.0017680035,0.060998827],"study_design_scores_gemma":[0.13089499,0.41044426,0.4397467,0.000046446858,0.0017652892,0.000971924,0.00013658652,0.0042894306,0.008935514,0.00029144474,0.00242964,0.000047684767],"about_ca_topic_score_codex":0.00037697234,"about_ca_topic_score_gemma":0.0006308119,"teacher_disagreement_score":0.0017672864,"about_ca_system_score_codex":0.0005589622,"about_ca_system_score_gemma":0.000702244,"threshold_uncertainty_score":0.0093464255},"labels":[],"label_agreement":null},{"id":"W2950296737","doi":"10.1097/01.hs9.0000563780.03390.ca","title":"PS1376 LENALIDOMIDE MAINTENANCE POSITIVELY IMPACTS OUTCOMES IN MULTIPLE MYELOMA WITHOUT NEGATIVE IMPACTS IN RELAPSE: AN ANALYSIS OF REAL WORLD DATA FROM THE MYELOMA CANADA RESEARCH NETWORK NATIONAL DATABASE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Vancouver General Hospital; Princess Margaret Cancer Centre; Ottawa Hospital; Dalhousie University; Université de Montréal; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Bortezomib; Oncology; Internal medicine; Maintenance therapy; Chemotherapy","score_opus":0.0944339017398557,"score_gpt":0.38919401619865,"score_spread":0.2947601144587943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950296737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9222727,0.0022567145,0.00022691417,0.00050614355,0.000014861305,0.000113702685,0.073077224,0.00002794393,0.0015037784],"genre_scores_gemma":[0.9672997,0.0004575062,0.0003558708,0.0001609116,0.000012815191,0.000057407968,0.031436745,0.000011309669,0.00020770276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562067,0.0009422081,0.0004533489,0.00076196314,0.0015902681,0.00063150405],"domain_scores_gemma":[0.9859977,0.0033426816,0.004612159,0.0013494692,0.003592008,0.0011060074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003748304,0.0003587467,0.0009217019,0.001853315,0.00070577307,0.0014817487,0.0013616022,0.00039440245,0.001628693],"category_scores_gemma":[0.015205048,0.00017234957,0.0010788671,0.007484703,0.0005016941,0.0004227881,0.00080947625,0.0005399668,0.00018966442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011854861,0.000053969063,0.98508656,0.00018952794,0.0008373597,0.000056797522,0.000094765186,0.0007242564,0.00007677254,0.00015418713,0.0044988766,0.0070413374],"study_design_scores_gemma":[0.000117136566,0.00008542957,0.9942258,0.000059723636,0.00041976786,0.00008446442,0.00017026,0.0019450943,0.000079963356,0.000057520076,0.0027359622,0.000018817482],"about_ca_topic_score_codex":0.8212788,"about_ca_topic_score_gemma":0.8727126,"teacher_disagreement_score":0.17872119,"about_ca_system_score_codex":0.01116976,"about_ca_system_score_gemma":0.018912187,"threshold_uncertainty_score":0.35954738},"labels":[],"label_agreement":null},{"id":"W2950319468","doi":"10.1097/01.hs9.0000565876.04604.d2","title":"PB1843 EFFECT OF ADHERENCE TO PHYSICAL THERPY REGIMEN ON JOINTS OUTCOMES FOR HEMOPHILIAC CHILDREN AT ZAGAZIG UNIVERSITY HOSPITALS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Physical therapy; Regimen; Outpatient clinic; Attendance; Test (biology); Joint pain; Clotting factor; Internal medicine","score_opus":0.013227288999329902,"score_gpt":0.2962124569902549,"score_spread":0.282985167990925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950319468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994136,0.0002159676,0.0000068670106,0.000066367225,0.000004700882,0.000013994693,0.000080202175,0.0000017334231,0.00019653125],"genre_scores_gemma":[0.99932873,0.0001980602,0.00007617369,0.000037783655,0.0000065093036,0.000024907156,0.00012660123,6.822573e-7,0.00020049885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995648,0.00012902457,0.000035451514,0.000045587596,0.00009283183,0.00013218913],"domain_scores_gemma":[0.9989992,0.00013875507,0.00042951683,0.000036999678,0.00008647404,0.0003090565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007828246,0.00019488875,0.00035963408,0.00032732892,0.00039040227,0.0003745336,0.00020787695,0.0002832143,0.0024964141],"category_scores_gemma":[0.001568486,0.00011701928,0.00040993016,0.00035078503,0.00016815978,0.00015334759,0.00032710243,0.0005634374,0.000175387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020374632,0.0022213773,0.9715385,0.00013260863,0.000096329946,0.0001596915,0.0005082544,0.000102729646,0.0004798658,0.000046284986,0.00074171746,0.021935374],"study_design_scores_gemma":[0.00009753116,0.0027137722,0.9960574,0.00003581274,0.00003676176,0.00008591767,0.00034582286,0.000064896565,0.00009124214,0.000004357188,0.0004627789,0.000003937244],"about_ca_topic_score_codex":0.011859965,"about_ca_topic_score_gemma":0.0130285015,"teacher_disagreement_score":0.011859965,"about_ca_system_score_codex":0.0006127158,"about_ca_system_score_gemma":0.00084605324,"threshold_uncertainty_score":0.023581862},"labels":[],"label_agreement":null},{"id":"W2950360095","doi":"10.1097/01.hs9.0000566660.48019.07","title":"PB2043 UPPER AND LOWER GASTROINTESTINAL ENDOSCOPY FINDINGS IN PATIENTS WITH ISOLATED FERRITIN DEFICIENCY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Esophageal and GI Pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Iron-deficiency anemia; Endoscopy; Iron deficiency; Ferritin; Hepatology; Anemia; Helicobacter pylori; Gastritis","score_opus":0.004365030723828843,"score_gpt":0.21130576093141065,"score_spread":0.2069407302075818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950360095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99910706,0.00023510416,0.000035541656,0.000028816841,0.0000049317855,0.000005470518,0.0000655863,0.000004334983,0.0005131566],"genre_scores_gemma":[0.999701,0.000077181445,0.00005298041,0.000016637972,0.0000084262565,0.0000027832302,0.00007616603,0.0000011537879,0.00006362556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975675,0.000036797723,0.000028813782,0.00005810012,0.00004825929,0.00007125232],"domain_scores_gemma":[0.9991304,0.00016498452,0.00034914733,0.000024151572,0.000050086146,0.00028123622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029329956,0.0004080587,0.00038235495,0.0011564955,0.00046264613,0.0003694989,0.00023277782,0.00042838464,0.0029580928],"category_scores_gemma":[0.0013557095,0.00025880564,0.00028292064,0.0006632879,0.00043574208,0.00038144988,0.00040963286,0.0005170408,0.00030453256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016308535,0.000026790975,0.9879759,0.000014598681,0.000009600234,0.01006683,0.000061722254,0.000021963988,0.00053453003,0.000012285235,0.00007817394,0.0010344189],"study_design_scores_gemma":[0.000011845307,0.0002535739,0.94761884,0.000012834853,0.000020431244,0.051328477,0.00022664932,0.00012553045,0.00020848753,0.000021644579,0.00016723263,0.000004604333],"about_ca_topic_score_codex":0.0019125975,"about_ca_topic_score_gemma":0.0015599249,"teacher_disagreement_score":0.0029580928,"about_ca_system_score_codex":0.00032473076,"about_ca_system_score_gemma":0.00027549992,"threshold_uncertainty_score":0.009895802},"labels":[],"label_agreement":null},{"id":"W2950383245","doi":"10.1097/01.hs9.0000562228.80333.3e","title":"PS982 THE ROLE OF STAT3 ISOFORMS IN ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"STAT3; Myeloid leukemia; Cancer research; STAT protein; Transactivation; Biology; Myeloid; Leukemia; Medicine; Immunology; Transcription factor; Signal transduction; Cell biology; Gene; Genetics","score_opus":0.00818188320902069,"score_gpt":0.2644259495847453,"score_spread":0.2562440663757246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950383245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97264534,0.019495212,0.0021706014,0.0003342534,0.000054117787,0.000042193144,0.0013593746,0.0000930201,0.003805903],"genre_scores_gemma":[0.9895012,0.005149185,0.0010750026,0.00010303283,0.0000424063,0.000030234074,0.0021754785,0.0000152351,0.0019082438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992025,0.0000103027305,0.000010244317,0.000014129354,0.000031045987,0.000014121447],"domain_scores_gemma":[0.9999256,0.000009728061,0.00003243448,0.0000043008977,0.000009397888,0.000018508386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018507568,0.00026977813,0.000138379,0.00059346686,0.00015479347,0.00029560717,0.00014377908,0.00021859004,0.0017038317],"category_scores_gemma":[0.00011498676,0.0000761684,0.00019555756,0.00055938185,0.00021295983,0.0001760223,0.00016910477,0.0003049463,0.0006250589],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029081644,0.00009945826,0.042137224,0.0004344407,0.000052371895,0.0010731155,0.000082276034,0.00057751755,0.9069807,0.00068553886,0.00096210244,0.04400716],"study_design_scores_gemma":[0.0003755139,0.0015402919,0.48999938,0.000102891245,0.00034527134,0.016299501,0.00026508013,0.004269174,0.4340832,0.0029946316,0.049697176,0.000027985481],"about_ca_topic_score_codex":0.0002675244,"about_ca_topic_score_gemma":0.00034302013,"teacher_disagreement_score":0.0017038317,"about_ca_system_score_codex":0.00024867235,"about_ca_system_score_gemma":0.00027775887,"threshold_uncertainty_score":0.005699873},"labels":[],"label_agreement":null},{"id":"W2950542774","doi":"10.1097/01.hs9.0000559388.41193.da","title":"PF294 IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"","keywords":"Medicine; International Prognostic Index; Internal medicine; Diffuse large B-cell lymphoma; Clinical endpoint; CHOP; Rituximab; Oncology; Lymphoma; Regimen; Gastroenterology; Randomized controlled trial","score_opus":0.01167698582169717,"score_gpt":0.27383872382028873,"score_spread":0.26216173799859155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950542774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975076,0.00140645,0.000058688773,0.00010456829,0.000024376479,0.000053196432,0.00030401474,0.000023840408,0.0005172376],"genre_scores_gemma":[0.99831104,0.00042582085,0.000121617006,0.00012642863,0.000030383178,0.000036080055,0.00058354845,0.0000038940275,0.00036133587],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99985075,0.000069955495,0.000007974967,0.000030517196,0.00001649246,0.000024344588],"domain_scores_gemma":[0.99974734,0.000058500274,0.00008174248,0.000017387769,0.00001670216,0.0000783594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056907034,0.00030702833,0.0006802881,0.00012390286,0.00014162672,0.00045617236,0.00019829629,0.00034957172,0.001371667],"category_scores_gemma":[0.0006641785,0.00012573542,0.00045977635,0.00021442394,0.0001727866,0.00027487366,0.00018159549,0.0007031213,0.00019635557],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5193148,0.010658678,0.21558253,0.0006899952,0.002458662,0.0004670611,0.00022790195,0.0030418418,0.02876607,0.000152125,0.0064723394,0.21216795],"study_design_scores_gemma":[0.07960902,0.26554343,0.6365509,0.00008721602,0.0022366717,0.0011870936,0.00015316234,0.0034888757,0.0042439005,0.0002970643,0.0065614986,0.00004114249],"about_ca_topic_score_codex":0.00056631514,"about_ca_topic_score_gemma":0.0012272368,"teacher_disagreement_score":0.001371667,"about_ca_system_score_codex":0.00032307438,"about_ca_system_score_gemma":0.00032828553,"threshold_uncertainty_score":0.004588723},"labels":[],"label_agreement":null},{"id":"W2950544845","doi":"10.1097/01.hs9.0000559524.28466.13","title":"PF328 PREDICTORS OF TREATMENT RESPONSE TO IMMUNOSUPPRESSANTS IN ACQUIRED HEMOPHILIA A","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Proportional hazards model; Partial thromboplastin time; Population; Single Center; Retrospective cohort study; Coagulation","score_opus":0.020589671907914595,"score_gpt":0.303439360244783,"score_spread":0.2828496883368684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950544845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993118,0.00032192713,0.000038600007,0.000037146052,0.0000030801486,0.0000022706981,0.0000887428,0.0000016924517,0.00019472759],"genre_scores_gemma":[0.99978715,0.000052864343,0.000023126106,0.0000065845124,0.0000070649926,0.0000016149805,0.00008817638,5.820587e-7,0.00003288005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997565,0.00007756746,0.000032771917,0.0000344129,0.000056410165,0.000042327258],"domain_scores_gemma":[0.9974093,0.0006552497,0.0013746988,0.000048316444,0.00017944103,0.00033300757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000522904,0.00016611924,0.00021832969,0.0004165495,0.00017363732,0.00035654294,0.00016759042,0.0002539074,0.0017977093],"category_scores_gemma":[0.002437149,0.00008148093,0.00025819836,0.0005234493,0.00018766371,0.00021326462,0.00019082463,0.00042670057,0.00019821028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013752369,0.00001403934,0.99872464,0.0000051755137,0.000011797767,0.000073412455,0.000010218348,0.000044727483,0.00009335851,0.0000055282526,0.000041828913,0.0008378042],"study_design_scores_gemma":[0.000010300956,0.00018031056,0.9984131,0.0000074916175,0.00001946808,0.00070092,0.000044030137,0.00039273888,0.000078075616,0.000018286264,0.00013328387,0.0000019403194],"about_ca_topic_score_codex":0.0009432835,"about_ca_topic_score_gemma":0.00076597335,"teacher_disagreement_score":0.0017977093,"about_ca_system_score_codex":0.00020810204,"about_ca_system_score_gemma":0.00019717994,"threshold_uncertainty_score":0.00601393},"labels":[],"label_agreement":null},{"id":"W2950604500","doi":"10.1097/01.hs9.0000562556.40615.f8","title":"PS1065 OPEN‐LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3‐MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Cohort; Chemotherapy; Surgery; Internal medicine; Gastroenterology; Adverse effect","score_opus":0.049429120927616754,"score_gpt":0.34203074886872575,"score_spread":0.292601627941109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950604500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933216,0.0008672475,0.000323322,0.0002902292,0.00013473799,0.001330853,0.0022929008,0.00007583459,0.0013633367],"genre_scores_gemma":[0.9873819,0.0009489953,0.0008664594,0.0008666718,0.00041729442,0.001699919,0.00535313,0.000024376375,0.0024413695],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991806,0.00037376542,0.00004768762,0.00018110982,0.00008198124,0.00013490846],"domain_scores_gemma":[0.998494,0.00022839585,0.00029226928,0.00013769271,0.000095121424,0.00075252727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022824327,0.002228869,0.0031776195,0.00060641865,0.0005272042,0.0012288562,0.00097436266,0.0015721605,0.0060678283],"category_scores_gemma":[0.0013390044,0.0007183128,0.002653505,0.0004909683,0.0016517115,0.0015164085,0.00057023036,0.004209987,0.0014229435],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9371862,0.027712435,0.00511622,0.0002382233,0.0012969498,0.00014292015,0.00010655408,0.0008226244,0.0070785843,0.00010566106,0.0016574911,0.018536257],"study_design_scores_gemma":[0.64045846,0.33887276,0.016057977,0.00002032739,0.00082558737,0.00015175826,0.00005000392,0.0007399851,0.0012189661,0.00015814157,0.0014119449,0.000034061162],"about_ca_topic_score_codex":0.001060409,"about_ca_topic_score_gemma":0.0023234244,"teacher_disagreement_score":0.0060678283,"about_ca_system_score_codex":0.0012960938,"about_ca_system_score_gemma":0.0021309764,"threshold_uncertainty_score":0.020298958},"labels":[],"label_agreement":null},{"id":"W2950620394","doi":"10.1097/01.hs9.0000561796.30124.a4","title":"S879 RESULTS OF ASTRAL‐1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN‐AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Clinical endpoint; Cytarabine; Randomized controlled trial; Regimen; Induction chemotherapy; Oncology; Gastroenterology; Chemotherapy; Surgery","score_opus":0.03473661491423022,"score_gpt":0.3619602162914029,"score_spread":0.32722360137717266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950620394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722545,0.0054313415,0.0008444068,0.002615678,0.00078904943,0.0059494814,0.0047532795,0.00014241037,0.007219819],"genre_scores_gemma":[0.9730958,0.0025804983,0.0026487138,0.0038634026,0.00055504387,0.006883767,0.004612796,0.00007551897,0.005684505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99910283,0.00062747236,0.000044247896,0.00010362208,0.000054278426,0.00006752045],"domain_scores_gemma":[0.99892104,0.0003531549,0.0002790333,0.00007689342,0.000070554306,0.00029938758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020772063,0.0012940371,0.0017366277,0.0003251756,0.00033454894,0.0008929562,0.0006341451,0.0014399888,0.009629204],"category_scores_gemma":[0.0022136085,0.00042542306,0.0021960638,0.00033744064,0.0009000538,0.0008110308,0.00036843648,0.0037722674,0.0012656022],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9688325,0.0057998397,0.0009968242,0.00061261817,0.0012832354,0.00005349966,0.00006202088,0.0006006304,0.0035668383,0.00027301317,0.003601247,0.014317826],"study_design_scores_gemma":[0.9138167,0.077910475,0.0025386747,0.00006378719,0.0015858329,0.000055621324,0.000034209508,0.0006354008,0.00063679734,0.00046259142,0.002240069,0.000019731633],"about_ca_topic_score_codex":0.00048571388,"about_ca_topic_score_gemma":0.0018575275,"teacher_disagreement_score":0.009629204,"about_ca_system_score_codex":0.00063611486,"about_ca_system_score_gemma":0.0010116945,"threshold_uncertainty_score":0.032212853},"labels":[],"label_agreement":null},{"id":"W2950623518","doi":"10.1097/01.hs9.0000559048.84930.7b","title":"PF208 MN1 IS INDISPENSABLE FOR MLL‐REARRANGED ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Cancer research; Leukemia; Myeloid leukemia; clone (Java method); Cell culture; Myeloid; Cytotoxic T cell; Oncogene; U937 cell; Apoptosis; Cell cycle; Molecular biology; In vitro; Immunology; Genetics; Gene","score_opus":0.020453164644980325,"score_gpt":0.29962421660561406,"score_spread":0.27917105196063374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950623518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165183,0.00086078944,0.0034966127,0.00011853393,0.00003487564,0.000030469362,0.0018064675,0.00031321755,0.0016871539],"genre_scores_gemma":[0.99321955,0.0002031217,0.0020875293,0.000027760967,0.0000052677815,0.00002686575,0.0019089171,0.000057514324,0.0024635817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985695,0.000020310976,0.000015627269,0.000032255226,0.00005023062,0.000024696086],"domain_scores_gemma":[0.9997838,0.00005151847,0.00006582749,0.000026956432,0.000014104286,0.00005792907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009178499,0.00039903313,0.00026736935,0.00029159017,0.000227125,0.0002531426,0.00030693936,0.00030228644,0.003871505],"category_scores_gemma":[0.00020852967,0.000108750915,0.00021409363,0.00014043243,0.00021582078,0.00011080395,0.0002674257,0.00038230867,0.0020947184],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014197016,0.000025041305,0.00057642616,0.00003644746,0.000003856599,0.00018916912,0.000012005134,0.00011060887,0.99719656,0.00011625132,0.000102577345,0.0014890986],"study_design_scores_gemma":[0.000020332249,0.00014847181,0.009394973,0.0000121226485,0.000016050742,0.0017255633,0.00003136574,0.0018805154,0.97839624,0.00009301669,0.0082730055,0.000008301373],"about_ca_topic_score_codex":0.0007861587,"about_ca_topic_score_gemma":0.0009917273,"teacher_disagreement_score":0.003871505,"about_ca_system_score_codex":0.00041226647,"about_ca_system_score_gemma":0.0002876524,"threshold_uncertainty_score":0.012951434},"labels":[],"label_agreement":null},{"id":"W2950630840","doi":"10.1097/01.hs9.0000560636.62389.3a","title":"PF587 SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SAIT Polytechnic; Alberta Cancer Foundation; Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; Royal Victoria Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Tolerability; Lenalidomide; Medicine; Multiple myeloma; Refractory (planetary science); Dexamethasone; Internal medicine; Oncology; Bortezomib; Pharmacology; Phases of clinical research; Progressive disease; Adverse effect; Gastroenterology; Toxicity; Chemotherapy; Materials science","score_opus":0.01371024063456188,"score_gpt":0.2593603018621555,"score_spread":0.24565006122759359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950630840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99318165,0.0046156254,0.00009079435,0.00052125764,0.00003808352,0.00010844082,0.000172068,0.000020810312,0.0012512043],"genre_scores_gemma":[0.99773103,0.0010701738,0.00024519154,0.00033931824,0.00006309754,0.00004406914,0.00019403944,0.0000020946359,0.00031088578],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997571,0.0000910355,0.000026704955,0.000045323584,0.000040964722,0.000038854443],"domain_scores_gemma":[0.9996997,0.000061012397,0.000073400355,0.000009666065,0.000016228822,0.00014007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059998885,0.0003791745,0.00101629,0.00032512544,0.00032178086,0.00043323176,0.00027913295,0.00045100143,0.0012669486],"category_scores_gemma":[0.000758115,0.00020942473,0.0005612789,0.00042948392,0.0002241059,0.00035498774,0.00025284593,0.00077257864,0.00022680125],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.114339784,0.005484896,0.55611587,0.0010939119,0.0017876372,0.0073959148,0.00096497714,0.0030264135,0.020973988,0.00030952904,0.005433409,0.2830737],"study_design_scores_gemma":[0.020402376,0.127581,0.81475544,0.0002766721,0.002033228,0.01375888,0.00071834633,0.0046415213,0.0033361893,0.0006060865,0.011819405,0.000070774],"about_ca_topic_score_codex":0.000921777,"about_ca_topic_score_gemma":0.0031132882,"teacher_disagreement_score":0.0012669486,"about_ca_system_score_codex":0.00077012985,"about_ca_system_score_gemma":0.00073239586,"threshold_uncertainty_score":0.0055877566},"labels":[],"label_agreement":null},{"id":"W2950632884","doi":"10.1097/01.hs9.0000564556.92986.0e","title":"PS1577 PLATELET COUNT AND MEAN PLATELET VOLUME IN ACUTE STROKE: A SYSTEMATIC REVIEW AND META‐ANALYSIS","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Strictly standardized mean difference; Meta-analysis; Internal medicine; Stroke (engine); Confidence interval; Mean platelet volume; Inclusion and exclusion criteria; Subgroup analysis; Platelet; Pathology; Alternative medicine","score_opus":0.04291832931752954,"score_gpt":0.3239036019234264,"score_spread":0.28098527260589684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950632884","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056066914,0.9922611,0.0004260628,0.00023807301,0.00014692929,0.00043023183,0.0006119748,0.00002340875,0.0002554952],"genre_scores_gemma":[0.1634294,0.8291509,0.002376989,0.00086617086,0.00034299566,0.0023490656,0.0009973898,0.000026516389,0.00046053235],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99007416,0.004796427,0.002867535,0.0008514882,0.001092891,0.00031742427],"domain_scores_gemma":[0.98265415,0.012372933,0.0029922363,0.00044494923,0.0013192089,0.00021650027],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.011820109,0.0026334394,0.01724723,0.006314939,0.00072585023,0.0036011382,0.0021166136,0.0026864086,0.0045266757],"category_scores_gemma":[0.029814135,0.0014759256,0.033040397,0.008599642,0.0007485992,0.0019254916,0.0014849084,0.0017955278,0.0003932182],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014252705,0.000028929666,0.0039499975,0.4963452,0.48875514,0.00013622722,0.00008076662,0.0003977945,0.00014867996,0.000115963245,0.00059580867,0.008020213],"study_design_scores_gemma":[0.0005631534,0.00020826506,0.003907425,0.03540481,0.9579816,0.00010581188,0.0000455964,0.00019524359,0.00009390798,0.00016085774,0.0013123688,0.000020896507],"about_ca_topic_score_codex":0.0060302946,"about_ca_topic_score_gemma":0.012324921,"teacher_disagreement_score":0.9827528,"about_ca_system_score_codex":0.002553022,"about_ca_system_score_gemma":0.0046687415,"threshold_uncertainty_score":0.062511444},"labels":[],"label_agreement":null},{"id":"W2950636832","doi":"10.1097/01.hs9.0000561096.37776.87","title":"PF703 LONG‐TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; McMaster University","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Tolerability; Placebo; Internal medicine; Syk; Nausea; Immune thrombocytopenia; Platelet","score_opus":0.03448255536868397,"score_gpt":0.36925396620834694,"score_spread":0.334771410839663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950636832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679711,0.019586543,0.0009108612,0.0012167284,0.00019629294,0.0016259613,0.0029895254,0.00014398865,0.0053590504],"genre_scores_gemma":[0.9902338,0.003295908,0.0009229997,0.0007512372,0.000109832785,0.0009933301,0.0025069949,0.000016812302,0.0011691361],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994155,0.00026228608,0.00007034072,0.000063720254,0.00008684743,0.00010130947],"domain_scores_gemma":[0.9994967,0.00011388903,0.00017382308,0.000032740285,0.00007798688,0.000104808285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020455634,0.0004164532,0.000833712,0.00014772546,0.00030664538,0.00060429197,0.0003034501,0.0005357218,0.0028410275],"category_scores_gemma":[0.0013365434,0.00012748767,0.0010542234,0.00028939833,0.00020239693,0.0004599383,0.00020652013,0.001072035,0.0005911568],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49863657,0.004584438,0.03278033,0.0036662773,0.0036992861,0.0006777897,0.00044273984,0.0016733975,0.02701062,0.0005985872,0.022646723,0.40358326],"study_design_scores_gemma":[0.4479535,0.30189678,0.1584681,0.00084565906,0.0041894447,0.005682196,0.00019033525,0.0031634346,0.018983724,0.00089977874,0.057624254,0.00010289353],"about_ca_topic_score_codex":0.00047507518,"about_ca_topic_score_gemma":0.0016278652,"teacher_disagreement_score":0.0028410275,"about_ca_system_score_codex":0.00054893974,"about_ca_system_score_gemma":0.00091841095,"threshold_uncertainty_score":0.010818064},"labels":[],"label_agreement":null},{"id":"W2950646286","doi":"10.1097/01.hs9.0000564672.91201.a6","title":"S1606 SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; Royal Victoria Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Tolerability; Medicine; Refractory (planetary science); Internal medicine; Oncology; Dexamethasone; Proteasome inhibitor; Phases of clinical research; Carfilzomib; Multiple myeloma; Pharmacology; Lenalidomide; Gastroenterology; Toxicity; Adverse effect; Biology","score_opus":0.006718724720766075,"score_gpt":0.23815034598627274,"score_spread":0.23143162126550668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950646286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630994,0.0019270879,0.00013311795,0.00015985811,0.00004674364,0.00014848597,0.00029501924,0.00002376158,0.0009558869],"genre_scores_gemma":[0.9975867,0.0005638302,0.00026238026,0.00021543923,0.00008301916,0.0001010621,0.0005051876,0.0000062379013,0.00067613926],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971646,0.00011771193,0.000030124811,0.000047163034,0.000050599607,0.000037829326],"domain_scores_gemma":[0.99940383,0.00011851992,0.0001755484,0.000037212376,0.000044316683,0.0002205731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000844226,0.00046781873,0.0013048863,0.00032452185,0.00022790897,0.00062323414,0.00031799165,0.00072265905,0.0021939573],"category_scores_gemma":[0.00073998893,0.00023812383,0.0008724449,0.00028434303,0.00034654932,0.00052631675,0.00024403473,0.0014916451,0.00067727844],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5746802,0.025976269,0.057156634,0.0010894967,0.002141635,0.00096540066,0.00041204374,0.00390631,0.088230416,0.0002700412,0.0035232394,0.24164827],"study_design_scores_gemma":[0.11491536,0.7481857,0.1060536,0.000121782316,0.0012538632,0.0022559175,0.0001353157,0.004148041,0.013683348,0.00023444647,0.008951591,0.000061009123],"about_ca_topic_score_codex":0.00024753643,"about_ca_topic_score_gemma":0.00060974096,"teacher_disagreement_score":0.0021939573,"about_ca_system_score_codex":0.000565578,"about_ca_system_score_gemma":0.0005819305,"threshold_uncertainty_score":0.007339537},"labels":[],"label_agreement":null},{"id":"W2950661198","doi":"10.1097/01.hs9.0000559348.09806.86","title":"PF284 OCCUPATIONAL PESTICIDES EXPOSURE IS ASSOCIATED WITH AN INCREASED RISK OF ACUTE MYELOID LEUKEMIA: A META-ANALYSIS OF CASE-CONTROL STUDIES INCLUDING 2981 PATIENTS AND 248705 CONTROLS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Human Health and Disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Odds ratio; Medicine; Confidence interval; Meta-analysis; Population; Internal medicine; Leukemia; Myeloid leukemia; Oncology; Environmental health","score_opus":0.05383176886792042,"score_gpt":0.3324609436776316,"score_spread":0.2786291748097112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950661198","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042546887,0.95173633,0.0023795369,0.00033566338,0.00027774746,0.00032328488,0.0017243826,0.00006496159,0.00061126275],"genre_scores_gemma":[0.70618576,0.283947,0.003794846,0.0008688966,0.00041349864,0.0011763768,0.0028298048,0.00008595749,0.00069788174],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98885965,0.004853445,0.0030125396,0.001785962,0.0010808953,0.00040756355],"domain_scores_gemma":[0.9839685,0.011402927,0.002346673,0.0008826592,0.0011788047,0.00022044584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012171042,0.0027316723,0.011306486,0.0056625092,0.0008212978,0.0032813046,0.0019038662,0.0024295568,0.0033876188],"category_scores_gemma":[0.024764353,0.0013990406,0.04031912,0.008191435,0.0005927783,0.0013305944,0.0013103941,0.0016830186,0.00033096576],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045638736,0.000040849554,0.024604432,0.06432977,0.898666,0.00032515364,0.00007322948,0.0006838176,0.00040918353,0.00010780371,0.00046888614,0.0057269027],"study_design_scores_gemma":[0.0004331877,0.000178443,0.00992988,0.0028903773,0.984899,0.0001480211,0.000032890646,0.00027234727,0.00014713444,0.0001638149,0.0008867882,0.000018139477],"about_ca_topic_score_codex":0.004398417,"about_ca_topic_score_gemma":0.0052217776,"teacher_disagreement_score":0.012171042,"about_ca_system_score_codex":0.0014981448,"about_ca_system_score_gemma":0.00162094,"threshold_uncertainty_score":0.06436741},"labels":[],"label_agreement":null},{"id":"W2950731790","doi":"10.1097/01.hs9.0000562564.17744.e5","title":"PS1067 AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA: PRELIMINARY RESULTS OF EARLIER STEROID USE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Refractory (planetary science); Cohort; Tocilizumab; Lymphoma; Gastroenterology; Clinical endpoint; Surgery; Oncology; Chimeric antigen receptor; Cancer; Disease; Randomized controlled trial; Immunotherapy","score_opus":0.012470315148255274,"score_gpt":0.23937852626221545,"score_spread":0.22690821111396017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950731790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971499,0.0016100156,0.000078846126,0.00009334038,0.000016987038,0.00007694236,0.00014396031,0.000015500575,0.00081466325],"genre_scores_gemma":[0.99790275,0.00093097147,0.00017884286,0.00014938206,0.0000466261,0.000061017083,0.00032789438,0.0000038632006,0.00039863714],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997328,0.00012057996,0.000019570778,0.000036426598,0.000045813278,0.00004493544],"domain_scores_gemma":[0.99961543,0.00010776696,0.000085877204,0.000033969838,0.00002713803,0.00012972625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067823834,0.0003297111,0.00060457626,0.00018720976,0.00014824573,0.0004611722,0.00022138897,0.00020658414,0.00178096],"category_scores_gemma":[0.0007524284,0.00009672511,0.0005429415,0.00027634966,0.00020495999,0.00031288268,0.00020338973,0.00079077086,0.00029532544],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31422105,0.023603097,0.11875269,0.0009709466,0.0017102216,0.0007555061,0.00050116744,0.0024151274,0.0332862,0.00013379761,0.0021496324,0.50150055],"study_design_scores_gemma":[0.07884208,0.509132,0.38872644,0.00013295331,0.0022219198,0.0011129774,0.00027496638,0.002348111,0.008233839,0.00021295967,0.008716748,0.00004496966],"about_ca_topic_score_codex":0.00073697895,"about_ca_topic_score_gemma":0.0019364782,"teacher_disagreement_score":0.00178096,"about_ca_system_score_codex":0.00042159337,"about_ca_system_score_gemma":0.00047412748,"threshold_uncertainty_score":0.0059579015},"labels":[],"label_agreement":null},{"id":"W2950773020","doi":"10.1097/01.hs9.0000562404.53930.45","title":"PS1027 ASSESSMENT OF MOLECULAR MRD KINETICS BY ERROR‐CORRECTED NEXT‐GENERATION SEQUENCING PROVIDES INDEPENDENT PROGNOSTIC INFORMATION IN ADULT AML PATIENTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research; University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Minimal residual disease; Induction chemotherapy; Chemotherapy; Proportional hazards model; Stage (stratigraphy); Point mutation; DNA sequencing; Gene; Mutation; Leukemia; Biology; Genetics","score_opus":0.01952076263891619,"score_gpt":0.26385232389323277,"score_spread":0.24433156125431657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950773020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987239,0.00014353095,0.0006696758,0.000024177505,0.0000018919794,0.0000066977154,0.00018171336,0.000018379616,0.00022996281],"genre_scores_gemma":[0.99821377,0.00006376344,0.0010392284,0.000016943906,0.0000048820657,0.000009557654,0.00045137867,0.0000046868454,0.00019587344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981195,0.000045724588,0.000022804903,0.000040103627,0.000054656888,0.0000247324],"domain_scores_gemma":[0.99931216,0.00027731515,0.0001985594,0.000054851072,0.00010088127,0.000056247925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050458574,0.00018837542,0.00022833506,0.0003176166,0.00007604234,0.00023494534,0.00013108816,0.00024069012,0.0008090849],"category_scores_gemma":[0.001583051,0.00009309035,0.00009132402,0.000217572,0.000113177695,0.00017375905,0.00016126124,0.00021578888,0.00025404012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026156565,0.0001013953,0.90229666,0.000045364995,0.00004281539,0.00034593145,0.00013341272,0.0021948211,0.048118018,0.000081054146,0.0004510315,0.04357388],"study_design_scores_gemma":[0.00008116771,0.00133452,0.93055356,0.000014072238,0.00009231594,0.0020892303,0.000088920286,0.01778387,0.0456676,0.00024061679,0.0020401224,0.000013995842],"about_ca_topic_score_codex":0.00042856127,"about_ca_topic_score_gemma":0.0005701991,"teacher_disagreement_score":0.0008090849,"about_ca_system_score_codex":0.00016736475,"about_ca_system_score_gemma":0.00012573638,"threshold_uncertainty_score":0.002706647},"labels":[],"label_agreement":null},{"id":"W2950780445","doi":"10.1097/01.hs9.0000562468.89369.69","title":"PS1043 OUTCOMES OF PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A POPULATION‐BASED REAL‐WORLD STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary; Western University","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Refractory (planetary science); Myeloid leukemia; Regimen; Population; Chemotherapy regimen; Intensive care; Chemotherapy; Pediatrics; Surgery; Intensive care medicine","score_opus":0.01713439800318669,"score_gpt":0.2992449930988417,"score_spread":0.28211059509565506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950780445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953236,0.0003890629,0.00004788091,0.00010106832,0.0000048893003,0.000025944415,0.0035290965,0.000003915549,0.0005745969],"genre_scores_gemma":[0.9969975,0.0002501505,0.000038398462,0.00005848002,0.000010829731,0.000021676831,0.0025514415,0.0000017497129,0.000069733775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943846,0.0001379684,0.00007968125,0.000141199,0.00012139586,0.00008121378],"domain_scores_gemma":[0.9981573,0.00021140095,0.0011030058,0.000099842175,0.00018705812,0.00024138881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067136704,0.00019249602,0.00035454144,0.0009161863,0.0004413903,0.000900255,0.0005714456,0.0004970881,0.00141268],"category_scores_gemma":[0.0027673643,0.0002380262,0.00046692154,0.0029469808,0.0003170218,0.00065635965,0.00053915835,0.0005637159,0.00029572527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010878829,0.000031647247,0.99853957,0.000021783984,0.00008621248,0.000054753025,0.000060207254,0.000057971527,0.000037810278,0.00001868201,0.0002966482,0.00068585883],"study_design_scores_gemma":[0.000027275815,0.00007584199,0.9989201,0.000010984279,0.000054744858,0.00018388302,0.00018574407,0.0001447527,0.000011821398,0.000020848533,0.0003595659,0.0000044250287],"about_ca_topic_score_codex":0.0319945,"about_ca_topic_score_gemma":0.035847366,"teacher_disagreement_score":0.0319945,"about_ca_system_score_codex":0.0011280365,"about_ca_system_score_gemma":0.00092938007,"threshold_uncertainty_score":0.063616514},"labels":[],"label_agreement":null},{"id":"W2950809516","doi":"10.1097/hs9.0000000000000205","title":"Screening for cancer in unprovoked venous thromboembolism","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Calgary; University of Ottawa","funders":"Servier; Sanofi; Bayer; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Cancer; Malignancy; Venous thromboembolism; Confidence interval; Incidence (geometry); Occult; Clinical trial; Internal medicine; Randomized controlled trial; Pathology; Thrombosis; Alternative medicine","score_opus":0.02311906044994245,"score_gpt":0.3087215694838521,"score_spread":0.28560250903390966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950809516","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.050341964,0.86480635,0.001791181,0.042447597,0.0063917013,0.0004977389,0.018186515,0.00017381056,0.01536315],"genre_scores_gemma":[0.6580951,0.28170115,0.003775642,0.029785298,0.01325496,0.0008433921,0.009647045,0.000057920424,0.0028395317],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99446326,0.0026388322,0.0010589503,0.000511263,0.0011428198,0.00018484816],"domain_scores_gemma":[0.97523785,0.016159687,0.005553108,0.00044834285,0.0019775317,0.00062346226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039502257,0.00046321805,0.0016522108,0.001990673,0.0002836891,0.0013160438,0.0010088556,0.0022967719,0.008999622],"category_scores_gemma":[0.051566,0.00037274233,0.0020976488,0.0020095846,0.0003407916,0.0009971396,0.0007645812,0.0019492797,0.00073209376],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00730669,0.00024117331,0.1991663,0.1080081,0.016635874,0.0006714392,0.000569098,0.0008183678,0.00037531444,0.0019979435,0.13828126,0.5259285],"study_design_scores_gemma":[0.0072136624,0.002270933,0.5376414,0.21799967,0.053376064,0.0049171117,0.0008422453,0.002676987,0.001320887,0.010697833,0.16072576,0.00031750998],"about_ca_topic_score_codex":0.007263087,"about_ca_topic_score_gemma":0.010187351,"teacher_disagreement_score":0.008999622,"about_ca_system_score_codex":0.00072219636,"about_ca_system_score_gemma":0.0011715407,"threshold_uncertainty_score":0.030106723},"labels":[],"label_agreement":null},{"id":"W2950880743","doi":"10.1097/01.hs9.0000560844.39623.aa","title":"PF640 MULTIPLE MYELOMA TREATMENT LANDSCAPE FROM 2011 TO 2017 IN ALBERTA, CANADA: RESULTS FROM THE POPULATION‐BASED “IDENTIFYING OUTCOMES IN REAL‐WORLD MULTIPLE MYELOMA” (INFORMM) STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Multiple myeloma; Lenalidomide; Medicine; Population; Bortezomib; Autologous stem-cell transplantation; Transplantation; Family medicine; Internal medicine; Environmental health","score_opus":0.045912224532869875,"score_gpt":0.3112283706097278,"score_spread":0.26531614607685794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950880743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8877749,0.003579336,0.00033935887,0.0017922752,0.00006409017,0.00021677747,0.100452036,0.0000921349,0.0056891944],"genre_scores_gemma":[0.9565346,0.0018992196,0.0005960806,0.0009664029,0.000044121494,0.00011314422,0.037771378,0.000035525245,0.0020394113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997843,0.00015934234,0.00015645541,0.00033054088,0.0008469943,0.0006636859],"domain_scores_gemma":[0.99507904,0.0001933593,0.0008441751,0.00016279335,0.0027069214,0.0010137247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015518012,0.0006373488,0.000798205,0.0021777393,0.0024742738,0.0017355153,0.002370209,0.0006374327,0.0019889295],"category_scores_gemma":[0.0034265514,0.00043790738,0.001128109,0.009865336,0.0008454379,0.0005433374,0.001725819,0.001197899,0.0004499219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032547352,0.000063600855,0.9804041,0.00014358599,0.00019781051,0.000113243106,0.00052112446,0.00037495192,0.00013949999,0.0001982241,0.0106358025,0.0068825055],"study_design_scores_gemma":[0.000043140553,0.000031792835,0.99497,0.000097921824,0.00012022407,0.0000972754,0.0010972411,0.00049233565,0.00005867529,0.00004187775,0.0029266903,0.00002285022],"about_ca_topic_score_codex":0.99656665,"about_ca_topic_score_gemma":0.9973693,"teacher_disagreement_score":0.051934637,"about_ca_system_score_codex":0.051934637,"about_ca_system_score_gemma":0.058390968,"threshold_uncertainty_score":0.37681395},"labels":[],"label_agreement":null},{"id":"W2950895705","doi":"10.1097/01.hs9.0000559856.05874.69","title":"PF411 ENESTOP 192‐WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) FOLLOWING SECOND‐LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nilotinib; Internal medicine; Gastroenterology; Imatinib mesylate; Surgery; Myeloid leukemia; Imatinib","score_opus":0.018766925244077012,"score_gpt":0.2870449102057383,"score_spread":0.2682779849616613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950895705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953738,0.002204045,0.00013640794,0.00017097611,0.000024275114,0.000057525398,0.0010417085,0.00002084193,0.00097042555],"genre_scores_gemma":[0.99763143,0.00031809596,0.000084836785,0.00010824115,0.000022790111,0.000049224855,0.0010942875,0.0000040106156,0.0006870859],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99971575,0.00011411145,0.000019394587,0.000055035427,0.000044224234,0.000051391104],"domain_scores_gemma":[0.999445,0.000103364975,0.00024357082,0.000037913596,0.000028992949,0.00014115078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009615513,0.0002891716,0.0005972266,0.0001344904,0.00014538171,0.00049539545,0.0002576765,0.00037358774,0.002679869],"category_scores_gemma":[0.0008198579,0.00009240818,0.0006884949,0.00015410307,0.00018190155,0.0005480577,0.00027157273,0.00083418435,0.0004242019],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54506123,0.006666206,0.13586423,0.00080358045,0.0021876083,0.000395717,0.00022267747,0.0047598197,0.022798661,0.00023815966,0.008280979,0.27272108],"study_design_scores_gemma":[0.050479334,0.25422305,0.6698395,0.00011712247,0.0026137992,0.0013261081,0.00013261972,0.0041991076,0.009233074,0.00030566848,0.0074461917,0.00008442871],"about_ca_topic_score_codex":0.00037396332,"about_ca_topic_score_gemma":0.00060427294,"teacher_disagreement_score":0.002679869,"about_ca_system_score_codex":0.0004089136,"about_ca_system_score_gemma":0.00028056302,"threshold_uncertainty_score":0.008965015},"labels":[],"label_agreement":null},{"id":"W2950944873","doi":"10.1097/01.hs9.0000563756.72895.a3","title":"PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW‐UP OF THE PHASE 2, RANDOMIZED ELOQUENT‐3 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Lenalidomide; Medicine; Internal medicine; Dexamethasone; Oncology; Multiple myeloma; Combination therapy; Ixazomib; Refractory (planetary science); Progression-free survival; Bortezomib; Overall survival; Carfilzomib","score_opus":0.025348177318384468,"score_gpt":0.31251581433105274,"score_spread":0.2871676370126683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950944873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782462,0.0106579065,0.0008577224,0.001385933,0.00031608052,0.0018186751,0.0032932535,0.00018241008,0.0032419132],"genre_scores_gemma":[0.98303264,0.0041266275,0.0014489985,0.0022646065,0.00032754845,0.001343903,0.0053078006,0.000057882822,0.0020900052],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991732,0.00040536924,0.0000419132,0.00012366589,0.00011290886,0.00014282725],"domain_scores_gemma":[0.99898916,0.00023346022,0.00025076978,0.000098728065,0.00008501992,0.00034283558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031609957,0.001303397,0.0018974049,0.00042568223,0.00032675028,0.0015405312,0.0008877787,0.0011625134,0.0039726906],"category_scores_gemma":[0.0017366366,0.00041222732,0.0026133,0.0005403882,0.00082907756,0.0012949113,0.00045221328,0.0034123622,0.0010847496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8318126,0.020892354,0.0037135663,0.0011747144,0.004105468,0.0001855282,0.00019334392,0.0018577732,0.010932483,0.00047964192,0.0067747976,0.11787773],"study_design_scores_gemma":[0.83523345,0.1393503,0.01514035,0.00012340322,0.0020103867,0.0002819848,0.000071076494,0.0011910466,0.0016852405,0.0006097163,0.004254795,0.00004820112],"about_ca_topic_score_codex":0.00090823835,"about_ca_topic_score_gemma":0.0025607843,"teacher_disagreement_score":0.0039726906,"about_ca_system_score_codex":0.0014296126,"about_ca_system_score_gemma":0.0012244221,"threshold_uncertainty_score":0.016717136},"labels":[],"label_agreement":null},{"id":"W2950949385","doi":"10.1097/01.hs9.0000560700.97828.31","title":"PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTH‐RELATED QUALITY OF LIFE IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D‐RD) VS RD: MAIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Quality of life (healthcare); Lenalidomide; Health related quality of life; Visual analogue scale; Internal medicine; Multiple myeloma; Daratumumab; Physical therapy; Disease","score_opus":0.1367159433928387,"score_gpt":0.3582859021089189,"score_spread":0.2215699587160802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950949385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961052,0.0020126426,0.00014016232,0.00020229933,0.00005246292,0.00014726925,0.0004164962,0.00004011278,0.00088329037],"genre_scores_gemma":[0.9982969,0.00037634547,0.00028015685,0.000111422014,0.00003564462,0.00011807429,0.00029478612,0.0000024193262,0.0004842687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99981195,0.000072070965,0.000016438747,0.00003548112,0.000027622791,0.00003645645],"domain_scores_gemma":[0.99968576,0.000063486696,0.000109558954,0.000017345195,0.000012455741,0.000111395435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006791212,0.00030993903,0.0009585872,0.0002107928,0.00020021018,0.00045032887,0.00023042166,0.00033979202,0.0029610519],"category_scores_gemma":[0.00068155455,0.00011806727,0.0005958575,0.00025642416,0.00026005102,0.00031028403,0.00022803046,0.0010562163,0.0004234851],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.631916,0.014224825,0.026180461,0.0008091763,0.0009358226,0.00023698516,0.00017564656,0.0017069419,0.028153941,0.00017450185,0.0026334624,0.29285228],"study_design_scores_gemma":[0.24865744,0.52474666,0.20685223,0.00014661589,0.0010142782,0.0011414743,0.00012092172,0.0033580672,0.008180893,0.00035286677,0.00538383,0.000044762553],"about_ca_topic_score_codex":0.0004266038,"about_ca_topic_score_gemma":0.0009167464,"teacher_disagreement_score":0.0029610519,"about_ca_system_score_codex":0.0003839764,"about_ca_system_score_gemma":0.00040348098,"threshold_uncertainty_score":0.009905636},"labels":[],"label_agreement":null},{"id":"W2950984087","doi":"10.1097/01.hs9.0000563784.11014.52","title":"PS1377 IMPROVEMENT IN HEALTH‐RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT‐ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University; Hotel Dieu Hospital","funders":"","keywords":"Medicine; Daratumumab; Bortezomib; Multiple myeloma; Internal medicine; Autologous stem-cell transplantation; Oncology","score_opus":0.03098393264413396,"score_gpt":0.3156171613640681,"score_spread":0.28463322871993413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950984087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980567,0.0005584624,0.00006841353,0.0001677831,0.000034477078,0.00022096274,0.00048887474,0.000008593267,0.00039576978],"genre_scores_gemma":[0.99687153,0.00047244143,0.00019696908,0.00033345868,0.000079312296,0.0003363565,0.001072879,0.0000036098313,0.0006335071],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99965227,0.00014840001,0.000023609828,0.00006784644,0.000058706577,0.000049129172],"domain_scores_gemma":[0.9991146,0.00011301319,0.00025246502,0.00006248709,0.000060378065,0.00039708024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012554786,0.0006357078,0.0014306252,0.00017970557,0.0003052014,0.000823321,0.0004651734,0.0006845985,0.0024778554],"category_scores_gemma":[0.0008104904,0.00026970432,0.0018781296,0.0003921225,0.0004541821,0.00037747523,0.0004500853,0.0015203166,0.00043094924],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81643057,0.017591603,0.089427285,0.0006516154,0.0056373873,0.00020611365,0.00019584512,0.0013724697,0.012125796,0.00020379669,0.0025822124,0.053575225],"study_design_scores_gemma":[0.42972988,0.23526853,0.32248423,0.00007716068,0.004544662,0.0003291949,0.00014155282,0.0015876321,0.0024846555,0.00020783338,0.0030860098,0.00005863311],"about_ca_topic_score_codex":0.0016806633,"about_ca_topic_score_gemma":0.0033127156,"teacher_disagreement_score":0.0024778554,"about_ca_system_score_codex":0.0008127816,"about_ca_system_score_gemma":0.0016390871,"threshold_uncertainty_score":0.008289278},"labels":[],"label_agreement":null},{"id":"W2951024782","doi":"10.1097/01.hs9.0000565672.55016.07","title":"PB1792 AGE AS AN INDEPENDENT PREDICTIVE FACTOR IN SURVIVAL OUTCOMES OF MULTIMODALITY TREATMENTS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A REVIEW FROM TERTIARY INSTITUTION","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Primary central nervous system lymphoma; Radiation therapy; Proportional hazards model; Hazard ratio; Internal medicine; Salvage therapy; Survival analysis; Retrospective cohort study; Multivariate analysis; Lymphoma; Log-rank test; Surgery; Chemotherapy; Confidence interval","score_opus":0.05474239867495916,"score_gpt":0.3460365340602778,"score_spread":0.2912941353853186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951024782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026907215,0.97115964,0.00012972481,0.00033205922,0.0001154732,0.00003020667,0.00047053007,0.0000069745056,0.0008481961],"genre_scores_gemma":[0.13530926,0.8621598,0.00045049106,0.00049242197,0.0004689942,0.000087639666,0.00080304,0.000010304003,0.00021798404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991873,0.00015263329,0.00032093283,0.00013475466,0.00016257788,0.00004183281],"domain_scores_gemma":[0.995083,0.0028089904,0.0013511003,0.00008604942,0.0005522436,0.00011866318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015551146,0.00029634053,0.001160544,0.0039742305,0.00023695947,0.00096266647,0.00074600906,0.00050066673,0.0023064525],"category_scores_gemma":[0.0049976325,0.00022701416,0.0010732189,0.0054778093,0.0003692908,0.0008007613,0.00036345545,0.0004449079,0.00029930056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012126749,0.000169937,0.3525004,0.08466524,0.004006849,0.0017783229,0.00061090157,0.00036413345,0.0008855175,0.000489641,0.014112155,0.53920424],"study_design_scores_gemma":[0.00021398945,0.000778231,0.7610366,0.06444524,0.02123462,0.021381,0.0015743098,0.00060358725,0.0011707017,0.0005278772,0.12690727,0.00012655937],"about_ca_topic_score_codex":0.0021299021,"about_ca_topic_score_gemma":0.002735408,"teacher_disagreement_score":0.0039742305,"about_ca_system_score_codex":0.0004737563,"about_ca_system_score_gemma":0.001330182,"threshold_uncertainty_score":0.0082243085},"labels":[],"label_agreement":null},{"id":"W2951051106","doi":"10.1097/01.hs9.0000559844.15284.b3","title":"PF408 DASFREE 2‐YEAR UPDATE: DASATINIB DISCONTINUATION IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP) AND DEEP MOLECULAR RESPONSE (DMR)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Discontinuation; Medicine; Internal medicine; Clinical endpoint; Oncology; Myeloid leukemia; Imatinib; Gastroenterology; Clinical trial","score_opus":0.005851570532110407,"score_gpt":0.24902571653131772,"score_spread":0.2431741459992073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951051106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5649923,0.27794445,0.0064194356,0.04115831,0.0036698992,0.0027281858,0.051050853,0.0019170076,0.05011963],"genre_scores_gemma":[0.8271606,0.088724025,0.006005443,0.019734584,0.003092698,0.002810462,0.04093291,0.00025445578,0.01128483],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99927276,0.0002785343,0.00009413815,0.00007904384,0.0001918167,0.00008376718],"domain_scores_gemma":[0.99843353,0.00038864225,0.00064543955,0.000047800528,0.00026020303,0.00022433235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026578596,0.00052947446,0.0015109702,0.00039099876,0.00025378953,0.0012684574,0.0005663653,0.0011855412,0.003988742],"category_scores_gemma":[0.002492671,0.00028355687,0.0009855265,0.00066310837,0.00019258578,0.000932548,0.0003826408,0.0018493833,0.0013812055],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05876002,0.0014451152,0.02002904,0.004277121,0.0015538711,0.0004506542,0.00023426366,0.0018569065,0.00927245,0.00086107,0.15049915,0.75076026],"study_design_scores_gemma":[0.10257662,0.062912636,0.16158077,0.0019641805,0.0051238323,0.0037076725,0.00020652892,0.0042346176,0.0063476944,0.0021301925,0.64904225,0.00017307755],"about_ca_topic_score_codex":0.0009864245,"about_ca_topic_score_gemma":0.00325015,"teacher_disagreement_score":0.003988742,"about_ca_system_score_codex":0.00092023425,"about_ca_system_score_gemma":0.0010315749,"threshold_uncertainty_score":0.014056265},"labels":[],"label_agreement":null},{"id":"W2951075811","doi":"10.1097/01.hs9.0000562932.11356.53","title":"PS1162 COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Ibrutinib; Venetoclax; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Neutropenia; Discontinuation; Leukemia; Chemotherapy","score_opus":0.0057942809302078385,"score_gpt":0.2487847723173081,"score_spread":0.24299049138710027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951075811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99225473,0.0037499561,0.00043616627,0.00014382099,0.00002049667,0.00010120451,0.00030513207,0.00005299883,0.0029355432],"genre_scores_gemma":[0.9973009,0.0008232802,0.0007171518,0.00011826387,0.00003471167,0.000049904305,0.0005091686,0.000006988234,0.00043969182],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997547,0.000060052207,0.00003048134,0.00005561066,0.00006022151,0.000038857168],"domain_scores_gemma":[0.9996207,0.000068354246,0.0001593202,0.000021584894,0.000033843487,0.00009618199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004606151,0.00026281978,0.00054223253,0.00045587943,0.0003652037,0.0004863998,0.00024248935,0.00022635644,0.0017878975],"category_scores_gemma":[0.0006981476,0.00012763194,0.00030345615,0.00059955014,0.00020604237,0.00028333688,0.00023647737,0.00047863496,0.0003332251],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017976323,0.00092598354,0.67768645,0.0005358571,0.000251166,0.0028647534,0.0003777755,0.0011582,0.03416515,0.00017852664,0.0044347052,0.25944513],"study_design_scores_gemma":[0.0024024257,0.021717671,0.93716574,0.00017877702,0.0005259833,0.011009465,0.00018769113,0.0021539335,0.009442781,0.00021044239,0.0149765,0.000028679191],"about_ca_topic_score_codex":0.0009702825,"about_ca_topic_score_gemma":0.002665987,"teacher_disagreement_score":0.0017878975,"about_ca_system_score_codex":0.00057381624,"about_ca_system_score_gemma":0.00074123393,"threshold_uncertainty_score":0.0059811473},"labels":[],"label_agreement":null},{"id":"W2951076122","doi":"10.1097/01.hs9.0000562392.68284.f5","title":"PS1024 IMPACT OF MINIMAL RESIDUAL DISEASE AND COMPLETE REMISSION (CR)/CR WITH PARTIAL HEMATOLOGIC RECOVERY ON SURVIVAL AFTER GILTERITINIB THERAPY IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Adverse effect; Nausea; Refractory (planetary science); Myeloid leukemia; Neutropenia; Chemotherapy","score_opus":0.01674566369118301,"score_gpt":0.27405793809520557,"score_spread":0.25731227440402255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951076122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729365,0.0011472168,0.00006138466,0.00015833387,0.000019924459,0.000034341454,0.00019822732,0.000019717363,0.0010670702],"genre_scores_gemma":[0.99928206,0.00012107223,0.000039948885,0.00006486769,0.000017169827,0.000013668954,0.00028647805,0.000002228108,0.00017266338],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998435,0.000043517426,0.000013854752,0.000032238157,0.000027657958,0.000039245904],"domain_scores_gemma":[0.99955827,0.00009905997,0.000096485484,0.000019648913,0.00002373398,0.00020282819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055043586,0.00023285727,0.00060083356,0.00017517942,0.00019432114,0.00044062792,0.00022038771,0.00032687176,0.0017143552],"category_scores_gemma":[0.00083175965,0.000068170106,0.0004685297,0.00017062775,0.00019203349,0.0003525485,0.00018853715,0.00062493165,0.00024813236],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30790967,0.0039190305,0.3149543,0.00053621974,0.0012308971,0.0010365386,0.0003352636,0.0050544133,0.035911635,0.00036983815,0.0057828645,0.32295924],"study_design_scores_gemma":[0.01277371,0.14505178,0.82118344,0.000076105825,0.0012304313,0.0024440251,0.00020467113,0.0046716826,0.0050789258,0.000459647,0.0067691864,0.000056345474],"about_ca_topic_score_codex":0.0008389369,"about_ca_topic_score_gemma":0.0016152645,"teacher_disagreement_score":0.0017143552,"about_ca_system_score_codex":0.0005321466,"about_ca_system_score_gemma":0.00055151636,"threshold_uncertainty_score":0.0057350397},"labels":[],"label_agreement":null},{"id":"W2951090524","doi":"10.1097/01.hs9.0000564792.15111.43","title":"S1636 FRACTIONATED DOSING OF ARI‐0001 CELLS (A3B1:CD8:4–1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Apheresis Group","funders":"","keywords":"Medicine; Cytokine release syndrome; Cyclophosphamide; Fludarabine; Internal medicine; Cohort; Cytokine; CD8; Toxicity; Immunology; Dosing; Gastroenterology; Immune system; Cancer; Chemotherapy; Immunotherapy","score_opus":0.012196298858509851,"score_gpt":0.25969541848738176,"score_spread":0.24749911962887192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951090524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898595,0.00030769283,0.00022685337,0.000027736733,0.000010681701,0.000019574167,0.000045968092,0.000033179396,0.00034228433],"genre_scores_gemma":[0.99889225,0.000101606405,0.00051245675,0.000031821273,0.000012747441,0.000016036029,0.00011714562,0.000004235474,0.00031174545],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999659,0.000006462285,0.000002269813,0.000007778177,0.000005346041,0.0000122331485],"domain_scores_gemma":[0.9998977,0.000014694352,0.000023516648,0.000009983419,0.0000038476373,0.000050347287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117125106,0.00018745643,0.0003599713,0.00009029985,0.00006663031,0.00019095768,0.00018519485,0.0001517616,0.0025323746],"category_scores_gemma":[0.00019230395,0.000057946476,0.00021032161,0.000072464936,0.00013304244,0.00015510936,0.000102274396,0.00046048342,0.00029097366],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05273275,0.013525266,0.035455998,0.0002625931,0.00035864595,0.00036727372,0.00026603887,0.0041608224,0.53439933,0.00046838497,0.003102622,0.35490033],"study_design_scores_gemma":[0.017157096,0.317003,0.41069284,0.00008710782,0.0006902223,0.0032594302,0.00022229383,0.010869404,0.22562788,0.00057894347,0.013755971,0.000055889483],"about_ca_topic_score_codex":0.00035217043,"about_ca_topic_score_gemma":0.00079424813,"teacher_disagreement_score":0.0025323746,"about_ca_system_score_codex":0.00016137322,"about_ca_system_score_gemma":0.0002062653,"threshold_uncertainty_score":0.008471608},"labels":[],"label_agreement":null},{"id":"W2951135883","doi":"10.1097/01.hs9.0000559340.02182.80","title":"PF282 THE EFFECT OF MODERN THERAPEUTICS IN ADULT ACUTE MYELOID LEUKEMIA (AML): POPULATION‐BASED ANALYSIS OF LONG‐TERM OUTCOMES FROM THE MANITOBA CANCER REGISTRY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Cancer registry; Relative survival; Population; Cancer; Cohort; Myeloid leukemia; Demography; Internal medicine; Pediatrics; Environmental health","score_opus":0.022140299836415783,"score_gpt":0.31686439306914493,"score_spread":0.29472409323272913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951135883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98158616,0.001085603,0.00016284092,0.00032329178,0.000013342472,0.00004700923,0.015629794,0.000020740528,0.0011313128],"genre_scores_gemma":[0.99068296,0.0006462349,0.00017099973,0.00011114713,0.000013181443,0.000050483584,0.007896406,0.000006880079,0.00042164992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990133,0.0001625708,0.00010032273,0.0001950684,0.00030628833,0.00022243524],"domain_scores_gemma":[0.9965403,0.00022687497,0.0014048342,0.00030496658,0.0009691059,0.00055379636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013360209,0.00032015753,0.00038312154,0.0018244201,0.0007940835,0.0008897621,0.0011150643,0.00029708425,0.0013057496],"category_scores_gemma":[0.0034081454,0.0003255935,0.00055383024,0.0056762206,0.00046909542,0.00029463053,0.0009403501,0.00051562116,0.0002937885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006331053,0.000011127265,0.99807227,0.000017556942,0.000081471844,0.000030507537,0.000087421446,0.00009244611,0.000084989944,0.00002315678,0.00057399273,0.0008617181],"study_design_scores_gemma":[0.000012515816,0.000026318132,0.998572,0.00001393832,0.000048010337,0.00006261233,0.00024331975,0.00016069988,0.000039466886,0.00001045557,0.0008061163,0.0000044801905],"about_ca_topic_score_codex":0.84598875,"about_ca_topic_score_gemma":0.8834039,"teacher_disagreement_score":0.15401125,"about_ca_system_score_codex":0.007063498,"about_ca_system_score_gemma":0.008749089,"threshold_uncertainty_score":0.30983645},"labels":[],"label_agreement":null},{"id":"W2951153020","doi":"10.1097/01.hs9.0000561560.35825.0d","title":"S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3‐YEAR UPDATE OF THE ECHELON‐1 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"ABVD; Dacarbazine; Procarbazine; Medicine; Brentuximab vedotin; Vinblastine; Bleomycin; Vincristine; Internal medicine; Oncology; Population; Chemotherapy; Lymphoma; Cyclophosphamide; Hodgkin lymphoma","score_opus":0.00953334348027245,"score_gpt":0.25238860756793524,"score_spread":0.24285526408766278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951153020","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2309892,0.7211917,0.0015124603,0.011694524,0.002075224,0.0008430293,0.009787289,0.00018993363,0.02171655],"genre_scores_gemma":[0.54216516,0.3907399,0.0043684714,0.030411422,0.0028391967,0.0015276114,0.023128947,0.00019046864,0.0046287766],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987759,0.0004564622,0.00017782346,0.00010447492,0.00036351688,0.0001218154],"domain_scores_gemma":[0.9960693,0.0010885022,0.001247313,0.00015400579,0.0009785456,0.00046223792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062582074,0.00044669522,0.0015945741,0.0006935608,0.00021094098,0.0018133594,0.0008514917,0.0008749828,0.0026714734],"category_scores_gemma":[0.003724935,0.0002717193,0.0020914318,0.0013432698,0.0002671385,0.0012933938,0.00059885567,0.0020444558,0.0006444421],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024785357,0.0012532654,0.03949864,0.008931828,0.0048422213,0.00020745465,0.00035005755,0.0018138548,0.0037966818,0.0013844998,0.067150295,0.8459858],"study_design_scores_gemma":[0.03536105,0.03552003,0.2373811,0.01516841,0.019980043,0.0024270138,0.00060703943,0.0033916596,0.0041677305,0.0028978116,0.64288783,0.00021034153],"about_ca_topic_score_codex":0.0019010277,"about_ca_topic_score_gemma":0.007098317,"teacher_disagreement_score":0.0062582074,"about_ca_system_score_codex":0.0015681059,"about_ca_system_score_gemma":0.0013814371,"threshold_uncertainty_score":0.03309697},"labels":[],"label_agreement":null},{"id":"W2951165653","doi":"10.1097/01.hs9.0000559032.62059.eb","title":"PF204 TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"CD34; CD38; Haematopoiesis; Stem cell; Biology; Cancer research; Myeloid leukemia; Leukemia; Cytotoxic T cell; Cord blood; T-cell receptor; Hematopoietic stem cell; Immunology; T cell; Immune system; Cell biology; In vitro","score_opus":0.02690869596386572,"score_gpt":0.3173762327065463,"score_spread":0.29046753674268055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951165653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920636,0.0020838573,0.0028864443,0.00012152858,0.000028463237,0.000041296786,0.0010963086,0.00015989157,0.0015186373],"genre_scores_gemma":[0.99164647,0.0009859079,0.0034686634,0.0000806525,0.000012853402,0.00007475444,0.0021620314,0.000028106719,0.0015406118],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999012,0.000010281049,0.0000043007644,0.000022391421,0.000033865897,0.00002800765],"domain_scores_gemma":[0.9999683,0.0000074777495,0.000007961206,0.000003098467,0.000006400909,0.0000067397405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000989056,0.00026334325,0.00022589075,0.00026697657,0.00013727516,0.00022583627,0.00014166374,0.00021347478,0.001769394],"category_scores_gemma":[0.00009132742,0.00007629758,0.0001824221,0.0002053336,0.0001247404,0.0001245968,0.00015783038,0.0003810697,0.00046779067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029008457,0.000032234657,0.0004654147,0.000059724163,0.0000058402084,0.00005277837,0.000009391026,0.00035092267,0.994118,0.00006364356,0.00016535204,0.0043865945],"study_design_scores_gemma":[0.000029988953,0.00065741985,0.0043062014,0.000008206001,0.00003293039,0.00036924754,0.000026827012,0.0025820816,0.98710155,0.00009523746,0.00478572,0.000004589802],"about_ca_topic_score_codex":0.00029681018,"about_ca_topic_score_gemma":0.00038006002,"teacher_disagreement_score":0.001769394,"about_ca_system_score_codex":0.00030640632,"about_ca_system_score_gemma":0.00018542279,"threshold_uncertainty_score":0.005919218},"labels":[],"label_agreement":null},{"id":"W2951223200","doi":"10.1097/01.hs9.0000559496.29967.d6","title":"PF321 REAL‐WORLD TREATMENT PATTERNS OF PATIENTS DIAGNOSED WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE UNITED STATES (US)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Lymphoma; Internal medicine; International Prognostic Index; Diagnosis code; Medical diagnosis; Oncology; Retrospective cohort study; Population; Radiology","score_opus":0.00875889552529891,"score_gpt":0.23278754855979186,"score_spread":0.22402865303449296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951223200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854704,0.00041332646,0.00013931446,0.0002425393,0.000008111349,0.000022987382,0.01234006,0.00001656583,0.00134665],"genre_scores_gemma":[0.99287206,0.00018240177,0.00014921126,0.00011544545,0.000011344462,0.000030874347,0.0064572915,0.0000044867597,0.00017688969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993175,0.00013559837,0.0001281295,0.00019047504,0.00012772386,0.00010053922],"domain_scores_gemma":[0.99762934,0.00032738212,0.0015501255,0.00009101761,0.00020554745,0.00019668562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044632307,0.0001399432,0.00016163595,0.0010783123,0.00026152347,0.0005590306,0.00032012368,0.0002914398,0.0021254728],"category_scores_gemma":[0.0024461206,0.00014850561,0.0002562079,0.0022565653,0.00020037805,0.00047988992,0.00039189996,0.00040375802,0.00034336155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008134654,0.000021724072,0.9970619,0.000012346019,0.000023600403,0.000038438615,0.000037310132,0.00010061945,0.00006012498,0.000027934619,0.00086107774,0.0016734778],"study_design_scores_gemma":[0.000011454979,0.000056942135,0.9978021,0.000017830633,0.000016085993,0.00035849615,0.00022773442,0.00037597673,0.00007031764,0.000037355778,0.0010213827,0.000004283374],"about_ca_topic_score_codex":0.016770346,"about_ca_topic_score_gemma":0.01770655,"teacher_disagreement_score":0.016770346,"about_ca_system_score_codex":0.0008492238,"about_ca_system_score_gemma":0.00058594835,"threshold_uncertainty_score":0.03334546},"labels":[],"label_agreement":null},{"id":"W2951229452","doi":"10.1097/01.hs9.0000562388.60660.bc","title":"PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG‐120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Gastroenterology; Isocitrate dehydrogenase; IDH1; Adverse effect; Azacitidine; Bone marrow; Nausea; Leukemia; Cytarabine; Chemistry; Mutant","score_opus":0.013060103779296627,"score_gpt":0.2728298898142398,"score_spread":0.25976978603494316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951229452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226624,0.0039056188,0.00041978882,0.00025907392,0.000055443124,0.00046362408,0.0004217792,0.00006741874,0.002140831],"genre_scores_gemma":[0.99567586,0.0015858868,0.0007678625,0.00015406538,0.00003563838,0.00016528204,0.00062256143,0.000009435137,0.0009835293],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998604,0.000047766553,0.000012998884,0.000025406249,0.00002780563,0.000025650263],"domain_scores_gemma":[0.99982953,0.0000327205,0.000031645246,0.000013194531,0.0000103711445,0.00008241276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003623618,0.0004068348,0.00096348906,0.0002930036,0.00017842537,0.00037571214,0.0004334387,0.0002647331,0.0014001082],"category_scores_gemma":[0.00034928604,0.00018692508,0.0003688206,0.0002823058,0.0002368838,0.00023031385,0.00021500312,0.0009461625,0.00030361852],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18575664,0.016210116,0.048654463,0.0013253905,0.0013303128,0.0029935692,0.0005226576,0.0041580442,0.29766318,0.0005436635,0.0076575424,0.43318444],"study_design_scores_gemma":[0.11509199,0.43015733,0.27475768,0.0002469468,0.0023006245,0.010572151,0.00036084768,0.008722832,0.11044061,0.0007458037,0.04649678,0.000106507694],"about_ca_topic_score_codex":0.0007237676,"about_ca_topic_score_gemma":0.0035165525,"teacher_disagreement_score":0.0014001082,"about_ca_system_score_codex":0.00064311834,"about_ca_system_score_gemma":0.0005984614,"threshold_uncertainty_score":0.004683852},"labels":[],"label_agreement":null},{"id":"W2951250026","doi":"10.1097/01.hs9.0000567584.58810.12","title":"PB2279 EFFECT OF EDUCATIONAL TRAINING PROGRAM ON IMPROVING PEDIATRIC ONCOLOGY NURSES, PRACTICE REGARDING NON PHARMACOLOGICAL PAIN MANAGEMENT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Innovations in Medical Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Checklist; Massage; Observational study; Psychological intervention; Reflexology; Physical therapy; Pediatric oncology; Family medicine; Nursing; Alternative medicine; Internal medicine; Psychology; Cancer","score_opus":0.013517080295208006,"score_gpt":0.38406880210148703,"score_spread":0.37055172180627904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951250026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961559,0.00047355224,0.00012367564,0.00025761424,0.00010054586,0.00071949256,0.00015797626,0.000032357962,0.0019788549],"genre_scores_gemma":[0.99212646,0.00072182063,0.0018535668,0.00017138285,0.000106317966,0.0015507445,0.00022068666,0.000007864424,0.0032411253],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995147,0.00018971559,0.00003207746,0.000054701115,0.00007907142,0.00012975944],"domain_scores_gemma":[0.99790347,0.0007731511,0.00034204422,0.00006803648,0.00018150921,0.0007318331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008068114,0.00031378452,0.00052400713,0.00027039228,0.0002786809,0.00029617982,0.0003601369,0.0005032825,0.012872664],"category_scores_gemma":[0.0027269723,0.0001464063,0.00043331704,0.00023861245,0.00014556093,0.00020592904,0.00036424265,0.0007219672,0.0007364468],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09032478,0.26460645,0.069929875,0.0038052022,0.0003783298,0.00042545077,0.0013668427,0.001129706,0.010019786,0.00027746102,0.0051974333,0.5525387],"study_design_scores_gemma":[0.013121612,0.27016243,0.70117897,0.00079094066,0.00056055456,0.00014276436,0.0007583521,0.0012183116,0.0049506193,0.00010431485,0.0069844923,0.000026491238],"about_ca_topic_score_codex":0.0026153615,"about_ca_topic_score_gemma":0.002117612,"teacher_disagreement_score":0.012872664,"about_ca_system_score_codex":0.00034971203,"about_ca_system_score_gemma":0.001462156,"threshold_uncertainty_score":0.043063343},"labels":[],"label_agreement":null},{"id":"W2951328102","doi":"10.1097/01.hs9.0000561272.36751.47","title":"PF747 DEFIBROTIDE TREATMENT IN ADULTS WITH SEVERE OR VERY SEVERE VENO‐OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE STUDY INTERIM RESULTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Defibrotide; Medicine; Hepatic veno-occlusive disease; Transplantation; Interim analysis; Surgery; Population; Hematopoietic stem cell transplantation; Internal medicine; Hematopoietic cell; Clinical trial; Haematopoiesis; Stem cell","score_opus":0.00913459838911086,"score_gpt":0.23552118520770793,"score_spread":0.22638658681859708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951328102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691927,0.0075932723,0.0012326731,0.00091986044,0.00021915325,0.002270668,0.011502385,0.00011523196,0.006954041],"genre_scores_gemma":[0.96506196,0.0019069585,0.0029309297,0.0018950114,0.00041878835,0.002352114,0.023082003,0.000030775882,0.0023215099],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99855965,0.0006786601,0.00012416078,0.0001896323,0.00021195662,0.0002358705],"domain_scores_gemma":[0.99786097,0.0004136586,0.00072460104,0.00021838144,0.0002200388,0.00056240044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042807525,0.000818015,0.001563528,0.00028191844,0.0003507553,0.0012811164,0.0005620661,0.0009372574,0.0023677545],"category_scores_gemma":[0.0020758712,0.00027866045,0.0024910825,0.00033458468,0.00037729339,0.00084659917,0.00041299136,0.0017412223,0.0006131735],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72272587,0.013550085,0.11150475,0.0010660582,0.009431202,0.00039507292,0.00020328871,0.0025937473,0.011098055,0.0006946347,0.013754757,0.11298258],"study_design_scores_gemma":[0.327664,0.3490555,0.28269276,0.00035719184,0.006964943,0.0011047482,0.00013333683,0.0021219754,0.0062874816,0.00066543533,0.022841632,0.00011092335],"about_ca_topic_score_codex":0.0006161348,"about_ca_topic_score_gemma":0.0014576529,"teacher_disagreement_score":0.0042807525,"about_ca_system_score_codex":0.0007218358,"about_ca_system_score_gemma":0.0013103836,"threshold_uncertainty_score":0.022639036},"labels":[],"label_agreement":null},{"id":"W2951331135","doi":"10.1097/01.hs9.0000562572.63485.4f","title":"PS1070 THE ECHELON‐2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE‐BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T‐CELL LYMPHOMAS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; CHOP; Internal medicine; Prednisone; Vincristine; Anaplastic large-cell lymphoma; Cyclophosphamide; Oncology; CD30; Lymphoma; Gastroenterology; Surgery; Chemotherapy","score_opus":0.025085509203232586,"score_gpt":0.2964247673137847,"score_spread":0.2713392581105521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951331135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98637694,0.004178345,0.00064034143,0.00093045307,0.00063672545,0.002522211,0.0016316463,0.00014540949,0.0029379984],"genre_scores_gemma":[0.98515296,0.0022127423,0.0012740978,0.00163073,0.00058265787,0.0029352554,0.0024283421,0.000050704548,0.0037325558],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99918956,0.00049313164,0.0000368316,0.00012549722,0.000057282497,0.00009769726],"domain_scores_gemma":[0.9988469,0.00036048287,0.00024656754,0.00011635768,0.000070353075,0.00035933423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025497663,0.0017576329,0.0022519415,0.0003646151,0.00035136388,0.0013128576,0.00094771606,0.001578184,0.005603725],"category_scores_gemma":[0.0018977923,0.00058404147,0.001890655,0.0003147613,0.0011927964,0.001550511,0.00043124944,0.0039027208,0.0012043696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98234206,0.004004432,0.00038834612,0.00034134754,0.000674259,0.000033690285,0.000038064056,0.00030307038,0.0016164863,0.000077323006,0.00071469485,0.009466218],"study_design_scores_gemma":[0.95684224,0.040519804,0.0012367308,0.00002075411,0.00030670996,0.000033019613,0.0000137216075,0.0003274733,0.00020516125,0.00013875935,0.00034424997,0.000011276414],"about_ca_topic_score_codex":0.0005777896,"about_ca_topic_score_gemma":0.0012609144,"teacher_disagreement_score":0.005603725,"about_ca_system_score_codex":0.0008673791,"about_ca_system_score_gemma":0.00082834275,"threshold_uncertainty_score":0.018746376},"labels":[],"label_agreement":null},{"id":"W2951347740","doi":"10.1097/01.hs9.0000563296.27415.ad","title":"PS1254 CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA AFTER RETREATMENT WITH SECOND‐LINE RITUXIMAB‐CONTAINING CHEMOTHERAPY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont; University of Toronto","funders":"","keywords":"Medicine; Rituximab; Follicular lymphoma; Chemotherapy; Radiation therapy; Surgery; Internal medicine; CHOP; Lymphoma","score_opus":0.005708754038137033,"score_gpt":0.2138741022099388,"score_spread":0.20816534817180177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951347740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99930644,0.00013507158,0.00001286982,0.000025995943,0.0000032250155,0.0000047540793,0.00012993957,0.0000017141818,0.00037995857],"genre_scores_gemma":[0.99952126,0.000036929097,0.000007781053,0.000020610336,0.000006862028,0.0000035512248,0.00030309727,9.894271e-7,0.00009894687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999843,0.000017275612,0.000011751039,0.000031881707,0.000037011723,0.0000590031],"domain_scores_gemma":[0.99928194,0.00009152293,0.00026404663,0.000024623529,0.00009335157,0.00024447186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002120262,0.00016795531,0.00028128378,0.0005049745,0.00037243278,0.0004383524,0.00032069426,0.00038936065,0.0010903234],"category_scores_gemma":[0.0013227277,0.000115788534,0.00031326117,0.0006467698,0.00028130898,0.00025486108,0.0001671297,0.00038544726,0.00024631692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004798473,0.000042013966,0.9966074,0.00000550114,0.000031625314,0.0003682448,0.000076986726,0.00010771393,0.00040807427,0.000011475075,0.00018829838,0.0016727453],"study_design_scores_gemma":[0.000020999243,0.00031308856,0.9985464,0.0000037767236,0.000020331843,0.0006177259,0.000079612946,0.00012864356,0.00004870718,0.000012389531,0.00020441528,0.000003963385],"about_ca_topic_score_codex":0.02347863,"about_ca_topic_score_gemma":0.019725014,"teacher_disagreement_score":0.02347863,"about_ca_system_score_codex":0.0011713967,"about_ca_system_score_gemma":0.00059323356,"threshold_uncertainty_score":0.046683908},"labels":[],"label_agreement":null},{"id":"W2951365685","doi":"10.1097/01.hs9.0000566860.46379.37","title":"PB2094 A SINGLE CENTRE EXPERIENCE WITH AZACITIDINE FOR MDS, AML AND CMML IN RELATION TO CYTOGENETIC RISK AND PERFORMANCE STATUS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Azacitidine; Medicine; Myelodysplastic syndromes; Chronic myelomonocytic leukemia; Internal medicine; International Prognostic Scoring System; Cytogenetics; Oncology; Bone marrow","score_opus":0.014594104408073412,"score_gpt":0.25887850042652266,"score_spread":0.24428439601844926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951365685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99614054,0.0015418514,0.0002698484,0.000101721445,0.000008195867,0.000050259958,0.00011474891,0.000011437759,0.0017613518],"genre_scores_gemma":[0.99794453,0.00070580817,0.00039197394,0.000098247634,0.00002535931,0.000022714796,0.00027537576,0.000007058418,0.0005289487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914086,0.00031359898,0.0001238728,0.00014318609,0.00018621527,0.000092339156],"domain_scores_gemma":[0.9980762,0.00055784674,0.00060706714,0.000117790325,0.0001868949,0.0004541553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00111881,0.00022063285,0.00039404354,0.00038068392,0.00048301846,0.0006630218,0.000346745,0.00029524858,0.0019908263],"category_scores_gemma":[0.0035956793,0.00020185036,0.00039335073,0.00070105644,0.00031129504,0.00034751688,0.00066539657,0.00047792195,0.0004498477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046858545,0.0012974008,0.83715117,0.00040884296,0.00027815704,0.017319823,0.0044190767,0.000818559,0.011478686,0.00018918674,0.0018594585,0.12009372],"study_design_scores_gemma":[0.0006228945,0.020177737,0.8694805,0.0001623014,0.00029966692,0.09368663,0.0017793773,0.0008759459,0.003575272,0.00012803078,0.0091439625,0.00006776196],"about_ca_topic_score_codex":0.0018685136,"about_ca_topic_score_gemma":0.0036737637,"teacher_disagreement_score":0.0019908263,"about_ca_system_score_codex":0.00084047444,"about_ca_system_score_gemma":0.000550344,"threshold_uncertainty_score":0.0066599846},"labels":[],"label_agreement":null},{"id":"W2951443426","doi":"10.1097/01.hs9.0000565788.38670.37","title":"PB1821 REAL‐WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) PATIENTS INITIATED ON ANTI‐CANCER THERAPIES IN THE UNITED STATES (US)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Lymphoma; Diagnosis code; Internal medicine; Oncology; Medical diagnosis; Cancer; Retrospective cohort study; Population; Pathology","score_opus":0.030268310438438563,"score_gpt":0.2996516692063359,"score_spread":0.2693833587678973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951443426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96831536,0.0005399922,0.00014673168,0.00034520135,0.000018145654,0.000029563054,0.02888377,0.0000149460075,0.0017063473],"genre_scores_gemma":[0.98520315,0.00031229615,0.00019629515,0.00012593392,0.000029433448,0.000048825623,0.013782287,0.0000060881844,0.00029555763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990326,0.00023206456,0.0002169035,0.00017000435,0.00022253183,0.00012583498],"domain_scores_gemma":[0.99621385,0.0005200257,0.0024578453,0.0001258854,0.00034083618,0.00034158526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061535195,0.00021411669,0.0002372943,0.0015002219,0.00029039333,0.001000809,0.00048528297,0.0002959365,0.0025587366],"category_scores_gemma":[0.003473883,0.00025523044,0.00042967903,0.0029883916,0.00018182074,0.0005157531,0.0007065864,0.0006199385,0.00036063525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000093581606,0.000045204626,0.995533,0.000027213859,0.00008364986,0.000046735706,0.00003182824,0.00031352055,0.000035930654,0.00009066676,0.0020525474,0.0016461774],"study_design_scores_gemma":[0.000017894046,0.000053180458,0.9958538,0.00004199357,0.000041306736,0.00026405178,0.00020352722,0.0016970091,0.000069526424,0.00006822576,0.0016843651,0.000005337452],"about_ca_topic_score_codex":0.028074477,"about_ca_topic_score_gemma":0.025347343,"teacher_disagreement_score":0.028074477,"about_ca_system_score_codex":0.001371125,"about_ca_system_score_gemma":0.0010021314,"threshold_uncertainty_score":0.055822134},"labels":[],"label_agreement":null},{"id":"W2951452128","doi":"10.1097/01.hs9.0000559332.56440.58","title":"PF280 INTENSIVE TREATMENT OF ELDERLY AML PATIENTS IS SAFE AND FEASIBLE, PRINCESS MARGARET CANCER CENTRE EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; Acute promyelocytic leukemia; Induction chemotherapy; Hazard ratio; Cumulative incidence; Cancer; Proportional hazards model; Incidence (geometry); Population; Cohort; Oncology; Chemotherapy; Pediatrics; Confidence interval","score_opus":0.02058978345610138,"score_gpt":0.3075071428970854,"score_spread":0.28691735944098407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951452128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97820276,0.0075086453,0.00049907056,0.002227483,0.000061867446,0.00008150787,0.0004001873,0.000028935086,0.010989427],"genre_scores_gemma":[0.99236876,0.00417854,0.00055023667,0.0008114038,0.00013538598,0.00003313972,0.0005534929,0.0000126755485,0.0013564718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975306,0.000077075645,0.000026474321,0.000027938759,0.00007009203,0.000045425564],"domain_scores_gemma":[0.9988673,0.00020418515,0.00038918818,0.00005007859,0.00012458909,0.00036481643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005425582,0.00009334911,0.00012839462,0.00020931933,0.00034239053,0.00048508437,0.0001967889,0.00019551096,0.0028061473],"category_scores_gemma":[0.0017964767,0.0000821682,0.00012955618,0.00054997776,0.00017520915,0.00031966527,0.00054961565,0.0003415776,0.0003353583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008327646,0.00021503228,0.7248491,0.00053420843,0.0001143582,0.009879677,0.002388399,0.00044718126,0.003275093,0.00057103,0.022107467,0.23478559],"study_design_scores_gemma":[0.000082018094,0.0011239675,0.91187096,0.0002427605,0.00006300714,0.022269119,0.0015109108,0.00028472807,0.0006591543,0.00022376241,0.06164976,0.000019928708],"about_ca_topic_score_codex":0.002188996,"about_ca_topic_score_gemma":0.0051329955,"teacher_disagreement_score":0.0028061473,"about_ca_system_score_codex":0.0005788967,"about_ca_system_score_gemma":0.00067579554,"threshold_uncertainty_score":0.009387553},"labels":[],"label_agreement":null},{"id":"W2951457160","doi":"10.1097/01.hs9.0000559376.17429.23","title":"PF291 A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL‐2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1‐MUTATED (MIDH1) MYELOID MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Venetoclax; Ven; IDH1; Medicine; Tolerability; Internal medicine; Oncology; Refractory (planetary science); Myeloid; Myeloid leukemia; Gastroenterology; Leukemia; Adverse effect; Chronic lymphocytic leukemia; Chemistry; Biology; Mutation","score_opus":0.016503030005904973,"score_gpt":0.3079110771014915,"score_spread":0.29140804709558654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951457160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97336483,0.0042209704,0.0016894164,0.0015592813,0.00022219533,0.006482721,0.005576728,0.00035422493,0.0065295505],"genre_scores_gemma":[0.97516483,0.0021505838,0.0036139605,0.001484379,0.00014471717,0.003480522,0.00731452,0.00006584778,0.006580626],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99968255,0.00015616791,0.000011531622,0.00005398264,0.000034264664,0.000061409526],"domain_scores_gemma":[0.9996147,0.00006042223,0.00006112619,0.000022817414,0.000031239084,0.0002096814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011625112,0.0012747652,0.00096370664,0.0003149405,0.0003679726,0.0007572612,0.00065683183,0.0011889747,0.006579893],"category_scores_gemma":[0.00066743244,0.00043504316,0.0006848397,0.0002544973,0.00067304267,0.00067618943,0.00029398434,0.0026922312,0.0012833282],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5491193,0.11213607,0.006138195,0.0014997602,0.0008970769,0.00075842615,0.000457813,0.005767937,0.1358045,0.0011205679,0.02809261,0.15820777],"study_design_scores_gemma":[0.5692559,0.39851913,0.009541267,0.0000734343,0.00021437787,0.00080543,0.00005518153,0.0025162129,0.008415824,0.0005923302,0.009970111,0.00004086361],"about_ca_topic_score_codex":0.0009327142,"about_ca_topic_score_gemma":0.0028286146,"teacher_disagreement_score":0.006579893,"about_ca_system_score_codex":0.0009001315,"about_ca_system_score_gemma":0.0018999976,"threshold_uncertainty_score":0.022011995},"labels":[],"label_agreement":null},{"id":"W2951500503","doi":"10.1097/01.hs9.0000564124.13888.22","title":"PS1465 SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Anemia; Internal medicine; Clinical endpoint; Gastroenterology; Ruxolitinib; Polycythemia vera; Regimen; Dosing; Surgery; Clinical trial; Bone marrow","score_opus":0.01047886968490293,"score_gpt":0.22865220476873951,"score_spread":0.21817333508383657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951500503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140596,0.0035783155,0.00026661053,0.00043219075,0.000082213395,0.00041431928,0.0012602424,0.000065266475,0.0024948374],"genre_scores_gemma":[0.99324495,0.0012042763,0.00046660876,0.00044710704,0.00011310545,0.00040253354,0.002285121,0.000010538622,0.0018257507],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996984,0.00014983681,0.000022582572,0.00004884403,0.00003899902,0.00004150046],"domain_scores_gemma":[0.99961877,0.00008098107,0.00012328512,0.000025243722,0.00003070121,0.00012085999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001114382,0.0005787811,0.0013836768,0.00015678773,0.0001864763,0.00081072364,0.00040453934,0.0008376421,0.0040375753],"category_scores_gemma":[0.0009216399,0.00022186799,0.0011906497,0.00022921564,0.00032289425,0.00060542417,0.00023760741,0.0016475478,0.0008966513],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7955753,0.011643458,0.015102598,0.0016271275,0.0019674578,0.00023589407,0.0002113081,0.0029713365,0.027213575,0.00036937272,0.008162978,0.13491957],"study_design_scores_gemma":[0.54702264,0.36832348,0.06663427,0.00015078462,0.0017861627,0.0006949354,0.00008552968,0.0034139664,0.004175685,0.00043543056,0.0072148954,0.000062245825],"about_ca_topic_score_codex":0.00037956942,"about_ca_topic_score_gemma":0.0010542234,"teacher_disagreement_score":0.0040375753,"about_ca_system_score_codex":0.00049982703,"about_ca_system_score_gemma":0.00068083685,"threshold_uncertainty_score":0.013507068},"labels":[],"label_agreement":null},{"id":"W2951608335","doi":"10.1097/01.hs9.0000558816.91319.ce","title":"S149 FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION‐FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Minimal residual disease; Gastroenterology; Venetoclax; Hazard ratio; Clinical endpoint; Obinutuzumab; Population; Surrogate endpoint; Progression-free survival; Oncology; Surgery; Confidence interval; Randomized controlled trial; Chronic lymphocytic leukemia; Bone marrow; Leukemia; Chemotherapy","score_opus":0.0093089771667384,"score_gpt":0.25355556727727147,"score_spread":0.24424659011053307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951608335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723345,0.0017455664,0.00008196112,0.000060109065,0.00002687157,0.00010629543,0.0001602861,0.000014464638,0.0005710328],"genre_scores_gemma":[0.9984327,0.00044990113,0.0001905092,0.00009820687,0.00003337722,0.00010721735,0.00027703628,0.0000030349304,0.0004081286],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997881,0.000103408645,0.00001433262,0.000028034277,0.000024493098,0.000041645653],"domain_scores_gemma":[0.99966216,0.000082943276,0.000103579776,0.00001632753,0.0000126390505,0.00012242357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068602955,0.00030669977,0.0009351278,0.0001749137,0.00014738987,0.0004230052,0.00035649078,0.00047754217,0.0036279764],"category_scores_gemma":[0.00053285214,0.000149264,0.000542109,0.00024255755,0.00027995836,0.000294571,0.00016682321,0.00067248964,0.0002764983],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77732617,0.00865501,0.026275037,0.000777153,0.001069863,0.00019074707,0.00014510748,0.0021769993,0.033623654,0.00018003338,0.0021066482,0.14747354],"study_design_scores_gemma":[0.36101457,0.4729441,0.14768249,0.00017934905,0.0012876769,0.0010263523,0.00011324906,0.0030587676,0.0070691286,0.00024543045,0.0053287097,0.00005020817],"about_ca_topic_score_codex":0.0006796061,"about_ca_topic_score_gemma":0.0025881405,"teacher_disagreement_score":0.0036279764,"about_ca_system_score_codex":0.00047530961,"about_ca_system_score_gemma":0.0006394894,"threshold_uncertainty_score":0.012136817},"labels":[],"label_agreement":null},{"id":"W2951773279","doi":"10.1097/01.hs9.0000560744.31107.fc","title":"PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Ibrutinib; Rituximab; Medicine; Internal medicine; Oncology; Waldenstrom macroglobulinemia; Placebo; Lymphoma; Leukemia; Chronic lymphocytic leukemia; Pathology","score_opus":0.027596417593564685,"score_gpt":0.3061365200328294,"score_spread":0.2785401024392647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951773279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97555625,0.016226422,0.00025673767,0.00065718504,0.0002165212,0.00030138958,0.004482947,0.000024241608,0.0022782572],"genre_scores_gemma":[0.9912844,0.0019664553,0.00031308114,0.000528419,0.00024609998,0.00040099293,0.0044021267,0.000008830721,0.0008494811],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.997439,0.0013981144,0.00022105081,0.0003390341,0.000356836,0.00024592804],"domain_scores_gemma":[0.99621636,0.0011959822,0.0014727397,0.00024184019,0.00033566516,0.0005375132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006324045,0.0009378001,0.0016561489,0.0004664135,0.0002819268,0.0011254209,0.00060612796,0.0010864327,0.0025752406],"category_scores_gemma":[0.004564142,0.00029092425,0.0039941804,0.0007225199,0.0003758094,0.0008657867,0.0006396738,0.0020071943,0.00048005488],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.784688,0.00265294,0.1153886,0.0024166065,0.021697367,0.00021966144,0.00022066421,0.0018388798,0.0023823918,0.00024744516,0.00522372,0.06302367],"study_design_scores_gemma":[0.21246292,0.15794984,0.57289153,0.0006052991,0.038441908,0.0007053556,0.00023240747,0.0023426656,0.0026816565,0.0006909134,0.010838486,0.00015699059],"about_ca_topic_score_codex":0.00052311434,"about_ca_topic_score_gemma":0.0006321152,"teacher_disagreement_score":0.006324045,"about_ca_system_score_codex":0.00054328603,"about_ca_system_score_gemma":0.00054847373,"threshold_uncertainty_score":0.03344512},"labels":[],"label_agreement":null},{"id":"W2951809321","doi":"10.1097/hs9.0000000000000197","title":"Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Chronic lymphocytic leukemia; Leukemia; Medicine; Mathematics; Computational biology; Immunology; Biology","score_opus":0.047759829510846945,"score_gpt":0.3091606406097494,"score_spread":0.26140081109890245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951809321","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027007875,0.5970552,0.0024506038,0.32761317,0.061730497,0.00007544655,0.00014359149,0.00025125992,0.0079794135],"genre_scores_gemma":[0.01568717,0.47770432,0.005496213,0.2973729,0.1859106,0.0002113045,0.00021351005,0.00013295378,0.017271008],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980317,0.00058569806,0.00019922413,0.0002141513,0.00080092927,0.00016823714],"domain_scores_gemma":[0.9945845,0.0027746982,0.0004735403,0.00023980353,0.0012032009,0.00072431937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037370566,0.0010209345,0.00209241,0.000563548,0.0006935661,0.0027240354,0.0016412579,0.0057854885,0.011411302],"category_scores_gemma":[0.007199259,0.00038047583,0.0012543913,0.0005098974,0.0016049119,0.007496845,0.0012552178,0.008268888,0.0048352806],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007240601,0.000192883,0.0006301917,0.0037699472,0.00019539855,0.0013176976,0.0002205002,0.00022055171,0.0019993475,0.0059278524,0.4449998,0.5398018],"study_design_scores_gemma":[0.00021976189,0.0006100755,0.0008495181,0.0019487033,0.00017475922,0.0033116334,0.00029800067,0.0002109368,0.0008775323,0.009940273,0.98149765,0.00006116369],"about_ca_topic_score_codex":0.00056449446,"about_ca_topic_score_gemma":0.0018800398,"teacher_disagreement_score":0.011411302,"about_ca_system_score_codex":0.001086968,"about_ca_system_score_gemma":0.0012488175,"threshold_uncertainty_score":0.03817463},"labels":[],"label_agreement":null},{"id":"W2951857323","doi":"10.1097/01.hs9.0000564816.09273.68","title":"S1642 DEVELOPMENT OF A CLINICAL PREDICTION RULE FOR VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACUTE LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Interquartile range; Pulmonary embolism; Internal medicine; Thrombosis; Acute leukemia; Venous thrombosis; Deep vein; Retrospective cohort study; Myeloid leukemia; Logistic regression; Surgery; Leukemia","score_opus":0.016252410817581442,"score_gpt":0.29079610340659334,"score_spread":0.2745436925890119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951857323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9151195,0.0009816902,0.069368795,0.0027082912,0.00028953474,0.0005705887,0.005512169,0.0009296478,0.0045197094],"genre_scores_gemma":[0.9756654,0.00017927268,0.019813243,0.00014065478,0.000098140714,0.000120592595,0.003586543,0.000014416749,0.0003818006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990478,0.00028550797,0.00017846964,0.00015715517,0.00025714212,0.00007382705],"domain_scores_gemma":[0.9947909,0.0030014208,0.00071909826,0.00013999555,0.0010693264,0.0002792137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020285482,0.00066881423,0.00086670625,0.0019294029,0.00035820814,0.0012118137,0.0007295047,0.00065595604,0.002060406],"category_scores_gemma":[0.012582833,0.00021939435,0.00080263405,0.0008370995,0.00019170529,0.00043925928,0.00047850428,0.00088704645,0.0010161952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053409935,0.0002093509,0.91999096,0.000069718204,0.00014361879,0.000388299,0.000034238194,0.023102036,0.0004785175,0.00019770935,0.005543624,0.049307752],"study_design_scores_gemma":[0.00024990566,0.00051812676,0.21267895,0.00019686233,0.0002933264,0.0016892579,0.00013231354,0.7763647,0.0019667477,0.0022420217,0.0036317601,0.000036033238],"about_ca_topic_score_codex":0.004330795,"about_ca_topic_score_gemma":0.0039377483,"teacher_disagreement_score":0.004330795,"about_ca_system_score_codex":0.00051687943,"about_ca_system_score_gemma":0.0013067295,"threshold_uncertainty_score":0.01072818},"labels":[],"label_agreement":null},{"id":"W2951897386","doi":"10.1097/01.hs9.0000564396.90858.34","title":"PS1534 EFFICACY AND SAFETY OF STEM CELL MOBILISATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Plerixafor; Salvage therapy; Etoposide; Apheresis; Regimen; Granulocyte colony-stimulating factor; Internal medicine; Neutropenia; Gemcitabine; Surgery; Chemotherapy; Oncology; Urology; Gastroenterology; CXCR4","score_opus":0.007516110765720078,"score_gpt":0.22500030285622663,"score_spread":0.21748419209050654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951897386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981673,0.0008742698,0.00006904521,0.000041349504,0.000008873053,0.000051490628,0.0000966117,0.000016517772,0.00067450956],"genre_scores_gemma":[0.99908507,0.0002697766,0.000076688164,0.000054641532,0.000019498357,0.000044479933,0.00022733894,0.0000028323589,0.00021962925],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99982125,0.00006424505,0.000020258893,0.000028349396,0.00003105832,0.00003476774],"domain_scores_gemma":[0.99968207,0.000083888015,0.00010411427,0.000024628174,0.000014491915,0.00009071201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004831946,0.00025852994,0.00079780916,0.00037052238,0.0001430693,0.00046203745,0.00024483082,0.00031048703,0.0018627758],"category_scores_gemma":[0.00088082487,0.000115198134,0.00042686574,0.0003254619,0.00034802628,0.00035187104,0.0002272673,0.0005388118,0.0003849053],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30916277,0.0074710827,0.2209853,0.0009811613,0.0012027144,0.0025549724,0.00058794377,0.006719859,0.05595693,0.00039992953,0.0032650903,0.39071235],"study_design_scores_gemma":[0.026303673,0.49215242,0.44623163,0.00018724486,0.0012659386,0.0040102163,0.00032234626,0.005890464,0.016165875,0.0004217854,0.006997397,0.000051087824],"about_ca_topic_score_codex":0.0005195819,"about_ca_topic_score_gemma":0.0009785341,"teacher_disagreement_score":0.0018627758,"about_ca_system_score_codex":0.00073830015,"about_ca_system_score_gemma":0.0004852911,"threshold_uncertainty_score":0.0062315464},"labels":[],"label_agreement":null},{"id":"W2952050362","doi":"10.1097/01.hs9.0000567332.39511.c6","title":"PB2213 SPLANCHNIC VEIN THROMBOSIS IN MYELOPROLOFERATIVE NEOPLASMS; A PROSPECTIVE ANALYSIS OF THROMBOSIS OUTCOME","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Thrombosis; Thrombocytosis; Thrombus; Portal vein thrombosis; Prospective cohort study; Polycythaemia; Internal medicine; Budd–Chiari syndrome; Myelofibrosis; Polycythemia vera; Radiology; Splenic vein; Surgery; Gastroenterology; Portal hypertension; Bone marrow; Platelet; Inferior vena cava; Cirrhosis","score_opus":0.027074326728748103,"score_gpt":0.3238680065348369,"score_spread":0.2967936798060888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952050362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99902034,0.00022785098,0.000035150068,0.000019665458,0.0000039436304,0.000011699388,0.00045271486,0.0000013571934,0.00022722776],"genre_scores_gemma":[0.99899083,0.00010473466,0.00003661787,0.000012712398,0.00001329864,0.000017351613,0.00070223486,0.0000013946234,0.00012079939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994923,0.0001878729,0.000042650197,0.00009648878,0.000090656744,0.00008996737],"domain_scores_gemma":[0.99857354,0.00020197491,0.0006115638,0.00008752677,0.0001530075,0.00037245467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009106151,0.00032362805,0.00039877358,0.00077503046,0.0004195531,0.0006585458,0.00026990828,0.00042561797,0.0022067209],"category_scores_gemma":[0.0015675812,0.00029512984,0.0004919767,0.0014250571,0.00024652225,0.00041358356,0.00057679013,0.0005814385,0.00044813447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040376213,0.000029584977,0.99883705,0.000008914727,0.000039346454,0.00009847121,0.000022116723,0.000018010684,0.000066532746,0.000007847504,0.000059603582,0.00040871056],"study_design_scores_gemma":[0.000035745146,0.0003559924,0.99886936,0.000007261056,0.000038378617,0.0003660551,0.00006319911,0.00009702066,0.00002931155,0.000013296097,0.000121399884,0.0000028212833],"about_ca_topic_score_codex":0.0023188628,"about_ca_topic_score_gemma":0.0019070322,"teacher_disagreement_score":0.0023188628,"about_ca_system_score_codex":0.00025222785,"about_ca_system_score_gemma":0.00037890405,"threshold_uncertainty_score":0.007382214},"labels":[],"label_agreement":null},{"id":"W2952131264","doi":"10.1097/01.hs9.0000558648.00957.de","title":"S107 FIVE‐YEAR FOLLOW‐UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Chlorambucil; Internal medicine; Hazard ratio; Adverse effect; Neutropenia; Progression-free survival; Bendamustine; Clinical endpoint; Oncology; Leukemia; Randomized controlled trial; Confidence interval; Toxicity; Chemotherapy","score_opus":0.021839086168430458,"score_gpt":0.28791569770824105,"score_spread":0.2660766115398106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952131264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950578,0.0009117488,0.000119853226,0.00010091422,0.000023662205,0.00008254323,0.0022865098,0.0000148551235,0.0014021666],"genre_scores_gemma":[0.9953868,0.00017092976,0.00007171668,0.00012591315,0.000025974581,0.000081697544,0.0033934962,0.0000028698848,0.00074064307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995726,0.00008685437,0.000059188882,0.00009757861,0.00007978457,0.000103966835],"domain_scores_gemma":[0.99848443,0.0003180526,0.00056567066,0.000079990416,0.00021068296,0.00034123514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009403268,0.00028779503,0.0008360867,0.0006649706,0.00051846704,0.00063768245,0.0003498654,0.00081630354,0.004158534],"category_scores_gemma":[0.001435582,0.00017816933,0.0011299234,0.0005778956,0.00018771114,0.00060392753,0.00034612324,0.0008568317,0.0008710303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027168857,0.0010099432,0.9438352,0.00012552182,0.00048309853,0.0006072314,0.00016891434,0.0004973294,0.0018932637,0.0000457816,0.002086119,0.02207869],"study_design_scores_gemma":[0.0012265833,0.009987118,0.9848298,0.00003300125,0.0005264753,0.0006472902,0.00009690085,0.00057060574,0.00041297838,0.000045690114,0.0016011934,0.000022389127],"about_ca_topic_score_codex":0.002385797,"about_ca_topic_score_gemma":0.002249394,"teacher_disagreement_score":0.004158534,"about_ca_system_score_codex":0.00073505566,"about_ca_system_score_gemma":0.00041530866,"threshold_uncertainty_score":0.0139116645},"labels":[],"label_agreement":null},{"id":"W2952140490","doi":"10.1097/01.hs9.0000564652.16751.86","title":"S1601 NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM THE PHASE 2 CHECKMATE 436 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Brentuximab vedotin; Nivolumab; Medicine; CD30; Lymphoma; Anaplastic large-cell lymphoma; Oncology; Internal medicine; Cancer research; Immune system; Immunology; Immunotherapy","score_opus":0.011245016612673695,"score_gpt":0.25012934407963827,"score_spread":0.23888432746696459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952140490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99316967,0.0037665593,0.00017617272,0.00018047649,0.000062780266,0.0004872633,0.00081930985,0.00005359081,0.0012842068],"genre_scores_gemma":[0.99122965,0.0031309929,0.000605264,0.00063799584,0.00009181407,0.00059786136,0.002106691,0.000021775833,0.0015779409],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997811,0.00010346138,0.00001281984,0.000033854983,0.000033831264,0.000034950313],"domain_scores_gemma":[0.9997582,0.000041167597,0.00006231595,0.000021573085,0.000020466909,0.0000962949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010744608,0.00067005126,0.001141669,0.00024254667,0.00017188003,0.0008322781,0.00052917906,0.0006178395,0.002398209],"category_scores_gemma":[0.0005175375,0.00028838805,0.0011726499,0.0002330214,0.0003719564,0.00039890836,0.00021291758,0.0013870351,0.0006184646],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6439698,0.03411044,0.016837401,0.0028941338,0.0047466257,0.00038628603,0.0003523874,0.0040160455,0.06963454,0.0004037726,0.008135627,0.21451306],"study_design_scores_gemma":[0.50163424,0.4236881,0.05221147,0.00019949337,0.0030400867,0.00075059675,0.00010247418,0.0023727268,0.007393772,0.00026056846,0.008286592,0.00005984647],"about_ca_topic_score_codex":0.00077503675,"about_ca_topic_score_gemma":0.0021693108,"teacher_disagreement_score":0.002398209,"about_ca_system_score_codex":0.00070075615,"about_ca_system_score_gemma":0.00065202254,"threshold_uncertainty_score":0.008022845},"labels":[],"label_agreement":null},{"id":"W2952175842","doi":"10.1097/01.hs9.0000559784.51441.da","title":"PF393 A RANDOMISED JOINT AUSTRALASIAN (ALLG) AND FRENCH (FILO) STUDY OF LENALIDOMIDE CONSOLIDATION IN PATIENTS WITH RESIDUAL CLL AFTER FRONT‐LINE TREATMENT WITH FC/FCR (THE CLL6 TRIAL)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Lenalidomide; Medicine; Minimal residual disease; Fludarabine; Internal medicine; Oncology; Progression-free survival; Cyclophosphamide; Chronic lymphocytic leukemia; Surgery; Leukemia; Chemotherapy; Multiple myeloma","score_opus":0.015111516384380777,"score_gpt":0.2572424225864546,"score_spread":0.2421309062020738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952175842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851372,0.0047064866,0.0003363606,0.0018833443,0.00041750044,0.0023055244,0.0016865591,0.000083560306,0.0034434737],"genre_scores_gemma":[0.9873592,0.0015625419,0.0009357449,0.002060156,0.00043031393,0.0024620076,0.0016940167,0.000017161476,0.0034789112],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99911183,0.000561436,0.00003131432,0.000100158824,0.00004681456,0.00014842943],"domain_scores_gemma":[0.9990276,0.0001481697,0.00019075366,0.000065137465,0.00006994451,0.00049840903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018432129,0.001248996,0.0016386027,0.00028496832,0.00039869227,0.0011226695,0.0006309644,0.0018083147,0.005080847],"category_scores_gemma":[0.0011856914,0.00036978594,0.0016060056,0.00035192663,0.0007617725,0.0007318628,0.0005449161,0.0025596411,0.0007803876],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96936136,0.0050754286,0.0015297853,0.00024416542,0.0006529515,0.000063604515,0.00006246037,0.00033477263,0.0025900144,0.00016613233,0.0019132786,0.01800617],"study_design_scores_gemma":[0.9311024,0.06192107,0.004066207,0.00003990614,0.00035953632,0.00006812395,0.00002173905,0.00021176846,0.0002455379,0.00017548056,0.0017743006,0.000013983238],"about_ca_topic_score_codex":0.0025564823,"about_ca_topic_score_gemma":0.004269418,"teacher_disagreement_score":0.005080847,"about_ca_system_score_codex":0.0015487692,"about_ca_system_score_gemma":0.0016465888,"threshold_uncertainty_score":0.016997159},"labels":[],"label_agreement":null},{"id":"W2952177114","doi":"10.1097/01.hs9.0000562400.45413.a7","title":"PS1026 ENASIDENIB ASSOCIATED WITH IMPROVED SURVIVAL COMPARED WITH STANDARD OF CARE FOR R/R AML PATIENTS WITH AN IDH2 MUTATION BASED ON DATA FROM STUDY AG221‐C‐001 AND A REVIEW OF PATIENT CHARTS IN FRANCE","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Alberta","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Propensity score matching; IDH2; Hematopoietic stem cell transplantation; Transplantation; Confidence interval; Mutation; IDH1; Biology","score_opus":0.050355798225258826,"score_gpt":0.351584830850553,"score_spread":0.30122903262529416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952177114","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962708,0.0006917837,0.00037138994,0.000110037785,0.000010565969,0.000061416395,0.0014501265,0.000016316955,0.0010175342],"genre_scores_gemma":[0.9979043,0.0001162604,0.00014356202,0.00007849397,0.000010307162,0.00002948896,0.0015750531,0.0000036535978,0.00013884116],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840146,0.0006489219,0.00012433495,0.0004337544,0.00027617108,0.000115374394],"domain_scores_gemma":[0.9973385,0.00067000475,0.0014665412,0.00015654045,0.00018964565,0.00017876184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019394903,0.00020804768,0.00049485697,0.0006740797,0.00014839662,0.0005526337,0.00025066882,0.0002578011,0.0025750436],"category_scores_gemma":[0.0036402596,0.00008084828,0.0011783773,0.00078199257,0.00019047815,0.0003130626,0.00033675868,0.00026505563,0.00018584012],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015539108,0.00025159767,0.9430337,0.00016983072,0.0023000021,0.00016989534,0.00008725319,0.0022152383,0.0010931621,0.000211366,0.0025933112,0.03233564],"study_design_scores_gemma":[0.001065578,0.0030320021,0.9887782,0.000030117742,0.0008390622,0.00034758876,0.00007653593,0.003232327,0.0003462046,0.00013919997,0.0020989191,0.000014250024],"about_ca_topic_score_codex":0.004137487,"about_ca_topic_score_gemma":0.0045519397,"teacher_disagreement_score":0.004137487,"about_ca_system_score_codex":0.0011542233,"about_ca_system_score_gemma":0.0008637691,"threshold_uncertainty_score":0.010257125},"labels":[],"label_agreement":null},{"id":"W2952260994","doi":"10.1097/01.hs9.0000563768.57648.ea","title":"PS1373 A TWENTY‐FOUR YEAR EXPERIENCE OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN AMYLOIDOSIS PATIENTS IN THE UNITED KINGDOM","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Univariate analysis; Internal medicine; Proportional hazards model; Cohort; AL amyloidosis; Amyloidosis; Survival analysis; Transplantation; Log-rank test; Oncology; Multivariate analysis; Surgery; Immunology; Immunoglobulin light chain","score_opus":0.028762564540519484,"score_gpt":0.2877169989745835,"score_spread":0.258954434434064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952260994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312156,0.002815359,0.00028445604,0.0008323114,0.00005516241,0.00003351109,0.00020556789,0.000012537713,0.0026394394],"genre_scores_gemma":[0.99442977,0.0024511467,0.00028935203,0.0006361233,0.00007196499,0.00002131135,0.00031574318,0.000011863771,0.0017727793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994357,0.0001935879,0.000066707114,0.0000706545,0.00011152465,0.000121736026],"domain_scores_gemma":[0.9986804,0.00015782446,0.00033626828,0.00005790798,0.00018189114,0.00058561505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069117855,0.00022583046,0.00021768095,0.0003126516,0.00045751626,0.0008767224,0.00026469096,0.0004208999,0.002990633],"category_scores_gemma":[0.0016467002,0.00017604747,0.0003031063,0.0006114405,0.00038588716,0.00040484607,0.0010710822,0.00044217694,0.00075990986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013259769,0.00048430648,0.8346679,0.00031979033,0.00013212011,0.02927435,0.008830885,0.0008101003,0.006742754,0.00038501545,0.007397438,0.10962944],"study_design_scores_gemma":[0.00016388131,0.004206511,0.9030153,0.00030156015,0.00009130499,0.041552667,0.005138311,0.00048013343,0.0011551265,0.00017014313,0.043666296,0.000058736226],"about_ca_topic_score_codex":0.0072690374,"about_ca_topic_score_gemma":0.008993168,"teacher_disagreement_score":0.0072690374,"about_ca_system_score_codex":0.0014076038,"about_ca_system_score_gemma":0.001191335,"threshold_uncertainty_score":0.014453411},"labels":[],"label_agreement":null},{"id":"W2952276066","doi":"10.1097/01.hs9.0000564512.99374.a4","title":"PS1566 HEMATOPOIETIC STEM CELL GRAFTS AS A SOURCE FOR RECONSTITUTING INNATE LYMPHOID CELLS FOLLOWING STEM CELL TRANSPLANTATION","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Mesenchymal stem cell research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Stem cell; Innate lymphoid cell; Interleukin-7 receptor; Stromal cell; Immunology; CD34; Biology; Haematopoiesis; Stem cell factor; Progenitor cell; Lymphopoiesis; Bone marrow; Transplantation; Hematopoietic stem cell transplantation; Cancer research; Medicine; Cell biology; T cell; Immune system; Innate immune system; Internal medicine","score_opus":0.01976166850489929,"score_gpt":0.26874222606698317,"score_spread":0.24898055756208387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952276066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885267,0.0019988741,0.0054701143,0.000089423964,0.00010153348,0.00020757063,0.00067632034,0.00023873786,0.0026906736],"genre_scores_gemma":[0.9884496,0.000932173,0.006053598,0.00007574846,0.000040590647,0.00018151331,0.001592977,0.000054136322,0.0026196449],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998381,0.000024216668,0.0000150006945,0.000023924129,0.00007361748,0.00002503197],"domain_scores_gemma":[0.99991035,0.000016733202,0.000021957989,0.000016620568,0.000008470881,0.000025848814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021803638,0.0005182207,0.00027480055,0.0004062769,0.00012264114,0.0002776347,0.00023726808,0.00032683686,0.0032434037],"category_scores_gemma":[0.00012195472,0.00008290915,0.00021001243,0.0002911851,0.00024725904,0.00019635895,0.00025549973,0.0008112863,0.0011122565],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022833848,0.000088175744,0.0003472011,0.000072800554,0.000006197265,0.00010172301,0.000025887084,0.00014927551,0.9951664,0.00012776908,0.00012216985,0.0035640432],"study_design_scores_gemma":[0.0000531778,0.0011609424,0.002643113,0.000017522134,0.00003388378,0.00047471546,0.000020383315,0.00075031957,0.9897786,0.00008235405,0.004980225,0.0000047684844],"about_ca_topic_score_codex":0.00013901327,"about_ca_topic_score_gemma":0.00015432012,"teacher_disagreement_score":0.0032434037,"about_ca_system_score_codex":0.00014538865,"about_ca_system_score_gemma":0.00016641952,"threshold_uncertainty_score":0.01085031},"labels":[],"label_agreement":null},{"id":"W2952294434","doi":"10.1097/01.hs9.0000561352.05716.6c","title":"PF767 PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF ONE OR TWO DOSES OF DONOR LYMPHOCYTES DEPLETED OF HOST ALLOREACTIVE T‐CELLS (ATIR101) FOLLOWING T‐CELL‐DEPLETED HAPLOIDENTICAL HSCT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Graft-versus-host disease; Immunosuppression; Immune system; T cell; Immunology; Ex vivo; CD34; Stem cell; Transplantation; Haematopoiesis; Clinical endpoint; Internal medicine; Gastroenterology; In vivo; Clinical trial; Biology","score_opus":0.05400656725039787,"score_gpt":0.3857418889832553,"score_spread":0.3317353217328574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952294434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380165,0.0008726553,0.0006143051,0.00028587398,0.000111551475,0.0021301915,0.00082165725,0.00009296071,0.0012690716],"genre_scores_gemma":[0.9874462,0.0010169635,0.0016929619,0.0006565503,0.00015169621,0.003617674,0.0026090287,0.000026392872,0.0027825166],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995937,0.00018867088,0.000016416563,0.00007491901,0.00003543689,0.000090870395],"domain_scores_gemma":[0.9993253,0.00013368353,0.00013300484,0.00006331485,0.00003939212,0.00030532898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016742535,0.0017773854,0.001637231,0.00048954017,0.0003524695,0.0008934567,0.00080485555,0.0016064508,0.0031219176],"category_scores_gemma":[0.00093966455,0.00048573813,0.00082972087,0.0003444433,0.0012502958,0.000772709,0.0002795239,0.003188834,0.0008597649],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68445545,0.13096468,0.004360229,0.0007758406,0.00090678665,0.00059917656,0.00033807388,0.0066247354,0.089232616,0.00062108226,0.004543105,0.076578245],"study_design_scores_gemma":[0.2880372,0.6986648,0.0037717407,0.000025414067,0.00023688051,0.00033346907,0.00004199997,0.0010359979,0.005924508,0.0001829703,0.0017188501,0.000026119416],"about_ca_topic_score_codex":0.0006178304,"about_ca_topic_score_gemma":0.001295855,"teacher_disagreement_score":0.0031219176,"about_ca_system_score_codex":0.000932864,"about_ca_system_score_gemma":0.0018199432,"threshold_uncertainty_score":0.010443866},"labels":[],"label_agreement":null},{"id":"W2952375224","doi":"10.1097/01.hs9.0000562928.03733.42","title":"PS1161 EFFICACY AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS PREVIOUSLY TREATED WITH VENETOCLAX IN THE MURANO STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Venetoclax; Medicine; Bendamustine; Ibrutinib; Internal medicine; Rituximab; Hazard ratio; Chronic lymphocytic leukemia; Population; Oncology; Refractory (planetary science); Clinical endpoint; Confidence interval; Leukemia; Randomized controlled trial; Lymphoma","score_opus":0.010360389187044253,"score_gpt":0.2625796229925551,"score_spread":0.25221923380551087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952375224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684227,0.001849067,0.00002656156,0.00007847708,0.00001817865,0.000048662285,0.00025144324,0.0000075584658,0.0008778349],"genre_scores_gemma":[0.9983791,0.0005111629,0.000050797426,0.00008971449,0.000033833214,0.000043868742,0.00056511036,0.0000025634217,0.00032388652],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996656,0.00016959081,0.000018240016,0.00006040318,0.000042038846,0.00004404604],"domain_scores_gemma":[0.9994168,0.00011912306,0.00026084084,0.00004404411,0.000027898535,0.0001313206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010090403,0.0003304979,0.0008752426,0.00019938359,0.00021185566,0.0006517352,0.0002711378,0.0003466283,0.001274997],"category_scores_gemma":[0.0011772739,0.00016205895,0.0005706632,0.0002780299,0.0002355004,0.00030671555,0.00030777857,0.00074305997,0.00019186347],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47112247,0.003968007,0.35848293,0.000941361,0.0030475513,0.0004670933,0.0004555101,0.0016489618,0.02012877,0.0002504393,0.004685668,0.13480125],"study_design_scores_gemma":[0.08221079,0.087125726,0.81806886,0.00012652818,0.0019185185,0.00073868054,0.00015000938,0.0016897257,0.0014714014,0.00018853578,0.006270446,0.000040847284],"about_ca_topic_score_codex":0.0010607222,"about_ca_topic_score_gemma":0.0022943257,"teacher_disagreement_score":0.001274997,"about_ca_system_score_codex":0.0005419644,"about_ca_system_score_gemma":0.00040993444,"threshold_uncertainty_score":0.005336404},"labels":[],"label_agreement":null},{"id":"W2952463147","doi":"10.1097/01.hs9.0000561068.22529.45","title":"PF696 SAFETY AND EFFICACY OF SELF‐ADMINISTERED ROMIPLOSTIM IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP): RESULTS OF AN INTEGRATED ANALYSIS OF FIVE CLINICAL TRIALS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Romiplostim; Medicine; Clinical trial; Subgroup analysis; Immune thrombocytopenia; Placebo; Internal medicine; Pediatrics; Platelet; Confidence interval; Alternative medicine; Thrombopoietin","score_opus":0.0475940576395064,"score_gpt":0.3800442237727957,"score_spread":0.33245016613328926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952463147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83989435,0.1477357,0.003176297,0.0005255791,0.00012864513,0.0027717354,0.0034022692,0.00015905593,0.002206312],"genre_scores_gemma":[0.98566437,0.009819632,0.0015553847,0.00033439996,0.00011196233,0.0007025175,0.0015500664,0.00002949813,0.00023214913],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98413754,0.009609049,0.0019112974,0.001550853,0.0019939581,0.00079735316],"domain_scores_gemma":[0.9843017,0.007497103,0.005765145,0.00070750114,0.0011542729,0.00057422253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024766523,0.001419493,0.0051461128,0.0019237493,0.00031850595,0.0026027532,0.0006399915,0.0013412238,0.00158288],"category_scores_gemma":[0.01567446,0.00053435634,0.011729445,0.0025403087,0.0006317677,0.00160069,0.00081030664,0.0011383106,0.00020178495],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4072041,0.0022813536,0.10741778,0.012629305,0.28812507,0.00022120705,0.00040662795,0.0044237026,0.006932742,0.00029569922,0.001678526,0.16838391],"study_design_scores_gemma":[0.13237129,0.11817176,0.37582332,0.002252685,0.3552804,0.00066849065,0.00032229314,0.0049385466,0.0033130564,0.0006582553,0.005970134,0.00022983697],"about_ca_topic_score_codex":0.0006579367,"about_ca_topic_score_gemma":0.0016534013,"teacher_disagreement_score":0.024766523,"about_ca_system_score_codex":0.0014853779,"about_ca_system_score_gemma":0.0014346801,"threshold_uncertainty_score":0.13097942},"labels":[],"label_agreement":null},{"id":"W2952482267","doi":"10.1097/01.hs9.0000558668.31452.51","title":"S112 MLL FUSIONS AFFECT SPLICING TO INDUCE EXPLOITABLE METABOLIC DEPENDENCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Genetics","funders":"","keywords":"PKM2; Biology; Cell biology; Warburg effect; Small hairpin RNA; Alternative splicing; Glycolysis; Cell growth; RNA splicing; Cancer research; Exon; Chemistry; Pyruvate kinase; Gene; Biochemistry; RNA; Metabolism","score_opus":0.027358971629896298,"score_gpt":0.30676860134906336,"score_spread":0.27940962971916705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952482267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935807,0.0005194752,0.005767625,0.00016990762,0.00006581902,0.000091757116,0.0010067192,0.0003419832,0.0026785901],"genre_scores_gemma":[0.9929636,0.00022533252,0.0023152453,0.000073732524,0.000010125985,0.000044566317,0.0011112357,0.0000973339,0.0031588485],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998388,0.000023522485,0.000021681259,0.000030864805,0.000058439997,0.00002670403],"domain_scores_gemma":[0.99985325,0.000043397416,0.000049590573,0.000018610142,0.000011337768,0.000023768802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016751692,0.00035736477,0.00021464119,0.00014132414,0.00013881206,0.00032041434,0.00019751846,0.00044266786,0.0038966953],"category_scores_gemma":[0.00017585185,0.0001262678,0.00024732365,0.00015587173,0.00021932136,0.00013846821,0.00026960918,0.0006595263,0.0010324026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082430604,0.000029780595,0.0001350512,0.000022392529,0.000004393769,0.0000978995,0.000010244385,0.00012092076,0.9983004,0.00014615682,0.000085511376,0.0009649171],"study_design_scores_gemma":[0.000025238449,0.00022603058,0.0011938706,0.0000052913156,0.000011783962,0.00035791603,0.000015484999,0.0012620903,0.99242145,0.00007515905,0.00440159,0.000004144188],"about_ca_topic_score_codex":0.00026378603,"about_ca_topic_score_gemma":0.0004032885,"teacher_disagreement_score":0.0038966953,"about_ca_system_score_codex":0.00031494108,"about_ca_system_score_gemma":0.00016296514,"threshold_uncertainty_score":0.013035715},"labels":[],"label_agreement":null},{"id":"W2952497968","doi":"10.1097/01.hs9.0000563764.80519.69","title":"PS1372 B‐CELL MATURATION ANTIGEN ANTIBODY‐DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES FROM A PHASE I STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Interim analysis; Pharmacokinetics; Antibody; Pharmacology; Immunology; Clinical trial","score_opus":0.045145304319847965,"score_gpt":0.3849031199403042,"score_spread":0.3397578156204562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952497968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942152,0.0023309893,0.00054940104,0.00021545446,0.0000357434,0.00089645566,0.0006456146,0.00008005994,0.0010310557],"genre_scores_gemma":[0.9940479,0.0015522296,0.00094445015,0.0002783378,0.000045008623,0.0005240631,0.0012700896,0.000020619404,0.0013173515],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954957,0.00020416452,0.000029474828,0.00006148234,0.00007012777,0.00008513668],"domain_scores_gemma":[0.9994904,0.00009981585,0.00012498775,0.000054583947,0.00005190665,0.0001782576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018568884,0.0009782233,0.0012725597,0.00034237208,0.00024154903,0.000732717,0.00052496046,0.00063015515,0.0016632797],"category_scores_gemma":[0.0008402666,0.0003659776,0.0010722143,0.00036420987,0.0006233479,0.0006154068,0.00028130016,0.0022039108,0.00052906404],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5187721,0.05535445,0.015944019,0.001566866,0.0033486823,0.00051390694,0.0006776728,0.0076877805,0.1142766,0.00040389775,0.005925439,0.27552855],"study_design_scores_gemma":[0.31720403,0.6214267,0.03147165,0.000055680153,0.0015225112,0.00062438054,0.00008604474,0.0020301156,0.021913616,0.00018979255,0.0034304955,0.000044967357],"about_ca_topic_score_codex":0.0025761754,"about_ca_topic_score_gemma":0.005779621,"teacher_disagreement_score":0.0025761754,"about_ca_system_score_codex":0.001390407,"about_ca_system_score_gemma":0.001587736,"threshold_uncertainty_score":0.010088205},"labels":[],"label_agreement":null},{"id":"W2952510707","doi":"10.1097/01.hs9.0000568164.69011.0e","title":"PB2425 THE IMPACT OF SPECIMEN VOLUME AND HAEMOLYSIS ON ROUTINE COAGULATION TEST RESULTS: REDUCING THE RECOLLECTION BURDEN IN A HIGH‐THROUGHPUT LABORATORY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hatch (Canada)","funders":"","keywords":"Prothrombin time; Coagulation testing; Medicine; Haemolysis; Fibrinogen; Coagulation; Partial thromboplastin time; Surgery; Pathology; Internal medicine; Immunology","score_opus":0.009792584339988671,"score_gpt":0.2631019778187466,"score_spread":0.2533093934787579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952510707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98062277,0.003504969,0.009022515,0.00093066297,0.00010118136,0.0005484469,0.00037209658,0.00034515414,0.004552232],"genre_scores_gemma":[0.98206353,0.00097229,0.0144667225,0.00019062484,0.0000749623,0.00025310542,0.00032303226,0.000056841694,0.0015989983],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.989374,0.0037506921,0.0007285795,0.00061161345,0.0051541217,0.00038106073],"domain_scores_gemma":[0.9742373,0.0114909625,0.0065797493,0.0013560615,0.0053382725,0.0009975227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010249236,0.00058696873,0.0006623284,0.00066550466,0.00045275653,0.0021022013,0.0011768108,0.00045502587,0.0035813933],"category_scores_gemma":[0.027378824,0.00026680762,0.00063439267,0.00083257916,0.00081058237,0.00093373226,0.0010350001,0.00059970707,0.0009201904],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015498854,0.0021247326,0.43337354,0.0024017526,0.00064097636,0.0013849969,0.0022075148,0.005417042,0.0885514,0.0006217941,0.006918344,0.44085905],"study_design_scores_gemma":[0.00046410164,0.031202583,0.83685595,0.00048226616,0.0008381629,0.002528649,0.0012389979,0.015734661,0.092704915,0.0007126922,0.017102867,0.0001341983],"about_ca_topic_score_codex":0.0057653417,"about_ca_topic_score_gemma":0.0054052,"teacher_disagreement_score":0.010249236,"about_ca_system_score_codex":0.0015257376,"about_ca_system_score_gemma":0.0028020726,"threshold_uncertainty_score":0.05420381},"labels":[],"label_agreement":null},{"id":"W2952592194","doi":"10.1097/01.hs9.0000564128.13888.1d","title":"PS1466 CYTOREDUCTION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: A SYSTEMATIC REVIEW","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Randomized controlled trial; Essential thrombocythemia; Anagrelide; Internal medicine; Observational study; Aspirin; Relative risk; Placebo; Hydroxycarbamide; Surgery; Polycythemia vera; Chemotherapy; Confidence interval; Pathology","score_opus":0.08401434338757563,"score_gpt":0.39626701586450297,"score_spread":0.31225267247692734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952592194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010862736,0.9979942,0.000071720526,0.00016357869,0.00006518618,0.00018692572,0.0002103463,0.0000056894114,0.00021607404],"genre_scores_gemma":[0.017299602,0.98110723,0.00035615123,0.0005316657,0.000086884465,0.00031826363,0.00018073738,0.000003341251,0.00011626093],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9972704,0.0010540975,0.0009017812,0.00021673329,0.0004757649,0.00008124057],"domain_scores_gemma":[0.99115974,0.0059704697,0.0018867515,0.00010794721,0.00072372187,0.00015146103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003158423,0.0008633339,0.005865119,0.0036306267,0.0003907791,0.0011803292,0.0011530307,0.0012760971,0.004830581],"category_scores_gemma":[0.013818082,0.00043869374,0.0052299923,0.004248634,0.0005593621,0.0010929592,0.0006861969,0.00087058684,0.0002507097],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056163146,0.00001941172,0.000534596,0.9416651,0.011091373,0.00005993675,0.0000794498,0.00008367262,0.00014634588,0.00011825754,0.0015598367,0.04408049],"study_design_scores_gemma":[0.001956626,0.00074074586,0.006997218,0.82833564,0.1358489,0.00049717125,0.00018973196,0.000180486,0.00024231427,0.00041603151,0.024550688,0.000044453696],"about_ca_topic_score_codex":0.005256963,"about_ca_topic_score_gemma":0.014896605,"teacher_disagreement_score":0.005865119,"about_ca_system_score_codex":0.0019246002,"about_ca_system_score_gemma":0.0050728023,"threshold_uncertainty_score":0.016703546},"labels":[],"label_agreement":null},{"id":"W2952644065","doi":"10.1097/01.hs9.0000559996.44290.19","title":"PF446 EVALUATING EX VIVO EXPANSION OF FUNCTIONALLY COMPETENT MULTI-SPECIFIC T LYMPHOCYTES TO MINOR HISTOCOMPATIBILITY ANTIGEN FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Minor histocompatibility antigen; Immunology; CD8; T cell; Cytotoxic T cell; Stem cell; Priming (agriculture); Antigen; Haematopoiesis; Major histocompatibility complex; Biology; Cancer research; Immune system; Medicine; In vitro; Cell biology","score_opus":0.12491271604417466,"score_gpt":0.36601823181520166,"score_spread":0.241105515771027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952644065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917413,0.0014790074,0.004573967,0.00008645649,0.000052482945,0.00016950363,0.00018039987,0.0000664383,0.001650477],"genre_scores_gemma":[0.99034506,0.0008847757,0.0059739966,0.00006763826,0.000037080885,0.00018503489,0.0006081534,0.000019282825,0.0018790513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991846,0.000024516976,0.000006107946,0.000011284247,0.000019348507,0.000020390775],"domain_scores_gemma":[0.99995375,0.000012781254,0.000009143344,0.0000050305252,0.00000704851,0.000012188702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016606397,0.00030817554,0.00015254402,0.00014432674,0.0000784985,0.00014704133,0.00015435071,0.00025196033,0.0023545094],"category_scores_gemma":[0.00010658273,0.000049045633,0.00015613533,0.00008135779,0.00008291342,0.00013389501,0.00012739617,0.000519595,0.0004269956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004207897,0.0005261432,0.00023361649,0.00008717214,0.000006054328,0.000060678285,0.00001957803,0.00049959385,0.9897231,0.00010724648,0.00013804277,0.008178038],"study_design_scores_gemma":[0.00022782653,0.009842036,0.0015833189,0.000014118044,0.000050074585,0.00048899493,0.000013806502,0.0019691421,0.98120433,0.00007921337,0.0045222943,0.000004860206],"about_ca_topic_score_codex":0.00007734056,"about_ca_topic_score_gemma":0.00009393739,"teacher_disagreement_score":0.0023545094,"about_ca_system_score_codex":0.000093609306,"about_ca_system_score_gemma":0.00011340121,"threshold_uncertainty_score":0.007876575},"labels":[],"label_agreement":null},{"id":"W2952690147","doi":"10.1097/01.hs9.0000558800.37954.72","title":"S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Multiple myeloma; Autologous stem-cell transplantation; Hazard ratio; Lenalidomide; Clinical endpoint; Thalidomide; Bortezomib; Surgery; Oncology; Gastroenterology; Randomized controlled trial; Confidence interval","score_opus":0.044020976145244646,"score_gpt":0.3431851252762097,"score_spread":0.29916414913096506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952690147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852642,0.004003445,0.0005676333,0.0006694136,0.00037794936,0.003916053,0.002072516,0.00015739445,0.002971379],"genre_scores_gemma":[0.9820322,0.002259866,0.0018404375,0.0017542788,0.0003746241,0.0037842388,0.0036640011,0.000046368266,0.0042440235],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995074,0.00027247216,0.000022913457,0.000081417915,0.00004296655,0.00007276543],"domain_scores_gemma":[0.99915934,0.00019145063,0.0001980591,0.00005652538,0.00005325551,0.00034141872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019169963,0.0015585516,0.0021187044,0.00034224452,0.00038316776,0.0013540657,0.00073297153,0.0012177484,0.005631159],"category_scores_gemma":[0.0010849951,0.0005835891,0.0021262525,0.00031910258,0.00083773426,0.00062347593,0.00035551251,0.002880692,0.00090596086],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9532967,0.013669075,0.0012947738,0.00050659,0.0012733496,0.000071310285,0.00007946941,0.00078411214,0.0068327948,0.00020438076,0.002450208,0.019537063],"study_design_scores_gemma":[0.8821698,0.111462,0.0031236715,0.00003181376,0.00048769885,0.00007486348,0.00002009826,0.00057652756,0.0006517763,0.00018697379,0.0011966282,0.00001807899],"about_ca_topic_score_codex":0.0009120574,"about_ca_topic_score_gemma":0.002957402,"teacher_disagreement_score":0.005631159,"about_ca_system_score_codex":0.0009188631,"about_ca_system_score_gemma":0.0016288279,"threshold_uncertainty_score":0.018838048},"labels":[],"label_agreement":null},{"id":"W2952759225","doi":"10.1097/01.hs9.0000565740.21637.cb","title":"PB1809 REAL‐WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS OF PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMBCL) PATIENTS INITIATED ON ANTI‐CANCER THERAPIES IN THE UNITED STATES (US)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Medical diagnosis; Lymphoma; Cancer; Health care; Internal medicine; Oncology; Pathology","score_opus":0.032379214920534936,"score_gpt":0.2922569784763064,"score_spread":0.25987776355577147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952759225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97871256,0.00048299588,0.0001238181,0.00021560615,0.000011283548,0.000022091863,0.019227134,0.000010107767,0.0011943876],"genre_scores_gemma":[0.9898891,0.00026669892,0.00015332211,0.00007727782,0.000019188426,0.00003539069,0.009381782,0.000003924495,0.0001733534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991673,0.00020867391,0.00018069973,0.0001470919,0.00018349824,0.00011271583],"domain_scores_gemma":[0.99683577,0.00049795053,0.0020680171,0.000104573934,0.00023609243,0.00025755807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006298051,0.00018944933,0.00022470884,0.001429759,0.00023223867,0.0008605607,0.00044559332,0.00030682582,0.0019369418],"category_scores_gemma":[0.003148997,0.0002571758,0.00047492713,0.0028149772,0.00019414058,0.0004907493,0.00059962843,0.000579253,0.00027274658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009645031,0.000044641813,0.9962386,0.000029482304,0.000091558526,0.000048820315,0.000028333285,0.00036308233,0.0000375644,0.00009657605,0.0013161739,0.0016086188],"study_design_scores_gemma":[0.000015002166,0.000059998245,0.9961908,0.000041050524,0.000042289106,0.00029732194,0.0001783553,0.0019631942,0.000067200686,0.000077455275,0.0010621235,0.000005186385],"about_ca_topic_score_codex":0.024463596,"about_ca_topic_score_gemma":0.020738076,"teacher_disagreement_score":0.024463596,"about_ca_system_score_codex":0.0013728812,"about_ca_system_score_gemma":0.0008566672,"threshold_uncertainty_score":0.048642397},"labels":[],"label_agreement":null},{"id":"W2952813810","doi":"10.1097/01.hs9.0000560808.16752.64","title":"PF631 HEALTH‐RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW‐DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; McGill University Health Centre; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Daratumumab; Multiple myeloma; Regimen; Internal medicine; Cohort; Clinical endpoint; Dexamethasone; Progressive disease; Oncology; Clinical trial; Chemotherapy","score_opus":0.020931311982442687,"score_gpt":0.28274938292954693,"score_spread":0.26181807094710424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952813810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978375,0.0010777613,0.000045912486,0.00014977297,0.000019663785,0.000112904694,0.00019084282,0.000008298021,0.000557461],"genre_scores_gemma":[0.99898094,0.00023437986,0.0001275854,0.00013741973,0.00003010856,0.0000912023,0.00024532015,0.0000013210763,0.00015174018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999571,0.0001477487,0.000037034133,0.000075170814,0.00006947232,0.000099467165],"domain_scores_gemma":[0.9993734,0.00008156031,0.00020645911,0.00001918037,0.000030936942,0.00028852755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010904648,0.00038777784,0.0011440172,0.00030977506,0.0005794087,0.0007098331,0.0003118918,0.0003947163,0.0015175511],"category_scores_gemma":[0.001167821,0.00018564991,0.0011258599,0.0004275862,0.00023602167,0.0004958667,0.00039055862,0.00092074374,0.00023338581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19833075,0.0143811805,0.6180536,0.00055922545,0.0022995227,0.0009830632,0.0006911703,0.0025634263,0.009197241,0.00013929444,0.0031250997,0.14967641],"study_design_scores_gemma":[0.014871647,0.12340548,0.854132,0.0000883287,0.00086681574,0.00092974876,0.0002753918,0.0020678372,0.0009884541,0.00015938394,0.0021740277,0.000040707855],"about_ca_topic_score_codex":0.001305302,"about_ca_topic_score_gemma":0.002313029,"teacher_disagreement_score":0.0015175511,"about_ca_system_score_codex":0.0008541339,"about_ca_system_score_gemma":0.00079680665,"threshold_uncertainty_score":0.006197214},"labels":[],"label_agreement":null},{"id":"W2952817796","doi":"10.1097/01.hs9.0000560592.99613.ac","title":"PF576 NONSENSE‐MEDIATED MRNA DECAY IS A THERAPEUTIC TARGET IN MULTIPLE MYELOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Nonsense-mediated decay; Gene knockdown; RNA splicing; Cell culture; Biology; Molecular biology; Cancer cell; Translation (biology); Cancer research; Cancer; Messenger RNA; Cell biology; Chemistry; Gene; RNA; Biochemistry; Genetics","score_opus":0.01317766469733666,"score_gpt":0.2553419357255027,"score_spread":0.242164271028166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952817796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9298561,0.040192474,0.010919402,0.001961446,0.00031488738,0.0003252683,0.0013007184,0.00096335454,0.014166244],"genre_scores_gemma":[0.98517007,0.006206635,0.0042437976,0.00024961514,0.00004362373,0.00010122877,0.0012310755,0.00003947339,0.0027144945],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997991,0.000021527234,0.000015393185,0.00003542413,0.00008498262,0.00004367177],"domain_scores_gemma":[0.9999013,0.000018092258,0.000030868738,0.000012874781,0.0000145802605,0.000022365515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003755254,0.00044893034,0.00042399167,0.00046014888,0.0002379309,0.0004991821,0.00036088543,0.0005377733,0.0022068815],"category_scores_gemma":[0.00019065313,0.000109849534,0.0003143879,0.00047419273,0.0003022092,0.00025022874,0.000258835,0.0009550469,0.00052459235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014966216,0.00045715107,0.0011633546,0.000363326,0.000049044822,0.0003552641,0.00003665735,0.0007796737,0.9353272,0.0009994934,0.0016618277,0.057310373],"study_design_scores_gemma":[0.00035745,0.004266581,0.0056089037,0.000055807017,0.00011996586,0.0020535327,0.000029904637,0.002092489,0.9571585,0.00032921293,0.027914558,0.000013135454],"about_ca_topic_score_codex":0.00060525804,"about_ca_topic_score_gemma":0.00079380244,"teacher_disagreement_score":0.0022068815,"about_ca_system_score_codex":0.0008061981,"about_ca_system_score_gemma":0.00038725158,"threshold_uncertainty_score":0.00738281},"labels":[],"label_agreement":null},{"id":"W2952821043","doi":"10.1097/01.hs9.0000562176.15402.a3","title":"PS968 GENETIC LANDSCAPE OF FLT3‐MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Midostaurin; CEBPA; NPM1; Oncology; Neuroblastoma RAS viral oncogene homolog; Medicine; Internal medicine; Alectinib; Sanger sequencing; Myeloid leukemia; Cancer research; KRAS; Mutation; Biology; Genetics; Gene; Cancer; Crizotinib; Karyotype","score_opus":0.013724678406278864,"score_gpt":0.27149035263312354,"score_spread":0.25776567422684465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952821043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98929834,0.0013325647,0.00017170935,0.00057255774,0.000019343996,0.000057925743,0.0050019287,0.00002650125,0.0035191167],"genre_scores_gemma":[0.98762,0.0004992007,0.00042464343,0.0004736589,0.00003436102,0.00011963976,0.009909938,0.000021053404,0.00089757337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996798,0.00009394936,0.000020672409,0.00010049023,0.00006631474,0.0000389473],"domain_scores_gemma":[0.99981004,0.000043443197,0.000069454014,0.000017171247,0.000016969305,0.000043006738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054749806,0.00014697586,0.00036973553,0.00020345724,0.00024794484,0.0005666364,0.00029506147,0.00038362332,0.0048826896],"category_scores_gemma":[0.0007767136,0.0000950949,0.00020134734,0.00060878193,0.0002262231,0.00028176344,0.00030643816,0.0005220369,0.00061515137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10171602,0.001315298,0.5308215,0.0006663452,0.0011574236,0.00077225885,0.000497843,0.005268275,0.054777466,0.0015587305,0.043521646,0.25792715],"study_design_scores_gemma":[0.014097813,0.008433464,0.91594,0.00014830522,0.0015571176,0.0023025637,0.00042320206,0.0035900034,0.0054502226,0.0025553731,0.045448452,0.000053531203],"about_ca_topic_score_codex":0.0019656883,"about_ca_topic_score_gemma":0.003680839,"teacher_disagreement_score":0.0048826896,"about_ca_system_score_codex":0.00044687497,"about_ca_system_score_gemma":0.00045078437,"threshold_uncertainty_score":0.016334236},"labels":[],"label_agreement":null},{"id":"W2952833516","doi":"10.1097/01.hs9.0000563300.27415.88","title":"PS1255 EFFICACY OF R-BAC IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA POST BTK INHIBITOR THERAPY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Mantle cell lymphoma; Follicular lymphoma; Internal medicine; Surgery; Chemotherapy; Radiation therapy; Refractory (planetary science); Lymphoma; Gastroenterology; Aggressive lymphoma","score_opus":0.004571677957232424,"score_gpt":0.20793314056298617,"score_spread":0.20336146260575375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952833516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978531,0.0010805117,0.000029983843,0.000048620703,0.000008052345,0.000028796927,0.00007713788,0.0000106108855,0.00086294935],"genre_scores_gemma":[0.99930763,0.0002283316,0.00003805418,0.000047574984,0.000016336739,0.0000075467115,0.0002163873,0.0000013104068,0.00013683764],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999198,0.000015615304,0.0000050551794,0.000014847687,0.0000216869,0.000023044407],"domain_scores_gemma":[0.9997739,0.00003838155,0.00006240662,0.000010120551,0.00001949837,0.00009556681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021376686,0.00024809688,0.0004923907,0.000240296,0.00023069097,0.00028503354,0.00023020669,0.0001964876,0.0008078569],"category_scores_gemma":[0.00073286745,0.00007742934,0.00027677786,0.0002826613,0.00018156068,0.0001426126,0.00011625564,0.0003198177,0.00014729644],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070962735,0.0023474921,0.64416355,0.00046179633,0.00073215895,0.0021493125,0.0005121515,0.0026252095,0.019189691,0.00012931514,0.0026739952,0.2540527],"study_design_scores_gemma":[0.0013200705,0.017692592,0.9767104,0.00003141479,0.00027001183,0.0008881009,0.00007301157,0.00088246027,0.0007908611,0.000043725315,0.0012855766,0.000011844399],"about_ca_topic_score_codex":0.014155719,"about_ca_topic_score_gemma":0.02381509,"teacher_disagreement_score":0.014155719,"about_ca_system_score_codex":0.0011546352,"about_ca_system_score_gemma":0.000728303,"threshold_uncertainty_score":0.028146625},"labels":[],"label_agreement":null},{"id":"W2952913340","doi":"10.1097/01.hs9.0000562668.33884.40","title":"PS1094 MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐FRACTIONATED DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Dosing; Gastroenterology; Internal medicine; Chills; Refractory (planetary science); Immunotherapy; Cancer; Chimeric antigen receptor","score_opus":0.0064557568911769725,"score_gpt":0.21729705728347315,"score_spread":0.21084130039229618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952913340","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984511,0.0006538507,0.0002259559,0.000034174707,0.000004445029,0.00007759454,0.000047418478,0.000023733908,0.0004817247],"genre_scores_gemma":[0.9990706,0.0002929919,0.00026520298,0.00003736979,0.000005900446,0.000035462013,0.000079956655,0.0000028047236,0.00020971922],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99993324,0.000020312933,0.000006541334,0.000009730613,0.000014641396,0.000015459133],"domain_scores_gemma":[0.9999161,0.000019043095,0.00002915788,0.0000097484,0.000006851579,0.000019149324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025969397,0.0002181212,0.00032136607,0.00013484508,0.00012295354,0.00017290839,0.0002484657,0.00018252213,0.0007487097],"category_scores_gemma":[0.00031721956,0.000073621944,0.00017099225,0.00012693513,0.00012051132,0.00015586118,0.00011885606,0.00047202807,0.00015536633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03134385,0.007327652,0.036130812,0.0006949382,0.00053062045,0.00092390704,0.00037814368,0.006022727,0.23682182,0.00018458872,0.0024858124,0.6771551],"study_design_scores_gemma":[0.029460989,0.41767174,0.388898,0.00017353929,0.0008220452,0.007738165,0.00021568662,0.010616948,0.13197573,0.00046239467,0.011913048,0.00005174756],"about_ca_topic_score_codex":0.000526664,"about_ca_topic_score_gemma":0.0017369319,"teacher_disagreement_score":0.0007487097,"about_ca_system_score_codex":0.00028589193,"about_ca_system_score_gemma":0.00025838107,"threshold_uncertainty_score":0.0025047064},"labels":[],"label_agreement":null},{"id":"W2952930577","doi":"10.1097/01.hs9.0000559236.73191.39","title":"PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Midostaurin; Medicine; NPM1; Internal medicine; Oncology; Myeloid leukemia; Tyrosine kinase; Survival analysis; Cancer research; Biology; Genetics; Receptor; Gene","score_opus":0.005263333271571992,"score_gpt":0.25244300062050856,"score_spread":0.24717966734893657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952930577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990606,0.00030241688,0.000038576356,0.000042909836,0.0000221697,0.000073277704,0.0002031094,0.0000051833213,0.0002518872],"genre_scores_gemma":[0.9987243,0.00009956656,0.00012794504,0.000046458008,0.000051396033,0.00009223854,0.0005534439,0.0000020397474,0.0003026211],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993549,0.00028054442,0.00003781939,0.00015679786,0.00007430626,0.00009562336],"domain_scores_gemma":[0.9990609,0.00025656007,0.0002449393,0.00006961729,0.000038818165,0.00032909648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017797905,0.0005026449,0.0014167265,0.00033296784,0.00025482973,0.00059851387,0.00052729744,0.00075359404,0.0024406628],"category_scores_gemma":[0.001454423,0.0002387433,0.0013047918,0.00030414437,0.0006256388,0.0006566763,0.00046836335,0.00093571603,0.00032411033],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9007462,0.0029528185,0.06677163,0.0001441813,0.0008388973,0.000084145046,0.00008535496,0.0011229857,0.010079011,0.00008938088,0.00061022467,0.016475163],"study_design_scores_gemma":[0.16559716,0.4301551,0.3860824,0.00004627238,0.002928652,0.00055333885,0.0001901813,0.0031158172,0.007734256,0.00032720674,0.0031806773,0.000088956614],"about_ca_topic_score_codex":0.0005434787,"about_ca_topic_score_gemma":0.0011498086,"teacher_disagreement_score":0.0024406628,"about_ca_system_score_codex":0.000701552,"about_ca_system_score_gemma":0.0007069481,"threshold_uncertainty_score":0.009412587},"labels":[],"label_agreement":null},{"id":"W2952994283","doi":"10.1097/01.hs9.0000561608.73874.6a","title":"S832 A PHASE 2A STUDY OF THE LSD1 INHIBITOR IMG‐7289 FOR THE TREATMENT OF MYELOFIBROSIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Bone marrow; Myeloid; Internal medicine; Progenitor cell; Chronic myelomonocytic leukemia; Gastroenterology; Pharmacology; Oncology; Myelodysplastic syndromes; Immunology; Stem cell; Biology","score_opus":0.02639573131401898,"score_gpt":0.3162784913377868,"score_spread":0.28988276002376784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952994283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865346,0.003186208,0.0009161527,0.00090532465,0.00017016745,0.002245949,0.0029763668,0.0002155379,0.0028496205],"genre_scores_gemma":[0.98335475,0.0023059607,0.0025136666,0.0013933759,0.00010127521,0.0016836729,0.0040471875,0.00004506193,0.0045550317],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998436,0.000059409278,0.000008769758,0.000030697276,0.00002299725,0.000034459677],"domain_scores_gemma":[0.99979275,0.000022471777,0.000042629385,0.00001547472,0.000026024622,0.00010060919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000633644,0.0007538314,0.0010909048,0.00029241617,0.00028984481,0.0006726528,0.00052704266,0.00092056446,0.005524998],"category_scores_gemma":[0.0003248571,0.00035158588,0.0008860653,0.00023835505,0.00037328675,0.00038983067,0.00019832597,0.0023229814,0.0010843354],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39623836,0.07445522,0.0068501886,0.0021563391,0.0022912687,0.0009687593,0.00035953533,0.005517501,0.2423823,0.0009792282,0.02425796,0.24354331],"study_design_scores_gemma":[0.38383177,0.549635,0.01967768,0.00014344888,0.0009104328,0.0016294745,0.00010840632,0.0040255203,0.023424584,0.000511244,0.016033232,0.000069320595],"about_ca_topic_score_codex":0.0009623271,"about_ca_topic_score_gemma":0.0028943513,"teacher_disagreement_score":0.005524998,"about_ca_system_score_codex":0.00055065623,"about_ca_system_score_gemma":0.0010467577,"threshold_uncertainty_score":0.018482924},"labels":[],"label_agreement":null},{"id":"W2953069975","doi":"10.1097/01.hs9.0000561564.12955.95","title":"S821 NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMA: 2‐YEAR EXTENDED FOLLOW‐UP FROM COHORT D OF THE PHASE 2 CHECKMATE 205 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Dacarbazine; Nivolumab; Medicine; Vinblastine; Internal medicine; Oncology; Stage (stratigraphy); Cohort; Chemotherapy; Cancer; Immunotherapy","score_opus":0.012768751058135743,"score_gpt":0.27930889893961003,"score_spread":0.2665401478814743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953069975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99425405,0.0008690279,0.00015233111,0.00008824845,0.000040789542,0.00059721543,0.0032871156,0.000018087929,0.0006930887],"genre_scores_gemma":[0.9840539,0.0006964234,0.000506906,0.0005093816,0.000082118575,0.00077795,0.012146529,0.000011736828,0.0012149859],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996475,0.00014873437,0.000020218375,0.000071571136,0.00004740924,0.00006447834],"domain_scores_gemma":[0.99928707,0.00008456608,0.0001628348,0.00011687583,0.0000784668,0.00027014164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014627659,0.0006788863,0.0008876193,0.00024825896,0.00036031945,0.0007852973,0.00058166485,0.0005329133,0.0022065088],"category_scores_gemma":[0.000957834,0.00032471993,0.0014130292,0.00029321847,0.0002896741,0.00041899874,0.0004895836,0.0010424008,0.00044394977],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69736516,0.02447094,0.16583987,0.0011806688,0.0060287025,0.0005695227,0.0003587789,0.0025021986,0.019064805,0.00021939431,0.011773642,0.070626296],"study_design_scores_gemma":[0.24329887,0.26054528,0.46902344,0.00022534793,0.0052260356,0.0009985698,0.00027569002,0.0024362947,0.0043239784,0.0002180636,0.013346834,0.000081591024],"about_ca_topic_score_codex":0.0024601056,"about_ca_topic_score_gemma":0.0050842226,"teacher_disagreement_score":0.0024601056,"about_ca_system_score_codex":0.0008780495,"about_ca_system_score_gemma":0.0010520677,"threshold_uncertainty_score":0.0077359676},"labels":[],"label_agreement":null},{"id":"W2953077540","doi":"10.1097/01.hs9.0000562152.07779.48","title":"PS962 PHASE 1 RESULTS OF ZUMA‐4: KTE‐X19, AN ANTI‐CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Refractory (planetary science); Gastroenterology; Bone marrow; Acute lymphocytic leukemia; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Immunology; Leukemia; Lymphoblastic Leukemia; Biology","score_opus":0.00894242772849638,"score_gpt":0.2504569139496639,"score_spread":0.24151448622116753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953077540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555594,0.0007324691,0.00045440954,0.00015546795,0.000024441575,0.0008133231,0.0008628722,0.000053097316,0.0013480388],"genre_scores_gemma":[0.98632777,0.0012566793,0.0018449823,0.00029348905,0.00006223437,0.0015809764,0.0043007582,0.00005032885,0.004282786],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996401,0.00019429618,0.000019044177,0.000040485666,0.000047710688,0.000058371177],"domain_scores_gemma":[0.99965894,0.000068121015,0.000071825365,0.000034316177,0.000028457305,0.00013827086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011990789,0.0011297308,0.00082219875,0.00036573084,0.00033850796,0.00069528114,0.00060945883,0.0007666825,0.002524734],"category_scores_gemma":[0.00053902756,0.0003271745,0.0006377982,0.00023612702,0.00053070247,0.0005017022,0.00034521817,0.002217226,0.0006860459],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33243257,0.15075038,0.021586144,0.00093932025,0.0013169564,0.0011965795,0.0012065207,0.017241037,0.26357517,0.0008424173,0.0106373,0.1982756],"study_design_scores_gemma":[0.16190882,0.7228966,0.03541567,0.000057436242,0.00052252656,0.0016111552,0.00014539737,0.0040052654,0.06358527,0.00038024405,0.009424715,0.000047017475],"about_ca_topic_score_codex":0.00076198415,"about_ca_topic_score_gemma":0.001353441,"teacher_disagreement_score":0.002524734,"about_ca_system_score_codex":0.0007545358,"about_ca_system_score_gemma":0.0010292493,"threshold_uncertainty_score":0.008446097},"labels":[],"label_agreement":null},{"id":"W2953212652","doi":"10.1097/01.hs9.0000559476.99472.fd","title":"PF316 THE CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH AGGRESSIVE LARGE CELL LYMPHOMA AND DIABETES MELLITUS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Single Center; Retrospective cohort study; Diabetes mellitus; Aggressive lymphoma; Epidemiology; Medical record; Gastroenterology; Rituximab","score_opus":0.00951737541155937,"score_gpt":0.2762648557919237,"score_spread":0.26674748038036433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953212652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984712,0.000331086,0.000041332598,0.00008303976,0.0000076699935,0.0000053157382,0.00030956318,0.00000243999,0.00074840203],"genre_scores_gemma":[0.9993549,0.00011324626,0.000035367724,0.000039969516,0.000016304186,0.0000056436,0.00035175087,9.044644e-7,0.00008199929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99973756,0.000049806593,0.00004003538,0.000042741092,0.00006109069,0.00006870576],"domain_scores_gemma":[0.99836797,0.0002210485,0.00093098095,0.000036268033,0.00011851739,0.00032523525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032761772,0.00011575365,0.00019666078,0.00052320136,0.00027990446,0.00043197256,0.0001250857,0.00023960164,0.0016688115],"category_scores_gemma":[0.001809509,0.0000838875,0.00021786161,0.0011081136,0.00015606954,0.0003682042,0.000227763,0.00040868914,0.00023870482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000654053,0.000015629857,0.99867105,0.0000037749262,0.000009848512,0.00007995571,0.000012334051,0.000020797528,0.000062717096,0.0000059218823,0.00009274166,0.00095978106],"study_design_scores_gemma":[0.000008858686,0.00009708634,0.998589,0.0000073615415,0.000012811028,0.00078759616,0.00009736692,0.00011222329,0.000035502766,0.000025630035,0.00022416838,0.0000024624446],"about_ca_topic_score_codex":0.0014679492,"about_ca_topic_score_gemma":0.0016161798,"teacher_disagreement_score":0.0016688115,"about_ca_system_score_codex":0.00029371007,"about_ca_system_score_gemma":0.00029795192,"threshold_uncertainty_score":0.00558275},"labels":[],"label_agreement":null},{"id":"W2953312502","doi":"10.1097/01.hs9.0000564320.41781.43","title":"PS1515 PREMEDICATION WITH MONTELUKAST AND RUPATADINE DECREASES INFUSION TIME, RATE AND SEVERITY OF REACTIONS AND OVERALL COST OF RITUXIMAB ADMINISTRATION","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Rituximab; Diphenhydramine; Montelukast; Premedication; Anesthesia; Placebo; Internal medicine; Gastroenterology; Asthma; Lymphoma","score_opus":0.009343387075642133,"score_gpt":0.24884803119882437,"score_spread":0.23950464412318223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953312502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976676,0.0011015981,0.0001743491,0.00006305089,0.000019436075,0.00004719245,0.00008364204,0.000035441743,0.0008077974],"genre_scores_gemma":[0.9974074,0.0005512039,0.0007804102,0.00006168462,0.000025805535,0.00005018369,0.00023872103,0.0000062958884,0.00087837025],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998123,0.00004109306,0.000028996245,0.000029188906,0.000050215876,0.00003828826],"domain_scores_gemma":[0.999642,0.000048137284,0.00016528874,0.000018342189,0.000028021226,0.00009823771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001821098,0.00018851791,0.0003899134,0.00015973089,0.00008198966,0.00024162988,0.00018343829,0.0001849993,0.002689695],"category_scores_gemma":[0.00053278863,0.00006837245,0.00025879627,0.0001220564,0.000105974155,0.00020139743,0.00013161132,0.00035482872,0.0004991295],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059889767,0.009538006,0.040262345,0.0010339875,0.00039652217,0.00040034374,0.000289354,0.0013607916,0.47703755,0.00025160328,0.0032952128,0.40624458],"study_design_scores_gemma":[0.0055755842,0.28151524,0.2794353,0.00018131646,0.0009909268,0.0035215346,0.0002608264,0.003952722,0.40218478,0.00016521636,0.022166817,0.000049761933],"about_ca_topic_score_codex":0.00025254957,"about_ca_topic_score_gemma":0.00047999035,"teacher_disagreement_score":0.002689695,"about_ca_system_score_codex":0.00015072226,"about_ca_system_score_gemma":0.00036409928,"threshold_uncertainty_score":0.008997917},"labels":[],"label_agreement":null},{"id":"W2953376933","doi":"10.1097/01.hs9.0000559544.58960.b9","title":"PF333 RISK OF BLEEDING COMPLICATIONS AND ATRIAL FIBRILLATION ASSOCIATED WITH IBRUTINIB TREATMENT: A SYSTEMATIC REVIEW AND META‐ANALYSIS","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atrial fibrillation; Medicine; Ibrutinib; Adverse effect; Internal medicine; Meta-analysis; Confidence interval; Randomized controlled trial; Cardiology; Chronic lymphocytic leukemia; Leukemia","score_opus":0.11408786172607231,"score_gpt":0.38178448752326927,"score_spread":0.26769662579719694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953376933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003923945,0.9945649,0.00031763787,0.00016752043,0.00009928494,0.00016331895,0.0005028048,0.000016983138,0.0002435421],"genre_scores_gemma":[0.1531386,0.84235,0.0012828804,0.00067530706,0.0002799293,0.0009788165,0.0009133929,0.000024581903,0.0003564746],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99282455,0.003256018,0.001993711,0.0007929218,0.00083134306,0.00030155445],"domain_scores_gemma":[0.98564965,0.0105911335,0.0024048877,0.00032410055,0.00086674513,0.0001635216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009499621,0.0022703435,0.01413942,0.0056148693,0.0005835209,0.0028963003,0.0018397438,0.002265693,0.0043725693],"category_scores_gemma":[0.021491926,0.0010997987,0.034555726,0.0072154286,0.0006297985,0.0013512636,0.0011846924,0.0016809009,0.00031920115],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027503003,0.000026796128,0.0041172476,0.41106236,0.5651068,0.00012977865,0.00007394537,0.00052362133,0.00017612433,0.00011883009,0.0007569265,0.015157286],"study_design_scores_gemma":[0.0006115644,0.00017358719,0.0042941384,0.024831746,0.96777123,0.00011972965,0.000035648307,0.00018487284,0.00009102211,0.0001768892,0.0016856825,0.000023944487],"about_ca_topic_score_codex":0.006382409,"about_ca_topic_score_gemma":0.010692068,"teacher_disagreement_score":0.01413942,"about_ca_system_score_codex":0.002342605,"about_ca_system_score_gemma":0.003134645,"threshold_uncertainty_score":0.050239444},"labels":[],"label_agreement":null},{"id":"W2974616558","doi":"10.1097/hs9.0000000000000286","title":"Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Intensive care medicine; Normality; Pathological; Disease; Systematic review; MEDLINE; Pathology; Psychiatry","score_opus":0.11921303329455317,"score_gpt":0.3737422878019674,"score_spread":0.2545292545074142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974616558","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018428162,0.25090456,0.08923989,0.58315074,0.04591286,0.004720393,0.0020431252,0.0007507766,0.02143491],"genre_scores_gemma":[0.03469444,0.24822155,0.4870073,0.16729344,0.025382347,0.011663437,0.009546649,0.0005498156,0.01564107],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.93490344,0.027755152,0.020086419,0.003037231,0.011777269,0.0024405674],"domain_scores_gemma":[0.8785425,0.031577237,0.0078055905,0.0043915953,0.06876964,0.008913487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10306418,0.0017342666,0.0030977156,0.011704146,0.002733724,0.007651179,0.008976674,0.009425754,0.0052194153],"category_scores_gemma":[0.10167136,0.0013072025,0.0054171844,0.006429285,0.0047923215,0.006890101,0.009484472,0.016093729,0.0053652953],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106308114,0.00022843818,0.0024510634,0.013753797,0.00024274139,0.0008486824,0.0034833213,0.001009678,0.00094579766,0.047999986,0.58675736,0.34217277],"study_design_scores_gemma":[0.00009897192,0.00010455921,0.0035798296,0.04400168,0.00022206629,0.0015658914,0.002087444,0.0007957377,0.0003776214,0.03636192,0.9106564,0.00014783975],"about_ca_topic_score_codex":0.009847415,"about_ca_topic_score_gemma":0.010336885,"teacher_disagreement_score":0.10306418,"about_ca_system_score_codex":0.009159378,"about_ca_system_score_gemma":0.04573351,"threshold_uncertainty_score":0.545062},"labels":[],"label_agreement":null},{"id":"W2977758416","doi":"10.1097/01.hs9.0000564720.36943.22","title":"S1618 TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH‐RISK CYTOGENETIC ABNORMALITIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Oncology; Internal medicine; Clinical endpoint; Gastroenterology; Clinical trial","score_opus":0.0034592202711760155,"score_gpt":0.20954569199890194,"score_spread":0.20608647172772593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977758416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98661834,0.0064658076,0.00069019804,0.00042008038,0.00007230116,0.0003753495,0.0014480533,0.00024712604,0.0036627678],"genre_scores_gemma":[0.9927154,0.001995046,0.00084252335,0.0004932446,0.000076668584,0.0002560228,0.0019252034,0.000030691357,0.0016651644],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998437,0.000075492586,0.000012944607,0.000021981792,0.000018855355,0.00002698459],"domain_scores_gemma":[0.999718,0.000044868873,0.00009136287,0.000018425813,0.000014751464,0.0001125359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026744916,0.0003348859,0.0010019052,0.00023846143,0.000104291175,0.00036739878,0.00031411168,0.00047018618,0.004682467],"category_scores_gemma":[0.00043313572,0.0001172733,0.00045396635,0.0003516529,0.00022306538,0.00034457914,0.00019829854,0.00068768865,0.0006569739],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21611947,0.011511633,0.028973259,0.0019369386,0.0015535549,0.0015389298,0.00028269787,0.003212565,0.04476912,0.00085737207,0.012169456,0.67707497],"study_design_scores_gemma":[0.27743733,0.41638985,0.18947695,0.0005274823,0.0014857784,0.008582087,0.00033991502,0.0058824066,0.020192869,0.0013264434,0.078245945,0.000112984904],"about_ca_topic_score_codex":0.00039222438,"about_ca_topic_score_gemma":0.0012706418,"teacher_disagreement_score":0.004682467,"about_ca_system_score_codex":0.0003238231,"about_ca_system_score_gemma":0.0006282404,"threshold_uncertainty_score":0.015664458},"labels":[],"label_agreement":null},{"id":"W2977980618","doi":"10.1097/01.hs9.0000563228.79887.e0","title":"PS1237 DOSE DENSE ABVD (DD‐ABVD) AS FIRST LINE THERAPY IN EARLY‐STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI‐CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"ABVD; Dacarbazine; Medicine; Interim analysis; Vinblastine; Radiation therapy; Prospective cohort study; Surgery; Internal medicine; Nuclear medicine; Clinical trial; Chemotherapy; Vincristine","score_opus":0.01901969089911033,"score_gpt":0.3009490587376345,"score_spread":0.2819293678385242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977980618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722195,0.0015642807,0.00026657834,0.00008362884,0.000023033555,0.0003313419,0.0001634314,0.00001952725,0.00032615484],"genre_scores_gemma":[0.99618584,0.0013311242,0.0007508256,0.00020661732,0.00006759461,0.00046975882,0.00065115484,0.000011592773,0.00032547186],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995042,0.0003231951,0.000022481752,0.000049990525,0.000039793824,0.000060257833],"domain_scores_gemma":[0.99925226,0.00023466474,0.00013399003,0.00007491264,0.000036401867,0.00026763722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018561481,0.0007616114,0.0012664222,0.00041767993,0.00023881071,0.00055012037,0.00051384827,0.00055618084,0.0012238835],"category_scores_gemma":[0.00089612947,0.00031661193,0.0006947245,0.00042453804,0.000656958,0.00046799897,0.00025571248,0.001447817,0.00026542458],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5634599,0.111021094,0.036310446,0.0010832933,0.0019015688,0.00033871323,0.0006148373,0.005227417,0.059113525,0.00028800662,0.002278836,0.21836242],"study_design_scores_gemma":[0.23775874,0.72157377,0.032244205,0.000048431735,0.0006659523,0.00039751548,0.000069720016,0.0012658674,0.003971904,0.00013890839,0.0018391785,0.000025871008],"about_ca_topic_score_codex":0.00057705544,"about_ca_topic_score_gemma":0.00094498094,"teacher_disagreement_score":0.0018561481,"about_ca_system_score_codex":0.0004588444,"about_ca_system_score_gemma":0.00073120854,"threshold_uncertainty_score":0.009816349},"labels":[],"label_agreement":null},{"id":"W3005061455","doi":"10.1097/hs9.0000000000000327","title":"Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms","year":2020,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Council Western Australia; National Health and Medical Research Council; Queen's University; Queen's University Belfast; Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Odds ratio; Confidence interval; Internal medicine; Population; Cohort study; Cohort; Essential thrombocythemia; Demography; Pediatrics; Polycythemia vera; Environmental health","score_opus":0.025835282769332987,"score_gpt":0.24792468086158065,"score_spread":0.22208939809224765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005061455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456185,0.0024125846,0.00018862703,0.00017830123,0.000020459644,0.000017414322,0.000783599,0.000012287002,0.0018249131],"genre_scores_gemma":[0.99848205,0.00048133827,0.00019592851,0.000032073396,0.000029384693,0.000008321734,0.0002814974,0.0000033777333,0.00048597238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997652,0.00006649526,0.000024354185,0.000055262946,0.000043176133,0.000045564568],"domain_scores_gemma":[0.99926084,0.00012350382,0.00033733764,0.000051804782,0.000064353415,0.00016217296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023037729,0.00019714083,0.00024997813,0.0006668745,0.00029250566,0.0004761685,0.00024588587,0.00039355384,0.0024685208],"category_scores_gemma":[0.0013057846,0.0001661376,0.00032672097,0.0010259296,0.0001775527,0.00019887836,0.00024863466,0.00055917,0.00022002845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017332243,0.00007466479,0.9959015,0.000030893214,0.000110737994,0.00014030992,0.00005050945,0.000033992037,0.00045732537,0.000043922853,0.000086659355,0.002896116],"study_design_scores_gemma":[0.0000030206556,0.000058355377,0.99943334,0.000007823135,0.000029162347,0.00016077593,0.000029670358,0.00006460288,0.00003228812,0.00002960388,0.00014930317,0.0000020572127],"about_ca_topic_score_codex":0.004883107,"about_ca_topic_score_gemma":0.005938139,"teacher_disagreement_score":0.004883107,"about_ca_system_score_codex":0.00023914654,"about_ca_system_score_gemma":0.000212695,"threshold_uncertainty_score":0.009709358},"labels":[],"label_agreement":null},{"id":"W3005070954","doi":"10.1097/hs9.0000000000000319","title":"The Pediatric Acute Leukemia Fusion Oncogene ETO2‐GLIS2 Increases Self‐Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells‐Derived Model","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Fondation pour la Recherche Médicale; Cancéropôle Ile de France; Agence Nationale de la Recherche; CNIB","keywords":"Induced pluripotent stem cell; Stem cell; Cell biology; Oncogene; Cancer research; Leukemia; Biology; Embryonic stem cell; Neuroscience; Immunology; Apoptosis; Cell cycle; Genetics; Gene","score_opus":0.007684411805674912,"score_gpt":0.21624016842295227,"score_spread":0.20855575661727735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005070954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98906237,0.00061947166,0.0031536068,0.00021033251,0.000046331395,0.0000649445,0.0032900458,0.00013377442,0.0034191785],"genre_scores_gemma":[0.988675,0.0008379072,0.0021300265,0.00007136903,0.0000065051413,0.00006722139,0.0026600168,0.000030204104,0.0055216583],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998337,0.000021231846,0.000021283868,0.000031270432,0.00006091342,0.00003148439],"domain_scores_gemma":[0.99992156,0.000020587682,0.000021284884,0.000009862058,0.0000055616624,0.0000210566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019199743,0.00020988609,0.00015800021,0.00027477436,0.00016620939,0.00030228295,0.00023611804,0.00025896807,0.0026628303],"category_scores_gemma":[0.00008527767,0.00012585081,0.00020986189,0.0002655924,0.00018512369,0.0001841856,0.0001700557,0.00058557314,0.0003622332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005466542,0.0001459377,0.0006717194,0.00004716768,0.0000187433,0.00017033491,0.000043901513,0.0006456093,0.9926495,0.0011065712,0.0007044512,0.0032493428],"study_design_scores_gemma":[0.00008511101,0.00034809194,0.0046323994,0.000007142341,0.000031949367,0.0002892338,0.000056458426,0.0024674048,0.9839298,0.000114594826,0.008032201,0.0000056146005],"about_ca_topic_score_codex":0.0015562531,"about_ca_topic_score_gemma":0.0029573021,"teacher_disagreement_score":0.0026628303,"about_ca_system_score_codex":0.00040729268,"about_ca_system_score_gemma":0.0002976694,"threshold_uncertainty_score":0.008908093},"labels":[],"label_agreement":null},{"id":"W3005555374","doi":"10.1097/01.hs9.0000563932.34778.38","title":"PS1414 A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; Royal Victoria Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Carfilzomib; Internal medicine; Refractory (planetary science); Dexamethasone; Oncology; Phases of clinical research; Gastroenterology; Multiple myeloma; Lenalidomide; Adverse effect; Pharmacology; Chemotherapy","score_opus":0.029405700020044563,"score_gpt":0.32857225329266204,"score_spread":0.2991665532726175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005555374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987849,0.001725042,0.00076111837,0.0008188199,0.00011802871,0.0049588126,0.0014827197,0.00017510731,0.0021114352],"genre_scores_gemma":[0.97561103,0.0024071739,0.0039220164,0.0016615011,0.00020218635,0.005488329,0.0041588484,0.00007228004,0.006476627],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99951375,0.0002551053,0.000021025382,0.0000671089,0.00006433202,0.000078755715],"domain_scores_gemma":[0.9994357,0.00006883741,0.000092274575,0.000040488427,0.000044532902,0.00031818444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021168524,0.0019304401,0.001538498,0.0006527154,0.0005532467,0.0009807714,0.0011247445,0.0012459994,0.0058554206],"category_scores_gemma":[0.00070056185,0.0007064487,0.0012847089,0.00041554193,0.0008115256,0.0007989925,0.00047147562,0.0030473005,0.0011702051],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4906806,0.17512435,0.012017582,0.0016068302,0.0021482434,0.00057612394,0.0006158485,0.0052949544,0.118113324,0.0007024898,0.011306589,0.18181308],"study_design_scores_gemma":[0.49400604,0.48155627,0.011241856,0.000037676335,0.00044229883,0.00047078737,0.00006633302,0.0012939031,0.0057821004,0.0002518917,0.004819438,0.00003137195],"about_ca_topic_score_codex":0.0012987166,"about_ca_topic_score_gemma":0.0037734231,"teacher_disagreement_score":0.0058554206,"about_ca_system_score_codex":0.0011504457,"about_ca_system_score_gemma":0.0023673365,"threshold_uncertainty_score":0.019588292},"labels":[],"label_agreement":null},{"id":"W3005643883","doi":"10.1097/01.hs9.0000561572.20578.17","title":"S823 RANDOMIZED, OPEN‐LABEL, NON‐INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Clinical endpoint; Neutropenia; Refractory (planetary science); Multiple myeloma; Population; Daratumumab; Phases of clinical research; Gastroenterology; Randomized controlled trial; Surgery; Lenalidomide; Clinical trial; Toxicity","score_opus":0.0321007392232158,"score_gpt":0.3338785845535127,"score_spread":0.3017778453302969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005643883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98044306,0.002225996,0.0009779788,0.0011886456,0.0004884644,0.008692483,0.0025671208,0.00026667546,0.0031495916],"genre_scores_gemma":[0.9789083,0.0011578943,0.0018098278,0.0016439883,0.00034211072,0.008110443,0.00195755,0.000068047964,0.006001726],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990895,0.0005549898,0.000027328511,0.00012930087,0.000060454156,0.000138504],"domain_scores_gemma":[0.99877447,0.00026995264,0.00026065556,0.00009626797,0.00008782837,0.00051074394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003323873,0.0017451565,0.0025228902,0.0005227826,0.00069668965,0.0017871122,0.0012738331,0.0018682993,0.014643949],"category_scores_gemma":[0.0016112959,0.0010835005,0.0019025991,0.0006945163,0.0014819616,0.0012052619,0.00053378317,0.0044748625,0.0023519166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9636417,0.015122549,0.00092019304,0.0003591667,0.0005918081,0.00006297455,0.000114886214,0.000448014,0.0076183737,0.00012306629,0.0020242643,0.00897294],"study_design_scores_gemma":[0.9407328,0.055249263,0.001994243,0.000017036878,0.00016561087,0.000037083402,0.000024299834,0.00040571627,0.00027548018,0.00008131934,0.0010051999,0.000011974087],"about_ca_topic_score_codex":0.002346653,"about_ca_topic_score_gemma":0.0077006007,"teacher_disagreement_score":0.014643949,"about_ca_system_score_codex":0.0016812058,"about_ca_system_score_gemma":0.003573374,"threshold_uncertainty_score":0.04898888},"labels":[],"label_agreement":null},{"id":"W3005831402","doi":"10.1097/01.hs9.0000562224.72710.77","title":"PS981 LONG TERM AML SURVIVORS HAVE INCREASED MORTALITY AND HIGH PREVALENCE OF CLONAL HEMATOPOIESIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Bone marrow; Haematopoiesis; Oncology; Leukemia; Internal medicine; clone (Java method); Immunology; Stem cell; Biology; Gene","score_opus":0.02328574315126008,"score_gpt":0.30219314306076733,"score_spread":0.27890739990950725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005831402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978289,0.00043743267,0.00023006585,0.000054850414,0.00001053373,0.000009495455,0.00051984796,0.000012395952,0.00089640555],"genre_scores_gemma":[0.9973652,0.0003907455,0.00012373702,0.00003413409,0.000020236552,0.00002387363,0.00089073996,0.000006051537,0.0011453732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99990964,0.000008971729,0.00000625449,0.000025899428,0.000027088168,0.000022272197],"domain_scores_gemma":[0.999752,0.000028806004,0.00010685952,0.000013955789,0.000026310665,0.000072028444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115829724,0.00019168208,0.00020712493,0.00034417544,0.0003506478,0.00039196273,0.00015605257,0.00021083922,0.005187896],"category_scores_gemma":[0.00033602124,0.000055939367,0.00015223045,0.0005197973,0.0002009413,0.00026439788,0.00031213308,0.00039945636,0.00091893267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011121535,0.00022533665,0.95539945,0.00008086082,0.000054062435,0.0014567989,0.00029834837,0.00015459477,0.0153508,0.00023873175,0.0010872959,0.024541445],"study_design_scores_gemma":[0.000024194247,0.0010546531,0.98716927,0.000014746493,0.000072899595,0.0035642355,0.0003886705,0.00020958766,0.00214156,0.0003767,0.0049734595,0.000009990184],"about_ca_topic_score_codex":0.000607259,"about_ca_topic_score_gemma":0.0004911536,"teacher_disagreement_score":0.005187896,"about_ca_system_score_codex":0.00020754561,"about_ca_system_score_gemma":0.00021934122,"threshold_uncertainty_score":0.017355263},"labels":[],"label_agreement":null},{"id":"W3005887319","doi":"10.1097/01.hs9.0000560956.60646.c2","title":"PF668 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL‐401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Monocytosis; Refractory (planetary science); Internal medicine; Interleukin-3 receptor; Oncology; Phases of clinical research; Ruxolitinib; Myeloid; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.024210525989180925,"score_gpt":0.3103908181273837,"score_spread":0.2861802921382028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005887319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989035,0.0031094898,0.0008192239,0.0010932572,0.0001336562,0.0016603078,0.0020615056,0.00011017666,0.0019773068],"genre_scores_gemma":[0.9862911,0.0018685953,0.0018618617,0.0012538767,0.0003087739,0.0014924867,0.0050880928,0.000032291264,0.0018028604],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992163,0.00043080494,0.00005894453,0.000093153794,0.00008180665,0.00011896056],"domain_scores_gemma":[0.99892235,0.00024222437,0.00023561796,0.00008231419,0.000074737014,0.00044266743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032174399,0.0011975728,0.001302849,0.00032370948,0.0003774155,0.0008839252,0.00064035633,0.001232948,0.0037975572],"category_scores_gemma":[0.001635451,0.00037141962,0.0011694017,0.00032855733,0.0007534853,0.00096215564,0.00029717037,0.0024595018,0.0007983829],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74513495,0.038245626,0.015304273,0.0008095774,0.0016887723,0.0006382749,0.0003712225,0.0035850734,0.04141977,0.0003385946,0.008591094,0.14387277],"study_design_scores_gemma":[0.48382366,0.46828142,0.031704966,0.000089677655,0.0009995219,0.00094152184,0.000080844504,0.0016148883,0.0064928895,0.00033921545,0.0055853617,0.000045965648],"about_ca_topic_score_codex":0.00050858944,"about_ca_topic_score_gemma":0.0011344067,"teacher_disagreement_score":0.0037975572,"about_ca_system_score_codex":0.00077432586,"about_ca_system_score_gemma":0.0011212897,"threshold_uncertainty_score":0.017015696},"labels":[],"label_agreement":null},{"id":"W3005951838","doi":"10.1097/01.hs9.0000560716.15860.50","title":"PF607 MAINTENANCE WITH WEEKLY CARFILZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (IFM 2012–03)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Carfilzomib; Medicine; Lenalidomide; Multiple myeloma; Adverse effect; Melphalan; Maintenance therapy; Internal medicine; Oncology; Chemotherapy","score_opus":0.014678304737559142,"score_gpt":0.2619128628335819,"score_spread":0.24723455809602274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005951838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989843,0.00047290756,0.000058238777,0.00005643243,0.0000098170585,0.00010677829,0.000098609584,0.000008199918,0.00020488774],"genre_scores_gemma":[0.9979786,0.00036707468,0.0003229299,0.00020952916,0.000050757728,0.00017248043,0.00046527013,0.0000033368065,0.00042994972],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997776,0.00006300317,0.000016696073,0.00003976529,0.000029483268,0.00007344998],"domain_scores_gemma":[0.9997081,0.000024239653,0.000049351176,0.000014920648,0.000020575691,0.00018279966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075753697,0.0003832874,0.00076646253,0.00022739627,0.00033308312,0.00026226608,0.00023169766,0.00036371956,0.0007594223],"category_scores_gemma":[0.00041672203,0.00013849899,0.00030785223,0.00020459875,0.0002252696,0.00019655055,0.00026346053,0.00055389886,0.00027246305],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24013792,0.06271463,0.35444838,0.000787646,0.00074169715,0.003499589,0.0009356258,0.0019255222,0.08462736,0.00014476923,0.00633766,0.24369916],"study_design_scores_gemma":[0.03415944,0.34823215,0.5945421,0.00006793859,0.0006058406,0.0030110474,0.0001688419,0.0014522228,0.009493798,0.000082827144,0.008154365,0.00002958062],"about_ca_topic_score_codex":0.001791263,"about_ca_topic_score_gemma":0.0032372493,"teacher_disagreement_score":0.001791263,"about_ca_system_score_codex":0.000517557,"about_ca_system_score_gemma":0.00067224324,"threshold_uncertainty_score":0.0040062666},"labels":[],"label_agreement":null},{"id":"W3006069344","doi":"10.1097/01.hs9.0000562576.71109.e9","title":"PS1071 PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST-IN-CLASS ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO-001, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; Vincristine; Prednisone; Internal medicine; CHOP; Cyclophosphamide; Lymphoma; Oncology; Clinical endpoint; CD30; Gastroenterology; Randomized controlled trial; Chemotherapy","score_opus":0.0056829639859802645,"score_gpt":0.24285167385767537,"score_spread":0.2371687098716951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006069344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839166,0.0043634116,0.0012725844,0.0013330135,0.00016103599,0.0016518659,0.001974851,0.00017291258,0.0051537165],"genre_scores_gemma":[0.98507184,0.0027874412,0.002199013,0.0013991141,0.00015060038,0.0013982503,0.0034270976,0.000059403654,0.003507285],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996013,0.00020187491,0.00002403969,0.000056576922,0.000050446157,0.000065800974],"domain_scores_gemma":[0.9994554,0.00017185215,0.00008709824,0.000053514636,0.000045910594,0.0001863343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011626922,0.000989468,0.0011113299,0.00034015035,0.0003057413,0.0007890182,0.0005695959,0.0008104985,0.003836806],"category_scores_gemma":[0.0009553041,0.00035900756,0.0010865434,0.00033117508,0.0005904028,0.00068093126,0.00025186306,0.0028813784,0.00096046634],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35976154,0.07709023,0.009119204,0.0018665021,0.0030317856,0.00072959,0.00071774266,0.008370409,0.1396148,0.00074663537,0.015412337,0.3835392],"study_design_scores_gemma":[0.3487048,0.5903074,0.030896535,0.00007110856,0.0015400635,0.0006634829,0.00009880244,0.0022597834,0.013800365,0.0007640714,0.010849625,0.000044106608],"about_ca_topic_score_codex":0.00077758793,"about_ca_topic_score_gemma":0.0017604982,"teacher_disagreement_score":0.003836806,"about_ca_system_score_codex":0.00083529,"about_ca_system_score_gemma":0.00097388093,"threshold_uncertainty_score":0.012835383},"labels":[],"label_agreement":null},{"id":"W3006115592","doi":"10.1097/01.hs9.0000560972.91141.2d","title":"PF672 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL‐401) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chronic myelomonocytic leukemia; Internal medicine; Refractory (planetary science); Oncology; Clinical trial; Interleukin-3 receptor; Gastroenterology; Leukemia; Myelodysplastic syndromes; Bone marrow","score_opus":0.030930928187522036,"score_gpt":0.3385047405346094,"score_spread":0.30757381234708736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006115592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885473,0.0024298865,0.0006065313,0.001002978,0.00012825023,0.0019228796,0.0023256785,0.00014316669,0.0028932828],"genre_scores_gemma":[0.98385334,0.0013938391,0.0018129002,0.0010894433,0.0001889507,0.0018670885,0.0066799973,0.000040655763,0.0030737584],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999617,0.0001798617,0.000019253155,0.000047267666,0.000044751654,0.00009180088],"domain_scores_gemma":[0.9993876,0.00012896456,0.00011906654,0.000036345464,0.00005453895,0.00027348517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020943894,0.0010909821,0.0009718201,0.00031389523,0.0003393728,0.0007271078,0.00049892615,0.0011053255,0.0039456785],"category_scores_gemma":[0.0008777309,0.0003581004,0.0006537333,0.00025446143,0.000575475,0.00068158214,0.00023152101,0.002376459,0.00081826415],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.622846,0.06604409,0.01261177,0.0010382686,0.0013109234,0.000618064,0.00048093253,0.0055756466,0.095742084,0.0005962673,0.020170575,0.17296538],"study_design_scores_gemma":[0.51080054,0.44265708,0.023978068,0.000071388,0.0006199958,0.00063158653,0.00007284489,0.0021778662,0.010103523,0.00031382724,0.008534179,0.000038988826],"about_ca_topic_score_codex":0.0008576469,"about_ca_topic_score_gemma":0.0026864032,"teacher_disagreement_score":0.0039456785,"about_ca_system_score_codex":0.00087819016,"about_ca_system_score_gemma":0.0015468686,"threshold_uncertainty_score":0.013199627},"labels":[],"label_agreement":null},{"id":"W3006397179","doi":"10.1097/01.hs9.0000559920.12010.ca","title":"PF427 FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA: INITIAL RESULTS OF THE OPEN‐LABEL EXTENSION PERIOD OF THE SOAR PHASE 2 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Blood groups and transfusion","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Autoimmune hemolytic anemia; Syk; Clinical endpoint; Anemia; Internal medicine; Gastroenterology; Antibody; Immunology; Tyrosine kinase; Clinical trial","score_opus":0.03961826487134432,"score_gpt":0.3492578135471121,"score_spread":0.30963954867576776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006397179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880136,0.0050831186,0.00077378756,0.00066952966,0.0001022956,0.0013232025,0.0014572041,0.00008093359,0.0017086288],"genre_scores_gemma":[0.9866073,0.0034238528,0.0018925215,0.0010904297,0.00019778158,0.0014967915,0.00333096,0.0000385482,0.0019217194],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9992951,0.00032999556,0.000043195363,0.00008621257,0.00011471317,0.00013065108],"domain_scores_gemma":[0.9990927,0.00020263958,0.0001768329,0.00007190102,0.00012729496,0.0003285873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028109162,0.0013163164,0.0018534731,0.0003074932,0.00030327827,0.0008310082,0.0005323805,0.0010328533,0.0024640055],"category_scores_gemma":[0.0014093925,0.00028505907,0.0015007171,0.00028648236,0.0005540834,0.00084243366,0.00030328523,0.0021546674,0.0006298568],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5671114,0.0466322,0.009986501,0.002340076,0.003363675,0.0010468496,0.0008075707,0.0041638883,0.0782096,0.00050630287,0.011691446,0.2741405],"study_design_scores_gemma":[0.47604144,0.47425175,0.028607333,0.00012417219,0.0010759206,0.0013738038,0.00011900462,0.0018715332,0.0075090635,0.0003578522,0.008600276,0.00006776941],"about_ca_topic_score_codex":0.0005507371,"about_ca_topic_score_gemma":0.0016972666,"teacher_disagreement_score":0.0028109162,"about_ca_system_score_codex":0.00066754094,"about_ca_system_score_gemma":0.00108057,"threshold_uncertainty_score":0.014865696},"labels":[],"label_agreement":null},{"id":"W3129688332","doi":"10.1097/hs9.0000000000000540","title":"Hemophilia Gene Therapy: Approaching the First Licensed Product","year":2021,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Genetic enhancement; Clinical trial; Medicine; Intensive care medicine; Gene; Biology; Internal medicine; Genetics","score_opus":0.10629999907020828,"score_gpt":0.35996604074005584,"score_spread":0.2536660416698476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129688332","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012379093,0.9967955,0.00022632896,0.0006459289,0.00030010953,0.0000055612786,0.000017334725,0.000009516717,0.0018759432],"genre_scores_gemma":[0.0006113619,0.99765944,0.00027101245,0.00041713368,0.00018226785,0.000007220557,0.000021130347,0.0000028011468,0.00082760776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971217,0.000058209887,0.000034303084,0.000041322568,0.00013080561,0.000023048173],"domain_scores_gemma":[0.999585,0.00023712474,0.00004609485,0.00001084276,0.000088530265,0.000032447682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010824951,0.0006602662,0.0010578058,0.0018102094,0.00027013948,0.0015159977,0.0007700256,0.0018297109,0.0050288597],"category_scores_gemma":[0.0010148465,0.00027695895,0.00046914237,0.0012218683,0.00060932204,0.0026522824,0.00069980416,0.003017546,0.0030027765],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084705425,0.0000689865,0.000095153075,0.018101754,0.00004541809,0.0003154666,0.00012364864,0.00036431887,0.0043257955,0.015215093,0.04918533,0.91207427],"study_design_scores_gemma":[0.000010556612,0.000078881574,0.00016085885,0.0031010187,0.00003332696,0.00080013054,0.000048368333,0.00006507534,0.0004685226,0.0022911076,0.9929329,0.000009231741],"about_ca_topic_score_codex":0.00083870237,"about_ca_topic_score_gemma":0.0013230457,"teacher_disagreement_score":0.0050288597,"about_ca_system_score_codex":0.0007487126,"about_ca_system_score_gemma":0.0013727602,"threshold_uncertainty_score":0.016823232},"labels":[],"label_agreement":null},{"id":"W3157098966","doi":"10.1097/hs9.0000000000000562","title":"Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial","year":2021,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Incyte; Gilead Sciences; CTI Biopharma; Celgene; Sanofi; Bristol-Myers Squibb","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Quality of life (healthcare); Internal medicine; Clinical trial; Population; Physical therapy; Bone marrow","score_opus":0.027292318968595786,"score_gpt":0.2889486548959623,"score_spread":0.2616563359273665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157098966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219465,0.0051259855,0.000101273,0.00030501527,0.000078068224,0.00024830934,0.00066250685,0.00003732443,0.0012469142],"genre_scores_gemma":[0.99495345,0.0017619074,0.00029736187,0.00045292047,0.00012270226,0.00017132526,0.0016615957,0.0000037718937,0.00057486986],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997943,0.00008926646,0.0000235437,0.000025063333,0.000028923367,0.000038843067],"domain_scores_gemma":[0.99967563,0.000060418883,0.00009779327,0.000023266492,0.000024868374,0.000117908785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010379045,0.0004954842,0.0010171444,0.00018973877,0.00020398849,0.0005229745,0.00025253248,0.00053874584,0.0014174707],"category_scores_gemma":[0.0006727698,0.00014286902,0.0011299148,0.00020838696,0.00019199231,0.00031172714,0.00017891807,0.0011016977,0.00017558997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6003469,0.02209034,0.049478125,0.0015025033,0.0052247276,0.0004436986,0.00023028684,0.003466536,0.026533877,0.00022718884,0.008682993,0.28177273],"study_design_scores_gemma":[0.42023933,0.28891954,0.267432,0.0002396522,0.0036323844,0.0013468697,0.00013073676,0.0057200766,0.004980528,0.00027214203,0.0070062755,0.00008038696],"about_ca_topic_score_codex":0.0005134595,"about_ca_topic_score_gemma":0.0016710453,"teacher_disagreement_score":0.0014174707,"about_ca_system_score_codex":0.00026358743,"about_ca_system_score_gemma":0.00033848616,"threshold_uncertainty_score":0.0054890513},"labels":[],"label_agreement":null},{"id":"W3193211635","doi":"10.1097/hs9.0000000000000617","title":"Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial","year":2021,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Hazard ratio; Clinical endpoint; Myeloid leukemia; Randomized controlled trial; Surgery; Confidence interval","score_opus":0.021040620247418988,"score_gpt":0.31190299356853796,"score_spread":0.29086237332111897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193211635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98323387,0.008371958,0.0008260607,0.0009372043,0.00047805693,0.0027462018,0.0008170275,0.00017455005,0.0024150712],"genre_scores_gemma":[0.9801602,0.0057414225,0.002460868,0.0018749547,0.00044456677,0.0047945743,0.0017399336,0.000028473512,0.0027549053],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996939,0.00017431709,0.000015720334,0.000047070844,0.000026539159,0.000042478834],"domain_scores_gemma":[0.9994949,0.00012775346,0.00013707411,0.00004238751,0.000028162995,0.00016980313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011961893,0.00094881706,0.0018242153,0.00023815857,0.0002592089,0.0008077895,0.0005753691,0.0010046053,0.0039605335],"category_scores_gemma":[0.0009596011,0.00027005066,0.0014809191,0.00032835567,0.0006123979,0.00063617574,0.00030820433,0.0026300137,0.0006975503],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9015991,0.010975776,0.0014163906,0.0013278017,0.001262077,0.00015439205,0.00010974253,0.001079871,0.008337295,0.00038067545,0.0029103789,0.07044651],"study_design_scores_gemma":[0.90811086,0.08602339,0.0022307606,0.0000550526,0.00029726065,0.00012936592,0.000023561845,0.00066830596,0.0004826607,0.00031696568,0.001648497,0.000013268765],"about_ca_topic_score_codex":0.00032543862,"about_ca_topic_score_gemma":0.0011233311,"teacher_disagreement_score":0.0039605335,"about_ca_system_score_codex":0.0004667041,"about_ca_system_score_gemma":0.0008557739,"threshold_uncertainty_score":0.013249278},"labels":[],"label_agreement":null},{"id":"W4210423203","doi":"10.1097/01.hs9.0000821540.81071.fa","title":"P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Thalassemia; Medicine; Internal medicine; Placebo; Ineffective erythropoiesis; Blood transfusion; Gastroenterology; Anemia; Erythropoiesis; Pathology","score_opus":0.01872629741786702,"score_gpt":0.2970107363367706,"score_spread":0.2782844389189036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210423203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9112913,0.015139784,0.0038454316,0.0046747383,0.0030171226,0.048389114,0.0057014474,0.00080942723,0.0071315886],"genre_scores_gemma":[0.9092797,0.007284639,0.007961903,0.0073792012,0.0016147143,0.054713126,0.0031067715,0.00011963885,0.008540246],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986903,0.0006576016,0.0001050889,0.00026693524,0.00013512766,0.00014486744],"domain_scores_gemma":[0.9983551,0.00046563568,0.00042157603,0.00012105582,0.00016094011,0.00047569152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033226002,0.0028508161,0.003553522,0.0007195896,0.0008832722,0.0018310464,0.001457748,0.004215702,0.0113088265],"category_scores_gemma":[0.0033142776,0.0011322782,0.0031197283,0.0005110141,0.0015173699,0.0017402704,0.0005669443,0.0047233747,0.0015197861],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96809757,0.01142093,0.0003210749,0.0015590393,0.001435829,0.000053782005,0.000071783266,0.00017763092,0.0037396913,0.0001829161,0.0015813889,0.011358284],"study_design_scores_gemma":[0.96765894,0.030549388,0.0004528892,0.00003120453,0.00026960255,0.000019248788,0.000009996115,0.000099682664,0.00024917137,0.000078614445,0.0005699164,0.00001142018],"about_ca_topic_score_codex":0.0006713376,"about_ca_topic_score_gemma":0.0015413433,"teacher_disagreement_score":0.0113088265,"about_ca_system_score_codex":0.00076018187,"about_ca_system_score_gemma":0.0015808684,"threshold_uncertainty_score":0.037831783},"labels":[],"label_agreement":null},{"id":"W4210650909","doi":"10.1097/01.hs9.0000821448.70992.5a","title":"S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Deferiprone; Medicine; Deferoxamine; Clinical endpoint; Population; Anemia; Deferasirox; Sickle cell anemia; Thalassemia; Adverse effect; Randomized controlled trial; Subgroup analysis; Pediatrics; Internal medicine; Clinical trial; Disease; Meta-analysis","score_opus":0.0033041924031480007,"score_gpt":0.19530226310522733,"score_spread":0.19199807070207933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210650909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724998,0.01566169,0.00064901385,0.0010604686,0.0006596978,0.005086532,0.0025311941,0.00011750637,0.0017341962],"genre_scores_gemma":[0.9858181,0.003446238,0.0010957565,0.0010752911,0.0004752959,0.0052084285,0.0016045269,0.000014693862,0.0012617711],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990007,0.0005687518,0.000097962016,0.00016255466,0.00006662481,0.000103442064],"domain_scores_gemma":[0.99887806,0.00036053947,0.000396418,0.00007413924,0.00007874137,0.00021219536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016967093,0.0017169203,0.0040387814,0.00042481293,0.000288533,0.00089520053,0.00074003125,0.0015791985,0.006037684],"category_scores_gemma":[0.002788844,0.00048497593,0.0034404509,0.00042429467,0.000493958,0.00063857704,0.0003944679,0.0019137374,0.0003904903],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9849712,0.0008985154,0.0011983508,0.0010918191,0.004354816,0.000048463273,0.000032691096,0.00015696486,0.0008254497,0.0000745326,0.00053441443,0.005812798],"study_design_scores_gemma":[0.96180576,0.029359022,0.0036653534,0.000105461346,0.0036156047,0.000052368465,0.000035509478,0.00041824993,0.00018349318,0.00016720155,0.0005738161,0.000018193809],"about_ca_topic_score_codex":0.0010965739,"about_ca_topic_score_gemma":0.0025582912,"teacher_disagreement_score":0.006037684,"about_ca_system_score_codex":0.00081968564,"about_ca_system_score_gemma":0.0011791319,"threshold_uncertainty_score":0.020198047},"labels":[],"label_agreement":null},{"id":"W4220715528","doi":"10.1097/hs9.0000000000000694","title":"Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McMaster University; Impact","funders":"","keywords":"Interquartile range; Medicine; Logistic regression; Population; Internal medicine; Pediatrics","score_opus":0.01900083156459565,"score_gpt":0.27007809956408885,"score_spread":0.2510772679994932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220715528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99907863,0.00039838988,0.000094439325,0.000030060835,0.0000024171877,0.0000047248172,0.0002311189,0.0000023254804,0.00015795216],"genre_scores_gemma":[0.9993573,0.00012018664,0.000109079316,0.000014251237,0.0000054131588,0.0000048767497,0.00034010832,8.9824994e-7,0.00004795155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995134,0.0001704738,0.000080717335,0.00010512246,0.00007980587,0.000050504197],"domain_scores_gemma":[0.9972588,0.0011441943,0.0011206786,0.00014564373,0.00014377049,0.00018691146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096149725,0.00021386716,0.0004375033,0.0005063021,0.00014147435,0.00041607468,0.00018636911,0.00038450462,0.00077913137],"category_scores_gemma":[0.0034048967,0.00014439266,0.0005232617,0.0007185664,0.0001459693,0.00038856937,0.00026692363,0.00065634097,0.00018098287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034355812,0.000023847217,0.99671966,0.000013397503,0.000053600845,0.0000484235,0.00003888389,0.00012823322,0.00014998262,0.000009692442,0.00007074354,0.0023999838],"study_design_scores_gemma":[0.000012189354,0.00025854807,0.9982759,0.000009565335,0.00005196956,0.0003252831,0.000071151866,0.00064006425,0.00011940893,0.000034891378,0.0001961621,0.000004840325],"about_ca_topic_score_codex":0.0007511553,"about_ca_topic_score_gemma":0.0007970709,"teacher_disagreement_score":0.00096149725,"about_ca_system_score_codex":0.00018380245,"about_ca_system_score_gemma":0.00015493346,"threshold_uncertainty_score":0.005084932},"labels":[],"label_agreement":null},{"id":"W4225775959","doi":"10.1097/hs9.0000000000000705","title":"Concurrent Composite Lymphomas Collectively Bearing Three Diagnostic Entities of Shared Clonal Origin","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Lymphoma; Diffuse large B-cell lymphoma; Germinal center; Medicine; Internal medicine; Oncology; Cancer research; Pathology; B cell; Immunology; Antibody","score_opus":0.027527033035187592,"score_gpt":0.2662789280037343,"score_spread":0.23875189496854674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225775959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94385356,0.010693343,0.013301875,0.0017457068,0.0003686282,0.00066850986,0.0008501245,0.00082199107,0.027696166],"genre_scores_gemma":[0.991531,0.0011438235,0.004067002,0.000994512,0.0005278865,0.00006599994,0.00027896033,0.00007833353,0.0013124725],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99876046,0.000093264694,0.00013684163,0.00037542073,0.00020370005,0.00043039242],"domain_scores_gemma":[0.9969549,0.0006538974,0.00060961075,0.00060733204,0.00023921448,0.0009350133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055402215,0.002380546,0.0017739572,0.004168532,0.0029677039,0.003038647,0.0020263407,0.003092894,0.0045854654],"category_scores_gemma":[0.0038404,0.0013570609,0.0011490203,0.0031093496,0.0024381508,0.0028793393,0.0046252003,0.0034101445,0.0016470451],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001040034,0.00008609711,0.027581198,0.00011882399,0.000027082668,0.96106106,0.00033908463,0.000135522,0.0023786484,0.00078424317,0.00078068784,0.006603587],"study_design_scores_gemma":[0.000015145142,0.000027241373,0.0035095098,0.000017465498,0.000019777757,0.9944812,0.00010565902,0.00024046563,0.00048172264,0.00030459833,0.00078655215,0.000010751586],"about_ca_topic_score_codex":0.003758771,"about_ca_topic_score_gemma":0.0048040086,"teacher_disagreement_score":0.0045854654,"about_ca_system_score_codex":0.0018862466,"about_ca_system_score_gemma":0.0011584808,"threshold_uncertainty_score":0.015339971},"labels":[],"label_agreement":null},{"id":"W4226046585","doi":"10.1097/01.hs9.0000829592.26407.09","title":"P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Bible College","funders":"","keywords":"Daratumumab; Medicine; Lenalidomide; Internal medicine; Multiple myeloma; Hematology; Oncology; Family medicine","score_opus":0.03345863001137283,"score_gpt":0.2901135033741483,"score_spread":0.2566548733627755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226046585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858213,0.009877654,0.0002684108,0.0009290536,0.00035161816,0.00034437623,0.00079967885,0.00007853238,0.0015292909],"genre_scores_gemma":[0.98735356,0.0042410474,0.0009121147,0.0018666519,0.00043859964,0.00064294523,0.0024167725,0.000030559957,0.0020979238],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99939954,0.0003077254,0.00003708496,0.000108247106,0.00006496242,0.00008245096],"domain_scores_gemma":[0.99942195,0.0001393623,0.00016294779,0.000036634232,0.000018907911,0.00022015469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019724136,0.0013287631,0.0021528045,0.00044357538,0.0003684096,0.001811898,0.0009919131,0.0009343819,0.0026867485],"category_scores_gemma":[0.0012597279,0.00047470245,0.0028633196,0.0004694974,0.000968966,0.0012975847,0.00065985764,0.0024249628,0.0005483948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8982038,0.0053159688,0.00699459,0.00068597245,0.004698111,0.00012463711,0.00013845801,0.0017468948,0.0035956851,0.00029626518,0.0037521573,0.07444759],"study_design_scores_gemma":[0.8286121,0.13034026,0.02957721,0.00013602283,0.0034403834,0.0004106042,0.00017418289,0.0018891271,0.0009411901,0.0005448105,0.0038748416,0.000059327493],"about_ca_topic_score_codex":0.00128727,"about_ca_topic_score_gemma":0.003034931,"teacher_disagreement_score":0.0026867485,"about_ca_system_score_codex":0.001509274,"about_ca_system_score_gemma":0.0011566911,"threshold_uncertainty_score":0.010950625},"labels":[],"label_agreement":null},{"id":"W4244549863","doi":"10.1097/hs9.0000000000000081","title":"Relapsed/Refractory Hodgkin Lymphoma","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Download; Medicine; Glioblastoma; Refractory (planetary science); Internal medicine; Oncology; Library science; Cancer research; Computer science; World Wide Web; Biology","score_opus":0.017253013479712986,"score_gpt":0.2710261903154046,"score_spread":0.2537731768356916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244549863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80463547,0.038134497,0.002034421,0.0038114723,0.00070655154,0.00042463542,0.0028463576,0.0005359393,0.1468706],"genre_scores_gemma":[0.95762485,0.0065019345,0.00078517164,0.0028029967,0.0008363869,0.000061495346,0.0028930132,0.00005584625,0.028438274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998698,0.000013531815,0.000010586679,0.000027033926,0.000022390335,0.00005659493],"domain_scores_gemma":[0.9998443,0.000024011802,0.000018348699,0.000020968806,0.000017719398,0.00007456062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016976635,0.00024236638,0.00054228754,0.0003138629,0.00046067438,0.00049089926,0.00027183074,0.00027556534,0.0073794806],"category_scores_gemma":[0.00032291087,0.000077583514,0.00031389046,0.00030520515,0.0002595106,0.00027965318,0.00020128474,0.00045657525,0.0028932404],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00775194,0.0013387024,0.14760284,0.0010700207,0.0003065374,0.14261478,0.00057033054,0.00059993874,0.032145377,0.0029236884,0.068341054,0.5947347],"study_design_scores_gemma":[0.002013143,0.0070358,0.30141625,0.00072395225,0.00065420853,0.43567827,0.0006900142,0.0016106096,0.015965844,0.004624269,0.22950518,0.000082384875],"about_ca_topic_score_codex":0.0015438021,"about_ca_topic_score_gemma":0.004629351,"teacher_disagreement_score":0.0073794806,"about_ca_system_score_codex":0.0007419947,"about_ca_system_score_gemma":0.0005323833,"threshold_uncertainty_score":0.024686813},"labels":[],"label_agreement":null},{"id":"W4283217918","doi":"10.1097/hs9.0000000000000745","title":"A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Follicular lymphoma; Internal medicine; Refractory (planetary science); Retrospective cohort study; Rituximab; Confidence interval; Cohort; Oncology; Lymphoma; Surgery; Biology","score_opus":0.009417120956188822,"score_gpt":0.24231788140318222,"score_spread":0.2329007604469934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283217918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985317,0.00017402231,0.00016343189,0.000015493893,0.000004580974,0.000047384015,0.0008109809,0.000005064924,0.00024731504],"genre_scores_gemma":[0.99838746,0.00006337281,0.00013633861,0.000040347608,0.000013695206,0.000041394134,0.001200507,0.0000028988645,0.00011396646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988887,0.00030415537,0.00014515485,0.0003350677,0.00017622746,0.00015068776],"domain_scores_gemma":[0.9971987,0.00037738896,0.0012804576,0.00048372746,0.00027866382,0.0003810895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014846312,0.0002963326,0.00044393115,0.0007699347,0.00056267856,0.00067739666,0.0003501374,0.00038091262,0.0010245772],"category_scores_gemma":[0.0026499701,0.00032202146,0.00042151584,0.0008648014,0.00029839965,0.00072086207,0.000551765,0.000515909,0.0003047353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004492481,0.00008733795,0.9977315,0.000010632412,0.00006172338,0.00009027084,0.00007590426,0.000024744899,0.00017489784,0.000018042809,0.00011610998,0.0011596541],"study_design_scores_gemma":[0.000096540396,0.0013674157,0.99600476,0.000009462921,0.00008908208,0.00092804106,0.00025068654,0.00021925867,0.00014663179,0.000025606263,0.000852372,0.000010240185],"about_ca_topic_score_codex":0.003279973,"about_ca_topic_score_gemma":0.0036709495,"teacher_disagreement_score":0.003279973,"about_ca_system_score_codex":0.00047087783,"about_ca_system_score_gemma":0.00044784448,"threshold_uncertainty_score":0.007851601},"labels":[],"label_agreement":null},{"id":"W4283311013","doi":"10.1097/01.hs9.0000848268.24972.7c","title":"P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cumulative incidence; Internal medicine; Transplantation; Incidence (geometry); Oncology; Lymphoma; Gastroenterology; Cancer; Immunotherapy","score_opus":0.010859275549186656,"score_gpt":0.22239159879390863,"score_spread":0.211532323244722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283311013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929091,0.0030725007,0.0004332507,0.00014151433,0.000016524573,0.00011138137,0.0018829085,0.000009285424,0.0014235729],"genre_scores_gemma":[0.99714595,0.00036489315,0.00019775615,0.00013221378,0.00003170493,0.00008738589,0.0018767889,0.0000043113373,0.00015905648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981072,0.00062517,0.000276919,0.0003804932,0.0004358226,0.00017440644],"domain_scores_gemma":[0.99478537,0.0016983981,0.0026969996,0.00024292308,0.00028834463,0.00028795743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035545824,0.00025064565,0.00072927633,0.00044072975,0.00028326423,0.00083709275,0.0004428766,0.0004276979,0.001809819],"category_scores_gemma":[0.005970961,0.00010381818,0.0011159951,0.0008377367,0.00027695842,0.00071111345,0.00041062068,0.00081870094,0.0002312135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035495028,0.00051137846,0.87276226,0.0007940275,0.0018008283,0.00033800214,0.00020490018,0.0013921876,0.005698437,0.0003281404,0.0017358926,0.07893889],"study_design_scores_gemma":[0.0015127524,0.012677663,0.97392684,0.00012152426,0.0015339028,0.0012724701,0.00011112116,0.00153831,0.0025842604,0.00034465233,0.0043519433,0.000024639474],"about_ca_topic_score_codex":0.00038279573,"about_ca_topic_score_gemma":0.00068887026,"teacher_disagreement_score":0.0035545824,"about_ca_system_score_codex":0.00069762213,"about_ca_system_score_gemma":0.00069519767,"threshold_uncertainty_score":0.01879865},"labels":[],"label_agreement":null},{"id":"W4283312353","doi":"10.1097/01.hs9.0000843628.63947.e4","title":"S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Cytokine release syndrome; Chimeric antigen receptor; Cohort; Oncology; Antigen; Gastroenterology; Immunology; Cancer; Immunotherapy","score_opus":0.025269656908133178,"score_gpt":0.2987480830311138,"score_spread":0.2734784261229806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283312353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970092,0.0010325564,0.00014481625,0.00009823347,0.000019041881,0.00038991545,0.00047440242,0.000021307336,0.00081053056],"genre_scores_gemma":[0.9973636,0.0004984549,0.00033234002,0.00017696444,0.000051835435,0.00022670798,0.0008741764,0.0000047010926,0.00047119008],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972564,0.00011674117,0.000027527842,0.000049722563,0.0000402674,0.00004012434],"domain_scores_gemma":[0.99957556,0.000076520395,0.00014773216,0.000021567623,0.00004347122,0.00013509506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009796255,0.00047585226,0.0010252735,0.00029845742,0.00025789795,0.00047878036,0.00029808347,0.00044083776,0.0020692842],"category_scores_gemma":[0.0007949213,0.00018622843,0.001116102,0.000364121,0.00019534996,0.00031899064,0.00022679043,0.0005338361,0.00041264133],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.506559,0.009209551,0.20126747,0.0016314827,0.0036581047,0.0015731512,0.00039852798,0.004566552,0.059068598,0.00018118398,0.0029337967,0.2089526],"study_design_scores_gemma":[0.08369102,0.56707424,0.3145383,0.00015033114,0.0035512713,0.0023584268,0.00017847057,0.003906579,0.013687513,0.0001758773,0.010644373,0.000043493845],"about_ca_topic_score_codex":0.00074446015,"about_ca_topic_score_gemma":0.001858533,"teacher_disagreement_score":0.0020692842,"about_ca_system_score_codex":0.0008131186,"about_ca_system_score_gemma":0.0011213815,"threshold_uncertainty_score":0.0069224834},"labels":[],"label_agreement":null},{"id":"W4283314633","doi":"10.1097/01.hs9.0000844964.23639.25","title":"P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX-BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Venetoclax; Internal medicine; Ven; Cytarabine; Decitabine; Cohort; Oncology; Myeloid leukemia; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03312147384718491,"score_gpt":0.2934403156632037,"score_spread":0.26031884181601883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283314633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93261737,0.048161685,0.00035754312,0.0010859953,0.000058034948,0.00034696597,0.012714081,0.000017631042,0.0046407576],"genre_scores_gemma":[0.9868339,0.0069786822,0.00048653464,0.00041119562,0.000082706,0.00011902827,0.0048527494,0.000007812988,0.00022737525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590236,0.00160709,0.00081568037,0.00054938893,0.0009461945,0.000179186],"domain_scores_gemma":[0.9747014,0.0097662,0.012678431,0.0005216257,0.0016045106,0.00072776637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057044383,0.00016855083,0.0005851321,0.0013322891,0.00023149121,0.0011549917,0.0006006872,0.00043938134,0.002170052],"category_scores_gemma":[0.017199472,0.00015438751,0.0017571377,0.002582568,0.0002608608,0.00067526987,0.00078267086,0.0006443396,0.00022143689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013100822,0.00034172225,0.91546977,0.0032109157,0.0043037334,0.00008664302,0.00024277119,0.0002648524,0.00028315777,0.00023173234,0.0030306375,0.059433125],"study_design_scores_gemma":[0.0016585789,0.0027393578,0.98079795,0.0013961799,0.006142644,0.00046237884,0.0003965318,0.00042543985,0.00031743138,0.000112371505,0.0055149496,0.00003619699],"about_ca_topic_score_codex":0.0031893419,"about_ca_topic_score_gemma":0.0061170557,"teacher_disagreement_score":0.0057044383,"about_ca_system_score_codex":0.00094667106,"about_ca_system_score_gemma":0.0011325845,"threshold_uncertainty_score":0.030168295},"labels":[],"label_agreement":null},{"id":"W4283315560","doi":"10.1097/01.hs9.0000848220.74181.5a","title":"P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Calgary","funders":"","keywords":"Rituximab; Medicine; Transplantation; Internal medicine; Immunosuppression; Hematopoietic stem cell transplantation; Post-transplant lymphoproliferative disorder; Oncology; Salvage therapy; Immunology; Lymphoma; Chemotherapy","score_opus":0.016660536445774227,"score_gpt":0.29727953607706564,"score_spread":0.28061899963129144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283315560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504185,0.0013882241,0.000083363215,0.000064877655,0.0000053677572,0.0000775274,0.0028266304,0.0000057047732,0.00050650304],"genre_scores_gemma":[0.996075,0.00088198745,0.0002192804,0.00009501285,0.000012885881,0.000089360736,0.0025087344,0.000004581196,0.00011310561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898285,0.00014739625,0.00029276844,0.00027011815,0.00020830457,0.0000986497],"domain_scores_gemma":[0.9952573,0.000458278,0.0033057549,0.0001799497,0.00046062988,0.00033807658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010080588,0.00022759258,0.00037339138,0.0018399172,0.00061497575,0.0009035591,0.0005321365,0.0003372732,0.0011235463],"category_scores_gemma":[0.0023467243,0.00026938875,0.00041093904,0.0028991369,0.0004184816,0.000704686,0.0007010518,0.00035021466,0.00022173475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039111022,0.000015949201,0.9981363,0.0000595332,0.000032478554,0.00028417577,0.00017874384,0.000011469192,0.00008131933,0.000012150315,0.00020584535,0.0009429857],"study_design_scores_gemma":[0.000009798569,0.00007293204,0.99651897,0.000064292246,0.000058578014,0.0015539943,0.00075030606,0.00006908506,0.00009845127,0.000008385421,0.00078815036,0.0000070277893],"about_ca_topic_score_codex":0.013272782,"about_ca_topic_score_gemma":0.018517705,"teacher_disagreement_score":0.013272782,"about_ca_system_score_codex":0.0012470887,"about_ca_system_score_gemma":0.0013948599,"threshold_uncertainty_score":0.026391089},"labels":[],"label_agreement":null},{"id":"W4283315989","doi":"10.1097/01.hs9.0000843712.33707.fe","title":"S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Obinutuzumab; Internal medicine; Gastroenterology; Phases of clinical research; Follicular lymphoma; Progression-free survival; Refractory (planetary science); Randomized controlled trial; Surrogate endpoint; Surgery; Oncology; Clinical trial; Lymphoma; Chemotherapy; CD20","score_opus":0.013264919863490817,"score_gpt":0.27890062428605017,"score_spread":0.26563570442255935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283315989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99151003,0.0036174534,0.0002141843,0.0006252453,0.00020481726,0.0009800444,0.0007647552,0.0000923809,0.001991124],"genre_scores_gemma":[0.99387854,0.0016493807,0.00049572956,0.00052578415,0.00018184085,0.00060200103,0.0007045889,0.0000133938465,0.0019487225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99954104,0.00027438567,0.00001920854,0.000059011338,0.000034903227,0.000071477436],"domain_scores_gemma":[0.99959403,0.00009854733,0.000112623726,0.000025583806,0.00001755298,0.00015168163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015565605,0.0011085522,0.0016498655,0.00030924246,0.00020339226,0.0009897117,0.00076956535,0.00085460243,0.005320975],"category_scores_gemma":[0.00081330613,0.00045706404,0.001230305,0.0003077108,0.00068666926,0.0006973101,0.0003344807,0.002199485,0.00082566537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9507349,0.004928449,0.0011737107,0.0007229467,0.0009184818,0.00006704755,0.000075373166,0.00084575947,0.006200622,0.00016436186,0.0016954248,0.032472868],"study_design_scores_gemma":[0.8101492,0.1793593,0.004953249,0.000060844242,0.001098835,0.00011983622,0.000046030997,0.0010551146,0.001350383,0.00021290586,0.0015748546,0.000019452144],"about_ca_topic_score_codex":0.0010469023,"about_ca_topic_score_gemma":0.004176693,"teacher_disagreement_score":0.005320975,"about_ca_system_score_codex":0.00087012316,"about_ca_system_score_gemma":0.0009502012,"threshold_uncertainty_score":0.01780039},"labels":[],"label_agreement":null},{"id":"W4283318495","doi":"10.1097/01.hs9.0000844896.35718.c4","title":"P502: CLINICAL IMPLEMENTATION OF GERMLINE GENETIC TESTING FOR HEMATOLOGIC DISORDERS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hematology; Genetic testing; Internal medicine; Germline; Cancer; Oncology; Germline mutation; Lynch syndrome; Population; Referral; Family medicine; Mutation; Genetics; Biology","score_opus":0.0748785243221959,"score_gpt":0.4288595605038129,"score_spread":0.353981036181617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283318495","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9387649,0.0028313103,0.0055394783,0.0065632504,0.00020465376,0.001297822,0.0016886585,0.0008868728,0.042223006],"genre_scores_gemma":[0.98711526,0.0014065834,0.007658153,0.001307516,0.000094150404,0.00022361668,0.0007950561,0.00010415916,0.0012956093],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775827,0.00070786366,0.00028263326,0.00034586937,0.00059944956,0.00030591464],"domain_scores_gemma":[0.99222904,0.0019940068,0.0013953665,0.00043962421,0.0019769254,0.0019649675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034286932,0.00019955818,0.00014687877,0.0009405969,0.0008193818,0.0014212481,0.0007579247,0.000471259,0.0038815879],"category_scores_gemma":[0.012525967,0.00020854916,0.00018506104,0.00089284097,0.00047830638,0.00066669274,0.0013838534,0.0007206677,0.0010636593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021409312,0.00021212395,0.85417235,0.00014727643,0.000011487058,0.005378893,0.0018336932,0.00039092253,0.002036724,0.00030486437,0.0127051305,0.12259244],"study_design_scores_gemma":[0.000046081503,0.001158915,0.9298234,0.00061129197,0.00003639334,0.019943167,0.0047167866,0.0026056457,0.0029231273,0.000490957,0.037596114,0.00004807473],"about_ca_topic_score_codex":0.015205456,"about_ca_topic_score_gemma":0.017038774,"teacher_disagreement_score":0.015205456,"about_ca_system_score_codex":0.0015938659,"about_ca_system_score_gemma":0.003908254,"threshold_uncertainty_score":0.03023386},"labels":[],"label_agreement":null},{"id":"W4283320497","doi":"10.1097/01.hs9.0000845140.40137.c7","title":"P563: A RANDOMIZED, DOUBLE-BLIND, 2-ARM, MULTICENTER, PH3 STUDY OF VENETOCLAX & ORAL AZACITIDINE VS. ORAL AZACITIDINE AS MAINTENANCE THERAPY FOR PTS WITH AML IN FIRST REMISSION AFTER INTENSIVE CHEMOTHERAPHY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Azacitidine; Venetoclax; Internal medicine; Induction chemotherapy; Maintenance therapy; Chemotherapy; Ven; Gastroenterology; Oncology; Leukemia; Surgery; Chronic lymphocytic leukemia","score_opus":0.03767137095473121,"score_gpt":0.3261266026400179,"score_spread":0.2884552316852867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283320497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842003,0.0035689536,0.00062772346,0.0010622942,0.0006302747,0.0055542435,0.0015546163,0.00018191198,0.002619705],"genre_scores_gemma":[0.9780175,0.0028537079,0.0022329767,0.0020243202,0.00065500336,0.0068483497,0.001662501,0.00005447178,0.005651134],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99952936,0.0002234052,0.00002286949,0.00010497257,0.00003105452,0.00008831975],"domain_scores_gemma":[0.9993605,0.00011912851,0.00013292432,0.000050018145,0.00003355927,0.00030377303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001593259,0.0016549234,0.0026933467,0.00038895424,0.00062671094,0.0011923431,0.0010472374,0.0022941476,0.009058175],"category_scores_gemma":[0.0011544692,0.00069641677,0.0015339237,0.0004919797,0.0013065726,0.0011029446,0.00043103512,0.0031510678,0.0016071246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98189926,0.0064526717,0.00031511605,0.00023985938,0.00029481886,0.000025648515,0.000025863143,0.00011349696,0.0026808823,0.00006430804,0.00057702616,0.007311047],"study_design_scores_gemma":[0.96397245,0.03450354,0.0007390369,0.000011532512,0.00013023178,0.00001688171,0.000007511945,0.00011982056,0.00016156866,0.000064044005,0.00026689484,0.0000065062513],"about_ca_topic_score_codex":0.0009782512,"about_ca_topic_score_gemma":0.0020662625,"teacher_disagreement_score":0.009058175,"about_ca_system_score_codex":0.00076901884,"about_ca_system_score_gemma":0.0018636748,"threshold_uncertainty_score":0.030302644},"labels":[],"label_agreement":null},{"id":"W4283325455","doi":"10.1097/01.hs9.0000843736.56298.a7","title":"S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Chemoimmunotherapy; Hazard ratio; Internal medicine; Oncology; Refractory (planetary science); Phases of clinical research; Surgery; Clinical trial; Lymphoma; Confidence interval; Rituximab","score_opus":0.02406320880621695,"score_gpt":0.3345384065848873,"score_spread":0.3104751977786704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283325455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939546,0.0020215858,0.00013474558,0.00029613893,0.00009907216,0.00073671766,0.0018661395,0.000024676348,0.0008662643],"genre_scores_gemma":[0.989472,0.0010377504,0.00062479905,0.0010018207,0.00027383707,0.0015759461,0.004884773,0.000018486391,0.0011104923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99861157,0.00083699264,0.00007927175,0.00014899315,0.0001287396,0.00019441156],"domain_scores_gemma":[0.9981603,0.00039938686,0.00048625635,0.00018137594,0.00014788812,0.00062468176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043355282,0.001311516,0.0019095333,0.00040687242,0.00046997398,0.0012922746,0.0009079774,0.0014331207,0.0046376023],"category_scores_gemma":[0.0019959374,0.00043555564,0.004557779,0.00052447384,0.0008769279,0.00083837676,0.00065941096,0.0027401978,0.0008612079],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9449495,0.016977666,0.010597807,0.0004896653,0.0036702317,0.00006964085,0.00008519671,0.000675293,0.003400285,0.0000853623,0.001539778,0.017459633],"study_design_scores_gemma":[0.629186,0.31953642,0.042918034,0.0000638088,0.0036061103,0.00019435112,0.00010252372,0.0010102172,0.0014801283,0.00020846873,0.0016409976,0.00005307359],"about_ca_topic_score_codex":0.0008502436,"about_ca_topic_score_gemma":0.0025509961,"teacher_disagreement_score":0.0046376023,"about_ca_system_score_codex":0.0010875646,"about_ca_system_score_gemma":0.0015059278,"threshold_uncertainty_score":0.022928715},"labels":[],"label_agreement":null},{"id":"W4283326517","doi":"10.1097/01.hs9.0000843644.02496.66","title":"S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Oncology; Multiple myeloma; Adverse effect; Phases of clinical research; Refractory (planetary science); Clinical trial; Bortezomib","score_opus":0.035882064541854906,"score_gpt":0.30806208928966367,"score_spread":0.2721800247478088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283326517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63971734,0.2951602,0.0039105057,0.0074034715,0.0018232514,0.004330094,0.018369036,0.00075696595,0.028529167],"genre_scores_gemma":[0.78403157,0.13522607,0.011973245,0.011268539,0.0020888988,0.0025652945,0.04280093,0.00023346995,0.00981191],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99937004,0.0002433547,0.00006554615,0.000047166566,0.00019791734,0.00007606859],"domain_scores_gemma":[0.999241,0.00013511478,0.00029373917,0.00003227175,0.0001582651,0.00013954956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002742247,0.00066795584,0.0011331701,0.0006153722,0.00020687052,0.0010451026,0.0007749618,0.0008093482,0.004283926],"category_scores_gemma":[0.001193704,0.00024638503,0.0011398966,0.00064070185,0.00023156097,0.0005968997,0.00032685866,0.0011050949,0.0011035516],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07514418,0.005761216,0.012122869,0.005825459,0.0036869354,0.0006439128,0.00020585186,0.0021896395,0.051024754,0.00062556885,0.053551417,0.7892182],"study_design_scores_gemma":[0.1722084,0.18358251,0.12272011,0.0028766552,0.010949412,0.0068908036,0.00017727562,0.004311267,0.051916454,0.0008235521,0.44336882,0.0001747649],"about_ca_topic_score_codex":0.00092195004,"about_ca_topic_score_gemma":0.0020361354,"teacher_disagreement_score":0.004283926,"about_ca_system_score_codex":0.0007299456,"about_ca_system_score_gemma":0.0014748626,"threshold_uncertainty_score":0.014502585},"labels":[],"label_agreement":null},{"id":"W4283326697","doi":"10.1097/01.hs9.0000843684.97625.7e","title":"S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Myeloproliferative neoplasm; Oncology; Bone marrow","score_opus":0.02699854354408923,"score_gpt":0.26657649225316404,"score_spread":0.2395779487090748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283326697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752339,0.012530378,0.0005716365,0.0018211122,0.00022649251,0.00091473956,0.0032156177,0.00013180976,0.005354277],"genre_scores_gemma":[0.9850642,0.0041947747,0.00096888567,0.0016386902,0.0002815026,0.00054268085,0.0051290356,0.000021027417,0.0021591606],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997305,0.00014138919,0.00003003304,0.000030203884,0.000028210336,0.000039560637],"domain_scores_gemma":[0.99943095,0.00015442094,0.00013324441,0.000033010387,0.00004421712,0.0002041621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009799247,0.0006215119,0.0013893434,0.0002605578,0.00021676488,0.000672474,0.00041606688,0.0006982547,0.0055779945],"category_scores_gemma":[0.0008875871,0.00021224568,0.0013793521,0.00030914164,0.00023174187,0.00056057074,0.00024016542,0.001533184,0.000903183],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6737611,0.015322673,0.01877739,0.001994815,0.0033309916,0.00063304283,0.00019438256,0.001984168,0.03742528,0.0003048772,0.011397276,0.23487407],"study_design_scores_gemma":[0.4599499,0.41800895,0.09069175,0.00040563266,0.0033020973,0.001279246,0.0001428501,0.002204127,0.00564222,0.0004024919,0.017903507,0.00006722102],"about_ca_topic_score_codex":0.0005901167,"about_ca_topic_score_gemma":0.002548539,"teacher_disagreement_score":0.0055779945,"about_ca_system_score_codex":0.0005794866,"about_ca_system_score_gemma":0.0006668869,"threshold_uncertainty_score":0.018660188},"labels":[],"label_agreement":null},{"id":"W4283326710","doi":"10.1097/01.hs9.0000846056.58461.6d","title":"P793: SCREENING OF NATURALLY OCCURRING CXCR4 VARIANTS FOR IDENTIFICATION OF NOVEL PATHOGENIC MUTATIONS FOR WHIM SYNDROME","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Biology; CXCR4; Genetics; Primary immunodeficiency; Population; Chemokine receptor; Phenotype; Chemokine; Immunology; Gene; Immune system; Medicine","score_opus":0.033617274508355416,"score_gpt":0.2977253516566775,"score_spread":0.2641080771483221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283326710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925621,0.00075298635,0.0023141692,0.00010979327,0.000027165686,0.00012138181,0.0028434014,0.000083238294,0.001185704],"genre_scores_gemma":[0.9910048,0.00035440095,0.0039955485,0.00014538664,0.000023572613,0.00007644435,0.0035661594,0.00004970213,0.00078400155],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997174,0.00003422177,0.000030202453,0.00007700868,0.00010069126,0.000040458108],"domain_scores_gemma":[0.9998147,0.00006739582,0.00004482847,0.0000114164695,0.000025179295,0.0000365419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020708049,0.00041983253,0.00037060046,0.00072904327,0.0002358071,0.00026825513,0.00031557557,0.0005569373,0.0027263006],"category_scores_gemma":[0.00047609638,0.000094033116,0.0003983737,0.00058822485,0.00016537233,0.00008671983,0.000274573,0.00029702135,0.0007639898],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083175104,0.00016100373,0.081569895,0.00019327672,0.00009331636,0.01893659,0.0001803944,0.0005155462,0.88032424,0.0002854465,0.0012969719,0.015611538],"study_design_scores_gemma":[0.0002556244,0.0020815316,0.5035436,0.0000960429,0.00034933552,0.11246615,0.00034457125,0.007606185,0.35379967,0.0003538544,0.019033974,0.00006934806],"about_ca_topic_score_codex":0.00075694156,"about_ca_topic_score_gemma":0.0008861143,"teacher_disagreement_score":0.0027263006,"about_ca_system_score_codex":0.00023213174,"about_ca_system_score_gemma":0.00017332651,"threshold_uncertainty_score":0.009120345},"labels":[],"label_agreement":null},{"id":"W4283328755","doi":"10.1097/01.hs9.0000847280.69256.81","title":"P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Rituximab; Lenalidomide; Medicine; Follicular lymphoma; Internal medicine; Lymphoma; Phases of clinical research; Oncology; CD20; Gastroenterology; Clinical trial; Multiple myeloma","score_opus":0.031827012363458154,"score_gpt":0.3023487328686932,"score_spread":0.27052172050523504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283328755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843509,0.0036906519,0.0007847063,0.00090273685,0.0003549316,0.004765683,0.0018910009,0.00039212295,0.0028672752],"genre_scores_gemma":[0.9727615,0.0041766944,0.0035199225,0.0017788071,0.0003128177,0.007018508,0.0037830179,0.00010924801,0.0065394086],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995828,0.00015750843,0.000017969895,0.00008409194,0.00004614164,0.00011144399],"domain_scores_gemma":[0.99952245,0.00005867679,0.00008893607,0.000038203787,0.00003371212,0.000258091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020093122,0.0025483076,0.0028330188,0.0006197571,0.00059380376,0.0016164845,0.0017421062,0.0017384273,0.0057924013],"category_scores_gemma":[0.00081947044,0.0010803245,0.0022126178,0.00050832797,0.0013989047,0.0013043309,0.0005727442,0.0054987185,0.001749488],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8135797,0.09129884,0.0014718351,0.0010766245,0.0016344056,0.00015638949,0.00022104607,0.0011428193,0.028348744,0.000260743,0.0035668688,0.05724199],"study_design_scores_gemma":[0.69922787,0.29217744,0.0029895434,0.00004205074,0.00058451615,0.00016572808,0.000056850604,0.0006738373,0.0020117182,0.0002046537,0.0018349431,0.000030939394],"about_ca_topic_score_codex":0.0015260021,"about_ca_topic_score_gemma":0.004080098,"teacher_disagreement_score":0.0057924013,"about_ca_system_score_codex":0.0013844577,"about_ca_system_score_gemma":0.0023245898,"threshold_uncertainty_score":0.01937753},"labels":[],"label_agreement":null},{"id":"W4283328977","doi":"10.1097/01.hs9.0000845556.79615.3f","title":"P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Medicine; Idelalisib; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Tolerability; Rituximab; Progression-free survival; Oncology; Ibrutinib; Chemotherapy; Leukemia; Adverse effect; Lymphoma","score_opus":0.030805073093128868,"score_gpt":0.3009799521374058,"score_spread":0.27017487904427695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283328977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935962,0.0027843083,0.0001896862,0.00029910865,0.00011413491,0.0002803014,0.0014445842,0.00006608193,0.0012253985],"genre_scores_gemma":[0.9929924,0.0009782254,0.00037249338,0.00045522783,0.00022076996,0.00034023315,0.003403281,0.000015999249,0.0012213256],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99922216,0.00028310114,0.000050615312,0.00013706781,0.00010961587,0.00019749174],"domain_scores_gemma":[0.99849975,0.00028341438,0.00045642175,0.00012614287,0.000090363625,0.0005439473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028435884,0.0011737462,0.0018864764,0.00056281907,0.0004651226,0.0010702978,0.0008131403,0.0010293061,0.003082269],"category_scores_gemma":[0.0016412626,0.00029999908,0.0024717331,0.0005416679,0.0006310467,0.0015664308,0.0006765208,0.0029189873,0.00076968677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90354186,0.012537683,0.014408383,0.00028740606,0.0017366713,0.0001372216,0.00009250267,0.0019037359,0.0035239914,0.000082513085,0.0028502778,0.058897804],"study_design_scores_gemma":[0.25344405,0.61918664,0.108281784,0.00013476716,0.0040599057,0.0005328709,0.00016482975,0.004524994,0.003977486,0.0005962583,0.0050101574,0.000086221866],"about_ca_topic_score_codex":0.00091378356,"about_ca_topic_score_gemma":0.0016028396,"teacher_disagreement_score":0.003082269,"about_ca_system_score_codex":0.0011341803,"about_ca_system_score_gemma":0.0009797688,"threshold_uncertainty_score":0.01503849},"labels":[],"label_agreement":null},{"id":"W4283328999","doi":"10.1097/01.hs9.0000843512.62237.dc","title":"S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bosutinib; Discontinuation; Tolerability; Internal medicine; Adverse effect; Imatinib; Myeloid leukemia; Nilotinib; Gastroenterology","score_opus":0.010204334073727377,"score_gpt":0.2673810174070419,"score_spread":0.2571766833333145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283328999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82548743,0.08491761,0.002564193,0.0067105726,0.0012648614,0.003959455,0.050308745,0.0006257501,0.024161326],"genre_scores_gemma":[0.8739281,0.035244446,0.004561288,0.008528265,0.0018003584,0.002456499,0.05686336,0.00023579251,0.016381923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99904484,0.00040019868,0.00012858633,0.00012038763,0.0002169436,0.00008899968],"domain_scores_gemma":[0.9976059,0.0004918538,0.000960783,0.00011752,0.00036037335,0.0004635996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038539553,0.00094207947,0.0019838524,0.00061425584,0.00031570916,0.0013756454,0.0010147527,0.0012477231,0.00780628],"category_scores_gemma":[0.0027982593,0.00041315536,0.0033393644,0.00065769564,0.00030986988,0.00084875454,0.00047857774,0.0023366339,0.002580989],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4614447,0.006102102,0.033147424,0.005945761,0.009779987,0.0003675238,0.00026199222,0.0023916042,0.023690926,0.0004150642,0.045762207,0.4106907],"study_design_scores_gemma":[0.42567074,0.18454292,0.25276187,0.0024808748,0.01661062,0.001860153,0.0001751412,0.002496313,0.010612974,0.0008267296,0.10172952,0.00023218886],"about_ca_topic_score_codex":0.0014072298,"about_ca_topic_score_gemma":0.004376193,"teacher_disagreement_score":0.00780628,"about_ca_system_score_codex":0.0010332316,"about_ca_system_score_gemma":0.0013537233,"threshold_uncertainty_score":0.026114583},"labels":[],"label_agreement":null},{"id":"W4283329542","doi":"10.1097/01.hs9.0000845096.01949.78","title":"P552: TREATMENT OUTCOMES IN NEWLY DIAGNOSED, UNTREATED PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Ven; Venetoclax; Oncology; Randomized controlled trial; Leukemia; Gastroenterology","score_opus":0.01886784192203424,"score_gpt":0.2840499807896953,"score_spread":0.26518213886766107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283329542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043233377,0.99403363,0.00023228841,0.00015249966,0.000074871605,0.0001796193,0.0007695747,0.000013596981,0.0002205311],"genre_scores_gemma":[0.124589235,0.8709973,0.0011342234,0.0007317868,0.00021019588,0.00088134874,0.0011989988,0.000022603745,0.00023435272],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99237317,0.0029203189,0.0027278836,0.0009070171,0.000823592,0.0002479881],"domain_scores_gemma":[0.9826681,0.012040152,0.003475042,0.00038639866,0.0011866692,0.00024365258],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009524865,0.002050408,0.015364829,0.007871968,0.00062034925,0.0029578537,0.0020257228,0.0018453748,0.0038696995],"category_scores_gemma":[0.022110177,0.0010963028,0.025941195,0.010840157,0.0006721254,0.0015868971,0.0014932432,0.0013912845,0.0003097966],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014732472,0.000025697913,0.0045506964,0.5894549,0.39101437,0.00014924952,0.00009825881,0.00034811633,0.0002004516,0.000102991646,0.0007095134,0.01187252],"study_design_scores_gemma":[0.00052644574,0.00019700264,0.0056255683,0.04812921,0.9426564,0.00013922098,0.0000757629,0.00013971777,0.00010076112,0.00015237273,0.0022291422,0.000028358168],"about_ca_topic_score_codex":0.0061376267,"about_ca_topic_score_gemma":0.013758144,"teacher_disagreement_score":0.9846352,"about_ca_system_score_codex":0.00232202,"about_ca_system_score_gemma":0.0034617074,"threshold_uncertainty_score":0.0503729},"labels":[],"label_agreement":null},{"id":"W4283331887","doi":"10.1097/01.hs9.0000843912.35755.7f","title":"S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Fludarabine; Internal medicine; Phases of clinical research; Lymphoma; Clinical endpoint; Refractory (planetary science); Oncology; Cyclophosphamide; Gastroenterology; Surgery; Chemotherapy; Clinical trial","score_opus":0.01166383156354024,"score_gpt":0.2766023768999559,"score_spread":0.2649385453364157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283331887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945087,0.0020966716,0.00016080606,0.00022456158,0.00004741239,0.00050773384,0.0007168448,0.000064739084,0.0016725857],"genre_scores_gemma":[0.9947431,0.00086854456,0.00045212955,0.00034837268,0.000047705216,0.0003785055,0.0015389625,0.0000113747765,0.0016113514],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998241,0.00008216064,0.0000132660625,0.000028247785,0.00002344161,0.000028833729],"domain_scores_gemma":[0.99977666,0.000026067895,0.00005087678,0.000010390316,0.000012438734,0.00012363275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006628582,0.0004884921,0.0007778436,0.00017940442,0.00019961852,0.00060798146,0.0004496713,0.00054893974,0.0043846173],"category_scores_gemma":[0.0003924095,0.00016138876,0.0003730306,0.00018288883,0.00040108626,0.00040344556,0.0002449296,0.0010319592,0.0008577176],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64990664,0.033455983,0.016017923,0.0016301738,0.0014176533,0.00058739557,0.00034654586,0.0034391417,0.08075123,0.0008080488,0.00901533,0.20262396],"study_design_scores_gemma":[0.31223834,0.62487435,0.034124393,0.00011610324,0.00069335254,0.0010342348,0.00012466195,0.0024225388,0.011953407,0.0002598208,0.012109458,0.000049324863],"about_ca_topic_score_codex":0.00074372906,"about_ca_topic_score_gemma":0.0019556056,"teacher_disagreement_score":0.0043846173,"about_ca_system_score_codex":0.0005410861,"about_ca_system_score_gemma":0.0008747431,"threshold_uncertainty_score":0.014667988},"labels":[],"label_agreement":null},{"id":"W4283333295","doi":"10.1097/01.hs9.0000845116.46694.aa","title":"P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Placebo; Myeloid leukemia; Internal medicine; Gastroenterology; Azacitidine; Population; Surgery; Pathology; Biology","score_opus":0.011609486325459929,"score_gpt":0.2448589086781847,"score_spread":0.23324942235272475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283333295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99271894,0.0055746892,0.00009925047,0.00022920092,0.000116805764,0.00017263315,0.00017838579,0.000025256224,0.0008847976],"genre_scores_gemma":[0.99640864,0.0019208932,0.00028856486,0.00024146051,0.000115235176,0.00013132126,0.00030825476,0.000004422562,0.0005812421],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997538,0.00009800548,0.000028886634,0.000042751733,0.000033915425,0.000042632277],"domain_scores_gemma":[0.9997714,0.000051469207,0.000057054953,0.00001404639,0.000012242369,0.0000936765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006399997,0.0004193764,0.0013450562,0.00020821199,0.00020448389,0.00057735114,0.00041328126,0.00045244306,0.0032982375],"category_scores_gemma":[0.00088688254,0.00021928184,0.00065380684,0.00021967673,0.0003572081,0.0003650476,0.00028645262,0.0009893506,0.00040975434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76360327,0.0076193735,0.008604811,0.0010912921,0.0014173464,0.00018873568,0.000143124,0.00085002393,0.03145977,0.00017473866,0.0015872513,0.18326034],"study_design_scores_gemma":[0.36608812,0.54768246,0.069393374,0.00021247608,0.0029212402,0.00063849543,0.00014050744,0.0012557125,0.006893009,0.00022312762,0.0045096558,0.00004167386],"about_ca_topic_score_codex":0.00064980105,"about_ca_topic_score_gemma":0.0013963811,"teacher_disagreement_score":0.0032982375,"about_ca_system_score_codex":0.00044310442,"about_ca_system_score_gemma":0.00050031533,"threshold_uncertainty_score":0.011033654},"labels":[],"label_agreement":null},{"id":"W4283366934","doi":"10.1097/01.hs9.0000846464.96684.8e","title":"P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Population; Oncology; Surgery; Gastroenterology","score_opus":0.04771458878182294,"score_gpt":0.29972435333488623,"score_spread":0.2520097645530633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283366934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98249316,0.008360577,0.001644904,0.0002831973,0.0004975864,0.0011852274,0.002523424,0.00006440999,0.0029475437],"genre_scores_gemma":[0.99489814,0.00082449423,0.00101301,0.0002492166,0.000100134595,0.0009151084,0.001164968,0.000012688263,0.00082231243],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.994743,0.0034848098,0.00044258186,0.0006636674,0.00040461912,0.00026140036],"domain_scores_gemma":[0.99703777,0.00162729,0.0007758112,0.00022063697,0.00013334218,0.0002051407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00428021,0.0014507353,0.0029502835,0.0006128162,0.00023405302,0.0011613484,0.0011843707,0.0010629669,0.005702743],"category_scores_gemma":[0.005946431,0.0004776967,0.0056900247,0.0005269857,0.00056038675,0.0012108997,0.0009795952,0.002425948,0.00045824365],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9468578,0.00088515057,0.0075499,0.0013653396,0.02687331,0.000040061208,0.000071810144,0.0014966783,0.0010798855,0.00031906352,0.0005928056,0.012868203],"study_design_scores_gemma":[0.5842365,0.25909403,0.07148265,0.00046831646,0.05791782,0.00030769792,0.00032897491,0.014538693,0.0030471089,0.002716852,0.005681037,0.00018027559],"about_ca_topic_score_codex":0.0009041254,"about_ca_topic_score_gemma":0.001282116,"teacher_disagreement_score":0.005702743,"about_ca_system_score_codex":0.00086048857,"about_ca_system_score_gemma":0.0005772705,"threshold_uncertainty_score":0.022636175},"labels":[],"label_agreement":null},{"id":"W4283370847","doi":"10.1097/01.hs9.0000848944.56958.95","title":"P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hemolysis; Ineffective erythropoiesis; Thalassemia; Adverse effect; Pyruvate kinase; Internal medicine; Erythropoiesis; Anemia; Pharmacology; Glycolysis; Metabolism","score_opus":0.0076543691600737904,"score_gpt":0.2325502291694925,"score_spread":0.22489586000941872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283370847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905088,0.0059041376,0.00024644364,0.00035355316,0.000111897105,0.0004996141,0.000919233,0.00006230519,0.0013940417],"genre_scores_gemma":[0.9936329,0.0021913461,0.00033127028,0.00068700727,0.00015233224,0.0005681309,0.0012325656,0.000010312609,0.0011940781],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99980325,0.00007118765,0.000020913645,0.000041358977,0.000025139634,0.000038234095],"domain_scores_gemma":[0.9996086,0.000061197614,0.00010783356,0.00002542913,0.000037663514,0.00015932845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006855949,0.00056020677,0.0010986876,0.00016522607,0.00025739265,0.0007608805,0.00037136083,0.0007832454,0.0035258133],"category_scores_gemma":[0.0007839223,0.00020372162,0.00082174444,0.00023069976,0.00031558488,0.00060597376,0.0002824299,0.0016774565,0.00077784166],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63352937,0.026703667,0.015666379,0.0018231649,0.002189329,0.0005335884,0.00023778994,0.0012517284,0.024787983,0.00016770589,0.0063530114,0.28675634],"study_design_scores_gemma":[0.2966907,0.6273674,0.06103037,0.00023677362,0.0016130297,0.0009232503,0.00013720797,0.0014197192,0.004457542,0.00019206117,0.0058889636,0.000043033324],"about_ca_topic_score_codex":0.00046312198,"about_ca_topic_score_gemma":0.00079755485,"teacher_disagreement_score":0.0035258133,"about_ca_system_score_codex":0.00044214493,"about_ca_system_score_gemma":0.00061143906,"threshold_uncertainty_score":0.011795044},"labels":[],"label_agreement":null},{"id":"W4283372513","doi":"10.1097/01.hs9.0000846600.20422.ca","title":"P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Daratumumab; Clinical endpoint; Oncology; Dexamethasone; Subgroup analysis; Clinical trial; Confidence interval","score_opus":0.03893365579631453,"score_gpt":0.3151773999234155,"score_spread":0.27624374412710095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283372513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925103,0.0061286218,0.00019102,0.00013244548,0.00007238521,0.0002093052,0.00039431537,0.00001059827,0.00035093402],"genre_scores_gemma":[0.99786747,0.0008004768,0.00020532198,0.00018758465,0.00009114071,0.00013787085,0.00050402264,0.00000510542,0.00020102547],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99803954,0.0011349757,0.00019563036,0.00027219448,0.00018133999,0.00017638388],"domain_scores_gemma":[0.9985084,0.00054180005,0.00036975383,0.00019896528,0.00008551419,0.00029559215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035740123,0.0009247493,0.0029942452,0.0005552812,0.00030245073,0.0010520302,0.00076460815,0.00078303047,0.0014390779],"category_scores_gemma":[0.002548172,0.00036202706,0.006685529,0.0006654394,0.00049615913,0.00052929483,0.00062953867,0.0011948262,0.00015883236],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83610034,0.0016987215,0.07488533,0.0012854034,0.04267177,0.0002127457,0.00020060787,0.0010714541,0.006823065,0.00017030534,0.0010679988,0.033812225],"study_design_scores_gemma":[0.29309443,0.17925398,0.41913792,0.00043101914,0.08997667,0.0011273215,0.0006320044,0.0046728696,0.0041725147,0.0010437635,0.006233455,0.00022407516],"about_ca_topic_score_codex":0.0010417625,"about_ca_topic_score_gemma":0.0027345575,"teacher_disagreement_score":0.0035740123,"about_ca_system_score_codex":0.00067814166,"about_ca_system_score_gemma":0.00095227204,"threshold_uncertainty_score":0.018901408},"labels":[],"label_agreement":null},{"id":"W4283376400","doi":"10.1097/01.hs9.0000846460.44039.3d","title":"P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre; University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Cytokine release syndrome; Adverse effect; Common Terminology Criteria for Adverse Events; Minimal residual disease; Oncology; Transplantation; Immunology; Gastroenterology; Immunotherapy; Cancer; Chimeric antigen receptor; Bone marrow","score_opus":0.024270762174428962,"score_gpt":0.29195613847621205,"score_spread":0.2676853763017831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283376400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57369477,0.14856943,0.013653484,0.011436746,0.002435618,0.0074976035,0.19692937,0.0016975729,0.0440854],"genre_scores_gemma":[0.63350916,0.03749741,0.01635922,0.012508323,0.0018912113,0.004408846,0.28218424,0.00056709506,0.011074424],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974189,0.0010919909,0.00024314332,0.0002269269,0.00079567696,0.00022338062],"domain_scores_gemma":[0.9959239,0.0010109096,0.0013937185,0.00025144478,0.0009396348,0.0004804843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00802533,0.0011841389,0.0017294283,0.00094313524,0.00039378516,0.0015046018,0.0016002686,0.0009746328,0.0048668445],"category_scores_gemma":[0.0043779532,0.00041546588,0.0016266791,0.0014166044,0.00029864328,0.0011041546,0.0007467182,0.0017528499,0.0019514378],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09943487,0.0043239556,0.058738522,0.007001716,0.008371298,0.00091694266,0.00031813144,0.005111548,0.050744817,0.000424381,0.12617491,0.638439],"study_design_scores_gemma":[0.07389325,0.09257201,0.43770447,0.0012802886,0.02785658,0.0046424936,0.00021533945,0.0031732037,0.028567197,0.00089451973,0.3289639,0.00023672164],"about_ca_topic_score_codex":0.0021413849,"about_ca_topic_score_gemma":0.005184676,"teacher_disagreement_score":0.00802533,"about_ca_system_score_codex":0.0012326585,"about_ca_system_score_gemma":0.0022465505,"threshold_uncertainty_score":0.0424425},"labels":[],"label_agreement":null},{"id":"W4283379313","doi":"10.1097/01.hs9.0000850132.55221.5c","title":"PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Venetoclax; Azacitidine; CD47; Medicine; Myeloid leukemia; Myeloid; Hypomethylating agent; Leukemia; Cancer research; Oncology; Minimal residual disease; Internal medicine; Immunology; Chronic lymphocytic leukemia; Biology; Receptor","score_opus":0.005121433250560848,"score_gpt":0.19006292908842065,"score_spread":0.1849414958378598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283379313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594057,0.003111011,0.00011441283,0.000085265,0.000019938649,0.000042020463,0.000083708925,0.00001559176,0.0005874325],"genre_scores_gemma":[0.9985067,0.0007497442,0.00012914045,0.00006448706,0.000036442834,0.000022958247,0.0001637111,0.0000034021803,0.00032336623],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998685,0.00003986733,0.000011412709,0.00003103035,0.000022115062,0.00002699795],"domain_scores_gemma":[0.9998097,0.000034793014,0.00004177934,0.000011776269,0.000011433464,0.00009047751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024404355,0.0003095628,0.00084206165,0.00020707438,0.00019634189,0.00027453163,0.00020921278,0.00029302452,0.0009140988],"category_scores_gemma":[0.0004387391,0.00017422825,0.00031873013,0.00024553423,0.00019729973,0.00022610904,0.000129695,0.0007143299,0.00022626754],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26363334,0.008979065,0.22759436,0.0011429489,0.0017180798,0.008048697,0.000997348,0.0042943517,0.2458533,0.00038528035,0.0028987457,0.23445445],"study_design_scores_gemma":[0.01837507,0.28942484,0.6098974,0.0001277748,0.0023176668,0.014245589,0.0003652663,0.005717253,0.043645423,0.00025463125,0.015540967,0.00008821124],"about_ca_topic_score_codex":0.0004834611,"about_ca_topic_score_gemma":0.0009200751,"teacher_disagreement_score":0.0009140988,"about_ca_system_score_codex":0.0003076046,"about_ca_system_score_gemma":0.00027128443,"threshold_uncertainty_score":0.0030579567},"labels":[],"label_agreement":null},{"id":"W4283379818","doi":"10.1097/01.hs9.0000846628.17113.b2","title":"P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Adverse effect; Multiple myeloma; Oncology; Clinical endpoint; Expanded access; Clinical trial; Surgery; Gastroenterology; Immunotherapy; Cancer","score_opus":0.016813890652781462,"score_gpt":0.28782187908842116,"score_spread":0.2710079884356397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283379818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941309,0.0023654995,0.00030293423,0.00021167082,0.00003634519,0.00069261633,0.0010103023,0.000051509545,0.0011980783],"genre_scores_gemma":[0.99358326,0.00087451277,0.0009541995,0.00042251832,0.00008840803,0.0007026878,0.00199848,0.000014896222,0.0013610583],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991435,0.00042544154,0.00006508988,0.00014821546,0.00012942162,0.00008830098],"domain_scores_gemma":[0.9991584,0.00012560813,0.00024445655,0.00007880358,0.000064783926,0.0003280162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002360241,0.0007745864,0.0016895313,0.0002501882,0.0002823179,0.00088262995,0.0010041494,0.0006652891,0.002587445],"category_scores_gemma":[0.0011875887,0.00042372316,0.0014786843,0.00030370624,0.0005503013,0.0008046209,0.00050691346,0.0021803395,0.0006538701],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7151961,0.038137764,0.028821051,0.0015726046,0.005013992,0.0003446232,0.00037743716,0.0034980944,0.054362334,0.00030679716,0.004893039,0.14747617],"study_design_scores_gemma":[0.35632625,0.5593088,0.06239378,0.000083954335,0.0025622435,0.00085065037,0.000089956964,0.002321063,0.007340748,0.00024662365,0.008424448,0.000051483297],"about_ca_topic_score_codex":0.00081206247,"about_ca_topic_score_gemma":0.0017838521,"teacher_disagreement_score":0.002587445,"about_ca_system_score_codex":0.0013347281,"about_ca_system_score_gemma":0.0013694415,"threshold_uncertainty_score":0.0124822855},"labels":[],"label_agreement":null},{"id":"W4283381234","doi":"10.1097/01.hs9.0000846956.81764.f3","title":"P1022: OUTCOMES IN MYELOPROLIFERATIVE NEOPLASM PATIENTS WITH OR WITHOUT PRIOR HISTORY OF CANCER: A POPULATION-BASED STUDY FROM ONTARIO","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloproliferative neoplasm; Polycythemia vera; Internal medicine; Cancer; Essential thrombocythemia; Oncology; Myelofibrosis; Population; Radiation therapy; Cohort; Retrospective cohort study; Hormonal therapy; Bone marrow; Breast cancer","score_opus":0.01836061546473317,"score_gpt":0.2678379448957078,"score_spread":0.24947732943097461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283381234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927124,0.00026331074,0.000045048615,0.00011519902,0.000006007209,0.000048812028,0.0055814455,0.000004534168,0.0012232376],"genre_scores_gemma":[0.9969355,0.00019944267,0.000056021378,0.00009110328,0.000007833752,0.000039424573,0.002288855,0.0000030606197,0.00037873714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993832,0.00003488793,0.000048727597,0.00015491537,0.00018068604,0.00019748326],"domain_scores_gemma":[0.99871385,0.00005362216,0.00051578385,0.00007077395,0.0003617072,0.0002842743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035671957,0.00032596744,0.0003915538,0.00086297444,0.0020155099,0.00082700985,0.0009766212,0.0004133492,0.0018546474],"category_scores_gemma":[0.0011897059,0.00042948042,0.00061845104,0.0029880237,0.0006433474,0.00044825682,0.0009244609,0.00049988827,0.00031759293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045473505,0.000017740098,0.99844676,0.000024400199,0.000029847235,0.0000786046,0.00031195936,0.000016577558,0.00012613846,0.000018740264,0.00043802548,0.00044568014],"study_design_scores_gemma":[0.000007438665,0.000021244752,0.9989303,0.000013308591,0.000017793585,0.00008338751,0.00038828197,0.00004135176,0.000014505191,0.000007418064,0.0004710786,0.0000038128444],"about_ca_topic_score_codex":0.8809727,"about_ca_topic_score_gemma":0.9289578,"teacher_disagreement_score":0.11902732,"about_ca_system_score_codex":0.009105614,"about_ca_system_score_gemma":0.008305117,"threshold_uncertainty_score":0.23945653},"labels":[],"label_agreement":null},{"id":"W4283384745","doi":"10.1097/01.hs9.0000851224.51567.a8","title":"PB2098: ‘REAL-WORLD’ TREATMENT PATTERNS AND PATHWAYS OF SECOND LINE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN UK, CANADA, FRANCE, GERMANY, ITALY AND SPAIN USING A PROSPECTIVE SURVEY OF PHYSICIANS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Lymphoma; Internal medicine; Refractory (planetary science); Pediatrics; Oncology","score_opus":0.012443807399632972,"score_gpt":0.23042647623620943,"score_spread":0.21798266883657647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283384745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99833256,0.00011705029,0.000018496163,0.000054944245,0.000002088512,0.00001746908,0.0010398701,0.0000025008117,0.0004149522],"genre_scores_gemma":[0.99865294,0.000100632016,0.000043542695,0.000058493275,0.0000036258302,0.000014385282,0.0009338057,0.0000017804895,0.000190818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990977,0.00021468222,0.000109333494,0.00016620537,0.00017431467,0.00023767847],"domain_scores_gemma":[0.9973974,0.0002960426,0.001177926,0.00010423228,0.0005201195,0.00050434814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006765334,0.00023466437,0.00024718267,0.0011391796,0.000525991,0.0010710766,0.0005555321,0.00059055706,0.001649078],"category_scores_gemma":[0.002321768,0.0002463343,0.0002672972,0.0020551172,0.00047419884,0.00046639124,0.0006753973,0.00035956607,0.00042130213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039788876,0.000015461515,0.9990588,0.0000066069356,0.000008637507,0.00005094523,0.00021893506,0.000021061938,0.000032641907,0.000006340693,0.00014130253,0.00039951084],"study_design_scores_gemma":[0.0000040177088,0.000043491138,0.9987936,0.000006170932,0.0000036746653,0.000119321914,0.00072236836,0.000063388434,0.000014323853,0.0000018431848,0.00022455606,0.00000321828],"about_ca_topic_score_codex":0.37670022,"about_ca_topic_score_gemma":0.339701,"teacher_disagreement_score":0.6232998,"about_ca_system_score_codex":0.0027647389,"about_ca_system_score_gemma":0.0013972045,"threshold_uncertainty_score":0.74901515},"labels":[],"label_agreement":null},{"id":"W4283389183","doi":"10.1097/01.hs9.0000850912.43010.d3","title":"PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"","keywords":"Lenalidomide; Daratumumab; Medicine; Internal medicine; Pomalidomide; Oncology; Multiple myeloma; Bortezomib; Dexamethasone","score_opus":0.02841387785979811,"score_gpt":0.30961096755874207,"score_spread":0.28119708969894397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283389183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98016983,0.0046690535,0.00069234887,0.0012783194,0.0005374404,0.008310024,0.0017769954,0.00022315695,0.0023428516],"genre_scores_gemma":[0.9797236,0.0027599917,0.0023521222,0.00263331,0.0005466976,0.0067006843,0.0019278362,0.000051101793,0.0033046736],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993513,0.00032514817,0.000036048175,0.00011310101,0.00006320303,0.00011106226],"domain_scores_gemma":[0.99909353,0.00016443778,0.00018958809,0.000056314722,0.00005961985,0.00043650423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028240466,0.0016011908,0.0021481223,0.0004872465,0.0006452408,0.001450865,0.0011823187,0.0017930648,0.005396069],"category_scores_gemma":[0.0014963341,0.0008472847,0.0020957054,0.00051261083,0.00128707,0.0011961282,0.0005504387,0.004727595,0.0011637016],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9446607,0.022498606,0.0015832894,0.00058069424,0.0010412053,0.00010048841,0.0001110959,0.0005458921,0.005103138,0.00013816632,0.0018029171,0.021833844],"study_design_scores_gemma":[0.90194607,0.09365294,0.0022271639,0.000023525186,0.00029474977,0.000074857846,0.000022098076,0.0004281704,0.00035759542,0.000141287,0.0008153665,0.000016216185],"about_ca_topic_score_codex":0.0017408164,"about_ca_topic_score_gemma":0.0051120585,"teacher_disagreement_score":0.005396069,"about_ca_system_score_codex":0.0014964467,"about_ca_system_score_gemma":0.00224304,"threshold_uncertainty_score":0.018051624},"labels":[],"label_agreement":null},{"id":"W4283392950","doi":"10.1097/01.hs9.0000847476.69621.cd","title":"P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Antibody-drug conjugate; Internal medicine; Cmax; Refractory (planetary science); Phases of clinical research; Gastroenterology; Lymphoma; Oncology; Antibody; Pharmacology; Toxicity; Adverse effect; Monoclonal antibody; Immunology","score_opus":0.012692541623903398,"score_gpt":0.29003734080215277,"score_spread":0.2773447991782494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283392950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666995,0.00073685165,0.0008077049,0.000104765946,0.000017953327,0.00043122438,0.00044175843,0.00008194449,0.00070792716],"genre_scores_gemma":[0.99540013,0.00048066347,0.0009383716,0.00025549275,0.000048851944,0.00030728386,0.0015820675,0.00003428449,0.0009528016],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967515,0.00014672118,0.000017950279,0.000060136488,0.000044754514,0.000055254804],"domain_scores_gemma":[0.9994943,0.00009530266,0.00010053389,0.000052950563,0.000038793663,0.00021802328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011315871,0.0009287666,0.00096989097,0.00025762245,0.00030694986,0.00089821743,0.0004795006,0.00063563307,0.0014746338],"category_scores_gemma":[0.00074627146,0.00031637657,0.00061525253,0.0002773019,0.0006629403,0.00055511,0.00023695608,0.001821731,0.0005246271],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26452464,0.12117778,0.031637553,0.000864737,0.0017889458,0.001589726,0.0011624219,0.007560436,0.33435908,0.00035901586,0.006223222,0.2287525],"study_design_scores_gemma":[0.12156254,0.7594804,0.056605693,0.00003571452,0.0010746388,0.0019010036,0.0001722202,0.0047878018,0.048580624,0.00021943828,0.0055120424,0.00006788293],"about_ca_topic_score_codex":0.0008074985,"about_ca_topic_score_gemma":0.0012844494,"teacher_disagreement_score":0.0014746338,"about_ca_system_score_codex":0.0007082948,"about_ca_system_score_gemma":0.00078272616,"threshold_uncertainty_score":0.005984485},"labels":[],"label_agreement":null},{"id":"W4283395768","doi":"10.1097/01.hs9.0000849792.13840.5e","title":"P1734: LESSONS FROM HIV- HAEMOPHILIA CRISIS AND CURRICULAR LEARNING IN POST COVID TIMES","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Interpreting and Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Haemophilia; Context (archaeology); Medical education; Curriculum; Psychology; Medicine; Pandemic; Family medicine; Coronavirus disease 2019 (COVID-19); Pediatrics; Pedagogy; History","score_opus":0.04389367298885071,"score_gpt":0.40279913000719353,"score_spread":0.3589054570183428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283395768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8298447,0.007741658,0.0019212927,0.10431509,0.005156016,0.00055551704,0.0003182509,0.00018031713,0.04996718],"genre_scores_gemma":[0.9578341,0.0068369866,0.002689544,0.008902776,0.0009692124,0.00053855224,0.00020485866,0.00010246123,0.021921467],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99628025,0.0021509656,0.00008476941,0.00018284803,0.00042428586,0.00087696104],"domain_scores_gemma":[0.99381,0.0023347025,0.000412932,0.00015963183,0.00048904435,0.0027937444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051628673,0.0006217497,0.0004581375,0.0010739962,0.0088351285,0.005141652,0.0022532395,0.0032344793,0.0110361865],"category_scores_gemma":[0.011147856,0.00041110849,0.00043543937,0.0011212523,0.006037865,0.0048561385,0.011577451,0.0054255305,0.0014603817],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015337889,0.00076153775,0.0043848846,0.0011953679,0.000009978865,0.0046154065,0.7994335,0.00014662156,0.00068872795,0.0044652093,0.050317187,0.13382816],"study_design_scores_gemma":[0.000040876956,0.00059423887,0.012444989,0.0014720743,0.000008235866,0.0013992776,0.8142483,0.00009047276,0.00063235103,0.002923287,0.16610548,0.00004026468],"about_ca_topic_score_codex":0.0028306204,"about_ca_topic_score_gemma":0.008639268,"teacher_disagreement_score":0.0110361865,"about_ca_system_score_codex":0.004544075,"about_ca_system_score_gemma":0.0052102106,"threshold_uncertainty_score":0.036919713},"labels":[],"label_agreement":null},{"id":"W4283396501","doi":"10.1097/01.hs9.0000848948.50002.24","title":"P1523: DEMOGRAPHICS, CLINICAL CHARACTERISTICS, AND REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH BETA-THALASSEMIA: A RETROSPECTIVE MEDICAL RECORD ABSTRACTION STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Medical record; Demographics; Anemia; Retrospective cohort study; Thalassemia; Pediatrics; Beta thalassemia; Blood transfusion; Internal medicine; Demography","score_opus":0.01256129364801823,"score_gpt":0.2802278295499557,"score_spread":0.26766653590193745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283396501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949745,0.00042562356,0.00010140818,0.000057289777,0.0000037469947,0.00010417719,0.0038673168,0.0000055402825,0.0004604632],"genre_scores_gemma":[0.9968587,0.00023737233,0.00017277441,0.000070955386,0.000009175642,0.0001292665,0.002424458,0.0000028623008,0.00009448171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985239,0.0002940879,0.00037714522,0.00029400934,0.00034521963,0.00016573805],"domain_scores_gemma":[0.9954204,0.00064415665,0.0028966889,0.00026458406,0.00046412172,0.00031010425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010331731,0.00024282643,0.000532208,0.0017881723,0.00056523795,0.00083977793,0.00044349907,0.00039893825,0.0015524597],"category_scores_gemma":[0.0040553776,0.00029343605,0.0005083721,0.0036017182,0.00031563215,0.0007242002,0.0006104678,0.0004982033,0.00039539515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050526418,0.000024990073,0.998776,0.000022814647,0.000021517984,0.00010322066,0.00014672011,0.000013633959,0.00004727305,0.0000072466883,0.00017202499,0.00061400083],"study_design_scores_gemma":[0.000009603411,0.000119437245,0.9978672,0.000029596531,0.000022337863,0.0006624003,0.0005938681,0.000110700574,0.00004956004,0.000008726585,0.00052108977,0.0000054738885],"about_ca_topic_score_codex":0.011530259,"about_ca_topic_score_gemma":0.009833407,"teacher_disagreement_score":0.011530259,"about_ca_system_score_codex":0.0009305727,"about_ca_system_score_gemma":0.0009891593,"threshold_uncertainty_score":0.022926271},"labels":[],"label_agreement":null},{"id":"W4283397661","doi":"10.1097/01.hs9.0000846624.61314.38","title":"P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Cohort; Adverse effect; Internal medicine; Pharmacology; Combination therapy; Oncology; Gastroenterology","score_opus":0.006609456375418366,"score_gpt":0.23269093646809835,"score_spread":0.22608148009267998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283397661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965634,0.0013998848,0.00022890883,0.00016117671,0.000044208646,0.00040035148,0.00027457796,0.00004471074,0.00088276586],"genre_scores_gemma":[0.9965463,0.00074559316,0.0006818573,0.00020195125,0.000055211876,0.00027255865,0.00055823254,0.000012957109,0.00092515367],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99943775,0.00025500852,0.000035384626,0.00010357124,0.00008168225,0.00008656533],"domain_scores_gemma":[0.9996106,0.000067911846,0.00007807554,0.00005467721,0.000020240335,0.00016848242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011450197,0.00095652585,0.0017035924,0.00047471983,0.00036436142,0.0009515565,0.0009800722,0.00073617103,0.0025001122],"category_scores_gemma":[0.00062766584,0.00043091617,0.001524033,0.00044494413,0.0006566425,0.000698675,0.00050217606,0.002536292,0.0007231626],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6258685,0.091361515,0.009434631,0.0008339287,0.0027728996,0.0004649154,0.0004411474,0.0038601314,0.09507073,0.0003835432,0.0029473987,0.16656066],"study_design_scores_gemma":[0.2091492,0.7462142,0.02189685,0.00004181337,0.0013001023,0.00067729165,0.00010971115,0.0018656722,0.013877523,0.00016758814,0.004648727,0.000051283652],"about_ca_topic_score_codex":0.0009964103,"about_ca_topic_score_gemma":0.0025578677,"teacher_disagreement_score":0.0025001122,"about_ca_system_score_codex":0.0011284886,"about_ca_system_score_gemma":0.0010720646,"threshold_uncertainty_score":0.008363724},"labels":[],"label_agreement":null},{"id":"W4283397932","doi":"10.1097/01.hs9.0000844608.72364.51","title":"P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"IDH1; Isocitrate dehydrogenase; Myeloid leukemia; Medicine; Peripheral blood mononuclear cell; Internal medicine; Bone marrow; Azacitidine; Placebo; Oncology; Gastroenterology; Mutation; Biology; Pathology; Genetics","score_opus":0.02239487869927134,"score_gpt":0.3108922617448699,"score_spread":0.2884973830455986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283397932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791485,0.0011970334,0.00007620489,0.000044285913,0.000013167267,0.00004694394,0.00018040936,0.000009201207,0.00051780435],"genre_scores_gemma":[0.99873024,0.0002361379,0.000116391144,0.00006183657,0.00002109358,0.000058497077,0.00043124365,0.0000031945858,0.0003412807],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99974424,0.00008270175,0.000018783308,0.00006517331,0.00005864421,0.000030437972],"domain_scores_gemma":[0.99966896,0.000068675174,0.00012249622,0.000013245965,0.00002660702,0.000100069985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005541502,0.0002158395,0.0007004958,0.0002534776,0.00013864275,0.00039065842,0.00018428732,0.00037777566,0.0016999809],"category_scores_gemma":[0.0007716468,0.0001199555,0.00039164527,0.00026335104,0.00017987975,0.00021533095,0.00018606673,0.0004428023,0.00028727308],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24271083,0.0029513482,0.50485003,0.00055601064,0.0015740711,0.00044811657,0.00031823013,0.0016641517,0.119943745,0.00014358279,0.0015401547,0.12329984],"study_design_scores_gemma":[0.003944712,0.04518747,0.93835014,0.000036463895,0.0005608588,0.0008689909,0.00009079114,0.0015261995,0.0066971695,0.00012663985,0.0025875312,0.00002298793],"about_ca_topic_score_codex":0.00027657763,"about_ca_topic_score_gemma":0.00041140546,"teacher_disagreement_score":0.0016999809,"about_ca_system_score_codex":0.00031510778,"about_ca_system_score_gemma":0.00019629979,"threshold_uncertainty_score":0.0056869984},"labels":[],"label_agreement":null},{"id":"W4283714328","doi":"10.1097/01.hs9.0000846716.90763.d0","title":"P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Oncology; Internal medicine; Cytokine release syndrome; Biomarker; Refractory (planetary science); Surrogate endpoint; Gastroenterology; Immunology; Immunotherapy; Cancer; Biology","score_opus":0.0712361846644057,"score_gpt":0.32797489408794434,"score_spread":0.2567387094235386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283714328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99714917,0.0010789325,0.0002480355,0.0001496444,0.000022150614,0.00016683727,0.0005516417,0.000028571902,0.0006051828],"genre_scores_gemma":[0.99743384,0.00023923628,0.0005011462,0.0001335195,0.000039086142,0.00013393625,0.00086942763,0.0000071387826,0.00064272614],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99960715,0.00014856848,0.000023399538,0.0000880836,0.00009556016,0.00003729211],"domain_scores_gemma":[0.999203,0.00019616312,0.00027666468,0.00005182012,0.00007359471,0.000198719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012463733,0.00057065795,0.0008712955,0.00024091998,0.00022898673,0.0008049618,0.00042142463,0.000580194,0.0017627372],"category_scores_gemma":[0.0013215169,0.0002152269,0.00047977766,0.0003039762,0.00031466887,0.00038088395,0.00028172365,0.0014162483,0.0005135679],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30304962,0.012514601,0.405084,0.00063267513,0.0017947501,0.000608784,0.0002958855,0.0029673327,0.12920865,0.00012991336,0.0038037642,0.13990998],"study_design_scores_gemma":[0.026251333,0.17784402,0.75016385,0.0000567257,0.001009667,0.0023865371,0.0001355325,0.0059694475,0.030710613,0.00024952192,0.005156321,0.00006637898],"about_ca_topic_score_codex":0.0004084097,"about_ca_topic_score_gemma":0.0006308627,"teacher_disagreement_score":0.0017627372,"about_ca_system_score_codex":0.00052243244,"about_ca_system_score_gemma":0.00039461325,"threshold_uncertainty_score":0.0065915585},"labels":[],"label_agreement":null},{"id":"W4283733969","doi":"10.1097/01.hs9.0000846900.48214.5b","title":"P1008: ASSOCIATION BETWEEN FRAILTY AND CLINICAL OUTCOMES IN MYELOPROLIFERATIVE NEOPLAMS: A POPULATION-BASED STUDY FROM ONTARIO, CANADA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Population; Cumulative incidence; Internal medicine; Cohort; Environmental health","score_opus":0.029322913248741055,"score_gpt":0.3064895132019538,"score_spread":0.27716659995321274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283733969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832734,0.00091183104,0.0002105807,0.00041297663,0.00001568678,0.00009630161,0.012614983,0.000013641083,0.0024505854],"genre_scores_gemma":[0.99534976,0.00044780844,0.00017076619,0.00013856289,0.000008820726,0.000046356,0.0028566893,0.000006878465,0.00097434974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930215,0.00004071758,0.000050658822,0.00016529844,0.00023503954,0.0002061896],"domain_scores_gemma":[0.9980083,0.00007877513,0.00045818576,0.00011013261,0.00091823796,0.0004264491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006644739,0.00043930803,0.00049484725,0.0010444337,0.0025412682,0.0009995616,0.0013562002,0.00043523623,0.0020580932],"category_scores_gemma":[0.0018721769,0.00038825852,0.00071167614,0.004019574,0.0007319852,0.00035988874,0.0009399869,0.0006031337,0.0003012438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007397146,0.000015992051,0.99588686,0.000040494455,0.000052935244,0.00010686057,0.0005190863,0.000054784818,0.00017694692,0.00007036845,0.0013645696,0.00163729],"study_design_scores_gemma":[0.000012731121,0.000015215884,0.998473,0.000024953537,0.000028141014,0.00006578106,0.00036832647,0.00011764526,0.000022436614,0.00002003517,0.0008453833,0.000006418721],"about_ca_topic_score_codex":0.9904266,"about_ca_topic_score_gemma":0.9934176,"teacher_disagreement_score":0.021704981,"about_ca_system_score_codex":0.021704981,"about_ca_system_score_gemma":0.024229448,"threshold_uncertainty_score":0.15748137},"labels":[],"label_agreement":null},{"id":"W4283734564","doi":"10.1097/01.hs9.0000849024.60193.ea","title":"P1542: COMORBIDITIES AND COMPLICATIONS ACROSS GENOTYPES IN ADULT PATIENTS WITH PYRUVATE KINASE DEFICIENCY: ANALYSIS FROM THE PEAK REGISTRY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Missense mutation; Medicine; Pyruvate kinase deficiency; Genotype; Internal medicine; Pediatrics; Compound heterozygosity; Frameshift mutation; Gastroenterology; Pyruvate kinase; Allele; Genetics; Mutation; Gene; Biology; Glycolysis","score_opus":0.013395521145066114,"score_gpt":0.24664726234078235,"score_spread":0.23325174119571623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283734564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853538,0.00028834492,0.00018353506,0.00007047715,0.000009099166,0.000055199478,0.013126451,0.000014223036,0.00089877995],"genre_scores_gemma":[0.9814755,0.00033972375,0.00026329717,0.000100619625,0.00003226146,0.00015384083,0.01743555,0.000014452551,0.00018470795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886525,0.00017559892,0.00020635275,0.00037017147,0.00023685822,0.0001457907],"domain_scores_gemma":[0.9974585,0.0003471464,0.0013186154,0.00026187286,0.00030559592,0.00030827042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010888895,0.00029237266,0.00058398244,0.0014411905,0.00043425988,0.000879765,0.0005888408,0.0003782596,0.001899589],"category_scores_gemma":[0.0030673132,0.00027310595,0.0006336859,0.0034526475,0.00020369947,0.0007223799,0.0011692869,0.0006443694,0.0005198927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013015041,0.000015133311,0.9979133,0.000021160551,0.000049876267,0.00009420915,0.000035541838,0.00003824726,0.00006614586,0.000024815585,0.0006567955,0.0009546558],"study_design_scores_gemma":[0.000020777497,0.00006573538,0.998126,0.000021169542,0.000050167953,0.0005666552,0.0002479654,0.0002261908,0.000049761835,0.000032743843,0.00058693776,0.000005973975],"about_ca_topic_score_codex":0.004473956,"about_ca_topic_score_gemma":0.004942427,"teacher_disagreement_score":0.004473956,"about_ca_system_score_codex":0.00035347042,"about_ca_system_score_gemma":0.0007364044,"threshold_uncertainty_score":0.008895814},"labels":[],"label_agreement":null},{"id":"W4291493138","doi":"10.1097/01.hs9.0000872968.02648.ef","title":"P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Disease; Pediatrics; Anemia; Fetal hemoglobin; Sickle cell anemia; Hemoglobin; Transfusion therapy; Newborn screening; Internal medicine; Blood transfusion; Pregnancy; Biology","score_opus":0.017200286557764077,"score_gpt":0.2639512468813468,"score_spread":0.24675096032358274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291493138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533314,0.0013101042,0.0012113559,0.00017907843,0.000024417564,0.00015349357,0.00030207977,0.000060503597,0.001425886],"genre_scores_gemma":[0.99007684,0.00064038136,0.0081730075,0.00014364059,0.000013017769,0.00007409605,0.00032411332,0.000010045489,0.0005449703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994085,0.00022550598,0.00004808842,0.00010502656,0.00015271106,0.000060111728],"domain_scores_gemma":[0.9993961,0.00015328813,0.00020229633,0.000017927288,0.00015055828,0.000079832804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006333053,0.00036231242,0.00023297365,0.0003785289,0.00020532284,0.00041736691,0.0004089984,0.0004874093,0.0011362031],"category_scores_gemma":[0.0012367895,0.00016315436,0.00013809057,0.0003093421,0.00039733184,0.00021524928,0.00032989882,0.00040790133,0.00036726502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011211091,0.00048416466,0.86594164,0.00043847863,0.00004014034,0.004213058,0.0012606338,0.00034614676,0.08202343,0.00013108738,0.0010070174,0.04299318],"study_design_scores_gemma":[0.00015225912,0.005155526,0.90252036,0.00023557179,0.000078301266,0.019540481,0.0020726256,0.0023786891,0.059753556,0.00008480187,0.007998434,0.000029396568],"about_ca_topic_score_codex":0.004667271,"about_ca_topic_score_gemma":0.0059019164,"teacher_disagreement_score":0.004667271,"about_ca_system_score_codex":0.00048508597,"about_ca_system_score_gemma":0.0004962339,"threshold_uncertainty_score":0.009280205},"labels":[],"label_agreement":null},{"id":"W4296686347","doi":"10.1097/hs9.0000000000000779","title":"U2AF1 S34/Q157 Variants Detected in cis Arise Sequentially in an MDS Patient With Serial Sequencing Spanning 18 Years","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Ontario Institute for Cancer Research; Queen's University","funders":"","keywords":"DNA sequencing; Computational biology; Genetics; Computer science; Biology; Psychology; Gene","score_opus":0.029689907945200766,"score_gpt":0.28319871875837477,"score_spread":0.253508810813174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296686347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748355,0.00030698525,0.00055366586,0.00018950185,0.000023246954,0.000032799344,0.00012183833,0.000034270608,0.0012541307],"genre_scores_gemma":[0.99868435,0.00016105246,0.00051491044,0.00012459632,0.000050845432,0.0000075172024,0.00012440281,0.000010095042,0.00032225868],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997141,0.000022592274,0.000039699786,0.00010209239,0.00004921189,0.00007227252],"domain_scores_gemma":[0.999338,0.00015407825,0.00014957237,0.000045057,0.00007633146,0.00023686593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020516002,0.00082335045,0.0004891234,0.0015528277,0.0011754312,0.00047015032,0.00045364106,0.0010387804,0.0015096011],"category_scores_gemma":[0.0012191347,0.00043023747,0.00042680677,0.0006280458,0.0005772593,0.00049996306,0.0005651876,0.00087717356,0.00043946112],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030182456,0.000114267255,0.22241989,0.000032495303,0.000030390804,0.7559509,0.0011740586,0.00023915028,0.011819766,0.00018898492,0.0004786503,0.0072496706],"study_design_scores_gemma":[0.000018051234,0.00036241216,0.09458008,0.000026669984,0.000055277353,0.89797986,0.00034771467,0.0005228035,0.0042224657,0.00017191125,0.0016878148,0.000025093826],"about_ca_topic_score_codex":0.00184362,"about_ca_topic_score_gemma":0.0023957654,"teacher_disagreement_score":0.00184362,"about_ca_system_score_codex":0.00042192749,"about_ca_system_score_gemma":0.0002826613,"threshold_uncertainty_score":0.0050501227},"labels":[],"label_agreement":null},{"id":"W4296908362","doi":"10.1097/hs9.0000000000000774","title":"Heterozygous Variants in the DNA-binding Domain of c-Myb May Affect Normal B/T Cell Development","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Newborn Screening Ontario; University of Ottawa; Children's Hospital of Eastern Ontario","funders":"","keywords":"Biology; Transcription factor; MYB; Thymocyte; CD8; Cell biology; T cell; Genetics; Immune system; Gene","score_opus":0.009115415642182254,"score_gpt":0.2121903345966441,"score_spread":0.20307491895446184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296908362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901686,0.0018943581,0.0032373942,0.00019484607,0.00007153277,0.000045650613,0.001306466,0.00023867894,0.002842517],"genre_scores_gemma":[0.9957137,0.00069826073,0.0013723907,0.000081665086,0.00004865988,0.000029556157,0.0005408061,0.000076667515,0.0014382735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982977,0.00003578385,0.000019585488,0.000054955686,0.000036755693,0.000023222812],"domain_scores_gemma":[0.9997849,0.00005019137,0.0000879907,0.0000115653365,0.000010108817,0.00005531154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013388888,0.0010352944,0.000330502,0.00071359304,0.00032549573,0.00028725556,0.00033701415,0.000810434,0.0070252283],"category_scores_gemma":[0.0003632983,0.00018576626,0.00022644518,0.0003460327,0.0005574878,0.0001808428,0.00030358753,0.00045919098,0.0008299849],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021918758,0.00017545169,0.013912628,0.00017032775,0.00014674322,0.023305457,0.00016500767,0.0005255954,0.9463674,0.0014612672,0.0008290683,0.010749133],"study_design_scores_gemma":[0.00076780457,0.00240557,0.40254614,0.00033517493,0.0011005607,0.23993291,0.00040917608,0.005192182,0.31515533,0.0050662495,0.026931968,0.00015696035],"about_ca_topic_score_codex":0.00082818925,"about_ca_topic_score_gemma":0.0006303726,"teacher_disagreement_score":0.0070252283,"about_ca_system_score_codex":0.00019981695,"about_ca_system_score_gemma":0.00016018923,"threshold_uncertainty_score":0.023501754},"labels":[],"label_agreement":null},{"id":"W4303983498","doi":"10.1097/01.hs9.0000890608.32200.eb","title":"P010: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Young adult; Stage (stratigraphy); Internal medicine; Hazard ratio; Pediatrics; Confidence interval","score_opus":0.17519443905383938,"score_gpt":0.4587363563995281,"score_spread":0.2835419173456887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303983498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9285653,0.0130716665,0.0058699497,0.0037856472,0.000121663616,0.0007550636,0.03470432,0.00019595135,0.012930476],"genre_scores_gemma":[0.98160684,0.002246484,0.0027911803,0.0020280085,0.00013813253,0.00066966994,0.009719927,0.000053825886,0.0007459815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911351,0.00507031,0.0010863843,0.0007422702,0.0016740029,0.0002918808],"domain_scores_gemma":[0.9381461,0.030038822,0.023481045,0.002679058,0.0035867216,0.0020682875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027041582,0.00025533777,0.0006729131,0.000807883,0.00033792917,0.0011910083,0.0005019825,0.00047150324,0.0034492055],"category_scores_gemma":[0.044928133,0.00015149095,0.00108241,0.0017830967,0.00044880903,0.0009382756,0.0015375298,0.0007331116,0.00024383237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006301407,0.000067568806,0.9100281,0.0011807207,0.0025294241,0.00013320723,0.0003185858,0.0010371632,0.00039212557,0.00096204993,0.01593616,0.061113413],"study_design_scores_gemma":[0.00081197027,0.00088501594,0.98400843,0.00055235776,0.0016502518,0.00052531663,0.0002804224,0.0013712659,0.0004328117,0.00082990277,0.008606011,0.0000461198],"about_ca_topic_score_codex":0.002868937,"about_ca_topic_score_gemma":0.0051463596,"teacher_disagreement_score":0.027041582,"about_ca_system_score_codex":0.0005921868,"about_ca_system_score_gemma":0.001459738,"threshold_uncertainty_score":0.14301127},"labels":[],"label_agreement":null},{"id":"W4303983518","doi":"10.1097/01.hs9.0000890604.66330.a0","title":"P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Brentuximab vedotin; Dacarbazine; ABVD; Medicine; Hazard ratio; Internal medicine; Vinblastine; Oncology; Population; Progression-free survival; Vincristine; Lymphoma; Confidence interval; Surgery; Chemotherapy; Hodgkin lymphoma; Cyclophosphamide","score_opus":0.008250420486286589,"score_gpt":0.23995847702341683,"score_spread":0.23170805653713022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303983518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95342255,0.031932615,0.0010989193,0.0012471015,0.0001524361,0.000466652,0.007476076,0.00010629086,0.0040974775],"genre_scores_gemma":[0.9808741,0.0076731187,0.0013516343,0.00086956116,0.00025381104,0.00020802247,0.0076325256,0.000027860686,0.0011093335],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994455,0.00022181975,0.00004932678,0.000093173825,0.00014796955,0.000042217758],"domain_scores_gemma":[0.9990569,0.0003302257,0.00033538282,0.000055522472,0.000104130755,0.000117863005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020573412,0.0003040339,0.0008096151,0.00031991253,0.000108840955,0.0005722992,0.0004254137,0.00026842294,0.0019463355],"category_scores_gemma":[0.0018328356,0.0001361852,0.001178868,0.0005645598,0.00018139007,0.0005046216,0.00033873506,0.0006707793,0.00021356069],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13760342,0.000977785,0.27734017,0.004660525,0.011181449,0.00034035544,0.00017376503,0.00262975,0.010487241,0.00029174137,0.014024348,0.54028946],"study_design_scores_gemma":[0.02319095,0.026162298,0.9177303,0.00043745266,0.010616328,0.0011832096,0.00008472961,0.0020204682,0.002151092,0.0003507908,0.016021602,0.00005086781],"about_ca_topic_score_codex":0.00080551545,"about_ca_topic_score_gemma":0.002988217,"teacher_disagreement_score":0.0020573412,"about_ca_system_score_codex":0.00050090416,"about_ca_system_score_gemma":0.0005682925,"threshold_uncertainty_score":0.010880411},"labels":[],"label_agreement":null},{"id":"W4304701174","doi":"10.1097/hs9.0000000000000787","title":"Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dyskeratosis congenita; CEBPA; Myeloid leukemia; Medicine; Germline; Bone marrow failure; Myeloid; Telomerase; Oncology; Internal medicine; Telomere; Germline mutation; Immunology; Mutation; Biology; Gene; Genetics; Haematopoiesis; Stem cell","score_opus":0.013380467579370657,"score_gpt":0.2523804352887737,"score_spread":0.23899996770940302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304701174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970016,0.0013838714,0.00013581854,0.00009263529,0.000039491308,0.000008989063,0.0005428404,0.000007642026,0.0007871327],"genre_scores_gemma":[0.99829715,0.00048359574,0.00007284955,0.000071756185,0.000060059032,0.000007331831,0.0007232681,0.0000024769213,0.0002814469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998795,0.000018341823,0.000012219918,0.000026819405,0.000024061106,0.00003898964],"domain_scores_gemma":[0.99965763,0.000050929506,0.00011951218,0.000015923184,0.00004091216,0.00011510431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019309457,0.00021150587,0.00038239433,0.0004204812,0.00031188942,0.00034798615,0.00016347328,0.0002719116,0.002144562],"category_scores_gemma":[0.0010021128,0.00008627574,0.00021242505,0.0005391288,0.000119129414,0.00031249545,0.00028178896,0.00037211305,0.00035575373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014604579,0.000028871118,0.9948372,0.000014621769,0.000026693373,0.0015115128,0.00007939039,0.00003892154,0.0002775297,0.000028045899,0.00028075321,0.0027303884],"study_design_scores_gemma":[0.0000061086844,0.00019691627,0.99387735,0.000017420802,0.000031611096,0.0046636714,0.0002105913,0.00012564959,0.00004479204,0.00010144127,0.0007179043,0.000006659076],"about_ca_topic_score_codex":0.0013448867,"about_ca_topic_score_gemma":0.001809528,"teacher_disagreement_score":0.002144562,"about_ca_system_score_codex":0.00015014375,"about_ca_system_score_gemma":0.00021509909,"threshold_uncertainty_score":0.007174313},"labels":[],"label_agreement":null},{"id":"W4308963956","doi":"10.1097/hs9.0000000000000801","title":"Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"Janssen Biotech; Novo Nordisk; Ascentage Pharma; Servier; Moderna; Celltrion; Incyte; Pharmacyclics; MEI Pharma; Karyopharm Therapeutics; Gilead Sciences; BeiGene; Sanofi; Cilag; TG Therapeutics; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Bendamustine; Chronic lymphocytic leukemia; Tolerability; Ofatumumab; Gastroenterology; Adverse effect; Oncology; Leukemia","score_opus":0.07152014511977556,"score_gpt":0.33529776259184485,"score_spread":0.2637776174720693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308963956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9603305,0.015685607,0.00070853514,0.0019178693,0.000449362,0.0016692146,0.0047957436,0.00023251244,0.0142106265],"genre_scores_gemma":[0.9771673,0.004404396,0.0014638585,0.0017910991,0.00067088107,0.001745425,0.008030199,0.000045697067,0.004681114],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991634,0.00054248,0.000034504676,0.000071597635,0.0000731846,0.000114891816],"domain_scores_gemma":[0.9989391,0.00033239645,0.00020150888,0.00008727877,0.00008398819,0.00035574994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030671076,0.00103748,0.0012988886,0.00037114,0.00035787068,0.0010399454,0.00071064907,0.0009222742,0.0038351114],"category_scores_gemma":[0.0021815484,0.00020181804,0.0016425428,0.0003246769,0.0005380264,0.0009178388,0.000377803,0.002539306,0.00060796813],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8855607,0.0064661126,0.0037243334,0.0010351667,0.0022324424,0.0001722892,0.00014421671,0.0017952031,0.004512187,0.0006612543,0.0165035,0.07719271],"study_design_scores_gemma":[0.84081703,0.118258625,0.01597054,0.00020899736,0.0021743558,0.0003635179,0.00008014902,0.0032229053,0.002110235,0.0013563058,0.015379985,0.000057375266],"about_ca_topic_score_codex":0.00065589324,"about_ca_topic_score_gemma":0.0022610442,"teacher_disagreement_score":0.0038351114,"about_ca_system_score_codex":0.00064465345,"about_ca_system_score_gemma":0.000706516,"threshold_uncertainty_score":0.01622063},"labels":[],"label_agreement":null},{"id":"W4362668845","doi":"10.1097/hs9.0000000000000863","title":"Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"Takeda Oncology; Blood Cancer UK; Genentech; Celgene; KWF Kankerbestrijding; Teva Pharmaceutical Industries; National Cancer Institute; Cancer Research UK; GlaxoSmithKline; Pfizer","keywords":"Medicine; Follicular lymphoma; Asymptomatic; Rituximab; Lymphoma; Stage (stratigraphy); Biopsy; International Prognostic Index; Internal medicine; Surgery; Oncology","score_opus":0.018462729907170905,"score_gpt":0.25210918094393764,"score_spread":0.23364645103676673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362668845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740666,0.0005664794,0.00012758824,0.000103101054,0.000011155736,0.00001939389,0.000109733235,0.00000717394,0.0016487086],"genre_scores_gemma":[0.99937516,0.00008247946,0.00016242354,0.00007873947,0.000020165484,0.000008131957,0.00015799137,0.0000026167831,0.00011233681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996301,0.00005253702,0.00005046378,0.00010506206,0.00007510868,0.00008683088],"domain_scores_gemma":[0.9989548,0.00028751665,0.00035059932,0.000056266108,0.000115838106,0.00023494975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047803926,0.00024650156,0.00038830665,0.00065630814,0.0004177795,0.000654838,0.0003765092,0.00059619866,0.002148068],"category_scores_gemma":[0.0025756252,0.00012211961,0.00028504306,0.00038890383,0.00038469234,0.00081575103,0.0003107586,0.00035639122,0.0005551481],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005137669,0.000059165202,0.98995435,0.000018202132,0.00002140136,0.00061150955,0.00007617929,0.000072248884,0.0015373568,0.000068872156,0.00018438001,0.0068826],"study_design_scores_gemma":[0.000060841452,0.0010314481,0.9886495,0.000050406637,0.00006189317,0.0067739724,0.00047560458,0.0007007983,0.0005737297,0.00043517002,0.0011760431,0.000010668129],"about_ca_topic_score_codex":0.0015219047,"about_ca_topic_score_gemma":0.0026376697,"teacher_disagreement_score":0.002148068,"about_ca_system_score_codex":0.00038678045,"about_ca_system_score_gemma":0.00032456085,"threshold_uncertainty_score":0.0071859956},"labels":[],"label_agreement":null},{"id":"W4364378600","doi":"10.1097/01.hs9.0000928476.36016.9a","title":"5607225 ADDITION OF THERAPEUTIC PLASMA EXCHANGE TO RED CELL EXCHANGE IMPROVES OUTCOMES OF FAT EMBOLISM SYNDROME IN SICKLE CELL DISEASE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Blood groups and transfusion","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Disease; Fat embolism; Neurocognitive; Complication; Internal medicine; Surgery; Intensive care medicine; Psychiatry","score_opus":0.016169864464464976,"score_gpt":0.24687736096864446,"score_spread":0.2307074965041795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364378600","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009597553,0.9885616,0.0000813478,0.0002718976,0.000118315984,0.0000809653,0.0004753238,0.000006201862,0.00080685416],"genre_scores_gemma":[0.11400492,0.88326937,0.0007681463,0.0007448126,0.00021044258,0.00017394368,0.00063452654,0.000005745303,0.000188144],"study_design_codex":"systematic_review","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9965798,0.0011174555,0.0014418041,0.00028883776,0.00049825636,0.00007387427],"domain_scores_gemma":[0.98816013,0.0076813563,0.0029619054,0.00011180395,0.00093860907,0.00014613113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037395768,0.00039450734,0.0030996848,0.004373815,0.00027916222,0.0012784834,0.0006800334,0.0009581891,0.003763799],"category_scores_gemma":[0.01627882,0.00027259454,0.0038921987,0.003721972,0.00043714186,0.0009696716,0.00048800852,0.00060603296,0.0002896208],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027958096,0.000117633506,0.011244093,0.76247764,0.023081858,0.00027827194,0.00022234405,0.00025969752,0.00092448626,0.00030982168,0.0028028213,0.19548556],"study_design_scores_gemma":[0.0035093988,0.00331746,0.10136238,0.67277056,0.16844966,0.002175909,0.00068687694,0.00035897005,0.0010062519,0.0008793454,0.045358315,0.00012486677],"about_ca_topic_score_codex":0.0022057844,"about_ca_topic_score_gemma":0.005452216,"teacher_disagreement_score":0.004373815,"about_ca_system_score_codex":0.0008594393,"about_ca_system_score_gemma":0.0021660824,"threshold_uncertainty_score":0.019777},"labels":[],"label_agreement":null},{"id":"W4365144810","doi":"10.1097/01.hs9.0000928200.69096.c5","title":"5612992 SICKLE CELL HEALTH AWARENESS, PERSPECTIVES, AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE AND IMPACT ON THE QUALITY OF LIFE OF PATIENTS AND CAREGIVERS IN THE UK","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Context (archaeology); Quality of life (healthcare); Disease; Computer-assisted web interviewing; Family medicine; Descriptive statistics; Burden of disease; Descriptive research; Gerontology; Nursing","score_opus":0.02599522399579153,"score_gpt":0.2985872115201608,"score_spread":0.2725919875243693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365144810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916187,0.0003900344,0.00004072762,0.00046512825,0.000012951182,0.000056221594,0.004170932,0.0000053771714,0.0032399425],"genre_scores_gemma":[0.9948614,0.0010110186,0.000118164106,0.0005401284,0.000012615438,0.00014403621,0.0022061216,0.0000048376824,0.0011017489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989371,0.0003666153,0.0002038982,0.00007999005,0.00025146772,0.00016096252],"domain_scores_gemma":[0.9971456,0.0006258482,0.0009098719,0.00010828887,0.0006615928,0.000548859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010589679,0.00014327065,0.00028553835,0.0007401941,0.00039492483,0.00078727165,0.00019921162,0.00034515138,0.003785515],"category_scores_gemma":[0.00493307,0.00015906229,0.00024280259,0.0011840588,0.00027066565,0.00047690165,0.0016610657,0.00035202506,0.00071938656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020199099,0.000052154905,0.94750506,0.00033150523,0.000041182724,0.0005864669,0.01107351,0.000074538286,0.00043983068,0.0001252872,0.013825021,0.025743453],"study_design_scores_gemma":[0.000011056421,0.00008327876,0.982841,0.0002340235,0.000009491283,0.00036764852,0.010876105,0.000042796215,0.000059865717,0.000017607153,0.005444721,0.000012480033],"about_ca_topic_score_codex":0.024901917,"about_ca_topic_score_gemma":0.032392193,"teacher_disagreement_score":0.024901917,"about_ca_system_score_codex":0.000781601,"about_ca_system_score_gemma":0.0008358159,"threshold_uncertainty_score":0.049513936},"labels":[],"label_agreement":null},{"id":"W4376106087","doi":"10.1097/01.hs9.0000936160.56974.35","title":"P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER-DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Centre Hospitalier Universitaire de Toulouse; Syddansk Universitet; Université de Toulouse; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; University of Alberta; University of Wolverhampton; National Institute for Health and Care Research; Massachusetts General Hospital; St Vincent's Hospital Melbourne; Université de Lille","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Biomarker; Progression-free survival; Overall survival","score_opus":0.04316716519591803,"score_gpt":0.31308169024064814,"score_spread":0.2699145250447301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376106087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5588736,0.40652007,0.001426932,0.0018194355,0.00037753707,0.00012114177,0.02786424,0.00008313804,0.0029138993],"genre_scores_gemma":[0.9782809,0.014843804,0.00060523703,0.0004394543,0.00022020217,0.00014911112,0.0050590555,0.000022615743,0.00037966837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985209,0.00038659887,0.00035138914,0.00044074535,0.00018258275,0.0001177809],"domain_scores_gemma":[0.9929276,0.0032500068,0.0025450196,0.0003160118,0.00074118556,0.00022020572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028707776,0.00046049175,0.0016829498,0.0024925629,0.00020512831,0.0010517952,0.00082081824,0.0010063818,0.0028486603],"category_scores_gemma":[0.009526984,0.0003620595,0.0070490246,0.0057765646,0.00019439452,0.0010653067,0.0006081852,0.0009900437,0.00031108377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008642659,0.000059245474,0.86349446,0.017769398,0.07607029,0.00025520255,0.00019205092,0.0011739798,0.0006638384,0.00030919412,0.0039420915,0.02742752],"study_design_scores_gemma":[0.00082274055,0.000997569,0.89608264,0.0025216627,0.08783517,0.00068812765,0.0002750162,0.0018193097,0.00035266049,0.0007982477,0.0077472487,0.000059506096],"about_ca_topic_score_codex":0.004595377,"about_ca_topic_score_gemma":0.0045845993,"teacher_disagreement_score":0.004595377,"about_ca_system_score_codex":0.000556438,"about_ca_system_score_gemma":0.0006876611,"threshold_uncertainty_score":0.015182316},"labels":[],"label_agreement":null},{"id":"W4378078281","doi":"10.1097/hs9.0000000000000886","title":"Bleeding and Thrombosis in Patients With Cirrhosis: What’s New?","year":2023,"lang":"en","type":"editorial","venue":"HemaSphere","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cirrhosis; Thrombosis; Medicine; Internal medicine; Cardiology","score_opus":0.009926677538678964,"score_gpt":0.24616217742995147,"score_spread":0.23623549989127252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378078281","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012916739,0.9056202,0.0004045576,0.07298485,0.0036906137,0.000030320994,0.0003704055,0.000041171592,0.003941098],"genre_scores_gemma":[0.08320139,0.87042737,0.0012012165,0.015829753,0.028119275,0.000056614175,0.0005260032,0.000015616768,0.000622707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890995,0.00027292233,0.00021364445,0.00014320543,0.00032880556,0.00013152567],"domain_scores_gemma":[0.9938061,0.0026161247,0.0014601768,0.0001526836,0.0011876584,0.0007772418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014042945,0.00056229735,0.0017448706,0.0022497464,0.0005513282,0.0026074192,0.0010046896,0.003552818,0.0039150375],"category_scores_gemma":[0.0068908194,0.00033012126,0.00080052856,0.003411028,0.0012365857,0.004254375,0.00060734584,0.0040781437,0.0007418115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000835096,0.00028128165,0.15848346,0.009112948,0.0005236718,0.003669621,0.00075566967,0.0002780363,0.00019383409,0.0024349994,0.07057053,0.7528609],"study_design_scores_gemma":[0.00033532313,0.0010076367,0.5700203,0.058989406,0.0021679087,0.06271025,0.0072418265,0.001670299,0.0002595247,0.018725347,0.2763828,0.00048937276],"about_ca_topic_score_codex":0.005025459,"about_ca_topic_score_gemma":0.005894541,"teacher_disagreement_score":0.005025459,"about_ca_system_score_codex":0.00074346975,"about_ca_system_score_gemma":0.0012293783,"threshold_uncertainty_score":0.013097107},"labels":[],"label_agreement":null},{"id":"W4379467996","doi":"10.1097/hs9.0000000000000900","title":"Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Antithrombotic; Hemostasis; Thrombosis; Atrial fibrillation; Clotting factor; Stroke (engine); Venous thrombosis; Intensive care medicine; Internal medicine; Physical therapy","score_opus":0.053939705051948755,"score_gpt":0.3947387255850169,"score_spread":0.3407990205330681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379467996","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007517736,0.1857498,0.023384126,0.41509938,0.013725464,0.0046099015,0.013644724,0.0018975248,0.33437136],"genre_scores_gemma":[0.057374015,0.32725862,0.19452548,0.2566879,0.012756764,0.012605858,0.0377087,0.00066241046,0.10042015],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99603987,0.0014060617,0.0008676356,0.00016735162,0.0012609995,0.00025809003],"domain_scores_gemma":[0.9908698,0.0029291993,0.0011383004,0.00016218328,0.004002506,0.0008979075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004468486,0.0007313169,0.0013629431,0.002230108,0.00065811357,0.0022363756,0.002132136,0.0062620905,0.01468289],"category_scores_gemma":[0.018919121,0.0004085273,0.0021884951,0.001507938,0.0005333137,0.001333925,0.0018342145,0.0040436196,0.010426546],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094174095,0.00025355513,0.0014464285,0.0019404165,0.000060322946,0.00035604308,0.00021294146,0.0006092852,0.00028982168,0.00374318,0.6987036,0.29229024],"study_design_scores_gemma":[0.0003505958,0.0001487,0.0047599836,0.015200094,0.0001362965,0.0008277316,0.00018876663,0.0007095274,0.00024313656,0.00432297,0.9730674,0.00004483489],"about_ca_topic_score_codex":0.010681688,"about_ca_topic_score_gemma":0.015191075,"teacher_disagreement_score":0.01468289,"about_ca_system_score_codex":0.0023165275,"about_ca_system_score_gemma":0.0072307577,"threshold_uncertainty_score":0.049119174},"labels":[],"label_agreement":null},{"id":"W4379792669","doi":"10.1097/hs9.0000000000000905","title":"Prevalence and Clinical Outcome of Omicron Breakthrough Infection in Patients With Hematologic Disease: A Prospective Observational Cohort Study","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; Medicine; Cohort study; Disease; Prospective cohort study; Cohort; Hematologic disease; Internal medicine; Outcome (game theory); Pediatrics; Intensive care medicine","score_opus":0.06786149260716626,"score_gpt":0.3959144969358488,"score_spread":0.32805300432868256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379792669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967884,0.0003115042,0.000089049354,0.000029603918,0.000010710587,0.000036089845,0.0024561116,0.0000039329852,0.0002746727],"genre_scores_gemma":[0.9969511,0.00016526094,0.00009429368,0.000040795283,0.000017257838,0.000046900706,0.0025648703,0.0000027199956,0.000116782234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993175,0.000116852534,0.000084375155,0.0002578934,0.00010924143,0.00011409852],"domain_scores_gemma":[0.9988405,0.00012563966,0.00043882738,0.0001736732,0.00016707674,0.00025440517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000967097,0.00036041666,0.0005948214,0.0005986143,0.0005999545,0.0007005599,0.00059788243,0.0006167258,0.0016416876],"category_scores_gemma":[0.0014999749,0.00046853034,0.0007480291,0.0011435366,0.00020732805,0.00067101367,0.0005790874,0.0009294606,0.00036644682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025910523,0.00005039663,0.9989361,0.00001144583,0.00009160031,0.00003887437,0.000030752773,0.000018670315,0.000114207025,0.000007809272,0.00016259111,0.00027855844],"study_design_scores_gemma":[0.000026624799,0.00018386307,0.99922514,0.00000790331,0.000042986703,0.00013343718,0.00008958541,0.00012843903,0.00001821651,0.000010308792,0.0001289748,0.0000045757947],"about_ca_topic_score_codex":0.006753262,"about_ca_topic_score_gemma":0.006319743,"teacher_disagreement_score":0.006753262,"about_ca_system_score_codex":0.00037260787,"about_ca_system_score_gemma":0.00048404513,"threshold_uncertainty_score":0.013427913},"labels":[],"label_agreement":null},{"id":"W4382313481","doi":"10.1097/01.hs9.0000936256.84340.a7","title":"P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Bone marrow; Internal medicine; CD8; Antibody; Oncology; Immunology; Immune system; Gastroenterology","score_opus":0.037613535713238215,"score_gpt":0.32640413410390967,"score_spread":0.28879059839067145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382313481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972933,0.001221926,0.00019878117,0.00009403692,0.000013834025,0.00018252007,0.0003257756,0.000025821217,0.0006441198],"genre_scores_gemma":[0.9976877,0.00027213796,0.00050826,0.00016434329,0.00004546997,0.00009954882,0.0008605929,0.0000064385176,0.0003555816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996006,0.00014407525,0.00002570552,0.0001056431,0.00007791521,0.000046015677],"domain_scores_gemma":[0.9994809,0.00010947039,0.00012673067,0.000053634336,0.00007597096,0.00015321899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015731255,0.00046634904,0.0006073004,0.00051066565,0.00030418986,0.0005866896,0.0004501514,0.00043368276,0.00078389584],"category_scores_gemma":[0.0009332778,0.00026882224,0.00034866357,0.00032109473,0.00036158576,0.00030344864,0.00025492572,0.00090825814,0.000248601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18469326,0.013188893,0.34733433,0.000786218,0.001235726,0.0019899788,0.0009466548,0.003125667,0.2590429,0.0003099295,0.0044412767,0.18290526],"study_design_scores_gemma":[0.025756262,0.21791157,0.68292123,0.000058256508,0.0011909605,0.0056765177,0.0002755536,0.0048221326,0.051167678,0.00026282456,0.0099015,0.00005557221],"about_ca_topic_score_codex":0.0008959015,"about_ca_topic_score_gemma":0.0012514587,"teacher_disagreement_score":0.0015731255,"about_ca_system_score_codex":0.00066919706,"about_ca_system_score_gemma":0.0006438301,"threshold_uncertainty_score":0.008319616},"labels":[],"label_agreement":null},{"id":"W4382513940","doi":"10.1097/01.hs9.0000936124.56965.24","title":"B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Pomalidomide; Medicine; Lenalidomide; Regimen; Internal medicine; Dexamethasone; Ixazomib; Oncology; Multiple myeloma; Carfilzomib; Clinical endpoint; Randomized controlled trial","score_opus":0.02313725160101678,"score_gpt":0.3011518509707363,"score_spread":0.27801459936971956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382513940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794748,0.010774858,0.00045971078,0.0010057085,0.00058544613,0.0032345145,0.0013765503,0.00021043663,0.0028780673],"genre_scores_gemma":[0.9871427,0.003196264,0.0010976987,0.0016058388,0.0004113372,0.0033871885,0.0012296878,0.000028078744,0.0019013349],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99941075,0.000294476,0.000038157574,0.00012385794,0.000040741506,0.00009203156],"domain_scores_gemma":[0.99912053,0.00022303095,0.0002588221,0.00007299891,0.000056623372,0.00026802538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018385429,0.0015584996,0.002681182,0.0003653381,0.00044647022,0.0013786547,0.0009313395,0.0017109246,0.0073833163],"category_scores_gemma":[0.0014095267,0.00063553825,0.0025958973,0.00046481876,0.000845967,0.0011271578,0.00043569328,0.0033552786,0.0011014212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9799622,0.0039575584,0.0005807902,0.00066288834,0.0012992779,0.000033059954,0.000036446778,0.00025320755,0.0012788583,0.00007215994,0.0009905264,0.010872959],"study_design_scores_gemma":[0.9627428,0.033812854,0.0017340452,0.000048742313,0.0005299237,0.000040965868,0.000014896772,0.00033682442,0.00014281896,0.00011069439,0.00047346018,0.000012139934],"about_ca_topic_score_codex":0.0010405142,"about_ca_topic_score_gemma":0.0024931415,"teacher_disagreement_score":0.0073833163,"about_ca_system_score_codex":0.00088207796,"about_ca_system_score_gemma":0.0011185181,"threshold_uncertainty_score":0.024699628},"labels":[],"label_agreement":null},{"id":"W4385644673","doi":"10.1097/01.hs9.0000967692.36989.7b","title":"S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Regimen; Oncology; Refractory (planetary science); Lenalidomide; Population; Multiple myeloma","score_opus":0.012653030857564059,"score_gpt":0.2517735670351252,"score_spread":0.23912053617756115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969709,0.0016941513,0.00008261615,0.00009850362,0.000038624086,0.00005409446,0.0003715641,0.000010582392,0.00067889463],"genre_scores_gemma":[0.99816257,0.0003512096,0.00015131585,0.00020359462,0.000057569563,0.000058850823,0.0005580704,0.0000033407396,0.00045347222],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995957,0.00016504688,0.000028452087,0.000073974974,0.00005007765,0.00008680943],"domain_scores_gemma":[0.9995018,0.00014733676,0.00014036236,0.000042559954,0.000019412437,0.00014851768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009986203,0.00025436585,0.00077227835,0.00028721255,0.00015713615,0.00075461133,0.00034023807,0.0005077471,0.0026831387],"category_scores_gemma":[0.0007418784,0.00012517889,0.001680365,0.00026546937,0.00026031173,0.00041036238,0.00030613333,0.0007980045,0.0002749924],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7308421,0.003788345,0.14108609,0.0005218867,0.005555495,0.00027057485,0.00018804254,0.0016868373,0.010397964,0.000314715,0.0025208734,0.10282699],"study_design_scores_gemma":[0.09424422,0.27508214,0.59825104,0.0002577814,0.0073288893,0.0013375875,0.00034431688,0.006508693,0.0053318883,0.0009261846,0.010314992,0.00007218052],"about_ca_topic_score_codex":0.00056869705,"about_ca_topic_score_gemma":0.0020196624,"teacher_disagreement_score":0.0026831387,"about_ca_system_score_codex":0.0007484676,"about_ca_system_score_gemma":0.0005034157,"threshold_uncertainty_score":0.008975983},"labels":[],"label_agreement":null},{"id":"W4385644723","doi":"10.1097/01.hs9.0000967696.13096.54","title":"S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Refractory (planetary science); Adverse effect; Gastroenterology; Multiple myeloma; Surgery","score_opus":0.018638708852403377,"score_gpt":0.2789849677210768,"score_spread":0.2603462588686734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99158305,0.0023468193,0.00048009917,0.0005491285,0.00007042428,0.0004967529,0.0015250777,0.00008166625,0.00286693],"genre_scores_gemma":[0.99328667,0.00063413475,0.00082222547,0.00048518364,0.00012089569,0.00026302497,0.002580839,0.000013943176,0.0017931059],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99986076,0.00005110559,0.000012457946,0.000024304583,0.00002315977,0.000028211454],"domain_scores_gemma":[0.99981457,0.000031249325,0.000056521145,0.000012267347,0.000013325965,0.00007207879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056762615,0.00028766805,0.00056458294,0.00016516904,0.00023575316,0.0003157378,0.00034260488,0.00033727486,0.005269056],"category_scores_gemma":[0.0003342534,0.000111232905,0.00049866777,0.0002388148,0.0001738794,0.00026849948,0.00019557397,0.0005884593,0.0008970321],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29543802,0.007261954,0.09265249,0.0012315518,0.0011839821,0.0017660699,0.00021650415,0.0021414647,0.0955586,0.00030025534,0.015237948,0.48701113],"study_design_scores_gemma":[0.29064125,0.2573363,0.3612282,0.00022211205,0.001635508,0.005077405,0.00012004546,0.0053738006,0.03227019,0.00047724103,0.04555302,0.00006497036],"about_ca_topic_score_codex":0.00059769873,"about_ca_topic_score_gemma":0.0016547305,"teacher_disagreement_score":0.005269056,"about_ca_system_score_codex":0.00056309084,"about_ca_system_score_gemma":0.0006442392,"threshold_uncertainty_score":0.017626703},"labels":[],"label_agreement":null},{"id":"W4385644849","doi":"10.1097/01.hs9.0000967680.90062.ca","title":"S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); CD38; Gastroenterology; Lenalidomide; Multiple myeloma; CD34","score_opus":0.020957787947047585,"score_gpt":0.2764088675186831,"score_spread":0.2554510795716355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8545604,0.092835225,0.00157151,0.0045668366,0.0006554187,0.0010372095,0.023702806,0.0003548721,0.020715766],"genre_scores_gemma":[0.9265093,0.022858618,0.0034125787,0.004272564,0.0007700464,0.0005630814,0.03732314,0.000112474176,0.00417812],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992716,0.00025570343,0.000099027595,0.000101270445,0.00018651229,0.00008595694],"domain_scores_gemma":[0.9989599,0.00021896015,0.0003398661,0.000044558885,0.00024683872,0.00018979824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021981942,0.00049312646,0.0012319244,0.00053721544,0.00019303143,0.0010437135,0.0005906485,0.0005495831,0.0037299197],"category_scores_gemma":[0.0015103228,0.00018046575,0.0018489602,0.0007991669,0.00014453277,0.0005455309,0.0004033104,0.000696841,0.0009927833],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08775925,0.0017386881,0.16806154,0.0065392884,0.01016088,0.0008684214,0.0003329404,0.0038888038,0.014620711,0.00032453137,0.0538687,0.6518363],"study_design_scores_gemma":[0.028010279,0.05936745,0.6817443,0.002762839,0.023878472,0.0054462166,0.0003678967,0.004639166,0.01358001,0.0006906331,0.17932566,0.00018715407],"about_ca_topic_score_codex":0.001797965,"about_ca_topic_score_gemma":0.004624998,"teacher_disagreement_score":0.0037299197,"about_ca_system_score_codex":0.0010061393,"about_ca_system_score_gemma":0.00077120133,"threshold_uncertainty_score":0.012477815},"labels":[],"label_agreement":null},{"id":"W4385655000","doi":"10.1097/01.hs9.0000975056.36410.cc","title":"PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Paroxysmal nocturnal hemoglobinuria; Eculizumab; Medicine; Anemia; Observational study; Internal medicine; Hemolysis; Hemoglobinuria; Pediatrics; Intensive care medicine; Complement system; Immunology; Antibody","score_opus":0.07548879676121699,"score_gpt":0.3284828945546748,"score_spread":0.2529940977934578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837624,0.0023349393,0.0006757235,0.000799523,0.00022695524,0.004494029,0.006014438,0.00005729375,0.0016347527],"genre_scores_gemma":[0.97259045,0.0014827593,0.0023721298,0.0018081242,0.00074819266,0.008448331,0.010449551,0.000041138414,0.0020593791],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983127,0.0010394393,0.000100138284,0.0002879908,0.00012621297,0.00013352376],"domain_scores_gemma":[0.99745363,0.00040154808,0.00084267074,0.0003536912,0.000245567,0.0007028611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032692386,0.0019316477,0.0029918288,0.00034463298,0.00070102204,0.0009994012,0.00086768245,0.001719099,0.0046772473],"category_scores_gemma":[0.0029065732,0.0007830701,0.0025807335,0.0006423475,0.00078323943,0.001572275,0.0008798497,0.0021689238,0.0012172706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8950941,0.013099399,0.05651379,0.0011533106,0.0067312126,0.00023151613,0.00018474681,0.0005927816,0.0030818782,0.00023711736,0.005128996,0.017951142],"study_design_scores_gemma":[0.6681891,0.176807,0.14385676,0.00015325792,0.004012557,0.00048004655,0.00016714055,0.001126014,0.0005514026,0.0004153571,0.0041421275,0.000099259516],"about_ca_topic_score_codex":0.0010706787,"about_ca_topic_score_gemma":0.0015699391,"teacher_disagreement_score":0.0046772473,"about_ca_system_score_codex":0.00077737,"about_ca_system_score_gemma":0.0015847945,"threshold_uncertainty_score":0.017289579},"labels":[],"label_agreement":null},{"id":"W4385655001","doi":"10.1097/01.hs9.0000974372.45108.8e","title":"PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME: A FIRST-IN-CLINIC PHASE 1 STUDY OF GSK3745417","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Sting; Myelodysplastic syndromes; Leukemia; Azacitidine; Tolerability; Stimulator of interferon genes; Internal medicine; Cancer research; Immunology; Bone marrow; Oncology; Immune system; Innate immune system; Biology; Adverse effect","score_opus":0.021151025363478813,"score_gpt":0.28826571158633224,"score_spread":0.26711468622285345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9050512,0.06871035,0.0014933321,0.003573141,0.0009817131,0.0038988309,0.005988555,0.0006028368,0.009700062],"genre_scores_gemma":[0.9067931,0.054599445,0.003405244,0.0060361093,0.0006073964,0.0033958345,0.008461353,0.0001272224,0.016574206],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99988985,0.00003705015,0.000007321843,0.000016720353,0.000016212136,0.00003289889],"domain_scores_gemma":[0.99982905,0.000024381443,0.000036719543,0.000010540913,0.000019049121,0.00008018764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061945216,0.0007403169,0.001519054,0.00025979182,0.00019201226,0.00080148346,0.0005257567,0.00083424605,0.0072216243],"category_scores_gemma":[0.00033132726,0.0002826882,0.0014108937,0.00022248742,0.00034575205,0.00046664343,0.00023590562,0.0024519674,0.0014354371],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19631948,0.038375247,0.0049416563,0.009717979,0.003759557,0.000727634,0.00054105336,0.0040645907,0.08869965,0.0015344617,0.049764592,0.60155416],"study_design_scores_gemma":[0.473882,0.41696075,0.020535557,0.0009824554,0.0029861657,0.0019326527,0.000276124,0.0033130643,0.015986385,0.0011276278,0.06190108,0.00011621057],"about_ca_topic_score_codex":0.0007891095,"about_ca_topic_score_gemma":0.002690753,"teacher_disagreement_score":0.0072216243,"about_ca_system_score_codex":0.00040705284,"about_ca_system_score_gemma":0.0008099048,"threshold_uncertainty_score":0.024158716},"labels":[],"label_agreement":null},{"id":"W4385655058","doi":"10.1097/01.hs9.0000975232.20009.f4","title":"PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Observational study; Adverse effect; Retrospective cohort study; Refractory (planetary science); Incidence (geometry); Oncology; Surgery","score_opus":0.12397344370946108,"score_gpt":0.3756518300853904,"score_spread":0.2516783863759293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94513756,0.02176301,0.0012433038,0.0010526133,0.00016563696,0.00050073344,0.026978273,0.00004669738,0.0031121064],"genre_scores_gemma":[0.966052,0.007953145,0.001423704,0.0010077028,0.00035251683,0.000512424,0.02209201,0.00002795117,0.00057857134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970471,0.0012735756,0.00062503637,0.00042221954,0.00051754835,0.0001145665],"domain_scores_gemma":[0.99055594,0.0027109731,0.0044399872,0.000786622,0.0011133843,0.000393113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039762,0.00026081083,0.0005297061,0.0009739863,0.00028065935,0.0013211797,0.0005065748,0.0004278451,0.0018510884],"category_scores_gemma":[0.008142512,0.0002467506,0.00079967163,0.0025471542,0.00020496096,0.00068904134,0.00065152865,0.0005862237,0.00048425118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025025562,0.00032741445,0.96994734,0.0010420599,0.001632484,0.00022182733,0.00017910582,0.00010865586,0.0003025856,0.00014808627,0.005367116,0.018220762],"study_design_scores_gemma":[0.00094135315,0.0011781799,0.9751359,0.00061902794,0.0019383859,0.0015720463,0.00045279894,0.00071324734,0.00029729737,0.00011852646,0.017005073,0.00002818377],"about_ca_topic_score_codex":0.0042711073,"about_ca_topic_score_gemma":0.00428673,"teacher_disagreement_score":0.0042711073,"about_ca_system_score_codex":0.00053298037,"about_ca_system_score_gemma":0.0011909674,"threshold_uncertainty_score":0.0210284},"labels":[],"label_agreement":null},{"id":"W4385655197","doi":"10.1097/01.hs9.0000976148.07947.e7","title":"PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Medicine; Hypomethylating agent; Azacitidine; Pharmacology; Leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Internal medicine; Lymphoma; Oncology; Bone marrow; DNA methylation","score_opus":0.01645214141555534,"score_gpt":0.26647213130217584,"score_spread":0.2500199898866205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913817,0.0026393095,0.00071595894,0.0004194626,0.00010169997,0.0012801773,0.0016144296,0.0002179826,0.0016291009],"genre_scores_gemma":[0.98652387,0.0020335994,0.0018784113,0.0005284075,0.00013948082,0.0012878793,0.0033055248,0.000048570226,0.0042542703],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972886,0.00010938598,0.000010961828,0.000050497554,0.000029836208,0.00007043837],"domain_scores_gemma":[0.9996563,0.000039352744,0.000055699074,0.000024438614,0.00002220978,0.00020201389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082798727,0.001392941,0.0016111233,0.00041080624,0.00033749003,0.0010018077,0.00069311843,0.00086799584,0.0059788562],"category_scores_gemma":[0.00055296364,0.0004787256,0.00097264035,0.000350874,0.00070199143,0.0006346702,0.00029339382,0.0025647103,0.0013710108],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63645846,0.08109801,0.004454923,0.00096727634,0.0010126736,0.00040595562,0.000353382,0.0019280437,0.099336915,0.00060446037,0.006835948,0.16654386],"study_design_scores_gemma":[0.25653714,0.71329355,0.010007776,0.00003671489,0.0005133832,0.00060693227,0.000082346494,0.0013630176,0.0113019645,0.00038487345,0.005834738,0.00003760298],"about_ca_topic_score_codex":0.0011720429,"about_ca_topic_score_gemma":0.0024829581,"teacher_disagreement_score":0.0059788562,"about_ca_system_score_codex":0.0010809916,"about_ca_system_score_gemma":0.0014875862,"threshold_uncertainty_score":0.020001233},"labels":[],"label_agreement":null},{"id":"W4385655501","doi":"10.1097/01.hs9.0000975184.86472.15","title":"PB2100: REAL-WORLD TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A RETROSPECTIVE CHART STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Retrospective cohort study; Salvage therapy; Pediatrics; Chemotherapy","score_opus":0.03435706065089352,"score_gpt":0.3202322981013255,"score_spread":0.285875237450432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926218,0.0007073787,0.00011297306,0.000061664316,0.0000049559894,0.000107385626,0.005168699,0.000010166509,0.0012049024],"genre_scores_gemma":[0.99709964,0.00045694553,0.00014973103,0.000060294755,0.000006094527,0.000044879485,0.002016624,0.000004303242,0.00016158458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991266,0.00011501322,0.00015544408,0.00022365426,0.00022641907,0.00015285096],"domain_scores_gemma":[0.996036,0.00041310018,0.0022570393,0.00015620442,0.0007752827,0.00036238588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006582572,0.00017888396,0.00026107355,0.002544616,0.0007864011,0.00082814664,0.00041730644,0.00026864107,0.0012891637],"category_scores_gemma":[0.0020974004,0.00022919619,0.0002292163,0.0048365723,0.00048176752,0.00046231726,0.0005547881,0.0002911185,0.00019198279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037264046,0.000012056527,0.9980141,0.000025244599,0.000014667048,0.00014188128,0.00022560815,0.00001933519,0.00006457466,0.000019689332,0.0003306341,0.0010949802],"study_design_scores_gemma":[0.0000038685453,0.0000383648,0.99713564,0.000031243115,0.000020678994,0.0005633095,0.0010517532,0.00007188984,0.00007823337,0.0000071141626,0.0009919171,0.0000059022086],"about_ca_topic_score_codex":0.2296637,"about_ca_topic_score_gemma":0.29760563,"teacher_disagreement_score":0.7703363,"about_ca_system_score_codex":0.002966767,"about_ca_system_score_gemma":0.0035772638,"threshold_uncertainty_score":0.45665383},"labels":[],"label_agreement":null},{"id":"W4385655633","doi":"10.1097/01.hs9.0000975804.42824.bf","title":"PB2268: PAX5 ABERRANT EXPRESSION INCORPORATED IN MIPI-SP RISK SCORING SYSTEM EXHIBITS ADDITIVE VALUE IN MANTLE CELL LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mental Health Research Canada","funders":"","keywords":"Mantle cell lymphoma; Medicine; Internal medicine; Proportional hazards model; Receiver operating characteristic; Lymphoma; Oncology; PAX5; International Prognostic Index; Immunohistochemistry; Cancer research; Diffuse large B-cell lymphoma; B cell; Immunology; Antibody","score_opus":0.014580188775644943,"score_gpt":0.23519362272452113,"score_spread":0.2206134339488762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892785,0.0026377044,0.0036123525,0.0002598325,0.0000692488,0.000047451245,0.00044552394,0.000113516326,0.0035358714],"genre_scores_gemma":[0.99740714,0.00027080934,0.0013836146,0.000020001171,0.00006389842,0.000019531639,0.00041192566,0.0000077833065,0.00041529344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99960476,0.00013418272,0.00004069217,0.00006589037,0.000114382805,0.000040199193],"domain_scores_gemma":[0.9993493,0.00016471438,0.0002084909,0.00003965995,0.00011797128,0.00011994671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010723819,0.00044688242,0.0003716819,0.0012572801,0.00020998118,0.0007393629,0.0002969602,0.00028521512,0.0026326042],"category_scores_gemma":[0.00205113,0.00010889089,0.00036481346,0.00067886716,0.00022888019,0.00039700244,0.0006815961,0.00037398402,0.00064002443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000901624,0.000036998197,0.9308829,0.00008404388,0.00014516302,0.00022098713,0.0000635278,0.00060910516,0.003888958,0.00011632784,0.00081459247,0.06223589],"study_design_scores_gemma":[0.00004944978,0.0007176614,0.9794963,0.00005701566,0.00039883883,0.0026594314,0.00016639337,0.009857786,0.0025377537,0.00066893146,0.0033659572,0.000024424453],"about_ca_topic_score_codex":0.00030976,"about_ca_topic_score_gemma":0.0005026641,"teacher_disagreement_score":0.0026326042,"about_ca_system_score_codex":0.0001914428,"about_ca_system_score_gemma":0.0002603718,"threshold_uncertainty_score":0.0088070035},"labels":[],"label_agreement":null},{"id":"W4385655716","doi":"10.1097/01.hs9.0000974860.48116.9c","title":"PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; International Prognostic Scoring System; Myelodysplastic syndromes; Demographics; Internal medicine; Pediatrics; Demography","score_opus":0.02821752694280383,"score_gpt":0.26571849908287903,"score_spread":0.2375009721400752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9451481,0.0017905693,0.00038853305,0.00081244967,0.000049967075,0.00019802245,0.04457116,0.00008951127,0.006951812],"genre_scores_gemma":[0.9615525,0.0013700206,0.00097244204,0.00023685687,0.00009860526,0.0002651328,0.03388392,0.000023487437,0.0015971219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995283,0.00011065372,0.000102586346,0.00006373346,0.00009357962,0.00010116469],"domain_scores_gemma":[0.99736613,0.0005176695,0.0011810621,0.000048413058,0.000498849,0.0003878724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082482555,0.00015924759,0.0002569557,0.0026449955,0.00027961,0.00047125027,0.00025718487,0.00028458683,0.004611292],"category_scores_gemma":[0.0030550777,0.0000860781,0.0003499477,0.0025852115,0.00013958829,0.00047474448,0.0005166353,0.0002786817,0.0008951758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020341644,0.00002678022,0.977967,0.00013835607,0.000027263448,0.00006826105,0.00031309863,0.0000957483,0.00012809972,0.000051171697,0.008402833,0.0125779165],"study_design_scores_gemma":[0.000011803356,0.000068728485,0.99305516,0.00009902556,0.000012943228,0.00032713628,0.0005946812,0.00018269902,0.00006432891,0.000035113884,0.0055413544,0.0000071951476],"about_ca_topic_score_codex":0.010849191,"about_ca_topic_score_gemma":0.012267588,"teacher_disagreement_score":0.010849191,"about_ca_system_score_codex":0.0005521644,"about_ca_system_score_gemma":0.00095588353,"threshold_uncertainty_score":0.021572053},"labels":[],"label_agreement":null},{"id":"W4385658467","doi":"10.1097/01.hs9.0000967408.39207.65","title":"S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Midostaurin; Medicine; Myeloid leukemia; Internal medicine; Oncology; Phosphoproteomics; Fms-Like Tyrosine Kinase 3; Refractory (planetary science); Biology; Kinase","score_opus":0.030261329363964085,"score_gpt":0.3435764329594033,"score_spread":0.31331510359543924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385658467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99862933,0.000063042,0.00077230216,0.000038871105,0.0000031285813,0.000013752073,0.00035819522,0.000013891134,0.000107655826],"genre_scores_gemma":[0.998355,0.000028729317,0.00040751445,0.000011237609,0.0000032424307,0.00001354341,0.0011011518,0.0000029422606,0.00007677066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998136,0.000045272835,0.000015240237,0.00007054882,0.000028022856,0.000027337392],"domain_scores_gemma":[0.9995881,0.00015184123,0.000116917174,0.000039719813,0.000035151465,0.00006832999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076576864,0.0006219776,0.0006039036,0.0006086363,0.00022686656,0.0007344941,0.00038552,0.00046689992,0.0010426621],"category_scores_gemma":[0.0012417265,0.00020394941,0.00078969134,0.00030592646,0.00022102891,0.00036769695,0.0005265433,0.00048393183,0.00033180902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028791518,0.00025716957,0.951171,0.000041352436,0.00032048573,0.00022884543,0.00013030207,0.019318828,0.011855556,0.0000642461,0.00042880172,0.013304291],"study_design_scores_gemma":[0.000107615604,0.0012680292,0.7863738,0.000014299337,0.00030721634,0.0008781693,0.00022159511,0.20313543,0.006340699,0.0004958246,0.0008264252,0.000030839154],"about_ca_topic_score_codex":0.001954474,"about_ca_topic_score_gemma":0.0018712861,"teacher_disagreement_score":0.001954474,"about_ca_system_score_codex":0.0005977713,"about_ca_system_score_gemma":0.00039332744,"threshold_uncertainty_score":0.0043371916},"labels":[],"label_agreement":null},{"id":"W4385666327","doi":"10.1097/01.hs9.0000967372.19440.62","title":"S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Blinatumomab; Internal medicine; Minimal residual disease; Oncology; Rituximab; Induction chemotherapy; Chemotherapy; Acute lymphocytic leukemia; Chemotherapy regimen; Lymphoblastic Leukemia; Leukemia; Lymphoma","score_opus":0.017448307798226627,"score_gpt":0.27229854191145964,"score_spread":0.254850234113233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408036,0.0033606743,0.00010065272,0.0003297564,0.00010594915,0.00019546926,0.0005117249,0.00004976484,0.0012656766],"genre_scores_gemma":[0.9955729,0.0012766247,0.00021547808,0.0003742984,0.00010627005,0.00011942749,0.001115606,0.000010547678,0.0012087433],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998441,0.00006374582,0.000017755154,0.000020534831,0.00002094286,0.000032924756],"domain_scores_gemma":[0.99973613,0.00005460945,0.0000751127,0.000018867067,0.00001561321,0.00009973124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000525539,0.0004313341,0.0011851292,0.00021803199,0.00013707308,0.0005476145,0.00036082044,0.0006404848,0.0070863627],"category_scores_gemma":[0.0005680359,0.0001442186,0.0010022512,0.00031975,0.00020745026,0.00038781535,0.00023920857,0.0008452592,0.00077017973],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6499733,0.008477923,0.02607103,0.0015176128,0.002100201,0.00026583776,0.0001737018,0.0017797932,0.028782537,0.0002343615,0.004517182,0.2761065],"study_design_scores_gemma":[0.25154993,0.46127862,0.24344282,0.0005441529,0.0060308664,0.0012567397,0.0002451787,0.0035651168,0.017679997,0.00045929986,0.01386318,0.00008420184],"about_ca_topic_score_codex":0.00061917206,"about_ca_topic_score_gemma":0.0017750807,"teacher_disagreement_score":0.0070863627,"about_ca_system_score_codex":0.00039241285,"about_ca_system_score_gemma":0.00054225937,"threshold_uncertainty_score":0.023706257},"labels":[],"label_agreement":null},{"id":"W4385666344","doi":"10.1097/01.hs9.0000967592.61626.0d","title":"S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Myelodysplastic syndromes; Cohort; Medicine; Internal medicine; Oncology; Overall survival; Library science; Bone marrow","score_opus":0.040441073439601675,"score_gpt":0.32979848741790174,"score_spread":0.28935741397830006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8498665,0.0011334842,0.0005075653,0.00031007422,0.00007528494,0.00011635343,0.14582027,0.00006179455,0.0021086705],"genre_scores_gemma":[0.5625733,0.0005933806,0.0008182227,0.0002835117,0.0001241943,0.000308927,0.43413824,0.000083045685,0.0010771481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990952,0.00015978546,0.0001511597,0.00022743166,0.00020842139,0.00015797978],"domain_scores_gemma":[0.9977107,0.00030973062,0.00091221737,0.00027687312,0.00043932436,0.0003511124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013135675,0.00044640983,0.00061924674,0.0025684237,0.0004637248,0.0010322217,0.00057766517,0.00033643152,0.0034234475],"category_scores_gemma":[0.0029722305,0.00022088355,0.0006702346,0.00404299,0.0002478061,0.0003763771,0.0013128014,0.00044242592,0.0010478117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010499238,0.000048152262,0.9508971,0.00024916267,0.00030299206,0.00024310619,0.00024509098,0.0004018349,0.0011872486,0.00022715898,0.027248787,0.017899403],"study_design_scores_gemma":[0.00012738016,0.000100318306,0.97666794,0.000150331,0.0001899036,0.0009216869,0.00034864235,0.00050662644,0.0004326421,0.00019682643,0.020336727,0.0000210672],"about_ca_topic_score_codex":0.0099654365,"about_ca_topic_score_gemma":0.015081175,"teacher_disagreement_score":0.0099654365,"about_ca_system_score_codex":0.0006083626,"about_ca_system_score_gemma":0.0014159887,"threshold_uncertainty_score":0.019814909},"labels":[],"label_agreement":null},{"id":"W4385666962","doi":"10.1097/01.hs9.0000970384.26808.c7","title":"P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Cytokine release syndrome; Adverse effect; Gastroenterology; Bortezomib; Oncology; Refractory (planetary science); Surgery; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.014217060108590156,"score_gpt":0.2678927841424802,"score_spread":0.25367572403389005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7898641,0.19845845,0.0024078123,0.00035526545,0.0001571875,0.0005913913,0.0059516877,0.00014229013,0.0020717916],"genre_scores_gemma":[0.9827418,0.012322516,0.0006812055,0.0002449252,0.00016424897,0.00023838445,0.003237141,0.000022124035,0.0003476799],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99634594,0.0019141755,0.0005852388,0.00053100416,0.00048440558,0.00013928705],"domain_scores_gemma":[0.9970047,0.0011071713,0.0012807708,0.00019453609,0.00026827704,0.00014458623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065778266,0.0012051396,0.0038794316,0.0015922853,0.00021922478,0.0014614112,0.000595,0.0007035811,0.0019345889],"category_scores_gemma":[0.0050784084,0.0005355087,0.009841707,0.0018021187,0.00030090194,0.0007746927,0.0008908351,0.0006864393,0.0003304144],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1664936,0.00044025973,0.10441736,0.013509802,0.5999081,0.00026559198,0.00016165015,0.002008079,0.007853142,0.00012088324,0.0023177776,0.102503836],"study_design_scores_gemma":[0.029471856,0.022065667,0.35089344,0.000985062,0.58392644,0.00091847073,0.00016800639,0.0022775596,0.0029270127,0.00034782593,0.0059098867,0.00010871427],"about_ca_topic_score_codex":0.00064000126,"about_ca_topic_score_gemma":0.00139212,"teacher_disagreement_score":0.0065778266,"about_ca_system_score_codex":0.00057915255,"about_ca_system_score_gemma":0.0005877802,"threshold_uncertainty_score":0.034787238},"labels":[],"label_agreement":null},{"id":"W4385666975","doi":"10.1097/01.hs9.0000970432.75766.0c","title":"P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Thames Valley Children's Centre; Princess Margaret Cancer Centre; McGill University Health Centre; University of Calgary","funders":"","keywords":"Lenalidomide; Pomalidomide; Daratumumab; Medicine; Internal medicine; Multiple myeloma; Cohort; Dexamethasone; Regimen; Clinical endpoint; Oncology; Gastroenterology; Surgery; Clinical trial","score_opus":0.04037242643722707,"score_gpt":0.3232737664310684,"score_spread":0.28290133999384137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928543,0.002651076,0.00012435995,0.0004531077,0.00006963816,0.00047392468,0.002357655,0.000026845884,0.0009892432],"genre_scores_gemma":[0.99076676,0.0010505748,0.00037864072,0.00059547165,0.00018607939,0.0006867203,0.0049747443,0.00001245739,0.0013485666],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993357,0.00036863398,0.00003940771,0.000098877106,0.00006368674,0.00009362924],"domain_scores_gemma":[0.9991868,0.00011998018,0.00028066314,0.000061343366,0.000054254524,0.0002970855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022101966,0.00079117896,0.0013020519,0.00038202797,0.00030667256,0.0011322513,0.0007483528,0.00081411446,0.0029430354],"category_scores_gemma":[0.001212388,0.00035006646,0.0022110152,0.00047038525,0.00036241364,0.00075021136,0.0007265678,0.001678773,0.0004968468],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7961965,0.009030157,0.109708756,0.0009355224,0.006770209,0.00018811911,0.00018764805,0.0020065648,0.0048940983,0.00018406934,0.006787364,0.06311101],"study_design_scores_gemma":[0.4420391,0.24635634,0.28672308,0.00028437687,0.008401865,0.00060700864,0.00025703292,0.0024896716,0.0021072268,0.0005644485,0.010088257,0.000081550206],"about_ca_topic_score_codex":0.0007954096,"about_ca_topic_score_gemma":0.0021725006,"teacher_disagreement_score":0.0029430354,"about_ca_system_score_codex":0.00087580393,"about_ca_system_score_gemma":0.001095737,"threshold_uncertainty_score":0.011688769},"labels":[],"label_agreement":null},{"id":"W4385667024","doi":"10.1097/01.hs9.0000969844.13426.20","title":"P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta Hospital; Queen Elizabeth II Health Sciences Centre; University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Decitabine; Medicine; Internal medicine; Chronic myelomonocytic leukemia; International Prognostic Scoring System; Monocytosis; Oncology; Leukemia; Gastroenterology; Bone marrow; Myelodysplastic syndromes","score_opus":0.0784401128588723,"score_gpt":0.41816012080025994,"score_spread":0.3397200079413876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913668,0.0042353123,0.00052262953,0.00037723948,0.000042802087,0.00074651936,0.00097513257,0.000057861427,0.0016756753],"genre_scores_gemma":[0.99266475,0.0017989161,0.00081419485,0.0002904533,0.000048804704,0.00043812703,0.0021224257,0.000017131915,0.0018051794],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99975723,0.000084146566,0.000022830767,0.000037947728,0.000048696485,0.00004910665],"domain_scores_gemma":[0.9997043,0.000051625422,0.00008870277,0.000021231122,0.00004248479,0.00009175016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011764461,0.00045433693,0.0006091354,0.0002292364,0.00029454206,0.0006895304,0.0003208423,0.00046905052,0.00317702],"category_scores_gemma":[0.0006775935,0.00016856016,0.000507049,0.00028524068,0.00030752018,0.00046833637,0.00026703588,0.0011376971,0.0005176451],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2843745,0.021186028,0.027996752,0.0014664955,0.0011940184,0.00074432004,0.0006756067,0.0026797042,0.18839632,0.000518228,0.009651794,0.46111616],"study_design_scores_gemma":[0.092724234,0.7078657,0.08917164,0.0002255635,0.001970864,0.0029343837,0.00031959097,0.0027830345,0.07013097,0.0005692736,0.031233255,0.00007150883],"about_ca_topic_score_codex":0.0005269844,"about_ca_topic_score_gemma":0.001451243,"teacher_disagreement_score":0.00317702,"about_ca_system_score_codex":0.0006705371,"about_ca_system_score_gemma":0.0010500386,"threshold_uncertainty_score":0.010628164},"labels":[],"label_agreement":null},{"id":"W4385667045","doi":"10.1097/01.hs9.0000970976.05785.80","title":"P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Discontinuation; Oncology; Gastroenterology; Bone marrow","score_opus":0.024068135180549254,"score_gpt":0.296001022558554,"score_spread":0.27193288737800475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51077455,0.14184977,0.004614095,0.019324753,0.0042122924,0.00873356,0.22309513,0.0015453286,0.08585056],"genre_scores_gemma":[0.6343258,0.04537039,0.007078312,0.023414636,0.0044661043,0.0066534444,0.25677025,0.0005209425,0.021400174],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99840146,0.0006038934,0.00021760636,0.00015667007,0.0004317462,0.00018865947],"domain_scores_gemma":[0.99576265,0.0010470555,0.0013575057,0.0002886937,0.0009475927,0.0005965346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042552515,0.0009177077,0.0021986545,0.0007634349,0.00036530953,0.0019643593,0.0011113029,0.0013623253,0.008893696],"category_scores_gemma":[0.003815451,0.00037265278,0.0022153754,0.0010923186,0.00026920208,0.0011163587,0.00066396466,0.0027636176,0.0029903103],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20334475,0.0048159976,0.025436321,0.009965306,0.0070348294,0.0007926253,0.00032240828,0.0030264216,0.024816103,0.0006809841,0.21205838,0.5077059],"study_design_scores_gemma":[0.15012074,0.118278444,0.25324336,0.004242733,0.01921379,0.0041969926,0.00024321635,0.0024824562,0.013158898,0.001828292,0.43270662,0.0002844531],"about_ca_topic_score_codex":0.0010666288,"about_ca_topic_score_gemma":0.0027816934,"teacher_disagreement_score":0.008893696,"about_ca_system_score_codex":0.0014097589,"about_ca_system_score_gemma":0.0013708129,"threshold_uncertainty_score":0.029752374},"labels":[],"label_agreement":null},{"id":"W4385667055","doi":"10.1097/01.hs9.0000968868.83152.da","title":"P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Servier; Agios Pharmaceuticals","keywords":"Medicine; Internal medicine; IDH1; Isocitrate dehydrogenase; Myeloid leukemia; Placebo; Azacitidine; Gastroenterology; Clinical endpoint; Randomized controlled trial; Pathology; Biology","score_opus":0.017165133778774964,"score_gpt":0.25780168387298313,"score_spread":0.24063655009420817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911616,0.0049143527,0.00027196348,0.0002898155,0.000077607154,0.00034290933,0.0019639658,0.000041114774,0.0009366625],"genre_scores_gemma":[0.99170715,0.0024507653,0.0006789566,0.0005174651,0.00025701147,0.0005324048,0.003209368,0.000016263883,0.00063054735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99921083,0.00047049444,0.000052918185,0.000105126426,0.00010039559,0.000060265775],"domain_scores_gemma":[0.998389,0.00043495063,0.0005700316,0.00010301774,0.00008034759,0.0004227934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018994967,0.0008863739,0.0020190033,0.00041256443,0.00019618301,0.000921076,0.0006818628,0.0008859053,0.0023739845],"category_scores_gemma":[0.001526505,0.0002873435,0.0017114321,0.0005616902,0.00058312615,0.0006944435,0.0004817273,0.0017803684,0.00034135752],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89734775,0.0039211074,0.02986276,0.000641835,0.0048127435,0.000091241716,0.00008583185,0.0009413036,0.007418699,0.000082741666,0.0017674826,0.053026408],"study_design_scores_gemma":[0.5949854,0.21741064,0.17226343,0.000121134035,0.007923705,0.0003768017,0.000090476795,0.0013317846,0.0018641346,0.00028792868,0.0032695637,0.000074976204],"about_ca_topic_score_codex":0.00044093822,"about_ca_topic_score_gemma":0.0009401664,"teacher_disagreement_score":0.0023739845,"about_ca_system_score_codex":0.00037391752,"about_ca_system_score_gemma":0.00051975675,"threshold_uncertainty_score":0.010045588},"labels":[],"label_agreement":null},{"id":"W4385667081","doi":"10.1097/01.hs9.0000972868.69615.42","title":"P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Pyruvate kinase deficiency; Iron deficiency; Anemia; Pyruvate kinase; Internal medicine; Pediatrics; Glycolysis; Metabolism","score_opus":0.00943849145740466,"score_gpt":0.21526379523876396,"score_spread":0.2058253037813593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9299526,0.051495302,0.0008048386,0.002776733,0.0006013224,0.0009398047,0.002239033,0.00026597237,0.0109244],"genre_scores_gemma":[0.9786784,0.012336801,0.0011914751,0.0019263782,0.00051412015,0.00053592684,0.001958912,0.000023814018,0.002834062],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99990845,0.000028848455,0.000013286656,0.000015633306,0.000014243508,0.000019660409],"domain_scores_gemma":[0.9997546,0.00005863397,0.00008271349,0.000010295593,0.000028191731,0.000065498614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033985733,0.00028854207,0.0008206118,0.00016891604,0.00021147866,0.00040308037,0.0002674048,0.00044155022,0.0060195574],"category_scores_gemma":[0.00064388535,0.000101212805,0.0007751007,0.00019781795,0.0001768829,0.00030551432,0.00022771282,0.000873629,0.0007032579],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20234585,0.0054993676,0.024846666,0.0066224732,0.0022277366,0.0007224264,0.00021500874,0.0011478304,0.030960454,0.0006218349,0.029198488,0.6955918],"study_design_scores_gemma":[0.30774355,0.27682027,0.27249002,0.0033588558,0.009470255,0.00781651,0.00043451943,0.0056293635,0.026228786,0.002155722,0.08768108,0.0001709959],"about_ca_topic_score_codex":0.00034719502,"about_ca_topic_score_gemma":0.0008783667,"teacher_disagreement_score":0.0060195574,"about_ca_system_score_codex":0.00026215232,"about_ca_system_score_gemma":0.000445806,"threshold_uncertainty_score":0.02013743},"labels":[],"label_agreement":null},{"id":"W4385667083","doi":"10.1097/01.hs9.0000967892.54405.ff","title":"S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Ruxolitinib; Clinical endpoint; Refractory (planetary science); Graft-versus-host disease; Internal medicine; Transplantation; Calcineurin; Hematopoietic stem cell transplantation; Phases of clinical research; Gastroenterology; Clinical trial; Surgery; Bone marrow; Myelofibrosis","score_opus":0.028344298142356752,"score_gpt":0.29474154981119316,"score_spread":0.26639725166883643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658618,0.022706892,0.000297751,0.0010743259,0.00009898117,0.00087212236,0.005251487,0.00007625031,0.0037603285],"genre_scores_gemma":[0.9812267,0.0068264506,0.00084286695,0.0012263232,0.0002011916,0.0007847513,0.007991176,0.000021288333,0.0008792391],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994803,0.00026378813,0.000043362037,0.00005867118,0.00009065168,0.000063270636],"domain_scores_gemma":[0.99943084,0.00010646943,0.0001911813,0.000028138182,0.000054594075,0.00018871807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013462264,0.00040272393,0.0010370713,0.00018008551,0.00020527293,0.000820525,0.00036807364,0.0006123634,0.002850709],"category_scores_gemma":[0.0009831276,0.00013039737,0.0009296453,0.0003640552,0.0002573176,0.0004880355,0.00036062684,0.0010328955,0.00054185896],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4792444,0.012941649,0.09251303,0.007338692,0.006745199,0.00096092414,0.00068034336,0.003268384,0.040172134,0.0008802954,0.03221493,0.32304],"study_design_scores_gemma":[0.35470167,0.3067498,0.25875735,0.0012687558,0.006004503,0.0039718184,0.0005781549,0.002287248,0.013967106,0.00048065715,0.051119894,0.000113014896],"about_ca_topic_score_codex":0.00051712064,"about_ca_topic_score_gemma":0.0024124254,"teacher_disagreement_score":0.002850709,"about_ca_system_score_codex":0.00053446635,"about_ca_system_score_gemma":0.0010913262,"threshold_uncertainty_score":0.009536564},"labels":[],"label_agreement":null},{"id":"W4385667085","doi":"10.1097/01.hs9.0000971256.60488.02","title":"P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Venetoclax; Ibrutinib; Medicine; Mantle cell lymphoma; Obinutuzumab; Internal medicine; Bendamustine; Regimen; Oncology; Adverse effect; Gastroenterology; Lymphoma; Rituximab; Leukemia; Chronic lymphocytic leukemia","score_opus":0.014988999691284768,"score_gpt":0.26361219385610113,"score_spread":0.24862319416481637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955813,0.0012094206,0.00012137414,0.00020196186,0.00003595019,0.000060607283,0.0018721265,0.000017330427,0.0008998003],"genre_scores_gemma":[0.9941261,0.0003609877,0.00013650862,0.00023544618,0.0000723175,0.00007104033,0.0042949715,0.000006649236,0.00069598324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999767,0.000057822897,0.000021622258,0.00006935467,0.000033700402,0.000050550556],"domain_scores_gemma":[0.99914503,0.00011681309,0.00027314646,0.00007071288,0.000083596875,0.00031069515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066537596,0.0003354619,0.0006880193,0.00036403455,0.0005899843,0.00066628086,0.0003764907,0.00070077524,0.001362154],"category_scores_gemma":[0.001163224,0.00019514072,0.00062344596,0.00050274556,0.00022065663,0.00080511445,0.00045376323,0.0009578021,0.00052994577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0575142,0.0021196061,0.85518533,0.00019258648,0.00082362717,0.0022461861,0.0004117608,0.00063824526,0.006576051,0.000075151656,0.0056426,0.06857464],"study_design_scores_gemma":[0.0018971871,0.011633927,0.98008955,0.000046559144,0.0005902615,0.0012117174,0.00014770497,0.0007385872,0.00068827777,0.00010702942,0.002816,0.00003323113],"about_ca_topic_score_codex":0.0019049692,"about_ca_topic_score_gemma":0.002350761,"teacher_disagreement_score":0.0019049692,"about_ca_system_score_codex":0.0005372833,"about_ca_system_score_gemma":0.0002739248,"threshold_uncertainty_score":0.0045568347},"labels":[],"label_agreement":null},{"id":"W4385667119","doi":"10.1097/01.hs9.0000968768.84940.f7","title":"P465: N-MYRISTOYLATION INHIBITION ABROGATES OXIDATIVE PHOSPHORYLATION TO TARGET ACUTE MYELOID LEUKEMIA STEM CELLS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta","funders":"","keywords":"Myristoylation; Myeloid leukemia; Signal transduction; Biology; Cancer research; Stem cell; Phosphorylation; Oxidative phosphorylation; Kinase; Leukemia; Cell biology; Immunology; Biochemistry","score_opus":0.009386436860841752,"score_gpt":0.2357359665776633,"score_spread":0.22634952971682154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883444,0.0024478727,0.0025367818,0.0002605708,0.00014788685,0.0001029691,0.0009496023,0.00031013007,0.004409687],"genre_scores_gemma":[0.99401444,0.0011504005,0.0009489008,0.00009771514,0.000019014002,0.00006284133,0.0009407836,0.000022829841,0.0027431457],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997968,0.000021181151,0.000028190285,0.000035080702,0.00006606607,0.000052686435],"domain_scores_gemma":[0.9999237,0.000007733396,0.000019393647,0.000009970759,0.0000070847027,0.000032102158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015372736,0.0003949525,0.00027974465,0.00019942084,0.00017225886,0.00027060093,0.00029561957,0.0002846205,0.003276757],"category_scores_gemma":[0.00007725705,0.000095144525,0.00031018557,0.00019093728,0.00025142927,0.00021239671,0.00022433315,0.00090030517,0.00079599227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007574316,0.00030763343,0.000267981,0.00014374265,0.000019231235,0.00009528713,0.000030632815,0.00030029312,0.991028,0.00042187766,0.0004289111,0.006199027],"study_design_scores_gemma":[0.00010991378,0.0013196424,0.0021617243,0.000011500661,0.00003262113,0.00026461235,0.000019043404,0.00088671193,0.98827237,0.0000674772,0.0068495516,0.0000047590584],"about_ca_topic_score_codex":0.00038522243,"about_ca_topic_score_gemma":0.0004273083,"teacher_disagreement_score":0.003276757,"about_ca_system_score_codex":0.00024140834,"about_ca_system_score_gemma":0.00031024648,"threshold_uncertainty_score":0.01096189},"labels":[],"label_agreement":null},{"id":"W4385667237","doi":"10.1097/01.hs9.0000970732.34300.9d","title":"P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"","keywords":"Cohort; Multiple myeloma; Medicine; Internal medicine; Oncology; Refractory (planetary science); Biology","score_opus":0.05037156805333891,"score_gpt":0.351355052474519,"score_spread":0.30098348442118006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97660124,0.009113799,0.0019141273,0.00030192427,0.00020843853,0.0004904563,0.007822426,0.000086417655,0.0034612967],"genre_scores_gemma":[0.99350667,0.00078354287,0.0009660581,0.00019932484,0.00010531667,0.0004028962,0.0030546987,0.000030030737,0.00095150765],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98507327,0.010702794,0.0009024844,0.0016937737,0.001368503,0.0002592571],"domain_scores_gemma":[0.96964574,0.022418844,0.005465843,0.0014239938,0.000554512,0.000491131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018916825,0.00082984107,0.0013187049,0.0013616678,0.0001632222,0.0013596268,0.0012734819,0.0010819822,0.0050007803],"category_scores_gemma":[0.02430884,0.0002981821,0.0039446554,0.0011117513,0.00050875166,0.0015998291,0.0011081136,0.0017792695,0.00074344245],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5914383,0.0022497305,0.1781715,0.006145086,0.07802392,0.00016830052,0.0005035686,0.0058823805,0.002578244,0.0017281044,0.00540806,0.12770288],"study_design_scores_gemma":[0.07784606,0.1733153,0.61177486,0.0012693063,0.08209321,0.0013204094,0.0008280364,0.02364333,0.008081571,0.0027662585,0.016780663,0.00028100496],"about_ca_topic_score_codex":0.00060609734,"about_ca_topic_score_gemma":0.00069474196,"teacher_disagreement_score":0.018916825,"about_ca_system_score_codex":0.0008399536,"about_ca_system_score_gemma":0.00034033298,"threshold_uncertainty_score":0.10004294},"labels":[],"label_agreement":null},{"id":"W4385667241","doi":"10.1097/01.hs9.0000970972.77960.03","title":"P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Systemic mastocytosis; Tryptase; Placebo; Internal medicine; Gastroenterology; Biomarker; Placebo-controlled study; Randomized controlled trial; Mast cell; Bone marrow; Immunology; Double blind; Pathology","score_opus":0.04868060214724758,"score_gpt":0.2799370876052603,"score_spread":0.23125648545801275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658712,0.016344823,0.0007462702,0.0018631746,0.0011050625,0.004263596,0.0028742743,0.0004184252,0.006513307],"genre_scores_gemma":[0.9757082,0.005688688,0.0015836256,0.0019664313,0.0010126025,0.0040514893,0.002844268,0.000042295305,0.007102371],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994931,0.00023799963,0.000028991468,0.00009507043,0.000067886125,0.00007693019],"domain_scores_gemma":[0.9994289,0.00013630225,0.00015294053,0.000047029742,0.00004963443,0.0001850787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014721572,0.0013191303,0.0025030237,0.00030506784,0.00040571278,0.0012191922,0.0009061892,0.0020753557,0.008989905],"category_scores_gemma":[0.0013210607,0.00043596103,0.0019713806,0.00028212793,0.0009582033,0.0009988967,0.00031199263,0.0029564,0.001574541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9613009,0.004116476,0.00043710155,0.0017106724,0.0012317405,0.000057814923,0.000052627533,0.0002958508,0.006585953,0.00022084406,0.002275069,0.02171496],"study_design_scores_gemma":[0.96258295,0.03441629,0.0013037252,0.00004335888,0.000309097,0.00003581666,0.000009830476,0.00015659822,0.00028476358,0.0000975438,0.0007492646,0.000010689276],"about_ca_topic_score_codex":0.0007271431,"about_ca_topic_score_gemma":0.0025610537,"teacher_disagreement_score":0.008989905,"about_ca_system_score_codex":0.00069017994,"about_ca_system_score_gemma":0.001055303,"threshold_uncertainty_score":0.030074239},"labels":[],"label_agreement":null},{"id":"W4385667275","doi":"10.1097/01.hs9.0000972412.18474.98","title":"P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Chimeric antigen receptor; Medicine; Immunotherapy; Cytokine; Lymphoma; Oncology; Internal medicine; Immunology; Immune system","score_opus":0.03743959570515347,"score_gpt":0.32109295928812887,"score_spread":0.2836533635829754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983596,0.00044544152,0.0002092255,0.00004721514,0.000017715878,0.000016073245,0.00033976152,0.000013409836,0.00055149733],"genre_scores_gemma":[0.997106,0.00019601184,0.00028887647,0.00008206538,0.0000103200455,0.000021300953,0.0010405823,0.0000144228325,0.0012403496],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999337,0.000008901954,0.000003297945,0.000015629976,0.000017212857,0.000021280903],"domain_scores_gemma":[0.9999275,0.000010392161,0.000018650331,0.0000035818643,0.000009075233,0.00003090183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083789884,0.0002520699,0.00027058466,0.00015971992,0.00008734227,0.0002289387,0.00011477314,0.00021458429,0.00374295],"category_scores_gemma":[0.00018279871,0.00006497901,0.00021046745,0.00011982026,0.00014008365,0.00015682467,0.000094082985,0.000339651,0.0005941672],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008452142,0.00032573976,0.004410076,0.00008057044,0.000041889823,0.00028000138,0.000029513787,0.0001544705,0.9689612,0.000061762126,0.00042634815,0.01677626],"study_design_scores_gemma":[0.0010462874,0.024360064,0.20898041,0.0000336068,0.00018821897,0.004189143,0.00027541825,0.0032710985,0.7450936,0.00023414135,0.012290926,0.000037013662],"about_ca_topic_score_codex":0.00029786388,"about_ca_topic_score_gemma":0.0003035783,"teacher_disagreement_score":0.00374295,"about_ca_system_score_codex":0.00016781891,"about_ca_system_score_gemma":0.00012968635,"threshold_uncertainty_score":0.012521446},"labels":[],"label_agreement":null},{"id":"W4385667297","doi":"10.1097/01.hs9.0000968132.86513.06","title":"S305: PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Western University","funders":"","keywords":"Medicine; ADAMTS13; Thrombotic thrombocytopenic purpura; Placebo; Internal medicine; Gastroenterology; Clinical endpoint; Adverse effect; Thrombotic microangiopathy; Randomized controlled trial; Platelet; Disease; Pathology","score_opus":0.024403662248074116,"score_gpt":0.29099441286025657,"score_spread":0.26659075061218246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96938914,0.0040174364,0.0013342255,0.0008661512,0.00059204095,0.018019713,0.0029134552,0.00031935622,0.0025485898],"genre_scores_gemma":[0.96193486,0.0024569544,0.0040346133,0.001786811,0.000560642,0.022257304,0.0024788436,0.00004347165,0.004446558],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993519,0.00035272972,0.000040733128,0.00010022187,0.00004986407,0.000104479266],"domain_scores_gemma":[0.999278,0.00015865103,0.00018200536,0.000058716843,0.00006604294,0.00025663443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021545303,0.001971614,0.0026124986,0.00041304316,0.0004683198,0.0008525435,0.00085591245,0.0020242077,0.009642081],"category_scores_gemma":[0.001481343,0.00079417735,0.0015085794,0.0004066438,0.00085021683,0.0009765695,0.00033967756,0.0024169497,0.0015222657],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9671157,0.011805921,0.00059402944,0.0005995226,0.00045192064,0.000040728595,0.000056063327,0.00031452024,0.0050554825,0.000101804064,0.0013042046,0.012560136],"study_design_scores_gemma":[0.9378088,0.06022801,0.00097421533,0.00001695701,0.00009505841,0.0000229256,0.00000881966,0.00017173632,0.00021771727,0.000055056105,0.00039330169,0.000007442292],"about_ca_topic_score_codex":0.00070611516,"about_ca_topic_score_gemma":0.0022296845,"teacher_disagreement_score":0.009642081,"about_ca_system_score_codex":0.00061692833,"about_ca_system_score_gemma":0.0021763968,"threshold_uncertainty_score":0.032256007},"labels":[],"label_agreement":null},{"id":"W4385667424","doi":"10.1097/01.hs9.0000969628.70235.a8","title":"P681: MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Bosutinib; Medicine; Dasatinib; Nilotinib; Ponatinib; Internal medicine; Oncology; Population; Myeloid leukemia; Imatinib","score_opus":0.05732872494174309,"score_gpt":0.3475958001907948,"score_spread":0.2902670752490517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662104,0.007689509,0.010557221,0.00059721613,0.0009889124,0.003198828,0.0059503163,0.00017606175,0.0046313847],"genre_scores_gemma":[0.98895395,0.0005632447,0.004734764,0.00034437975,0.00011047064,0.0025992151,0.0014037516,0.000021154,0.001268958],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9837046,0.012863469,0.00076389516,0.0012459661,0.000877028,0.00054507994],"domain_scores_gemma":[0.9893534,0.0073225694,0.0017581785,0.0008496877,0.0003884561,0.00032763768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01281234,0.0021292395,0.002739997,0.0009013798,0.00036852199,0.0011508913,0.0015737946,0.0014376944,0.010015745],"category_scores_gemma":[0.02586679,0.00048273304,0.008044801,0.00096878276,0.00083099987,0.001183264,0.0017431522,0.0024473858,0.0005305252],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76838464,0.00260644,0.029455919,0.005903703,0.1070274,0.00018371338,0.00036020894,0.0137582235,0.0020778233,0.00354609,0.0030961335,0.06359973],"study_design_scores_gemma":[0.270333,0.28853503,0.16015357,0.0012954619,0.1697173,0.00069207133,0.0008120563,0.06209327,0.008666305,0.020193303,0.017104285,0.00040450477],"about_ca_topic_score_codex":0.0020592923,"about_ca_topic_score_gemma":0.001435971,"teacher_disagreement_score":0.01281234,"about_ca_system_score_codex":0.0012312381,"about_ca_system_score_gemma":0.0010213917,"threshold_uncertainty_score":0.06775898},"labels":[],"label_agreement":null},{"id":"W4385667566","doi":"10.1097/01.hs9.0000970804.07945.f9","title":"P975: THREE-DIMENSIONAL TELOMERE PROFILING PREDICTS RISK OF RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Genomics; University of Manitoba","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Disease; Regimen; Cancer","score_opus":0.022002173980866648,"score_gpt":0.27496340337460623,"score_spread":0.2529612293937396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98872095,0.004088622,0.00029873985,0.00081567373,0.00011987642,0.000033411277,0.0024741674,0.00004854428,0.0034000168],"genre_scores_gemma":[0.99391264,0.0009528978,0.0003853894,0.0002495919,0.00015790532,0.00003328402,0.0023463115,0.0000076229862,0.0019542547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985826,0.000025593496,0.00002054627,0.000031166463,0.000040681618,0.000023784158],"domain_scores_gemma":[0.99934536,0.000089499335,0.00027192882,0.000023342176,0.00012312533,0.00014658396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034987828,0.00023987936,0.00028236985,0.00062706193,0.0003487851,0.00092886126,0.00037308718,0.0008107936,0.0041830544],"category_scores_gemma":[0.0013059834,0.00011331798,0.00051091786,0.00077727006,0.00012545183,0.00033005737,0.00040378398,0.000662193,0.0010187537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009961216,0.000117524236,0.96861917,0.00009678923,0.000113395414,0.0001819562,0.000057122965,0.00021230234,0.0013255605,0.00005445516,0.00364566,0.024579857],"study_design_scores_gemma":[0.000034706638,0.0002642288,0.9951159,0.00003870691,0.00012068053,0.0006349646,0.000112427224,0.0009203899,0.00050429837,0.00013753855,0.0021031268,0.00001298058],"about_ca_topic_score_codex":0.0015864348,"about_ca_topic_score_gemma":0.0018112892,"teacher_disagreement_score":0.0041830544,"about_ca_system_score_codex":0.00032689047,"about_ca_system_score_gemma":0.00022759347,"threshold_uncertainty_score":0.0139936805},"labels":[],"label_agreement":null},{"id":"W4385667600","doi":"10.1097/01.hs9.0000973232.36093.e7","title":"P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Disease Management Strategies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Immune thrombocytopenia; Quality of life (healthcare); Wish; Pediatrics; Family medicine; Internal medicine; Platelet","score_opus":0.034350664308736074,"score_gpt":0.30341095817431124,"score_spread":0.2690602938655752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98858076,0.0003526747,0.00014909678,0.0013835877,0.00003337276,0.00013401873,0.006429342,0.000016004486,0.0029211896],"genre_scores_gemma":[0.99491787,0.00033945363,0.00025742268,0.00062006596,0.00003048726,0.0001773844,0.0031206333,0.0000066346724,0.0005300841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988531,0.00044090627,0.0002193357,0.00009934701,0.00022437313,0.00016304637],"domain_scores_gemma":[0.9927168,0.0017596893,0.0036751945,0.00016241711,0.00061996287,0.0010658286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019910254,0.00017762349,0.0003468992,0.00061971374,0.00038277073,0.0007752395,0.00027087633,0.0005675585,0.004561874],"category_scores_gemma":[0.0103882365,0.00015717438,0.0007864652,0.0010249936,0.0002571508,0.0010662097,0.0012839162,0.0009389132,0.00059298653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020167812,0.000114605406,0.9846994,0.00013388779,0.000070952694,0.00007827202,0.00100256,0.00012837243,0.00006682402,0.000048495527,0.0045753,0.008879556],"study_design_scores_gemma":[0.000025532598,0.0002712719,0.9948533,0.000068925525,0.000026263722,0.00023390302,0.00207913,0.0002671287,0.000040591083,0.00005082211,0.0020712088,0.000011966443],"about_ca_topic_score_codex":0.0038506342,"about_ca_topic_score_gemma":0.004021594,"teacher_disagreement_score":0.004561874,"about_ca_system_score_codex":0.000441506,"about_ca_system_score_gemma":0.0005659949,"threshold_uncertainty_score":0.015260994},"labels":[],"label_agreement":null},{"id":"W4385667605","doi":"10.1097/01.hs9.0000970892.97539.5e","title":"P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Myeloproliferative neoplasm; Medicine; Kinome; Cancer research; Dasatinib; Internal medicine; Janus kinase 2; Immunology; Oncology; Pharmacology; Bone marrow; Kinase; Biology; Tyrosine kinase; Receptor","score_opus":0.050313681724031015,"score_gpt":0.3819137140479928,"score_spread":0.3316000323239618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968015,0.014924254,0.00089832273,0.0015678349,0.00015006223,0.00041656697,0.002662366,0.00020209594,0.01116357],"genre_scores_gemma":[0.9863495,0.0047377623,0.0008527465,0.0004276352,0.00009721786,0.00016331344,0.0046211854,0.000027876607,0.0027227562],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997247,0.00007138988,0.000031658165,0.000032639688,0.00008493351,0.000054545635],"domain_scores_gemma":[0.9996375,0.000076254204,0.000102018486,0.000030384983,0.00007941352,0.000074552736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007987353,0.00032443836,0.00060883065,0.00029887058,0.00020991091,0.00092190213,0.0003873692,0.0005676235,0.0039659264],"category_scores_gemma":[0.00055758585,0.00010700097,0.0003100454,0.00039681117,0.00029508144,0.0004117254,0.00022461524,0.0010498696,0.0010506394],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014309217,0.0064341645,0.02294229,0.0015724337,0.0003452683,0.0011723313,0.00024362956,0.0018903533,0.69110924,0.0014574651,0.015658097,0.2428655],"study_design_scores_gemma":[0.0084277345,0.14328302,0.23542967,0.0005214778,0.0008653698,0.010253622,0.00049085065,0.009639393,0.49506557,0.0015331544,0.094391026,0.000099093435],"about_ca_topic_score_codex":0.00030901257,"about_ca_topic_score_gemma":0.00082846865,"teacher_disagreement_score":0.0039659264,"about_ca_system_score_codex":0.0004660382,"about_ca_system_score_gemma":0.00044706865,"threshold_uncertainty_score":0.013267279},"labels":[],"label_agreement":null},{"id":"W4385667614","doi":"10.1097/01.hs9.0000971072.43107.6c","title":"P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Anemia; Blood transfusion; Internal medicine; Bone marrow","score_opus":0.00935522102421016,"score_gpt":0.21967169838021455,"score_spread":0.2103164773560044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967179,0.0008486741,0.0002601804,0.00019361277,0.000034159395,0.000041600008,0.001220372,0.0000171383,0.0006664496],"genre_scores_gemma":[0.9963201,0.00023868355,0.00031293766,0.00014904191,0.00007240865,0.00008581691,0.0020867796,0.0000053232898,0.00072882936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99970216,0.000077232275,0.000034959325,0.00008854191,0.000041822324,0.000055270844],"domain_scores_gemma":[0.9990847,0.00015356661,0.00038170183,0.00006168267,0.0001222579,0.00019598434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082690787,0.00026857527,0.0004922626,0.00043302923,0.00034659114,0.00081216847,0.00034289065,0.0005587781,0.0024023994],"category_scores_gemma":[0.001625299,0.00015065444,0.00071336696,0.0006149389,0.00015614188,0.00048365447,0.00037912477,0.0007540632,0.00045881842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011806122,0.0006313184,0.9524533,0.00011638257,0.0005246307,0.00035056256,0.00011642921,0.00035622035,0.0023057314,0.00009244161,0.0018794053,0.02936743],"study_design_scores_gemma":[0.0003708889,0.0036474294,0.9884494,0.000029831463,0.0005681437,0.00063557806,0.00014335813,0.0023914063,0.0006705221,0.0002224276,0.00284362,0.000027348899],"about_ca_topic_score_codex":0.00090690394,"about_ca_topic_score_gemma":0.001073563,"teacher_disagreement_score":0.0024023994,"about_ca_system_score_codex":0.00042359432,"about_ca_system_score_gemma":0.00043098623,"threshold_uncertainty_score":0.008036792},"labels":[],"label_agreement":null},{"id":"W4385667651","doi":"10.1097/01.hs9.0000971208.36694.eb","title":"P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Refractory (planetary science); Clinical endpoint; Phases of clinical research; Surrogate endpoint; Lymphoma; Clinical trial; Oncology; Surgery; Gastroenterology","score_opus":0.021690606153916586,"score_gpt":0.3096533414890721,"score_spread":0.2879627353351555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857211,0.010551569,0.00035225163,0.00036626976,0.000045521472,0.00021898893,0.0006188751,0.00007677088,0.0020487693],"genre_scores_gemma":[0.9939395,0.0031815767,0.00042902608,0.00032079645,0.00006644619,0.0001116257,0.0012019129,0.000012271915,0.0007366924],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976975,0.00007722718,0.000023722072,0.00004076131,0.000042514443,0.000046038345],"domain_scores_gemma":[0.999666,0.00008095586,0.00011953085,0.000022863369,0.000031130738,0.000079552905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009771009,0.00033929874,0.0009290543,0.00021142322,0.00013781131,0.00067476387,0.00034911177,0.00035102258,0.0016820865],"category_scores_gemma":[0.00065671856,0.00015874214,0.0005641244,0.00025795918,0.0001842831,0.00041705032,0.00017995833,0.0009061952,0.0003898736],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13315257,0.0048009567,0.0704414,0.001964914,0.0025867708,0.0007763781,0.00034245494,0.0022472958,0.07938879,0.00027767595,0.011256655,0.6927641],"study_design_scores_gemma":[0.1414912,0.3087443,0.44946727,0.00056307897,0.0063619195,0.007853323,0.00035121205,0.007099793,0.027454505,0.00050900714,0.04998707,0.000117351934],"about_ca_topic_score_codex":0.0004422988,"about_ca_topic_score_gemma":0.0017336146,"teacher_disagreement_score":0.0016820865,"about_ca_system_score_codex":0.0005865012,"about_ca_system_score_gemma":0.0004383852,"threshold_uncertainty_score":0.0056270957},"labels":[],"label_agreement":null},{"id":"W4385667659","doi":"10.1097/01.hs9.0000972428.19857.ae","title":"P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Medicine; Oncology; Chimeric antigen receptor; Internal medicine; Immunotherapy; Immunology; Cytokine; Immune system","score_opus":0.04156970555081718,"score_gpt":0.32604922160139255,"score_spread":0.28447951605057537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886775,0.00020005157,0.00014818671,0.000029577704,0.0000049471364,0.000016869624,0.00018213844,0.000009132247,0.0005413145],"genre_scores_gemma":[0.9986638,0.000049458748,0.00010035288,0.000040732688,0.0000063040115,0.000019793886,0.00058954005,0.000004635011,0.0005253551],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998646,0.000018094544,0.000010343298,0.000040951392,0.000030492338,0.000035524972],"domain_scores_gemma":[0.9997093,0.00005990443,0.00008787194,0.00002701969,0.000026207546,0.00008967481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018713051,0.0001488714,0.00024681928,0.00016336156,0.00012991519,0.00029335942,0.0001788171,0.0002953812,0.0029396426],"category_scores_gemma":[0.00046705303,0.00008270905,0.0002214679,0.00015025488,0.00018264557,0.0002369972,0.00018421265,0.0005672446,0.0005371476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032059345,0.002290258,0.37407845,0.00020203186,0.00020944297,0.0046197134,0.00043246336,0.0009484086,0.45841217,0.0005831086,0.0027488086,0.12341573],"study_design_scores_gemma":[0.0008469788,0.021635968,0.8740679,0.000021751084,0.00014171022,0.0113204345,0.00032988228,0.0022042948,0.08257015,0.00033543463,0.0064995573,0.000025935202],"about_ca_topic_score_codex":0.00037697336,"about_ca_topic_score_gemma":0.0004321968,"teacher_disagreement_score":0.0029396426,"about_ca_system_score_codex":0.00036516227,"about_ca_system_score_gemma":0.00018646564,"threshold_uncertainty_score":0.009834051},"labels":[],"label_agreement":null},{"id":"W4385667677","doi":"10.1097/01.hs9.0000970376.71405.63","title":"P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Tolerability; Multiple myeloma; Daratumumab; Dexamethasone; Oncology; Gastroenterology; Adverse effect","score_opus":0.019468430145642306,"score_gpt":0.2564835981051531,"score_spread":0.23701516795951078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432325,0.003326532,0.0001225925,0.00026726403,0.000047986945,0.0003737491,0.0006857323,0.000028603748,0.00082423794],"genre_scores_gemma":[0.9940467,0.0021170892,0.00043985154,0.00035095942,0.00009485845,0.00035846935,0.0013198013,0.000009309912,0.0012630774],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999785,0.00008658723,0.000017044542,0.00004538073,0.000020893587,0.00004512972],"domain_scores_gemma":[0.9997726,0.000031749783,0.000060922535,0.000013988843,0.000012826189,0.00010790444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006688305,0.0005902768,0.0011799093,0.0001953278,0.00017102697,0.00063410675,0.00039967117,0.00051517336,0.002131292],"category_scores_gemma":[0.00048539037,0.00028867193,0.000955781,0.0003396528,0.0003250377,0.00037831464,0.00028567857,0.0015034118,0.0004987015],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81144273,0.010290827,0.01655567,0.0009813803,0.0020861959,0.00019930411,0.00027017278,0.0023268624,0.028950622,0.00014320087,0.0036025615,0.12315048],"study_design_scores_gemma":[0.5730565,0.34752133,0.06340848,0.00012092792,0.002630561,0.0005073666,0.00012232982,0.0013365966,0.004591461,0.00020374998,0.0064604934,0.000040269024],"about_ca_topic_score_codex":0.00086543243,"about_ca_topic_score_gemma":0.0037645246,"teacher_disagreement_score":0.002131292,"about_ca_system_score_codex":0.0006232062,"about_ca_system_score_gemma":0.0007457571,"threshold_uncertainty_score":0.007129848},"labels":[],"label_agreement":null},{"id":"W4385667722","doi":"10.1097/01.hs9.0000968360.32403.e2","title":"P362: OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION USING REAL-WORLD DATA FROM HARMONY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Hematopoietic cell; Transplantation; Internal medicine; Lymphoblastic Leukemia; Pediatrics; Leukemia; Stem cell; Haematopoiesis","score_opus":0.0433941005268015,"score_gpt":0.3125400517115001,"score_spread":0.26914595118469864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95490986,0.000401136,0.0006556742,0.00021841908,0.000010237735,0.00012365973,0.042600993,0.000031982174,0.0010480958],"genre_scores_gemma":[0.9373037,0.00013148572,0.0010228568,0.000091128066,0.000018360046,0.00016928792,0.061114885,0.000017176753,0.0001310347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736565,0.0009907197,0.00042112387,0.00061854615,0.000402176,0.00020176831],"domain_scores_gemma":[0.9921171,0.0016538042,0.00408696,0.001100432,0.0005863052,0.00045550696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037322629,0.00025822004,0.00059539656,0.00154095,0.0002871187,0.0011657164,0.00082843984,0.00047956183,0.0010775037],"category_scores_gemma":[0.009666066,0.00021291821,0.0007375692,0.0035120358,0.0004539166,0.0007897813,0.0016702303,0.00042486578,0.00039514608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015325346,0.0000809057,0.9845583,0.00013399057,0.00035224837,0.0001295575,0.00028653926,0.0027756852,0.00019724212,0.00022159277,0.0033834556,0.0063479524],"study_design_scores_gemma":[0.000109572575,0.0002030839,0.9921137,0.000038729755,0.000093472634,0.00032025843,0.000251379,0.002559324,0.00021304576,0.00015085223,0.0039292565,0.000017439079],"about_ca_topic_score_codex":0.013165531,"about_ca_topic_score_gemma":0.0065183295,"teacher_disagreement_score":0.013165531,"about_ca_system_score_codex":0.0012367029,"about_ca_system_score_gemma":0.001076475,"threshold_uncertainty_score":0.026177824},"labels":[],"label_agreement":null},{"id":"W4385667785","doi":"10.1097/01.hs9.0000969412.43267.61","title":"P627: LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Oncology; Progression-free survival; Chronic lymphocytic leukemia; Population; Bruton's tyrosine kinase; Chemotherapy; Leukemia; Tyrosine kinase","score_opus":0.011910645621016498,"score_gpt":0.2973486943511449,"score_spread":0.2854380487301284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743843,0.0014664162,0.000085560256,0.000039084276,0.0000057956795,0.000022507207,0.0006101237,0.000005936624,0.00032606514],"genre_scores_gemma":[0.9980726,0.00017468489,0.00007473378,0.00003772846,0.000027948592,0.00003914439,0.001435558,0.0000024853289,0.0001350687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928683,0.00019495572,0.0000804747,0.00018552718,0.00014534572,0.000106832005],"domain_scores_gemma":[0.99695,0.0007004634,0.001357856,0.00018699923,0.00024358078,0.0005611938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002177385,0.00033252817,0.00069769094,0.000684886,0.00030876254,0.00093939825,0.00044101785,0.0005965289,0.0009750889],"category_scores_gemma":[0.002537448,0.00014916185,0.00090001646,0.0008541437,0.0002508991,0.00065996894,0.0006265655,0.0007331595,0.0001947498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03451107,0.00049024617,0.93814516,0.00017156624,0.0012655974,0.00016451051,0.00010956212,0.00087087037,0.0020267856,0.000045408662,0.0005388385,0.021660382],"study_design_scores_gemma":[0.001155116,0.007147563,0.9875579,0.000033823464,0.0007334949,0.00037808786,0.00008185205,0.0013776645,0.00052574463,0.00007712076,0.0009126097,0.00001911035],"about_ca_topic_score_codex":0.0009125164,"about_ca_topic_score_gemma":0.0012829114,"teacher_disagreement_score":0.002177385,"about_ca_system_score_codex":0.0005608989,"about_ca_system_score_gemma":0.0004243956,"threshold_uncertainty_score":0.01151526},"labels":[],"label_agreement":null},{"id":"W4385697375","doi":"10.1097/01.hs9.0000970688.75458.a8","title":"P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; McGill University; University of Toronto; Jewish General Hospital; Institute of Cancer Research","funders":"","keywords":"Medicine; Tocilizumab; Internal medicine; Multiple myeloma; Cytokine release syndrome; Incidence (geometry); Refractory (planetary science); Gastroenterology; Immunotherapy; Chimeric antigen receptor; Rheumatoid arthritis; Cancer","score_opus":0.0166835084563772,"score_gpt":0.2672355611624662,"score_spread":0.25055205270608905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712676,0.0015799442,0.00009143169,0.00012691057,0.00003872281,0.00012049157,0.00016554499,0.00004180064,0.0007083631],"genre_scores_gemma":[0.99816495,0.00043512954,0.000198799,0.00011074797,0.000042666292,0.00009229068,0.0002793848,0.000004139665,0.00067185325],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999874,0.00003701245,0.000009443491,0.00002174383,0.000022937453,0.000034894714],"domain_scores_gemma":[0.99981624,0.000034690533,0.000049912982,0.000010062762,0.000011901785,0.00007721096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022598488,0.00026811424,0.0009779703,0.00015935741,0.00016799454,0.00039663116,0.0002824404,0.0003862891,0.0030753931],"category_scores_gemma":[0.00056070864,0.0001413798,0.00037971526,0.00017745014,0.00015600883,0.00019835473,0.00015742096,0.0008559553,0.00040991843],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.413927,0.016150834,0.042518396,0.00096886454,0.0012187245,0.00044658812,0.00017494797,0.0015725082,0.099774234,0.00014394561,0.0063389163,0.4167651],"study_design_scores_gemma":[0.102799736,0.4300718,0.42446166,0.00015244378,0.0018066308,0.0016946358,0.0001269887,0.003232265,0.025982853,0.00017115631,0.009450315,0.000049579376],"about_ca_topic_score_codex":0.0006440323,"about_ca_topic_score_gemma":0.0017835042,"teacher_disagreement_score":0.0030753931,"about_ca_system_score_codex":0.00033434297,"about_ca_system_score_gemma":0.00045435946,"threshold_uncertainty_score":0.010288179},"labels":[],"label_agreement":null},{"id":"W4385697599","doi":"10.1097/01.hs9.0000977076.25234.7f","title":"PB2596: OPTIMIZING PLATELET TRANSFUSION FOR CLINICAL PRACTICE. DO PLATELETS AGE MATTER FOR THERAPEUTIC PLATELETS TRANSFUSION?","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Blood transfusion and management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Platelet; Platelet transfusion; Epinephrine; Medicine; Transfusion medicine; Adenosine diphosphate; Blood transfusion; Platelet aggregation; Chemistry; Immunology; Internal medicine","score_opus":0.0662538977394633,"score_gpt":0.37862377868737435,"score_spread":0.31236988094791107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697599","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.107857935,0.57571065,0.014768619,0.18567403,0.0067843203,0.0012479459,0.0019661537,0.0017800239,0.10421027],"genre_scores_gemma":[0.55602235,0.2997532,0.05969656,0.02987512,0.008002747,0.0016303508,0.0031143236,0.00057583547,0.041329555],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987587,0.000517964,0.0001748173,0.000093199524,0.0003748664,0.00008047767],"domain_scores_gemma":[0.99811494,0.0004384024,0.0005658206,0.00005882405,0.0004907435,0.00033138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034963726,0.00048249017,0.00067530654,0.0005084775,0.00031386712,0.0024975748,0.000674734,0.0010986746,0.013953263],"category_scores_gemma":[0.0077269706,0.00016337214,0.0003443471,0.0006559379,0.00032649614,0.0011278173,0.0006811841,0.00094184576,0.008636781],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013316491,0.00032673386,0.011155989,0.0021272865,0.000076301636,0.00023044155,0.00016787523,0.0006271627,0.0019474748,0.0023510554,0.08971534,0.88994265],"study_design_scores_gemma":[0.001160771,0.0040182522,0.11179652,0.012348104,0.000697961,0.0037202814,0.0015980882,0.006389199,0.009082581,0.016253272,0.832786,0.00014906336],"about_ca_topic_score_codex":0.001078527,"about_ca_topic_score_gemma":0.0013082711,"teacher_disagreement_score":0.013953263,"about_ca_system_score_codex":0.00089367037,"about_ca_system_score_gemma":0.0021410242,"threshold_uncertainty_score":0.046678305},"labels":[],"label_agreement":null},{"id":"W4385697656","doi":"10.1097/01.hs9.0000970368.33859.48","title":"P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Regimen; Oncology; Multiple myeloma; Lenalidomide; Hazard ratio; Confidence interval","score_opus":0.016896486216187306,"score_gpt":0.26855701842140345,"score_spread":0.2516605322052161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723166,0.0016531863,0.00008773319,0.00010067316,0.000037888018,0.00008430847,0.0003136649,0.000008874217,0.0004819779],"genre_scores_gemma":[0.99864846,0.00030659843,0.00009157768,0.000120876095,0.000059869228,0.0000745536,0.000393836,0.0000031877023,0.00030102805],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995926,0.00016088669,0.0000376348,0.00007809134,0.000048137383,0.00008265262],"domain_scores_gemma":[0.9994025,0.00020202696,0.00016811914,0.000052942774,0.000024844398,0.00014949775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010071986,0.0002922297,0.0011344219,0.00024793702,0.00013803555,0.00066028076,0.0003436576,0.00054490357,0.002111801],"category_scores_gemma":[0.0009539151,0.00015155553,0.0021293103,0.00031137012,0.00023566373,0.00043387813,0.00031677468,0.0010239576,0.00023381192],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84997475,0.0024021575,0.07040853,0.00063757884,0.006838814,0.0001272934,0.00012798897,0.0017019104,0.0074618226,0.00014987892,0.0016224394,0.058546875],"study_design_scores_gemma":[0.17276296,0.2918625,0.50272876,0.00027160902,0.012587169,0.0009779129,0.00034871732,0.0072133224,0.0045068134,0.0009751116,0.005683422,0.00008170495],"about_ca_topic_score_codex":0.0004300575,"about_ca_topic_score_gemma":0.0011680902,"teacher_disagreement_score":0.002111801,"about_ca_system_score_codex":0.000481034,"about_ca_system_score_gemma":0.0004431405,"threshold_uncertainty_score":0.0070646405},"labels":[],"label_agreement":null},{"id":"W4385697662","doi":"10.1097/01.hs9.0000977500.02308.e3","title":"PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical trial; Medical physics; Internal medicine; Oncology; Intensive care medicine","score_opus":0.08775879929521231,"score_gpt":0.3152991802851121,"score_spread":0.22754038098989982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697662","genre_codex":"dataset","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021362547,0.015166575,0.096506536,0.047780987,0.0069141104,0.09138634,0.506241,0.021623816,0.193018],"genre_scores_gemma":[0.09887445,0.01100976,0.25425726,0.015377949,0.0027326583,0.2418047,0.31760597,0.011665801,0.046671472],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9350391,0.03771067,0.014547253,0.0013280505,0.010024001,0.0013510248],"domain_scores_gemma":[0.7076269,0.19745022,0.022014068,0.012815408,0.054437533,0.005655952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0899049,0.0012862105,0.002592254,0.005239376,0.0009803659,0.0075487555,0.0030544738,0.0037778406,0.08352385],"category_scores_gemma":[0.32623476,0.0015221171,0.0037488113,0.0063513257,0.00191646,0.0050393855,0.0060573956,0.0058738636,0.045275647],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002471601,0.00029618284,0.0076573025,0.008542742,0.00041695323,0.00010075336,0.00071661244,0.0014270404,0.00031678745,0.011360364,0.83915603,0.12753761],"study_design_scores_gemma":[0.0032099343,0.00056937255,0.042041678,0.0072779986,0.00027647783,0.00029492468,0.00034375125,0.0018894532,0.00082261657,0.023694482,0.9192987,0.00028054125],"about_ca_topic_score_codex":0.0020200047,"about_ca_topic_score_gemma":0.0023686432,"teacher_disagreement_score":0.0899049,"about_ca_system_score_codex":0.0040090135,"about_ca_system_score_gemma":0.01462309,"threshold_uncertainty_score":0.47546822},"labels":[],"label_agreement":null},{"id":"W4385697716","doi":"10.1097/01.hs9.0000976796.54495.8a","title":"PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Anemia; Sickle cell anemia; Hemolytic anemia; Hemolysis; Adverse effect; Pharmacokinetics; Vaso-occlusive crisis; Disease; Internal medicine; Pharmacology; Gastroenterology","score_opus":0.03078124962771077,"score_gpt":0.3320431455114856,"score_spread":0.30126189588377483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697716","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93897194,0.038984895,0.001784121,0.00264708,0.00062808185,0.0035191132,0.005728068,0.00051617745,0.007220486],"genre_scores_gemma":[0.95420796,0.016616244,0.0042743627,0.0037287357,0.00042298055,0.004393468,0.0054048263,0.00012181677,0.010829733],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99974626,0.00011849803,0.0000126809355,0.000047990576,0.000026177266,0.000048341284],"domain_scores_gemma":[0.99961984,0.00006490656,0.000094087365,0.000025405418,0.000025162532,0.00017055929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011387174,0.0013242711,0.0020195462,0.0003009969,0.00029033158,0.0012750559,0.0007705964,0.0013824438,0.007108652],"category_scores_gemma":[0.0007653951,0.00043221618,0.0014942461,0.00029635918,0.00069060037,0.0010841406,0.00025792944,0.003434856,0.0012566234],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7761477,0.019863807,0.0040842905,0.003365782,0.00302357,0.00053066167,0.00030888923,0.0022683872,0.017131913,0.0013835819,0.016454889,0.15543637],"study_design_scores_gemma":[0.81698704,0.16332366,0.0065227654,0.00022132143,0.00066886086,0.0005576627,0.000094865456,0.0011886777,0.0014361058,0.0005007788,0.00845063,0.000047575864],"about_ca_topic_score_codex":0.0006508218,"about_ca_topic_score_gemma":0.0019327049,"teacher_disagreement_score":0.007108652,"about_ca_system_score_codex":0.00057146,"about_ca_system_score_gemma":0.0010190741,"threshold_uncertainty_score":0.023780823},"labels":[],"label_agreement":null},{"id":"W4385697895","doi":"10.1097/01.hs9.0000973532.28562.11","title":"P1665: USE OF DOACS IN THE MANAGEMENT OF UPPER EXTREMITY DEEP VENOUS THROMBOSIS; A SYSTEMATIC REVIEW","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Rivaroxaban; Apixaban; Edoxaban; Internal medicine; Venous thrombosis; Randomized controlled trial; Clinical trial; Relative risk; Thrombosis; Retrospective cohort study; MEDLINE; Meta-analysis; Cohort study; Intensive care medicine; Surgery; Warfarin; Confidence interval; Atrial fibrillation","score_opus":0.1280275703078243,"score_gpt":0.37147829852940983,"score_spread":0.24345072822158553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010983709,0.99651515,0.0001522293,0.00041481384,0.0001934003,0.0004426236,0.0008124957,0.000011682132,0.00035921665],"genre_scores_gemma":[0.014883859,0.9820754,0.00055966864,0.0007603686,0.00020860799,0.0007647757,0.0004968204,0.000007758278,0.00024282382],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.994961,0.001661556,0.0020107802,0.00036956917,0.0008277503,0.00016929195],"domain_scores_gemma":[0.9835137,0.010257765,0.00406234,0.00022014043,0.0017073862,0.00023854146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005640015,0.0013218846,0.008018458,0.00907026,0.0004902257,0.0021644083,0.001518255,0.0016798546,0.0067928135],"category_scores_gemma":[0.02308565,0.00077462924,0.0067918357,0.010700999,0.0006358281,0.0018252792,0.0011533947,0.0009319107,0.0005131554],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019939106,0.00000994767,0.00071155984,0.9660543,0.009517193,0.00006383876,0.00007146847,0.000056551104,0.000101095815,0.00009374889,0.0020170372,0.021103794],"study_design_scores_gemma":[0.00062524475,0.00021561174,0.00553975,0.85773605,0.11214046,0.00037081182,0.00018285158,0.00014115749,0.00018481353,0.00035758768,0.02246576,0.000039841965],"about_ca_topic_score_codex":0.0054122466,"about_ca_topic_score_gemma":0.012984209,"teacher_disagreement_score":0.00907026,"about_ca_system_score_codex":0.0025964181,"about_ca_system_score_gemma":0.0080597,"threshold_uncertainty_score":0.029827595},"labels":[],"label_agreement":null},{"id":"W4385697974","doi":"10.1097/01.hs9.0000976792.25698.9f","title":"PB2523: DI-2-ETHYLHEXYL PHTHALATE (DEHP) INHIBITS HEMOGLOBIN S POLYMERIZATION","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Phthalate; Polymerization; Chemistry; Hemoglobin; Valine; Buffy coat; Plasticizer; Phlebotomy; Food science; Biochemistry; Medicine; Surgery; Polymer; Organic chemistry; Amino acid","score_opus":0.01348634383864467,"score_gpt":0.25899750011339767,"score_spread":0.245511156274753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9288719,0.048898716,0.0045075994,0.0009764804,0.00048398023,0.0003650029,0.0014351053,0.0004958773,0.01396529],"genre_scores_gemma":[0.95599616,0.016945718,0.0035724526,0.0003431866,0.00011736488,0.00016998514,0.0016625621,0.000045421737,0.021147091],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989986,0.000021467484,0.0000073759024,0.00002234263,0.00002495269,0.000024032515],"domain_scores_gemma":[0.9999515,0.000008946574,0.000014202247,0.000003896202,0.000007251723,0.000014185409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012086934,0.0004076205,0.00020692124,0.00019719292,0.00016062499,0.00018908894,0.00022435113,0.00029699955,0.00587071],"category_scores_gemma":[0.00010061493,0.0001380653,0.00027804845,0.00012782365,0.00017998493,0.00012215339,0.00017752257,0.00039214717,0.0010510945],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012131375,0.0005443841,0.00062177144,0.00071822543,0.00004021695,0.00028795324,0.00003557473,0.00027779723,0.9702936,0.00018701397,0.0022040536,0.023576315],"study_design_scores_gemma":[0.00012761401,0.0036296218,0.006014209,0.000035810768,0.00004457993,0.0006664138,0.00002473448,0.0003843505,0.9734972,0.000050995848,0.015514908,0.000009566176],"about_ca_topic_score_codex":0.0006712724,"about_ca_topic_score_gemma":0.00093986106,"teacher_disagreement_score":0.00587071,"about_ca_system_score_codex":0.00014154261,"about_ca_system_score_gemma":0.00039605703,"threshold_uncertainty_score":0.019639432},"labels":[],"label_agreement":null},{"id":"W4385697985","doi":"10.1097/01.hs9.0000974984.02232.24","title":"PB2045: USE OF ANAKINRA IN THE TREATMENT OF ADULT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SYSTEMATIC REVIEW","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; McMaster University","funders":"","keywords":"Anakinra; Hemophagocytic lymphohistiocytosis; Medicine; Macrophage activation syndrome; Pediatrics; Retrospective cohort study; Internal medicine; Cytokine storm; Primary immunodeficiency; Immunology; Immune system","score_opus":0.12310567898537979,"score_gpt":0.38720029081714685,"score_spread":0.2640946118317671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010177968,0.99820006,0.00003526899,0.00009883145,0.000048962454,0.00008389829,0.00031185523,0.0000038206604,0.00019938777],"genre_scores_gemma":[0.009009731,0.99005985,0.0001713965,0.0002698977,0.000060091,0.00016143416,0.00019361368,0.000002096522,0.00007178465],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9975553,0.00060761225,0.0011678734,0.00021274174,0.00036253183,0.00009384345],"domain_scores_gemma":[0.9916095,0.005509403,0.0019229697,0.00009032736,0.0007421837,0.00012544695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024028898,0.0008314458,0.0053479588,0.006056798,0.00038854973,0.0014051079,0.0012542192,0.0014250143,0.00453204],"category_scores_gemma":[0.010142363,0.0005020095,0.0043304763,0.007911853,0.0005212024,0.0013042782,0.0008013556,0.00062648696,0.0003127917],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033556775,0.000014519867,0.00075630774,0.95169216,0.0043732096,0.00008726115,0.0000842744,0.00005880177,0.00018440692,0.00008180277,0.0013615085,0.04097016],"study_design_scores_gemma":[0.00048032711,0.00042253715,0.008239526,0.90217596,0.06417863,0.00068817794,0.00024375523,0.00008775942,0.00023138114,0.0001594025,0.023059787,0.00003266386],"about_ca_topic_score_codex":0.005099269,"about_ca_topic_score_gemma":0.013778339,"teacher_disagreement_score":0.006056798,"about_ca_system_score_codex":0.0016737418,"about_ca_system_score_gemma":0.004489252,"threshold_uncertainty_score":0.015161157},"labels":[],"label_agreement":null},{"id":"W4385698049","doi":"10.1097/01.hs9.0000970532.16622.f0","title":"P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Multiple myeloma; Refractory (planetary science); Lenalidomide; Oncology; Cohort; Surgery; Gastroenterology","score_opus":0.009288876697198186,"score_gpt":0.24197565072692845,"score_spread":0.23268677402973026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385698049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971011,0.0011952517,0.00013970351,0.000098533776,0.000016508597,0.00011616385,0.00083208317,0.0000110714,0.00048953353],"genre_scores_gemma":[0.9973015,0.00025194418,0.00014708967,0.00012058489,0.000049682574,0.00009417304,0.0017449441,0.000009215278,0.00028088907],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99958724,0.00011095422,0.00005802416,0.00008779478,0.00008163404,0.000074415024],"domain_scores_gemma":[0.99961424,0.00008632576,0.00010684337,0.000059345937,0.000038577236,0.00009461484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079389894,0.00047078382,0.0011651309,0.0004096001,0.00024494057,0.00064705254,0.0003527401,0.00040609197,0.0017363573],"category_scores_gemma":[0.0008328346,0.0001559077,0.002201225,0.00042672214,0.00018205354,0.00035066382,0.00045147608,0.0006060234,0.00037351082],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23038733,0.0021515433,0.6217717,0.0008654069,0.016081799,0.0007803007,0.0003952916,0.0017225975,0.03262441,0.0002245523,0.005224402,0.08777057],"study_design_scores_gemma":[0.025359716,0.027206168,0.9190143,0.0000965226,0.011596872,0.0019994418,0.00038965105,0.003427316,0.0042762263,0.00056167785,0.005998434,0.00007362742],"about_ca_topic_score_codex":0.0006585707,"about_ca_topic_score_gemma":0.0015457615,"teacher_disagreement_score":0.0017363573,"about_ca_system_score_codex":0.00042831237,"about_ca_system_score_gemma":0.00052117807,"threshold_uncertainty_score":0.0058086514},"labels":[],"label_agreement":null},{"id":"W4385698344","doi":"10.1097/01.hs9.0000971164.88567.72","title":"P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Refractory (planetary science); Medicine; Internal medicine; Oncology; Lymphoma; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","score_opus":0.014650674941796147,"score_gpt":0.2512173056998726,"score_spread":0.23656663075807646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385698344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960924,0.0070734597,0.0004669296,0.00016890018,0.00008504497,0.00029840262,0.00069567095,0.000027930007,0.0015744843],"genre_scores_gemma":[0.9977477,0.0005612472,0.0005618839,0.0001070192,0.00008890618,0.00016290491,0.00049198983,0.0000076222536,0.0002707889],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99682957,0.0017481282,0.00039344386,0.00038822388,0.00048623138,0.00015432159],"domain_scores_gemma":[0.99540365,0.0028247042,0.0010042794,0.00021574102,0.00022503735,0.00032671343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053859595,0.00052582537,0.0023791387,0.0007439889,0.00022624058,0.00094014267,0.00050054694,0.0008597686,0.001782495],"category_scores_gemma":[0.005505628,0.0002978917,0.002511111,0.000683097,0.0004179151,0.0010206918,0.00039538802,0.0011971359,0.000517615],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50692964,0.0025325662,0.2936474,0.0028367576,0.015399918,0.0003495428,0.000334031,0.005269027,0.019083517,0.00025966554,0.0011902647,0.15216759],"study_design_scores_gemma":[0.03800453,0.31430557,0.5883482,0.00039465632,0.019599155,0.0016239831,0.0003807545,0.011437717,0.015575771,0.0007324964,0.0094350735,0.00016203748],"about_ca_topic_score_codex":0.00020309305,"about_ca_topic_score_gemma":0.00036153887,"teacher_disagreement_score":0.0053859595,"about_ca_system_score_codex":0.0007981129,"about_ca_system_score_gemma":0.0003726139,"threshold_uncertainty_score":0.028484046},"labels":[],"label_agreement":null},{"id":"W4385698349","doi":"10.1097/01.hs9.0000970456.81043.cc","title":"P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Refractory (planetary science); Medicine; Internal medicine; Cohort; Dexamethasone; Oncology; Multiple myeloma; Lenalidomide; Gastroenterology","score_opus":0.031120390621193254,"score_gpt":0.29201849263677154,"score_spread":0.2608981020155783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385698349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982275,0.0070431037,0.0012423224,0.00050015765,0.0004893939,0.0011162113,0.0035344749,0.00008175092,0.003717624],"genre_scores_gemma":[0.9948295,0.000720555,0.00072147435,0.00037293398,0.00014500627,0.0005925372,0.0013122251,0.000012583156,0.0012931315],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9974686,0.0015987166,0.00018237329,0.00031548805,0.00025145465,0.00018329987],"domain_scores_gemma":[0.9979436,0.0009726072,0.0005693101,0.0001571906,0.00011853086,0.00023881863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002794883,0.00082215795,0.0022401784,0.00037438833,0.00017847013,0.0010305862,0.00075064576,0.0008582237,0.008053112],"category_scores_gemma":[0.004923459,0.0003105131,0.004859997,0.00038919144,0.00038295524,0.0008400605,0.000677211,0.0018682273,0.000704161],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9485501,0.0012116869,0.0053029503,0.00086313306,0.013319568,0.00003597681,0.00004529175,0.0013767004,0.0015121624,0.00020262919,0.0011696892,0.026410101],"study_design_scores_gemma":[0.4796864,0.38133383,0.08569141,0.00034348312,0.031991303,0.00028473878,0.00018428141,0.008030431,0.0035584203,0.0019633472,0.0068246033,0.00010771112],"about_ca_topic_score_codex":0.0008039009,"about_ca_topic_score_gemma":0.0013420965,"teacher_disagreement_score":0.008053112,"about_ca_system_score_codex":0.00086080143,"about_ca_system_score_gemma":0.0006281566,"threshold_uncertainty_score":0.026940405},"labels":[],"label_agreement":null},{"id":"W4385698393","doi":"10.1097/01.hs9.0000977272.39179.7d","title":"PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Bleed; Cochrane Library; Internal medicine; Pediatrics; Systematic review; Surgery; MEDLINE; Meta-analysis","score_opus":0.22911928166151782,"score_gpt":0.42180933272901006,"score_spread":0.19269005106749224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385698393","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00106584,0.9980477,0.00004923065,0.000117622745,0.000054062173,0.00012518678,0.00029282257,0.0000065261174,0.00024104417],"genre_scores_gemma":[0.010554249,0.9883519,0.00021235923,0.00030626336,0.000046378187,0.00020567923,0.00019126124,0.000003888727,0.00012802352],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99749905,0.0007833249,0.000961273,0.00020932623,0.00043759178,0.00010941619],"domain_scores_gemma":[0.9927401,0.0045147464,0.0018478314,0.00008706128,0.000669781,0.00014043308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025298968,0.0011222328,0.007076074,0.006797126,0.00049562874,0.0017900723,0.0014782513,0.0016278427,0.005594388],"category_scores_gemma":[0.01039208,0.0006725499,0.005376919,0.009012649,0.0006291608,0.0016649077,0.0010666364,0.000779626,0.00037531354],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002597927,0.000011336516,0.00039044328,0.9694941,0.0045010257,0.00008298233,0.00007539432,0.000047522943,0.00013906868,0.00008096555,0.001145267,0.023772065],"study_design_scores_gemma":[0.0004733771,0.00036762492,0.004865954,0.9038483,0.06976743,0.00056901923,0.00024247817,0.00009118149,0.00020340792,0.00016277879,0.01937485,0.000033635828],"about_ca_topic_score_codex":0.0068737124,"about_ca_topic_score_gemma":0.01766397,"teacher_disagreement_score":0.007076074,"about_ca_system_score_codex":0.0022771626,"about_ca_system_score_gemma":0.005350877,"threshold_uncertainty_score":0.018715143},"labels":[],"label_agreement":null},{"id":"W4385699036","doi":"10.1097/01.hs9.0000972748.88204.9a","title":"P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Bone and Joint Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Thalassemia; Osteopenia; Ineffective erythropoiesis; Bone mineral; Anemia; Osteoporosis; Placebo; Internal medicine; Beta thalassemia; Surgery; Erythropoiesis","score_opus":0.010005040724014438,"score_gpt":0.27798255912096614,"score_spread":0.2679775183969517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385699036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669768,0.015926642,0.0005076994,0.0022089812,0.00049618125,0.0014475334,0.0033739812,0.00021531654,0.008846978],"genre_scores_gemma":[0.9853774,0.0031194221,0.00066998135,0.0025373907,0.00054426497,0.0012094534,0.0033269457,0.00002559341,0.0031896795],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997439,0.00011294825,0.000020472982,0.000042948195,0.000031482366,0.000048239945],"domain_scores_gemma":[0.9995778,0.00010121419,0.000113673974,0.000028427059,0.00003852638,0.00014042994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092210853,0.00056218106,0.0012686924,0.00013218938,0.0002725979,0.0009216711,0.00042703588,0.0010710607,0.0058978195],"category_scores_gemma":[0.0011296441,0.00020929896,0.0013402303,0.00023124105,0.0002978122,0.00056363264,0.00022392775,0.0023800419,0.0008636601],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86619043,0.005748431,0.0073319757,0.0016401295,0.0019975929,0.00015279624,0.000093751325,0.00074553327,0.0072634933,0.00037313206,0.011975179,0.09648755],"study_design_scores_gemma":[0.7676471,0.17181939,0.043527987,0.00028005344,0.002547801,0.00052267936,0.000079343896,0.0019928743,0.0019060286,0.0009464988,0.008679173,0.000051074123],"about_ca_topic_score_codex":0.00038300158,"about_ca_topic_score_gemma":0.0012206231,"teacher_disagreement_score":0.0058978195,"about_ca_system_score_codex":0.00032732802,"about_ca_system_score_gemma":0.00053619716,"threshold_uncertainty_score":0.01973015},"labels":[],"label_agreement":null},{"id":"W4385699183","doi":"10.1097/01.hs9.0000972624.95131.86","title":"P1435: OUTCOMES OF COVID-19 INFECTION IN INDIVIDUALS WITH SICKLE CELL DISEASE OR SICKLE CELL TRAIT: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Centre Hospitalier de l’Université de Montréal; University of Toronto","funders":"","keywords":"Medicine; Sickle cell trait; Disease; Population; Meta-analysis; Acute chest syndrome; Cochrane Library; Sickle cell anemia; Pediatrics; Intensive care medicine; Inclusion and exclusion criteria; Confounding; Internal medicine; Pathology; Environmental health","score_opus":0.0739883264840827,"score_gpt":0.35140447403681047,"score_spread":0.27741614755272775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385699183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025851966,0.9953002,0.0002266285,0.00019304111,0.000101402205,0.00022521599,0.0010784249,0.000019222534,0.00027071574],"genre_scores_gemma":[0.0758073,0.91876036,0.0012517388,0.0008892204,0.00022976182,0.0011246423,0.0014896753,0.000032342192,0.00041502045],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9935329,0.0021921475,0.0024319324,0.0007343982,0.000823514,0.0002851933],"domain_scores_gemma":[0.98368925,0.011787321,0.0026645446,0.00037347397,0.0012607194,0.00022471773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007458839,0.0021045813,0.018101193,0.007225482,0.00074261153,0.0034429876,0.002104976,0.002108366,0.006053656],"category_scores_gemma":[0.023462368,0.0011064432,0.028875306,0.00900322,0.0006179938,0.0018699969,0.001694083,0.0016503141,0.0004105817],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084817427,0.000018238152,0.0034365037,0.78611064,0.19622275,0.00011058543,0.00008871835,0.0001978471,0.00018051449,0.00012439574,0.0010858333,0.011575862],"study_design_scores_gemma":[0.0004887434,0.0002117234,0.006400829,0.12810805,0.8588766,0.00019343602,0.00009679261,0.00017172049,0.00014251792,0.0002770642,0.004992988,0.000039521896],"about_ca_topic_score_codex":0.007789847,"about_ca_topic_score_gemma":0.015859503,"teacher_disagreement_score":0.018101193,"about_ca_system_score_codex":0.0024505006,"about_ca_system_score_gemma":0.0044522984,"threshold_uncertainty_score":0.039446592},"labels":[],"label_agreement":null},{"id":"W4385702448","doi":"10.1097/01.hs9.0000971168.59900.67","title":"P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); Cohort; Salvage therapy; Chemotherapy; Gastroenterology; Cancer; Immunotherapy","score_opus":0.03137807776785468,"score_gpt":0.3217374355978094,"score_spread":0.2903593578299547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8249877,0.04820788,0.0032354894,0.0058188485,0.0014817205,0.0061506517,0.087006666,0.000711936,0.022399155],"genre_scores_gemma":[0.83156925,0.020275494,0.008292733,0.008855051,0.0015774886,0.0057493793,0.11204404,0.00028190276,0.011354723],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99907196,0.00038290664,0.00011401295,0.00011144856,0.00021784056,0.00010180133],"domain_scores_gemma":[0.9979175,0.0004972756,0.00071440806,0.00013270124,0.00035961802,0.00037862602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028590779,0.0008809789,0.0019847655,0.0004965762,0.0003306917,0.0012112159,0.0008447289,0.0011922994,0.0061708307],"category_scores_gemma":[0.0022050699,0.00035457965,0.002085102,0.0007951447,0.00029706638,0.00086233043,0.00039108077,0.0018389671,0.0017700284],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37253517,0.012489711,0.045105565,0.005947199,0.010638267,0.0010834864,0.00034123272,0.0034052646,0.04858573,0.0002732495,0.07883591,0.4207593],"study_design_scores_gemma":[0.3454732,0.20542754,0.2944585,0.00088296126,0.016643062,0.003545599,0.00020675418,0.002157504,0.011454206,0.00069014874,0.118859,0.00020151616],"about_ca_topic_score_codex":0.001320667,"about_ca_topic_score_gemma":0.0034691372,"teacher_disagreement_score":0.0061708307,"about_ca_system_score_codex":0.00081436237,"about_ca_system_score_gemma":0.001215719,"threshold_uncertainty_score":0.020643532},"labels":[],"label_agreement":null},{"id":"W4385702552","doi":"10.1097/01.hs9.0000973276.11676.38","title":"P1600: USE OF RITUXIMAB PLUS STANDARD OF CARE FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Rituximab; Medicine; Regimen; Immune thrombocytopenia; Meta-analysis; Randomized controlled trial; Dosing; Internal medicine; Platelet; Systematic review; Immunology; MEDLINE; Pediatrics; Antibody; Intensive care medicine","score_opus":0.1647180651050469,"score_gpt":0.3795282762577729,"score_spread":0.214810211152726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003978495,0.9943414,0.00024647076,0.00017416134,0.00014559539,0.00033748307,0.00050322205,0.000020591215,0.00025264386],"genre_scores_gemma":[0.13701905,0.85761374,0.0014813041,0.0010009288,0.00028120467,0.0013587405,0.00087706087,0.000026845904,0.00034113432],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9923126,0.0034632827,0.0023274485,0.00073764793,0.0008852367,0.00027388957],"domain_scores_gemma":[0.9871379,0.008629015,0.0026668522,0.00029635447,0.0010400768,0.00022983422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008414056,0.0020303107,0.018573299,0.005642074,0.0005587627,0.0028998882,0.0020445397,0.0022917981,0.0049319835],"category_scores_gemma":[0.021415416,0.0010667234,0.0320224,0.006722031,0.0006665667,0.0016932631,0.0014164681,0.0018634604,0.00032717324],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025116748,0.000034555625,0.0018944215,0.6027621,0.37996843,0.00009159801,0.0000622009,0.0003075867,0.0001628942,0.00008972959,0.00061282277,0.011501958],"study_design_scores_gemma":[0.0014243358,0.00038145817,0.003913779,0.057737473,0.93399364,0.00010895169,0.000057702782,0.00018517037,0.000091109236,0.00016020713,0.0019202455,0.00002592963],"about_ca_topic_score_codex":0.0075525213,"about_ca_topic_score_gemma":0.015171961,"teacher_disagreement_score":0.018573299,"about_ca_system_score_codex":0.003060142,"about_ca_system_score_gemma":0.0038426188,"threshold_uncertainty_score":0.044498324},"labels":[],"label_agreement":null},{"id":"W4385702649","doi":"10.1097/01.hs9.0000975280.98608.35","title":"PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Daratumumab; CD38; Multiple myeloma; Medicine; Monoclonal antibody; Innate immune system; Acquired immune system; Immunology; Cancer research; Immune system; Antibody; Biology; Stem cell; Cell biology","score_opus":0.30247108323643784,"score_gpt":0.49072210878978006,"score_spread":0.18825102555334222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702649","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6943885,0.035248924,0.025501734,0.010879235,0.0016098098,0.180004,0.010321296,0.0010106978,0.041035783],"genre_scores_gemma":[0.7485044,0.018742716,0.075899296,0.008474098,0.0012198818,0.11435041,0.009803835,0.0003458043,0.02265955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997997,0.0012732956,0.00007479984,0.00016599582,0.00021469986,0.00027411836],"domain_scores_gemma":[0.9984907,0.00023941306,0.00025237838,0.00011796957,0.00023257126,0.0006670097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010288267,0.001217862,0.0014227484,0.0006747385,0.000654613,0.0015992967,0.0015346236,0.002145305,0.0056653423],"category_scores_gemma":[0.0024001626,0.00053301797,0.0013612858,0.00059015135,0.0009866412,0.0009420706,0.00085404,0.0041127815,0.001794428],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.303582,0.035961967,0.008559069,0.003907797,0.0013545137,0.00042632356,0.0006068344,0.006656185,0.071899444,0.007991402,0.027195519,0.5318589],"study_design_scores_gemma":[0.45102212,0.3970736,0.012005054,0.000945931,0.001248232,0.00062785816,0.00012954086,0.0036693716,0.023738662,0.0031678393,0.10628885,0.00008302981],"about_ca_topic_score_codex":0.00091288553,"about_ca_topic_score_gemma":0.003246101,"teacher_disagreement_score":0.010288267,"about_ca_system_score_codex":0.0016861607,"about_ca_system_score_gemma":0.00679785,"threshold_uncertainty_score":0.05441022},"labels":[],"label_agreement":null},{"id":"W4385702657","doi":"10.1097/01.hs9.0000972808.84024.73","title":"P1481: SYSTEMATICALLY REDUCED RED CELL PHOSPHATIDYLSERINE FLIPPASE ACTIVITY IS SUFFICIENT TO INDUCE HEREDITARY HEMOLYTIC ANEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Flippase; Phosphatidylserine; Biology; Red blood cell; Molecular biology; Biochemistry; Cell biology; Chemistry; Phospholipid; Membrane","score_opus":0.024815715547615153,"score_gpt":0.27410591985452976,"score_spread":0.2492902043069146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99673355,0.0005861388,0.0008331093,0.00008667842,0.000036327503,0.0000509202,0.000621557,0.000085674226,0.00096604315],"genre_scores_gemma":[0.99688405,0.00035777286,0.0006980775,0.00005765176,0.000019931726,0.000057960035,0.00064410974,0.00003702684,0.0012433674],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999089,0.00001727021,0.000014681505,0.000024648944,0.00001986449,0.000014537704],"domain_scores_gemma":[0.99988854,0.000030200132,0.00003774984,0.000011090847,0.000009361277,0.000022956518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090531605,0.00033124548,0.00028457004,0.00021648254,0.00011451755,0.00016298114,0.00020054262,0.00040137503,0.0026023213],"category_scores_gemma":[0.0001494976,0.00007915337,0.00016869408,0.00015372268,0.00024000359,0.00007421737,0.00016874331,0.00035783657,0.00068705546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003816906,0.000107582164,0.000522558,0.000056299796,0.000011035161,0.0010105721,0.000015166315,0.000053545537,0.995337,0.00008086229,0.00019330932,0.0022302908],"study_design_scores_gemma":[0.0001929376,0.0018584547,0.014178163,0.000033648255,0.000089776695,0.009059904,0.000047672493,0.0015241908,0.96630734,0.00013715237,0.0065579703,0.00001277056],"about_ca_topic_score_codex":0.0002115067,"about_ca_topic_score_gemma":0.00016430371,"teacher_disagreement_score":0.0026023213,"about_ca_system_score_codex":0.00017126377,"about_ca_system_score_gemma":0.00009289154,"threshold_uncertainty_score":0.008705616},"labels":[],"label_agreement":null},{"id":"W4385702799","doi":"10.1097/01.hs9.0000975724.65819.6e","title":"PB2248: BONE MARROW NECROSIS: RARE PRESENTATION OF CHRONIC MYELOID NEOPLASMS SYSTEMIC REVIEW AND CASE REPORT","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloproliferative neoplasm; Medicine; Myelofibrosis; Pathology; Bone marrow; Essential thrombocythemia; Myeloid; Internal medicine; Polycythemia vera","score_opus":0.020819081014949736,"score_gpt":0.2954762781996693,"score_spread":0.2746571971847196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702799","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034200486,0.95075506,0.0009040241,0.0017575646,0.0011784324,0.000114890696,0.00034118164,0.0000808623,0.010667429],"genre_scores_gemma":[0.23681715,0.7451144,0.0016986814,0.0034223695,0.0058048433,0.00012691149,0.0008005597,0.00003015145,0.0061849123],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9996681,0.00004577808,0.000119112,0.00005771576,0.00006396831,0.00004528503],"domain_scores_gemma":[0.99950993,0.00016338169,0.0001825422,0.000022604467,0.000057829533,0.00006370124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022762318,0.000921517,0.00093128235,0.0046712267,0.0005691818,0.0010449861,0.0007227696,0.0015835161,0.0037172276],"category_scores_gemma":[0.00095077214,0.00025981883,0.00044653704,0.004005738,0.00084586785,0.0013493623,0.00078168296,0.000662717,0.0017578773],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013675215,0.00010315548,0.019522361,0.020116953,0.00020957277,0.696133,0.0009400958,0.0003464827,0.006514798,0.0015460084,0.046215635,0.20821519],"study_design_scores_gemma":[0.000011529308,0.00004106307,0.007275241,0.0025198732,0.000103592414,0.9289492,0.00035981016,0.00007997112,0.00045726282,0.00046997107,0.05971278,0.000019710827],"about_ca_topic_score_codex":0.0006826317,"about_ca_topic_score_gemma":0.00094214955,"teacher_disagreement_score":0.0046712267,"about_ca_system_score_codex":0.00050353375,"about_ca_system_score_gemma":0.000801995,"threshold_uncertainty_score":0.012435317},"labels":[],"label_agreement":null},{"id":"W4385703588","doi":"10.1097/01.hs9.0000969476.05517.0d","title":"P643: CUMULATIVE REVIEW OF HEART FAILURE WITH ACALABRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING DATA FROM CLINICAL TRIALS AND POST-MARKETING EXPERIENCE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"MedDRA; Medicine; Chronic lymphocytic leukemia; Clinical trial; Population; Internal medicine; Cumulative incidence; Oncology; Adverse effect; Leukemia; Pharmacovigilance; Environmental health","score_opus":0.2531484660242522,"score_gpt":0.4870230859130047,"score_spread":0.23387461988875252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385703588","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010663494,0.9912062,0.0003130959,0.001403422,0.0003970263,0.00027843847,0.002813002,0.00003083625,0.0024917205],"genre_scores_gemma":[0.012825733,0.97968674,0.0006426458,0.0022371921,0.0008769948,0.00029613695,0.0026845767,0.000034681416,0.00071528216],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99011517,0.0031614755,0.0029666873,0.0007218482,0.0028266448,0.0002082155],"domain_scores_gemma":[0.95392257,0.019537112,0.015056671,0.0012805641,0.00942861,0.0007745869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013448732,0.0009329581,0.0035264683,0.01129444,0.00032149692,0.00235655,0.0013152881,0.0011001849,0.0069379155],"category_scores_gemma":[0.031131243,0.0005188415,0.004521505,0.013446207,0.0005732078,0.0018308128,0.0012580964,0.0012424038,0.0017494806],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015465427,0.000054480188,0.003087165,0.33389738,0.012058863,0.00019065026,0.00020346881,0.0004278102,0.0012930762,0.0009420117,0.06651135,0.5797872],"study_design_scores_gemma":[0.001646974,0.0015211985,0.031254034,0.32410672,0.04545642,0.0013520431,0.00021718329,0.00043161714,0.0009472554,0.001210716,0.591744,0.000111795525],"about_ca_topic_score_codex":0.004263857,"about_ca_topic_score_gemma":0.010290981,"teacher_disagreement_score":0.013448732,"about_ca_system_score_codex":0.002771544,"about_ca_system_score_gemma":0.0070002084,"threshold_uncertainty_score":0.07112455},"labels":[],"label_agreement":null},{"id":"W4385704562","doi":"10.1097/01.hs9.0000976692.37823.82","title":"PB2497: HEMATOLOGIC TOXICITIES WITH IMMUNOTHERAPY IN CANCER PATIENTS AT THE ALLAN BLAIR CANCER CENTRE: RETROSPECTIVE DATA COLLECTION STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority; Saskatchewan Health; University of Saskatchewan","funders":"","keywords":"Medicine; Cancer; Immunotherapy; Internal medicine; Oncology; Context (archaeology); Incidence (geometry); Neutropenia; Chemotherapy","score_opus":0.03287270210165945,"score_gpt":0.31162655776670695,"score_spread":0.2787538556650475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385704562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708783,0.0026050252,0.0004019813,0.00023580743,0.000021379637,0.0009522267,0.022077583,0.000038008242,0.0027896778],"genre_scores_gemma":[0.98215944,0.0019662266,0.0008533823,0.00034824968,0.00004087858,0.00095601083,0.0129694315,0.000021475613,0.0006849737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973016,0.0004826893,0.0006836533,0.00047261122,0.00079222623,0.00026716877],"domain_scores_gemma":[0.9846534,0.003081361,0.0076145786,0.00076745416,0.0029532893,0.0009300101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021635476,0.00030109653,0.00057187985,0.004185369,0.0010055462,0.0012101826,0.0007327243,0.00038240835,0.0025857855],"category_scores_gemma":[0.0054067774,0.00043215312,0.0004400247,0.008479505,0.00051249843,0.0006343923,0.00085721264,0.0006456609,0.00053828594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016126945,0.000059938673,0.9938046,0.00020252544,0.000041633684,0.00034081927,0.0004118572,0.00006316782,0.00019201514,0.0000350749,0.0012967755,0.0033903967],"study_design_scores_gemma":[0.000034162047,0.00023242089,0.9925132,0.00019148894,0.0000569937,0.0010121942,0.001437887,0.00019628138,0.0003633721,0.000017602159,0.003926394,0.000017996828],"about_ca_topic_score_codex":0.07014978,"about_ca_topic_score_gemma":0.075876296,"teacher_disagreement_score":0.07014978,"about_ca_system_score_codex":0.0037956347,"about_ca_system_score_gemma":0.0062033907,"threshold_uncertainty_score":0.13948292},"labels":[],"label_agreement":null},{"id":"W4385704654","doi":"10.1097/01.hs9.0000970536.69350.bb","title":"P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Cytokine; Cytokine release syndrome; Internal medicine; Cohort; Multiple myeloma; Immunology; Gastroenterology; Immunotherapy; Immune system","score_opus":0.016902216350578165,"score_gpt":0.2862964662391734,"score_spread":0.2693942498885952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385704654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984854,0.00012125361,0.00012771184,0.000035918325,0.0000053291933,0.000034147342,0.0009455176,0.0000073696488,0.00023738696],"genre_scores_gemma":[0.99610436,0.00005581918,0.00021562685,0.000069376656,0.000025625486,0.00007547769,0.0029596458,0.000010617473,0.00048347295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996847,0.00006211872,0.00002670814,0.000108667366,0.00006404403,0.000053838183],"domain_scores_gemma":[0.9995395,0.00006658621,0.00016298702,0.000059930473,0.00005375941,0.000117320495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058039173,0.00031246623,0.00034171893,0.00037904744,0.00031868578,0.0005196834,0.00030839068,0.00038889179,0.0018619957],"category_scores_gemma":[0.0005949101,0.00014869649,0.0005908335,0.00039100135,0.0002063601,0.00025127924,0.00038834385,0.0006228245,0.00048163615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010575711,0.00066657085,0.9454519,0.000051300965,0.00030327195,0.0005344062,0.00017158722,0.00024083281,0.029991226,0.00008399099,0.0012868441,0.010642294],"study_design_scores_gemma":[0.00030565515,0.0020546762,0.99250644,0.000006450553,0.00009953812,0.0012614018,0.00010016022,0.000470954,0.001815125,0.000053551244,0.0013148566,0.000011186575],"about_ca_topic_score_codex":0.0008471987,"about_ca_topic_score_gemma":0.0009675726,"teacher_disagreement_score":0.0018619957,"about_ca_system_score_codex":0.00027943624,"about_ca_system_score_gemma":0.00032790643,"threshold_uncertainty_score":0.0062289834},"labels":[],"label_agreement":null},{"id":"W4385704694","doi":"10.1097/01.hs9.0000977504.69432.f9","title":"PB2708: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE IN PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN’S DISEASE (IMCD): AN EXPLORATORY ANALYSIS OF THE SURVEY’S INTERNAL CONSTRUCT VALIDITY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Construct validity; Disease; Quality of life (healthcare); Likert scale; Scale (ratio); Construct (python library); Physical therapy; Family medicine; Clinical psychology; Internal medicine; Psychometrics; Psychology; Nursing","score_opus":0.023791958138850676,"score_gpt":0.28237069934428294,"score_spread":0.2585787412054323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385704694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99796885,0.0000829706,0.00016516309,0.0001443181,0.0000073635674,0.00015769924,0.0008262314,0.0000042192682,0.0006431831],"genre_scores_gemma":[0.9977222,0.00009425671,0.00056955364,0.00006766846,0.000012626655,0.00045771687,0.0008474735,0.0000034073423,0.00022512462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756914,0.0014331707,0.00027576246,0.00012692704,0.00037411353,0.0002207996],"domain_scores_gemma":[0.98959535,0.0050624576,0.0024109553,0.00040437424,0.0015765064,0.0009503525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005210285,0.00029206675,0.0004318105,0.0013606806,0.00049815915,0.00067964045,0.00045876025,0.00040993895,0.0019096787],"category_scores_gemma":[0.011617105,0.00018647152,0.0008322626,0.0012369722,0.0004624424,0.00060450047,0.0015535399,0.00065314415,0.00030106952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023923264,0.00025015644,0.9820094,0.00017823366,0.000099850055,0.000091799426,0.0025687367,0.00024846385,0.00019193428,0.00009317244,0.00096561894,0.013063317],"study_design_scores_gemma":[0.000031964293,0.0005603241,0.9943826,0.00004849821,0.00002103116,0.00010763082,0.0029079742,0.00055642804,0.00006863408,0.000044502376,0.0012593131,0.00001101966],"about_ca_topic_score_codex":0.002612466,"about_ca_topic_score_gemma":0.0028178243,"teacher_disagreement_score":0.005210285,"about_ca_system_score_codex":0.00074918725,"about_ca_system_score_gemma":0.0010404681,"threshold_uncertainty_score":0.02755493},"labels":[],"label_agreement":null},{"id":"W4385705588","doi":"10.1097/01.hs9.0000976912.69182.0b","title":"PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Autoimmune hemolytic anemia; Medicine; B-cell activating factor; Rituximab; Pharmacodynamics; Pharmacokinetics; Immunology; Antibody; Pure red cell aplasia; Internal medicine; Autoantibody; Anemia; Pharmacology; B cell","score_opus":0.11378934319641971,"score_gpt":0.4204725488922121,"score_spread":0.3066832056957924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385705588","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96824783,0.0024304062,0.0022977334,0.00080433657,0.00034096395,0.019474879,0.002401806,0.0002632221,0.0037388452],"genre_scores_gemma":[0.9584697,0.0016986232,0.007815794,0.002437606,0.00037199497,0.019671025,0.0030576559,0.00008617941,0.0063914545],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99907744,0.00038311366,0.000046178164,0.00019533803,0.00009000373,0.00020788806],"domain_scores_gemma":[0.99911577,0.00012469439,0.00014762113,0.00008042479,0.000060917588,0.00047067157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037137591,0.002364516,0.002746393,0.0006598671,0.00077804003,0.0016096676,0.0015398733,0.0025596274,0.007929325],"category_scores_gemma":[0.001236498,0.0010133485,0.0014454419,0.00051390065,0.0018478772,0.0015423079,0.0005034157,0.004116189,0.002460149],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69636595,0.17236224,0.003090277,0.0011870206,0.0010045188,0.00046236915,0.00032108233,0.0025413805,0.049200535,0.0007400263,0.004742385,0.067982174],"study_design_scores_gemma":[0.438594,0.55124587,0.003286233,0.000031962158,0.00022167365,0.00016050973,0.000039210594,0.00078503427,0.0024458983,0.00034222536,0.0028125842,0.000034727498],"about_ca_topic_score_codex":0.0012816382,"about_ca_topic_score_gemma":0.0027885935,"teacher_disagreement_score":0.007929325,"about_ca_system_score_codex":0.0019644594,"about_ca_system_score_gemma":0.0034629907,"threshold_uncertainty_score":0.026526213},"labels":[],"label_agreement":null},{"id":"W4385705882","doi":"10.1097/01.hs9.0000973540.85675.29","title":"P1667: ATTRIBUTES OF RANDOMIZED CONTROLLED TRIALS AND THEIR ASSOCIATIONS WITH FUNDING SOURCE IN VENOUS THROMBOEMBOLISM PROPHYLAXIS FOR PATIENTS WITH CANCER: A BIBLIOGRAPHICAL ANALYSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Academic Publishing and Open Access","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Randomized controlled trial; Sample size determination; MEDLINE; Exact test; Publication bias; Meta-analysis; Confounding; Internal medicine; Family medicine; Statistics; Mathematics","score_opus":0.07382410853550792,"score_gpt":0.37412042654940986,"score_spread":0.30029631801390194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385705882","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031555634,0.9236843,0.009444747,0.005959279,0.000906915,0.008664773,0.013848935,0.00017321687,0.005762204],"genre_scores_gemma":[0.4915076,0.42784292,0.033757117,0.005149859,0.0019091041,0.028848805,0.0093371235,0.00029658462,0.0013509233],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.5081535,0.16666402,0.2550497,0.009667018,0.058809936,0.0016557093],"domain_scores_gemma":[0.08130075,0.7797092,0.109842524,0.00892864,0.019228071,0.0009906944],"candidate_categories":["metaresearch","bibliometrics"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.20776507,0.0014298455,0.009823773,0.044307414,0.0019168111,0.0088701015,0.0032076112,0.0042867647,0.011919541],"category_scores_gemma":[0.7108002,0.0012254682,0.01695357,0.0830177,0.0036589494,0.007240286,0.0036688172,0.0034871341,0.0012936865],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034896722,0.00013427697,0.10915809,0.70420796,0.05840493,0.00068505196,0.0015689672,0.0008447493,0.00021276473,0.0033906095,0.006807095,0.111095846],"study_design_scores_gemma":[0.004113541,0.0015085106,0.16376294,0.5113964,0.24329868,0.0043206885,0.0029176844,0.0031077745,0.0006334441,0.014816323,0.049778827,0.00034521375],"about_ca_topic_score_codex":0.0025216185,"about_ca_topic_score_gemma":0.0041514505,"teacher_disagreement_score":0.9556926,"about_ca_system_score_codex":0.0074942377,"about_ca_system_score_gemma":0.012665283,"threshold_uncertainty_score":0.97696674},"labels":[],"label_agreement":null},{"id":"W4385705955","doi":"10.1097/01.hs9.0000971156.02746.02","title":"P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Refractory (planetary science); Oncology; Lymphoma; Cohort; Phases of clinical research; Cancer; Chemotherapy; Gastroenterology; Immunotherapy","score_opus":0.033128835339500215,"score_gpt":0.32422289692761935,"score_spread":0.2910940615881191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385705955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7246983,0.089885555,0.004912559,0.008036679,0.002188634,0.0077431104,0.12789422,0.0009312464,0.033709656],"genre_scores_gemma":[0.78733677,0.028201,0.009480709,0.010989841,0.0017620298,0.004937771,0.14435923,0.0002792762,0.012653339],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989141,0.00040889435,0.00013690068,0.0001292545,0.0002968218,0.00011391267],"domain_scores_gemma":[0.99797195,0.00045579343,0.0006766433,0.00012290641,0.00038751552,0.00038522034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033765084,0.00092568697,0.0018217909,0.00062255113,0.00035098192,0.0013041843,0.0009640134,0.0011564653,0.007246266],"category_scores_gemma":[0.0023115494,0.00036279665,0.0023159976,0.0008818196,0.00029992787,0.000976256,0.0004113843,0.0018061951,0.0018130091],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2657873,0.009897491,0.042561736,0.0071032913,0.012531916,0.000954922,0.00034450562,0.003784726,0.04152171,0.00035801722,0.10863559,0.5065188],"study_design_scores_gemma":[0.2642185,0.16447313,0.3519167,0.0013249094,0.020246973,0.0035563903,0.00023955127,0.0026326992,0.013271092,0.00081416825,0.17706573,0.00024014266],"about_ca_topic_score_codex":0.0018172684,"about_ca_topic_score_gemma":0.0052314317,"teacher_disagreement_score":0.007246266,"about_ca_system_score_codex":0.0010549442,"about_ca_system_score_gemma":0.0013225581,"threshold_uncertainty_score":0.02424115},"labels":[],"label_agreement":null},{"id":"W4385706381","doi":"10.1097/01.hs9.0000971268.84093.15","title":"P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Percentile; Internal medicine; Progression-free survival; Oncology; Overall survival; Statistics; Mathematics","score_opus":0.05043493318807855,"score_gpt":0.3075699623141653,"score_spread":0.2571350291260867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385706381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9389863,0.018516146,0.015854727,0.002195411,0.0034217201,0.0063639707,0.005979065,0.0002900252,0.008392635],"genre_scores_gemma":[0.98838603,0.00061885384,0.0047122147,0.0008518611,0.00023863903,0.0028688072,0.00095829845,0.000027031068,0.0013382268],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98598516,0.011261838,0.0006438854,0.0011293076,0.0005501423,0.00042960508],"domain_scores_gemma":[0.99198055,0.005705759,0.0010825996,0.00068334985,0.00023719607,0.0003104843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011645336,0.0016202943,0.0022761857,0.0006027263,0.0003802121,0.0011373911,0.0012261056,0.0017400021,0.009105364],"category_scores_gemma":[0.023500834,0.00042666355,0.007831672,0.00048560067,0.0008849925,0.0011307929,0.0013969942,0.00279494,0.0005202581],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77468973,0.0013631156,0.02036709,0.0073596807,0.121054895,0.00021942201,0.0002678286,0.0048831296,0.0020924201,0.003536248,0.0061756927,0.057990722],"study_design_scores_gemma":[0.41273335,0.15425116,0.11255256,0.002231631,0.22314388,0.0006029379,0.00049577944,0.04499572,0.0052813157,0.023705518,0.019701997,0.00030420956],"about_ca_topic_score_codex":0.0014538385,"about_ca_topic_score_gemma":0.001820696,"teacher_disagreement_score":0.011645336,"about_ca_system_score_codex":0.00089664455,"about_ca_system_score_gemma":0.0009921031,"threshold_uncertainty_score":0.061587155},"labels":[],"label_agreement":null},{"id":"W4385706419","doi":"10.1097/01.hs9.0000967312.24545.68","title":"S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Regimen; Interim analysis; Rituximab; Diffuse large B-cell lymphoma; Randomized controlled trial; Oncology; Lymphoma; Confidence interval","score_opus":0.014219195408720247,"score_gpt":0.2630733071617222,"score_spread":0.24885411175300198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385706419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97839737,0.010535161,0.00048127858,0.0015060009,0.00095546985,0.0022277064,0.0015128276,0.000116916584,0.0042672995],"genre_scores_gemma":[0.9864835,0.0030007756,0.00075011526,0.0016694013,0.0006874509,0.0018564034,0.0023717452,0.00002953436,0.0031510498],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989605,0.0006314093,0.00006842451,0.0001281541,0.000060821116,0.00015059228],"domain_scores_gemma":[0.99917644,0.00027074644,0.00017152604,0.000074267846,0.00003717128,0.00026988258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002289504,0.0013016757,0.002772791,0.00030326875,0.00021027871,0.0011895983,0.0008982311,0.0019048525,0.009359625],"category_scores_gemma":[0.0022385207,0.00034362447,0.002775663,0.00041489355,0.0011608662,0.0011119107,0.00052670797,0.002788515,0.0012710334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9794519,0.0012837818,0.0005395208,0.00076009426,0.0009116169,0.000034569064,0.00003667676,0.00040562623,0.0010979464,0.0001559566,0.000887551,0.014434747],"study_design_scores_gemma":[0.93848157,0.055386383,0.0029730354,0.00015132641,0.0009447008,0.00005190958,0.000032679913,0.00043879924,0.00028637506,0.00032773873,0.0009095796,0.000015875434],"about_ca_topic_score_codex":0.0012078736,"about_ca_topic_score_gemma":0.0029060896,"teacher_disagreement_score":0.009359625,"about_ca_system_score_codex":0.0012867348,"about_ca_system_score_gemma":0.0011798425,"threshold_uncertainty_score":0.031311095},"labels":[],"label_agreement":null},{"id":"W4385707156","doi":"10.1097/01.hs9.0000971348.10013.c4","title":"P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Propensity score matching; Oncology; Internal medicine; Progression-free survival; Rituximab; Population; Overall survival; Lymphoma","score_opus":0.09647680593430397,"score_gpt":0.37119411444094036,"score_spread":0.2747173085066364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88938403,0.048063856,0.018141687,0.0021217433,0.0035308625,0.016608238,0.010657151,0.000366514,0.011125837],"genre_scores_gemma":[0.9797805,0.0019483484,0.0057510845,0.00075136725,0.0002501866,0.007965638,0.0015730729,0.0000343037,0.0019456467],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9873296,0.010129009,0.0008443807,0.00079321547,0.00055876625,0.00034506054],"domain_scores_gemma":[0.9916768,0.006044858,0.0011446738,0.00057043217,0.00028988073,0.0002733374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010710145,0.0017315923,0.0033892244,0.00078939,0.00030298697,0.0011445066,0.0011965203,0.0019523202,0.011711054],"category_scores_gemma":[0.019645095,0.0004332049,0.010540747,0.0006387965,0.00088350073,0.0010928853,0.0014467804,0.002715676,0.0006442788],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75321007,0.0012666844,0.008536615,0.019324543,0.16452947,0.00015949165,0.000274608,0.0031292445,0.0019905556,0.002652508,0.003495262,0.041431054],"study_design_scores_gemma":[0.48833722,0.1240679,0.044524007,0.0031939722,0.28770977,0.00040453827,0.00041732777,0.017992191,0.0040452224,0.014305577,0.014778682,0.00022366158],"about_ca_topic_score_codex":0.0010866259,"about_ca_topic_score_gemma":0.001358687,"teacher_disagreement_score":0.011711054,"about_ca_system_score_codex":0.001023445,"about_ca_system_score_gemma":0.0010371177,"threshold_uncertainty_score":0.05664134},"labels":[],"label_agreement":null},{"id":"W4385707163","doi":"10.1097/01.hs9.0000970568.75232.84","title":"P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Internal medicine; Medicine; Carfilzomib; Multiple myeloma; Oncology; Subgroup analysis; Gastroenterology; Confidence interval; Bortezomib","score_opus":0.04083135418477333,"score_gpt":0.32573524028162926,"score_spread":0.2849038860968559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803155,0.015355587,0.00026851278,0.0005430554,0.000100990896,0.0001623207,0.0023573767,0.000034129756,0.00086252776],"genre_scores_gemma":[0.9903729,0.0038108204,0.00025736867,0.00057148165,0.00017213209,0.00016582364,0.004054221,0.000011303634,0.0005839244],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995378,0.0001923428,0.000042322117,0.000078171404,0.000074751544,0.00007469617],"domain_scores_gemma":[0.99893206,0.0002215684,0.00047054174,0.00007497725,0.000086416556,0.00021439622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018057284,0.0005170531,0.0012508419,0.0002212328,0.00023968733,0.00092575926,0.0004702756,0.0007540391,0.0011130277],"category_scores_gemma":[0.0012446458,0.00016090888,0.002161529,0.00048650225,0.0002683265,0.0005980631,0.0004424053,0.0015687981,0.00030758587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5266106,0.005677601,0.16748473,0.0026415149,0.013248343,0.00037602455,0.0003132053,0.0048969286,0.010140877,0.00022845704,0.008866233,0.2595155],"study_design_scores_gemma":[0.09828088,0.16719487,0.6988998,0.0004463304,0.01665538,0.0011963357,0.00018602626,0.0025952049,0.0031630965,0.00049767067,0.010790109,0.00009431597],"about_ca_topic_score_codex":0.000759491,"about_ca_topic_score_gemma":0.0016637612,"teacher_disagreement_score":0.0018057284,"about_ca_system_score_codex":0.0005428399,"about_ca_system_score_gemma":0.00061748107,"threshold_uncertainty_score":0.009549677},"labels":[],"label_agreement":null},{"id":"W4385707295","doi":"10.1097/01.hs9.0000970420.62475.d0","title":"P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Multiple myeloma; Daratumumab; Cytokine release syndrome; Oncology; Bortezomib; Refractory (planetary science); Gastroenterology; Surgery; Cancer; Clinical trial; Immunotherapy; Chimeric antigen receptor","score_opus":0.019967407386132292,"score_gpt":0.2765928248278406,"score_spread":0.2566254174417083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892764,0.0043896902,0.00034858438,0.0005580942,0.000100086014,0.00020408591,0.0029267392,0.000036204292,0.0021601352],"genre_scores_gemma":[0.99000096,0.0010205023,0.00029110617,0.00091699086,0.00013506024,0.00018717471,0.006184685,0.000011354208,0.0012521838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995796,0.000102716825,0.00004662959,0.000102431964,0.00006246707,0.00010616778],"domain_scores_gemma":[0.998941,0.00016510447,0.0002858837,0.00009463294,0.00011730763,0.00039602994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013811758,0.00027142957,0.0008852687,0.00030968295,0.00059459155,0.00095798605,0.00044264845,0.00067425956,0.0019108097],"category_scores_gemma":[0.0013495852,0.00019080534,0.0010726741,0.00046307236,0.00023817831,0.000723254,0.0006757002,0.0014169794,0.00052333105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1809054,0.004855456,0.5215905,0.0010067547,0.0035988519,0.0033916899,0.00085304567,0.0018998033,0.008117063,0.0003061125,0.020331303,0.25314412],"study_design_scores_gemma":[0.015731752,0.07060373,0.88003165,0.00038978196,0.0035099369,0.0027532922,0.0003284324,0.0016933666,0.0022803901,0.0004414149,0.02216004,0.0000761566],"about_ca_topic_score_codex":0.0015916661,"about_ca_topic_score_gemma":0.0029246067,"teacher_disagreement_score":0.0019108097,"about_ca_system_score_codex":0.0009369556,"about_ca_system_score_gemma":0.0008068998,"threshold_uncertainty_score":0.00730443},"labels":[],"label_agreement":null},{"id":"W4385707424","doi":"10.1097/01.hs9.0000970528.04188.9f","title":"P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; CD38; Medicine; Plasma cell; Internal medicine; Oncology; Bortezomib; Exome sequencing; Cohort; Immunology; Bone marrow; Biology; Gene; Phenotype; Genetics; Stem cell","score_opus":0.028456850265645473,"score_gpt":0.3646396066653157,"score_spread":0.3361827563996702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948571,0.00019295904,0.00019853002,0.00006923034,0.000006125813,0.000015753325,0.0042251507,0.00001487214,0.00042035882],"genre_scores_gemma":[0.99111813,0.0001092029,0.00033226848,0.00009698331,0.000016479735,0.00004868175,0.007563449,0.000021897453,0.0006929919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982184,0.000023318524,0.0000103736065,0.000079462865,0.00003191486,0.000033100798],"domain_scores_gemma":[0.9997688,0.00004073349,0.00008159002,0.000027193522,0.000024692235,0.00005696363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022656698,0.00025470537,0.00033388843,0.0003866562,0.00028208867,0.0006105821,0.00025987034,0.00034490039,0.003261586],"category_scores_gemma":[0.0005909492,0.00012496149,0.0004421894,0.000516075,0.00017636434,0.00016762142,0.00043551117,0.00044066654,0.0006156499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006492098,0.00020538192,0.9178848,0.000095354924,0.000444441,0.00047659775,0.00018880455,0.0005084577,0.049459554,0.00017238427,0.003585624,0.020486517],"study_design_scores_gemma":[0.000145704,0.00052110263,0.9919253,0.000014666295,0.00019459476,0.0011677417,0.0001466236,0.00091166643,0.0023408136,0.00016132472,0.002459737,0.000010739336],"about_ca_topic_score_codex":0.0011606683,"about_ca_topic_score_gemma":0.0017280994,"teacher_disagreement_score":0.003261586,"about_ca_system_score_codex":0.00018923558,"about_ca_system_score_gemma":0.00021891543,"threshold_uncertainty_score":0.010911107},"labels":[],"label_agreement":null},{"id":"W4385723082","doi":"10.1097/01.hs9.0000968448.07133.3e","title":"P385: COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS IN OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH NATIVE VS PEGYLATED ASPARAGINASE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Asparaginase; Adverse effect; Regimen; Internal medicine; Pediatrics; Leukemia; Gastroenterology; Lymphoblastic Leukemia","score_opus":0.023321284646198773,"score_gpt":0.34625746314514005,"score_spread":0.3229361784989413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385723082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99890447,0.0006742967,0.000033333934,0.00001922496,0.000008641363,0.000035351753,0.00016838683,0.0000013941997,0.00015486065],"genre_scores_gemma":[0.999071,0.0003079222,0.000065514534,0.000041763964,0.000024665049,0.00006470275,0.00034639778,7.1496504e-7,0.00007731958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995788,0.00013475658,0.00007137843,0.00008323025,0.00008280335,0.00004904271],"domain_scores_gemma":[0.99884677,0.0002559001,0.00057553424,0.000028908082,0.00007516657,0.00021766355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087105855,0.00023579765,0.00062072044,0.00033879108,0.00016101294,0.00033597462,0.00016005624,0.00028031974,0.00087305903],"category_scores_gemma":[0.0014695744,0.00009821565,0.00073486695,0.00041897257,0.00015967224,0.00033307707,0.00026196495,0.00037898638,0.00009371595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09298025,0.0014403667,0.8643463,0.0005488172,0.0013468527,0.00027143818,0.00022354956,0.0005154613,0.002286659,0.000056661313,0.00036669345,0.035616867],"study_design_scores_gemma":[0.0027806836,0.034727998,0.9591576,0.000051591735,0.0006896101,0.00046368112,0.0001862678,0.0004491992,0.00045424417,0.00004916204,0.0009764707,0.000013569589],"about_ca_topic_score_codex":0.00050371065,"about_ca_topic_score_gemma":0.0005976765,"teacher_disagreement_score":0.00087305903,"about_ca_system_score_codex":0.00043143056,"about_ca_system_score_gemma":0.0002844569,"threshold_uncertainty_score":0.004606664},"labels":[],"label_agreement":null},{"id":"W4385727291","doi":"10.1097/01.hs9.0000970360.06967.6b","title":"P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Interim analysis; Bortezomib; Internal medicine; Adverse effect; Tolerability; Clinical endpoint; Dexamethasone; Gastroenterology; Oncology; Surgery; Clinical trial","score_opus":0.028782846873924205,"score_gpt":0.35307287331456155,"score_spread":0.32429002644063737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385727291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97848547,0.0029047285,0.0018886167,0.0010746369,0.00032295822,0.0047557196,0.0062622433,0.0002594203,0.0040461705],"genre_scores_gemma":[0.9638191,0.0020990188,0.0054710004,0.0019998397,0.00023234094,0.006043891,0.014317811,0.00012476239,0.005892359],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99894613,0.0005363031,0.000050479244,0.0001422,0.00013155614,0.00019336322],"domain_scores_gemma":[0.99882823,0.00019451905,0.00027249532,0.00015671179,0.000118358614,0.0004295834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004633061,0.0013387059,0.0021524336,0.00042575534,0.0005960393,0.00169468,0.0011211844,0.0011561045,0.0036837186],"category_scores_gemma":[0.0020613177,0.00060423405,0.0025139097,0.00040267844,0.0007088572,0.0011023113,0.0005891591,0.0041282927,0.0011768686],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8073718,0.04993618,0.010288439,0.0008150339,0.004788848,0.00023583553,0.00028501044,0.0053055887,0.018716084,0.00052031304,0.011885326,0.08985164],"study_design_scores_gemma":[0.55698335,0.4040879,0.021749277,0.00006650824,0.002120307,0.00034469896,0.00007427226,0.0026075174,0.004484892,0.00059457,0.00683602,0.00005072193],"about_ca_topic_score_codex":0.0009385711,"about_ca_topic_score_gemma":0.0018576558,"teacher_disagreement_score":0.004633061,"about_ca_system_score_codex":0.0011916874,"about_ca_system_score_gemma":0.002429781,"threshold_uncertainty_score":0.024502218},"labels":[],"label_agreement":null},{"id":"W4385739932","doi":"10.1097/01.hs9.0000968596.43178.c6","title":"P422: TARGETING THE WT1MUT-MIR-193A TRANSCRIPTIONAL AXIS WITH INT-1B3, A NOVEL LIPID NANOPARTICLE-FORMULATED MIR-193A-3P MIMIC IN ACUTE MYELOID LEUKEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Cancer research; Myeloid leukemia; DNA methylation; Epigenetics; microRNA; Decitabine; Biology; Methylation; Gene silencing; Leukemia; Gene; Immunology; Gene expression; Genetics","score_opus":0.023723318740459826,"score_gpt":0.27592224410783833,"score_spread":0.25219892536737853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385739932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698795,0.001483819,0.0073338975,0.00018704728,0.000070515314,0.00009970824,0.0004354794,0.00027135914,0.0031303277],"genre_scores_gemma":[0.9919172,0.00066946325,0.0041608615,0.00008943976,0.000010120959,0.00011208528,0.00045180751,0.000049429804,0.0025395958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999199,0.00001022768,0.0000038928665,0.000021616284,0.000029180246,0.00001513756],"domain_scores_gemma":[0.9999819,0.0000023549542,0.0000052363716,0.0000016957523,0.000002655631,0.0000061735973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012123262,0.00030685271,0.00018123207,0.00013161585,0.000116314295,0.00021622633,0.00017501012,0.00032483385,0.00084843923],"category_scores_gemma":[0.00009239981,0.00012713866,0.00018284176,0.00009330782,0.00015705872,0.00014061494,0.00015823632,0.0003511466,0.0003527455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024425055,0.000043471813,0.00007145689,0.000036114157,0.000005890844,0.00004662955,0.000011077845,0.00022116867,0.9962478,0.000100993086,0.00016581427,0.002805206],"study_design_scores_gemma":[0.00006440786,0.00067336444,0.0007026429,0.00000354024,0.000019113897,0.00018895998,0.000009511799,0.002495107,0.9919316,0.00004578452,0.0038585572,0.0000072790244],"about_ca_topic_score_codex":0.00049605063,"about_ca_topic_score_gemma":0.0004675252,"teacher_disagreement_score":0.00084843923,"about_ca_system_score_codex":0.00021569879,"about_ca_system_score_gemma":0.00016453871,"threshold_uncertainty_score":0.0028383136},"labels":[],"label_agreement":null},{"id":"W4385856058","doi":"10.1097/01.hs9.0000971412.45898.1a","title":"P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Regimen; Post-hoc analysis; Internal medicine; Phases of clinical research; Clinical endpoint; Toxicity; Oncology; Nuclear medicine; Clinical trial; Surgery","score_opus":0.027672898584496907,"score_gpt":0.33315772246846176,"score_spread":0.30548482388396486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385856058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930957,0.0025685984,0.00036254284,0.00031825973,0.000053024018,0.00041923,0.0016505455,0.00008432665,0.0014477165],"genre_scores_gemma":[0.9920501,0.0010073328,0.00062109705,0.00031411045,0.00008692231,0.00032722586,0.0043925834,0.000022529457,0.0011780851],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961865,0.00019934996,0.000023884917,0.00006570504,0.00004324084,0.000049150676],"domain_scores_gemma":[0.9994609,0.000102777325,0.00015257842,0.00005503966,0.000041250016,0.00018741426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011823091,0.00054588687,0.0012379775,0.00019271199,0.00019943378,0.0008937253,0.00046569866,0.00052772835,0.0022517026],"category_scores_gemma":[0.00088169397,0.00023842392,0.0008675432,0.00035372746,0.00030432246,0.0006280054,0.00041277628,0.0015951002,0.0005710688],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7068452,0.011394773,0.04691231,0.0014539339,0.003013877,0.00058042246,0.00033716773,0.0035882334,0.042889778,0.00020696112,0.010490611,0.17228672],"study_design_scores_gemma":[0.34340787,0.40607035,0.22247422,0.00015433818,0.0027863963,0.001261194,0.00014590695,0.0030426346,0.0060933465,0.00032392875,0.014151987,0.00008781362],"about_ca_topic_score_codex":0.00041079492,"about_ca_topic_score_gemma":0.0013255986,"teacher_disagreement_score":0.0022517026,"about_ca_system_score_codex":0.0005052126,"about_ca_system_score_gemma":0.0005181632,"threshold_uncertainty_score":0.007532716},"labels":[],"label_agreement":null},{"id":"W4385856750","doi":"10.1097/01.hs9.0000972776.91875.6f","title":"P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Anemia; Hemoglobin; Hemolysis; Clinical endpoint; Pyruvate kinase; Placebo; Pyruvate kinase deficiency; Internal medicine; Randomized controlled trial; Gastroenterology; Clinical trial; Pharmacology; Glycolysis; Pathology; Metabolism","score_opus":0.012357796401671143,"score_gpt":0.2720941681591238,"score_spread":0.2597363717574527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385856750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802935,0.01112477,0.00042394272,0.0009332074,0.00020976961,0.0013364246,0.0022408876,0.000057206238,0.0033802288],"genre_scores_gemma":[0.99102753,0.0029219757,0.00047611995,0.0009247108,0.0003374569,0.001126525,0.0021398547,0.000013379877,0.0010325087],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9993642,0.00038570256,0.00005027265,0.00007676608,0.000046060286,0.00007700343],"domain_scores_gemma":[0.9991155,0.00031804247,0.0002711457,0.00007060695,0.000073913216,0.00015063533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017368887,0.0006835326,0.0014451431,0.00018968232,0.00015845087,0.0009160147,0.00037159794,0.00077106943,0.0032043345],"category_scores_gemma":[0.0020766507,0.00020552086,0.0024164116,0.0003342295,0.00037371545,0.00058036187,0.00033238903,0.0016668458,0.00042818865],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9119245,0.0021092426,0.012632804,0.0024819213,0.0075170505,0.00014019579,0.00011825151,0.00074340665,0.0038266145,0.0004116875,0.004276711,0.053817667],"study_design_scores_gemma":[0.8128154,0.101593785,0.06419786,0.000400578,0.011732032,0.0004820989,0.0001525519,0.0014989742,0.0013186614,0.0009486171,0.00480739,0.00005196226],"about_ca_topic_score_codex":0.00044424165,"about_ca_topic_score_gemma":0.0011870741,"teacher_disagreement_score":0.0032043345,"about_ca_system_score_codex":0.0004892724,"about_ca_system_score_gemma":0.000518575,"threshold_uncertainty_score":0.010719597},"labels":[],"label_agreement":null},{"id":"W4385955561","doi":"10.1097/01.hs9.0000972472.24418.bc","title":"P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; CD33; Plerixafor; Fludarabine; CD34; Myeloid; Hematopoietic stem cell transplantation; Stem cell; Melphalan; Busulfan; Haematopoiesis; Internal medicine; Immunology; Transplantation; Oncology; Chemotherapy; Immune system; CXCR4; Cyclophosphamide; Biology; Chemokine","score_opus":0.013684587279929656,"score_gpt":0.2551828161038957,"score_spread":0.24149822882396604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385955561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991763,0.0009778084,0.0012354092,0.00040357496,0.000101409925,0.00016588796,0.0023142828,0.00020325951,0.0028354495],"genre_scores_gemma":[0.987745,0.0006463497,0.0009434434,0.00022888658,0.000029558058,0.0001494088,0.0045321104,0.000057494766,0.0056678266],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99990225,0.000009014123,0.00000907399,0.000021264712,0.00003194645,0.00002649368],"domain_scores_gemma":[0.9999244,0.000008051534,0.00001831321,0.0000071906506,0.0000059953636,0.00003605881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014734604,0.0003649641,0.00037951153,0.00017335328,0.0002005388,0.0003107038,0.0002459079,0.0003978452,0.008228538],"category_scores_gemma":[0.00011682484,0.000118355165,0.00022055862,0.00016638571,0.00029848644,0.00024474773,0.0002603708,0.0012635299,0.0013874037],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035346977,0.0010338865,0.0013661807,0.00014021157,0.000037097456,0.0004992651,0.000043595664,0.00037627682,0.968113,0.00052126526,0.0026791843,0.02165546],"study_design_scores_gemma":[0.0033271634,0.030203583,0.03890249,0.000051933835,0.00019524926,0.0084052095,0.00014567746,0.003080641,0.8652996,0.0006976249,0.04965017,0.00004068896],"about_ca_topic_score_codex":0.00042293177,"about_ca_topic_score_gemma":0.0005671935,"teacher_disagreement_score":0.008228538,"about_ca_system_score_codex":0.00028320265,"about_ca_system_score_gemma":0.0003037404,"threshold_uncertainty_score":0.027527213},"labels":[],"label_agreement":null},{"id":"W4385955625","doi":"10.1097/01.hs9.0000970028.58190.a6","title":"P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital","funders":"","keywords":"Paroxysmal nocturnal hemoglobinuria; Medicine; Eculizumab; Bone marrow failure; Internal medicine; Myelodysplastic syndromes; Hemoglobinuria; Bone marrow; Aplastic anemia; Gastroenterology; Anemia; Immunology; Complement system; Antibody; Haematopoiesis","score_opus":0.031413617580858234,"score_gpt":0.2932572643693684,"score_spread":0.26184364678851013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385955625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282104,0.0027907554,0.0005581096,0.0005396288,0.000060636696,0.0005673847,0.0007042961,0.000022288237,0.0019359059],"genre_scores_gemma":[0.9963355,0.00062465545,0.00083595904,0.00019539564,0.000101395744,0.0005360991,0.0007390284,0.000009087456,0.00062272203],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9987502,0.00068347435,0.00011351153,0.00014662919,0.00022283987,0.00008331804],"domain_scores_gemma":[0.9983046,0.00063755683,0.00056762807,0.00006436729,0.00015969298,0.00026610968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002978081,0.00048106676,0.001324637,0.00027797424,0.00018707148,0.0005961319,0.00048298942,0.0005309823,0.002332832],"category_scores_gemma":[0.00251192,0.00010750856,0.001040545,0.00032548702,0.00027787936,0.0006455957,0.00032582358,0.0008304644,0.00034143322],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4491332,0.0058199964,0.20543839,0.0018277139,0.004788107,0.00035349198,0.00022374098,0.002993414,0.019746834,0.00039226218,0.004254327,0.30502856],"study_design_scores_gemma":[0.046821475,0.28852016,0.6297377,0.0002815316,0.004348396,0.0011617887,0.00025516827,0.0064218957,0.009705147,0.0008444362,0.0118140485,0.00008828123],"about_ca_topic_score_codex":0.00017896926,"about_ca_topic_score_gemma":0.0005716518,"teacher_disagreement_score":0.002978081,"about_ca_system_score_codex":0.0006110939,"about_ca_system_score_gemma":0.00064026995,"threshold_uncertainty_score":0.015749812},"labels":[],"label_agreement":null},{"id":"W4385955746","doi":"10.1097/01.hs9.0000969496.68553.26","title":"P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Venetoclax; Obinutuzumab; Medicine; Bendamustine; Rituximab; Ibrutinib; Internal medicine; IGHV@; Chlorambucil; Fludarabine; Oncology; Population; Chronic lymphocytic leukemia; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma","score_opus":0.04471865988519662,"score_gpt":0.3370424558678615,"score_spread":0.2923237959826649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385955746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99805045,0.0005278044,0.000070818875,0.00009045217,0.0000047019794,0.000015085932,0.0007426201,0.0000026929474,0.00049534265],"genre_scores_gemma":[0.9987225,0.00023309761,0.000060905284,0.000047813952,0.000015080004,0.000024593743,0.00080065324,0.0000019895197,0.000093256065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992766,0.0002447246,0.00011205569,0.00016638516,0.00010370753,0.00009642665],"domain_scores_gemma":[0.9964663,0.00041062266,0.0025717095,0.000107342144,0.00016597594,0.00027798789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011557692,0.00017877959,0.00024288293,0.0009811653,0.00033830435,0.0009273337,0.00032868484,0.00047095097,0.001398655],"category_scores_gemma":[0.002821683,0.00015009809,0.00037615598,0.0017675236,0.00038220827,0.00088284654,0.00071039004,0.00051897875,0.00023772728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056672236,0.000079611964,0.9954782,0.000030382786,0.00007313119,0.000053528212,0.00010013959,0.00007441025,0.000091378424,0.000021630694,0.00017933152,0.0032514997],"study_design_scores_gemma":[0.000091695605,0.0006492362,0.99664414,0.000041243195,0.00010657306,0.00053717836,0.00045100946,0.00030543673,0.00011390653,0.000047966245,0.0010008082,0.00001071766],"about_ca_topic_score_codex":0.0017288027,"about_ca_topic_score_gemma":0.0017878269,"teacher_disagreement_score":0.0017288027,"about_ca_system_score_codex":0.00061592576,"about_ca_system_score_gemma":0.00039909783,"threshold_uncertainty_score":0.006112337},"labels":[],"label_agreement":null},{"id":"W4386021597","doi":"10.1097/01.hs9.0000968124.64352.6e","title":"S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Medicine; Tolerability; Haemophilia; Haemophilia B; Adverse effect; Clotting factor; Haemophilia A; Clinical endpoint; Internal medicine; Surgery; Clinical trial","score_opus":0.06836513171879907,"score_gpt":0.37283611116258636,"score_spread":0.3044709794437873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386021597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968136,0.004204526,0.0013533601,0.0010515552,0.00023177397,0.009291086,0.008713019,0.000365402,0.0066533326],"genre_scores_gemma":[0.9567177,0.003128561,0.004953651,0.0032794527,0.00024261979,0.013150853,0.009419384,0.00008498679,0.009022931],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99963784,0.00018084017,0.000019448285,0.0000629231,0.000047513196,0.00005142245],"domain_scores_gemma":[0.9995763,0.000072730625,0.000087725355,0.00004031887,0.000054434448,0.00016847116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015859975,0.00095063576,0.0013545196,0.00027468635,0.00047087646,0.00085090974,0.00059623586,0.0014025611,0.014077103],"category_scores_gemma":[0.00084607216,0.00035418977,0.0014103162,0.000312178,0.0006294439,0.00075167377,0.00038025755,0.0022677784,0.00197488],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78192717,0.046026874,0.007861607,0.002496033,0.002078245,0.00037190854,0.00040889927,0.0012262336,0.038636427,0.0007784809,0.014037186,0.104150884],"study_design_scores_gemma":[0.718067,0.25446966,0.016043982,0.00011764884,0.0006368166,0.00043322443,0.00008072026,0.0008115068,0.0018007321,0.00037562847,0.0071232943,0.000039792558],"about_ca_topic_score_codex":0.00092497014,"about_ca_topic_score_gemma":0.0032214152,"teacher_disagreement_score":0.014077103,"about_ca_system_score_codex":0.00058225176,"about_ca_system_score_gemma":0.0014483078,"threshold_uncertainty_score":0.047092557},"labels":[],"label_agreement":null},{"id":"W4386021623","doi":"10.1097/01.hs9.0000967992.84731.80","title":"S270: TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Prenatal Screening and Diagnostics","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Thalassemia; Clinical endpoint; Internal medicine; Blood transfusion; Pediatrics; Clinical trial","score_opus":0.008949082000055683,"score_gpt":0.2283407603991669,"score_spread":0.21939167839911122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386021623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697296,0.01611759,0.00061711896,0.0024023887,0.0003657496,0.00041750065,0.0016441619,0.00011513746,0.008590766],"genre_scores_gemma":[0.9888758,0.0044186995,0.0004743761,0.0013453691,0.0003266847,0.00029135103,0.0015741172,0.000019956022,0.0026737126],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998958,0.00003998814,0.000009698638,0.000015944335,0.000013052539,0.000025465757],"domain_scores_gemma":[0.99972516,0.00007377207,0.00007107653,0.000009356069,0.000019469733,0.0001012574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038913244,0.00020968067,0.00050860306,0.00011522604,0.00016537501,0.00042793568,0.00018094647,0.00036438278,0.007094325],"category_scores_gemma":[0.0005049035,0.00006521453,0.00068953825,0.00016231225,0.00014706685,0.00025461309,0.0001679489,0.0007987022,0.0006723717],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3554657,0.0045669097,0.037564114,0.0029245801,0.0011903094,0.0010201365,0.00028018674,0.0018319953,0.023582097,0.0010575601,0.029107314,0.5414091],"study_design_scores_gemma":[0.23702574,0.4229849,0.19877742,0.0020879486,0.004311954,0.0050353594,0.0004424052,0.00556212,0.02798546,0.0024987566,0.09317851,0.00010946162],"about_ca_topic_score_codex":0.00027412438,"about_ca_topic_score_gemma":0.0006515131,"teacher_disagreement_score":0.007094325,"about_ca_system_score_codex":0.00034485155,"about_ca_system_score_gemma":0.0005163525,"threshold_uncertainty_score":0.0237329},"labels":[],"label_agreement":null},{"id":"W4386021670","doi":"10.1097/01.hs9.0000967980.32472.94","title":"S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Dosing; Pharmacokinetics; Pharmacodynamics; Adverse effect; Clinical trial; Internal medicine; Pediatrics","score_opus":0.019485327373507614,"score_gpt":0.29444070520883964,"score_spread":0.274955377835332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386021670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887841,0.005106739,0.00027639908,0.0002091264,0.00002425068,0.00012101509,0.004492848,0.00003622173,0.00094937015],"genre_scores_gemma":[0.98707575,0.0016024424,0.0006283201,0.0003445825,0.000087211345,0.0001509184,0.0091316905,0.00002205738,0.00095705094],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993561,0.00021047331,0.00006687937,0.00012990067,0.00017779275,0.000059000697],"domain_scores_gemma":[0.9984332,0.0002772449,0.00070699234,0.00009395883,0.00017927629,0.00030938137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017012738,0.00048808483,0.0011267756,0.0002647018,0.00022675973,0.00069232035,0.00037697444,0.00060070696,0.001739337],"category_scores_gemma":[0.0015400713,0.00027911883,0.0011824364,0.00035506405,0.00021021976,0.00047748137,0.0002450536,0.0009672283,0.00065255654],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19727173,0.0044395253,0.6335779,0.0014391737,0.004682178,0.001202984,0.00046740202,0.0036797936,0.036391865,0.00024954925,0.014006561,0.102591306],"study_design_scores_gemma":[0.036532667,0.0887906,0.83966386,0.00021340828,0.002396026,0.0036878036,0.00018871114,0.004097736,0.009011207,0.00022421138,0.015060653,0.00013310487],"about_ca_topic_score_codex":0.00082709856,"about_ca_topic_score_gemma":0.0012435924,"teacher_disagreement_score":0.001739337,"about_ca_system_score_codex":0.00039840292,"about_ca_system_score_gemma":0.0007045265,"threshold_uncertainty_score":0.008997321},"labels":[],"label_agreement":null},{"id":"W4386023903","doi":"10.1097/01.hs9.0000968792.87320.b0","title":"P471: POLO-LIKE KINASE 4 INHIBITION INDUCED ANTI-LEUKAEMIC EFFECTS THROUGH HISTONE MODIFICATION IN TP53 MUTATED ACUTE MYELOID LEUKAEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Health and Medical Research Fund; Innovation and Technology Commission; Li Shu Fan Medical Foundation","keywords":"Biology; Transcriptome; Cancer research; Myeloid leukemia; Gene; Epigenetics; Haematopoiesis; Myeloid; Genetics; Gene expression; Stem cell","score_opus":0.03625720728268949,"score_gpt":0.34509045741194355,"score_spread":0.30883325012925406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386023903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994531,0.0021659601,0.0009820934,0.00013389743,0.000044970373,0.000026792051,0.0012139541,0.00008224374,0.000819201],"genre_scores_gemma":[0.99286747,0.0013229307,0.00094456377,0.00010716613,0.000013557737,0.000052684238,0.002529139,0.000021329393,0.002141154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991024,0.0000076897695,0.0000064273595,0.000023163257,0.000027576021,0.000024972707],"domain_scores_gemma":[0.99996936,0.0000046069963,0.000011996672,0.0000025204465,0.000003349897,0.000008099244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081487386,0.0002572631,0.00031999673,0.00023332865,0.00015200373,0.00022341998,0.00010698699,0.00017125218,0.0020724642],"category_scores_gemma":[0.00007599659,0.00008100571,0.0002706956,0.00025871536,0.00017616131,0.00013116543,0.00014213852,0.00037897698,0.0003285357],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004981116,0.000045007346,0.0006195269,0.00008929643,0.000010528552,0.000052875766,0.000009886292,0.00013717024,0.9953316,0.000034673467,0.000120818295,0.0030504232],"study_design_scores_gemma":[0.00007531515,0.00096311956,0.02487255,0.0000115321,0.000062487954,0.00029305412,0.0000429893,0.0017334706,0.9675954,0.0000865042,0.004257259,0.0000062810554],"about_ca_topic_score_codex":0.00032376597,"about_ca_topic_score_gemma":0.00037305322,"teacher_disagreement_score":0.0020724642,"about_ca_system_score_codex":0.00022409672,"about_ca_system_score_gemma":0.00020899305,"threshold_uncertainty_score":0.0069330335},"labels":[],"label_agreement":null},{"id":"W4386023953","doi":"10.1097/01.hs9.0000969228.34230.b4","title":"P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Azacitidine; Internal medicine; Adverse effect; Myeloid leukemia; Induction chemotherapy; Regimen; Venetoclax; Oncology; Ven; Leukemia; Chemotherapy","score_opus":0.025608959099345466,"score_gpt":0.31400439331626406,"score_spread":0.2883954342169186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386023953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93739694,0.0030076185,0.045844827,0.004836348,0.00022839093,0.0010023732,0.0020210673,0.00018029653,0.005482101],"genre_scores_gemma":[0.9895188,0.0004895897,0.0072998344,0.00034102128,0.000069433416,0.00031007285,0.0006970122,0.000016222579,0.0012578992],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99633336,0.0028834366,0.00008620275,0.00027801763,0.00011880935,0.00030017816],"domain_scores_gemma":[0.9716562,0.025266632,0.0012805137,0.00017422735,0.0004324311,0.001190076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010683532,0.0013795005,0.002700981,0.0010913314,0.0005757902,0.0014323668,0.0012155968,0.0015658783,0.007252443],"category_scores_gemma":[0.015411906,0.0008087676,0.0034371305,0.0005069103,0.00077075313,0.00097613916,0.00130659,0.0026997214,0.00023223778],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010165635,0.00046102403,0.00925209,0.00027336556,0.0008925558,0.00013208874,0.00005963861,0.964124,0.0001853901,0.0043176697,0.00082613627,0.009310238],"study_design_scores_gemma":[0.0007051446,0.0011222251,0.001417497,0.00006845334,0.00050698273,0.00002434177,0.00003061355,0.9929375,0.000095352065,0.0028303706,0.00023940277,0.000022150101],"about_ca_topic_score_codex":0.019977238,"about_ca_topic_score_gemma":0.012532303,"teacher_disagreement_score":0.019977238,"about_ca_system_score_codex":0.0034090425,"about_ca_system_score_gemma":0.00455401,"threshold_uncertainty_score":0.056500614},"labels":[],"label_agreement":null},{"id":"W4386024046","doi":"10.1097/01.hs9.0000968416.51811.f0","title":"P376: VENO-OCCLUSIVE DISEASE RISK AND OTHER OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Hepatic veno-occlusive disease; Salvage therapy; Gastroenterology; Oncology; Transplantation; Surgery; Chemotherapy","score_opus":0.007626346877796342,"score_gpt":0.23954685595891162,"score_spread":0.23192050908111528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993223,0.00008933091,0.000018089044,0.00002890326,0.0000031401685,0.0000068414856,0.00031489824,0.0000010663598,0.00021554336],"genre_scores_gemma":[0.99921215,0.00004463658,0.000022764414,0.000022216285,0.000010407252,0.000008308629,0.00058257725,0.0000011174848,0.000095904856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997439,0.00004879392,0.00003059126,0.00005517819,0.000053507316,0.000068014175],"domain_scores_gemma":[0.9991542,0.00008096923,0.0004271915,0.000029417546,0.000053716092,0.000254496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035116883,0.0001854654,0.00031488194,0.0003945794,0.00033269753,0.00053392816,0.00028358473,0.00033668548,0.001605158],"category_scores_gemma":[0.0010445954,0.00014194458,0.0004541412,0.00081085035,0.00019358585,0.0004367976,0.0003843967,0.00058897183,0.0002850977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007813878,0.00007431039,0.99751556,0.000009128857,0.000031395666,0.00014652923,0.00003623914,0.000053774773,0.00020221804,0.000013507834,0.00012305693,0.0010128713],"study_design_scores_gemma":[0.00006899717,0.00079246203,0.99738914,0.000008946775,0.00004514135,0.00078888744,0.00013153737,0.0002773774,0.0001410423,0.00005183943,0.00029956803,0.000005135026],"about_ca_topic_score_codex":0.0019739622,"about_ca_topic_score_gemma":0.0019501565,"teacher_disagreement_score":0.0019739622,"about_ca_system_score_codex":0.00046522234,"about_ca_system_score_gemma":0.0003871141,"threshold_uncertainty_score":0.0053697824},"labels":[],"label_agreement":null},{"id":"W4386024051","doi":"10.1097/01.hs9.0000967672.15362.d7","title":"S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Oncology; Lenalidomide; Regimen; Expanded access","score_opus":0.014696673516677618,"score_gpt":0.24480891604604155,"score_spread":0.23011224252936394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98274326,0.006130148,0.00048602407,0.0010507625,0.00018304428,0.0012809156,0.0037030478,0.00012137225,0.004301506],"genre_scores_gemma":[0.9802106,0.003864062,0.0009926804,0.0016626399,0.00031767663,0.00085119973,0.007487394,0.00005822072,0.0045555164],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996673,0.00015620155,0.000023975312,0.000041381794,0.000046644494,0.00006457858],"domain_scores_gemma":[0.9995351,0.00008559738,0.0001061741,0.000031435866,0.000037627968,0.00020409284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010578366,0.0009292738,0.0015304207,0.00026677048,0.00025674707,0.0010464386,0.00047279245,0.0009747796,0.005318316],"category_scores_gemma":[0.0008282994,0.00035423183,0.0015798633,0.00032366073,0.00044771793,0.0006916381,0.00032440337,0.0022563771,0.0012585975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7654962,0.023524068,0.013164101,0.0017392628,0.0035968833,0.0004925486,0.00033448584,0.0018498058,0.03129159,0.00036400196,0.012897294,0.1452498],"study_design_scores_gemma":[0.48934293,0.45829067,0.031160176,0.00015790424,0.002467147,0.00094081054,0.000117794996,0.0011543757,0.0047068233,0.00031503665,0.011291535,0.00005485682],"about_ca_topic_score_codex":0.0006479745,"about_ca_topic_score_gemma":0.002427406,"teacher_disagreement_score":0.005318316,"about_ca_system_score_codex":0.0008124874,"about_ca_system_score_gemma":0.00084165815,"threshold_uncertainty_score":0.01779151},"labels":[],"label_agreement":null},{"id":"W4386024071","doi":"10.1097/01.hs9.0000967904.29417.23","title":"S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Fludarabine; Clinical endpoint; Hematopoietic stem cell transplantation; Population; Oncology; Transplantation; Total body irradiation; Randomized controlled trial; Gastroenterology; Surgery; Adverse effect; Chemotherapy; Cyclophosphamide","score_opus":0.031222843112105225,"score_gpt":0.31141390221384274,"score_spread":0.2801910591017375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97708845,0.0073802266,0.0005177924,0.0014048953,0.0004435816,0.0020463907,0.00438388,0.00025496102,0.0064799157],"genre_scores_gemma":[0.98517853,0.0018747167,0.00083604903,0.0011900173,0.00043637236,0.0012923025,0.00444006,0.000039246668,0.004712554],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997008,0.00017130685,0.000019295725,0.00004259125,0.000023912951,0.000042146385],"domain_scores_gemma":[0.99953663,0.00010870953,0.00012269722,0.000036604557,0.00002906837,0.00016628458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095451565,0.00065384706,0.001056628,0.00021954355,0.00016929867,0.0009608705,0.00053916144,0.000837151,0.009356836],"category_scores_gemma":[0.00088102213,0.0002007345,0.0015791466,0.00018534271,0.00043278866,0.0004315155,0.00022091178,0.0016885399,0.0011958327],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9461763,0.0026851974,0.0018043626,0.0012007526,0.0010834434,0.00014062962,0.000046309582,0.0005750383,0.015476969,0.00038617532,0.0049919523,0.025432784],"study_design_scores_gemma":[0.8582559,0.12230864,0.008977583,0.00014943043,0.0017660821,0.0003176493,0.000026410951,0.0005804904,0.002193268,0.00028170604,0.0051157577,0.000027018681],"about_ca_topic_score_codex":0.00041707358,"about_ca_topic_score_gemma":0.0010855746,"teacher_disagreement_score":0.009356836,"about_ca_system_score_codex":0.0003384481,"about_ca_system_score_gemma":0.0005634696,"threshold_uncertainty_score":0.031301677},"labels":[],"label_agreement":null},{"id":"W4386024076","doi":"10.1097/01.hs9.0000967492.06443.0a","title":"S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Obinutuzumab; Venetoclax; Medicine; Chronic lymphocytic leukemia; Internal medicine; Tolerability; Chlorambucil; Bendamustine; Oncology; Hazard ratio; Interquartile range; Clinical endpoint; Leukemia; Gastroenterology; Randomized controlled trial; Cyclophosphamide; Chemotherapy; Adverse effect; Confidence interval","score_opus":0.023674757635716876,"score_gpt":0.31049292788169774,"score_spread":0.2868181702459809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93640393,0.034105435,0.0013350148,0.003311514,0.0010047338,0.005048232,0.012233722,0.00023249735,0.0063248198],"genre_scores_gemma":[0.95414925,0.009549378,0.0025182979,0.004240468,0.0013224913,0.0050305426,0.016210243,0.00009022001,0.00688909],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973303,0.0019359598,0.00016489708,0.0001702636,0.00022040177,0.000178111],"domain_scores_gemma":[0.9961628,0.0011080418,0.0011465701,0.00029400003,0.00041128424,0.00087734737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005346392,0.00072171,0.0019366458,0.00042835702,0.0003681096,0.0013701792,0.00074079284,0.0019879767,0.006415844],"category_scores_gemma":[0.0047968714,0.00031455728,0.0032379401,0.00057854434,0.000478081,0.00080107193,0.0005706202,0.0019249914,0.0011649939],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9171126,0.0043265834,0.00607045,0.0012487045,0.0035381091,0.00006921249,0.000073872885,0.0005989562,0.0026608969,0.00020854945,0.006837138,0.0572549],"study_design_scores_gemma":[0.85710144,0.10220138,0.025434773,0.0003290409,0.0038314292,0.00015211251,0.000052607946,0.00057037163,0.00076130056,0.00029578357,0.009227969,0.000041850974],"about_ca_topic_score_codex":0.0009221486,"about_ca_topic_score_gemma":0.0018457912,"teacher_disagreement_score":0.006415844,"about_ca_system_score_codex":0.00085968786,"about_ca_system_score_gemma":0.0013214251,"threshold_uncertainty_score":0.028274715},"labels":[],"label_agreement":null},{"id":"W4386024134","doi":"10.1097/01.hs9.0000967716.49281.3f","title":"S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Bendamustine; Hazard ratio; Rituximab; Gastroenterology; Confidence interval; Neutropenia; Minimal residual disease; Chronic lymphocytic leukemia; Surgery; Oncology; Leukemia; Chemotherapy; Lymphoma","score_opus":0.02021042823609262,"score_gpt":0.26840182374875443,"score_spread":0.2481913955126618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98344004,0.0024192894,0.00032463064,0.00028981306,0.0000786559,0.0007186548,0.010820949,0.00005171931,0.0018563503],"genre_scores_gemma":[0.9545439,0.0008460092,0.0008201906,0.0009988965,0.00018167999,0.0012203696,0.0398044,0.000034813627,0.0015497121],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9987914,0.00056869665,0.00009725496,0.00021685362,0.00015277548,0.00017300442],"domain_scores_gemma":[0.99831235,0.00029071598,0.00047801906,0.00027335668,0.00022583189,0.00041966027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029052787,0.0006442902,0.0018772252,0.00043210658,0.000495002,0.0010162286,0.0007749655,0.000948488,0.001973331],"category_scores_gemma":[0.0017639768,0.0004044354,0.0024048772,0.00082623283,0.0004656188,0.00058483944,0.0006649994,0.0015182463,0.00061919773],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5158298,0.0074658436,0.33103308,0.0022138683,0.017566185,0.0008255424,0.00087765674,0.0020198699,0.024241721,0.00043210204,0.020407839,0.0770865],"study_design_scores_gemma":[0.10701174,0.07972778,0.7732438,0.00024985042,0.013860225,0.0013228136,0.00031255797,0.0012175363,0.0038045126,0.00040034766,0.018760322,0.00008857761],"about_ca_topic_score_codex":0.0021339394,"about_ca_topic_score_gemma":0.0069235144,"teacher_disagreement_score":0.0029052787,"about_ca_system_score_codex":0.0010912077,"about_ca_system_score_gemma":0.0010827018,"threshold_uncertainty_score":0.015364766},"labels":[],"label_agreement":null},{"id":"W4386024385","doi":"10.1097/01.hs9.0000969552.85501.cf","title":"P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Internal medicine; Myeloid leukemia; Oncology; Clinical endpoint; Clinical trial; Dasatinib; Imatinib","score_opus":0.01797731521387673,"score_gpt":0.2869151710919347,"score_spread":0.26893785587805796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455774,0.000640665,0.0005316507,0.00023232224,0.00011629918,0.0005484447,0.0019725095,0.00007215363,0.0013282214],"genre_scores_gemma":[0.9918349,0.00023750642,0.00080811535,0.00038979197,0.00019953617,0.0009910825,0.0033675474,0.000057542093,0.0021140352],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99579346,0.0026553664,0.00017616173,0.00051825104,0.00035125943,0.00050546735],"domain_scores_gemma":[0.9932389,0.0031933135,0.0016152328,0.00088402384,0.00034867405,0.0007197935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077045923,0.001439067,0.0028128885,0.0004561928,0.0004005244,0.0014130776,0.0011024751,0.0015258008,0.0053833853],"category_scores_gemma":[0.0061595473,0.00043303028,0.0064696567,0.0005123565,0.00095239416,0.0013990026,0.000732018,0.0038457538,0.0008482117],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96240205,0.0038584042,0.009902524,0.0002552565,0.0043225293,0.00007071108,0.00011463627,0.002443048,0.0032877985,0.00009462296,0.0024153732,0.0108329505],"study_design_scores_gemma":[0.30914047,0.51253945,0.13858034,0.000075420285,0.012471709,0.00039902542,0.00026842224,0.0100059565,0.0074650603,0.0006721676,0.008189122,0.00019287798],"about_ca_topic_score_codex":0.0006994332,"about_ca_topic_score_gemma":0.0014481823,"teacher_disagreement_score":0.0077045923,"about_ca_system_score_codex":0.0008783667,"about_ca_system_score_gemma":0.0012670072,"threshold_uncertainty_score":0.040746212},"labels":[],"label_agreement":null},{"id":"W4386024401","doi":"10.1097/01.hs9.0000969148.22118.7f","title":"P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Acute leukemia; Leukemia; Internal medicine; Refractory (planetary science); Myeloid leukemia; Compassionate Use; Oncology; Clinical trial","score_opus":0.038907020654257225,"score_gpt":0.3554261701329259,"score_spread":0.31651914947866866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893813,0.0030232808,0.00057201687,0.0008210969,0.000024414374,0.000100585334,0.00026559609,0.00003213012,0.005779549],"genre_scores_gemma":[0.9932707,0.0029196807,0.0010724078,0.00080471375,0.0000762724,0.00007049068,0.0006443327,0.000019023382,0.0011223721],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997552,0.00010007317,0.000019734352,0.000037388058,0.00003515369,0.000052390886],"domain_scores_gemma":[0.999423,0.0001101337,0.00016218197,0.000026108773,0.000046722125,0.00023184305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008098789,0.00013911432,0.00018103984,0.00010388591,0.00025506454,0.0005073415,0.00022430343,0.00017630128,0.0022014722],"category_scores_gemma":[0.0010612872,0.000062927174,0.00021251237,0.00034077273,0.00021630964,0.00042479328,0.00053561456,0.00041259237,0.0005903038],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009240501,0.0045626047,0.31543058,0.0004794407,0.00017294596,0.0019915327,0.001700641,0.0014897013,0.00842709,0.00090973557,0.011990419,0.6436048],"study_design_scores_gemma":[0.0070408834,0.086676456,0.67280704,0.00071082974,0.00046093826,0.0337317,0.0024975112,0.0051753707,0.014891793,0.0017640776,0.1741541,0.00008930055],"about_ca_topic_score_codex":0.0004899818,"about_ca_topic_score_gemma":0.00090539997,"teacher_disagreement_score":0.0022014722,"about_ca_system_score_codex":0.00061806716,"about_ca_system_score_gemma":0.0005644845,"threshold_uncertainty_score":0.0073646307},"labels":[],"label_agreement":null},{"id":"W4386024479","doi":"10.1097/01.hs9.0000968744.85748.62","title":"P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"NPM1; Medicine; Minimal residual disease; Internal medicine; Oncology; Myeloid leukemia; Bone marrow; Proportional hazards model; Gastroenterology; Karyotype; Biology","score_opus":0.06057304799164782,"score_gpt":0.3564517776467327,"score_spread":0.2958787296550849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975674,0.00069348706,0.0007054826,0.000033332963,0.000007617002,0.00012429495,0.0004209625,0.000018750563,0.00042874564],"genre_scores_gemma":[0.9977429,0.00017204514,0.0007327128,0.000045889657,0.000012410046,0.00009375741,0.0008305805,0.0000058196842,0.00036389354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932456,0.00019163665,0.00006051713,0.00017142785,0.00020515034,0.000046745732],"domain_scores_gemma":[0.99956185,0.000070907525,0.0001840598,0.00006349361,0.000056399178,0.00006325408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012419458,0.00027005273,0.00046818523,0.00024765352,0.00016061764,0.0004627449,0.0003857645,0.00034719319,0.0009902786],"category_scores_gemma":[0.00059252605,0.00011938106,0.00039490263,0.00024525114,0.00028757864,0.00019660097,0.00029661896,0.00034632706,0.00019496439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10274195,0.002411718,0.43954656,0.0007841911,0.0018120507,0.0003368113,0.00034585936,0.001623724,0.28802258,0.0003512216,0.0010487004,0.16097459],"study_design_scores_gemma":[0.0034467415,0.06659722,0.84329784,0.00004215891,0.0021668987,0.002085229,0.00013636034,0.0032882153,0.071644746,0.000242133,0.007022855,0.000029631483],"about_ca_topic_score_codex":0.00034330034,"about_ca_topic_score_gemma":0.00040656223,"teacher_disagreement_score":0.0012419458,"about_ca_system_score_codex":0.0004029576,"about_ca_system_score_gemma":0.0002202921,"threshold_uncertainty_score":0.006568134},"labels":[],"label_agreement":null},{"id":"W4386024524","doi":"10.1097/01.hs9.0000968592.70537.d0","title":"P421: TARGETED DISRUPTION OF HUMAN FLT3 ERADICATES LEUKEMIC STEM CELLS WITHOUT HARMING HEALTHY HEMATOPOIETIC STEM CELLS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; Haematopoiesis; Leukemia; Cancer research; Bone marrow; Myeloid leukemia; Biology; Immunology; Xenotransplantation; Hematopoietic stem cell; Transplantation; Medicine; Internal medicine; Cell biology","score_opus":0.039720430632781134,"score_gpt":0.3205576568430557,"score_spread":0.28083722621027457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98141277,0.0012612112,0.01041672,0.00028280466,0.0000769732,0.000070530245,0.0018806551,0.00072691264,0.0038713128],"genre_scores_gemma":[0.9887578,0.0006813298,0.0038384006,0.00010541885,0.000011414198,0.000069347734,0.001369594,0.00012579883,0.005040865],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985373,0.000011653158,0.000011655981,0.000041963514,0.000054703913,0.00002619234],"domain_scores_gemma":[0.99993396,0.000010786438,0.00002490352,0.000008732325,0.0000043353652,0.000017366798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012949752,0.0004814778,0.00023874921,0.00018862149,0.00019122277,0.0003315042,0.00025075607,0.00040027036,0.0024918753],"category_scores_gemma":[0.00008902259,0.000110316556,0.00024081065,0.00014251596,0.00038115706,0.00015496921,0.0002560797,0.00056549016,0.0007447554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056597913,0.000019142544,0.000085382584,0.000031612894,0.000004401622,0.00007916927,0.000011416155,0.00010925067,0.9980724,0.00015709351,0.000109634755,0.0012638473],"study_design_scores_gemma":[0.000020677124,0.00014848197,0.001247152,0.000005927418,0.00001515393,0.00047597018,0.000013729907,0.0009571319,0.9908405,0.00007727674,0.0061929235,0.000005199326],"about_ca_topic_score_codex":0.00064723234,"about_ca_topic_score_gemma":0.000813959,"teacher_disagreement_score":0.0024918753,"about_ca_system_score_codex":0.0002762377,"about_ca_system_score_gemma":0.00033928012,"threshold_uncertainty_score":0.008336127},"labels":[],"label_agreement":null},{"id":"W4386024586","doi":"10.1097/01.hs9.0000968552.93087.6b","title":"P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Internal medicine; Medicine; NPM1; Oncology; Myeloid leukemia; Azacitidine; Cytogenetics; Gastroenterology; Randomization; Bone marrow; Myeloid; Clinical trial; Gene; Biology; Genetics; DNA methylation; Karyotype","score_opus":0.02367151887753247,"score_gpt":0.2916650467869095,"score_spread":0.267993527909377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99499977,0.0019869886,0.00026010495,0.00027387068,0.000028354347,0.00017664269,0.0016296506,0.000014968418,0.00062968425],"genre_scores_gemma":[0.9963791,0.0003402548,0.00016939249,0.00020549729,0.00006466431,0.00025733697,0.0021895973,0.000009594467,0.00038463573],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99752325,0.0015486103,0.00011361745,0.00045370482,0.00018383056,0.00017698582],"domain_scores_gemma":[0.9973671,0.00075593055,0.0008446549,0.0005087437,0.00014942679,0.0003741628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051933723,0.00058887166,0.0011163763,0.00022762513,0.00036875063,0.000840217,0.000760172,0.0008066242,0.0022108783],"category_scores_gemma":[0.0031058164,0.0002858396,0.0012842598,0.00062866387,0.00042725273,0.0006536514,0.0007056366,0.0013449853,0.00039118275],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62282974,0.0016029535,0.30040988,0.00097292487,0.0134946825,0.00023282778,0.0002956283,0.0013183744,0.008968319,0.0004625928,0.005169625,0.044242386],"study_design_scores_gemma":[0.07640303,0.044592384,0.8560199,0.000105078354,0.011262523,0.00054611266,0.00023983409,0.0022910058,0.002202809,0.00091893284,0.005341044,0.000077453326],"about_ca_topic_score_codex":0.00054729957,"about_ca_topic_score_gemma":0.0006881576,"teacher_disagreement_score":0.0051933723,"about_ca_system_score_codex":0.0004454812,"about_ca_system_score_gemma":0.00044711228,"threshold_uncertainty_score":0.027465463},"labels":[],"label_agreement":null},{"id":"W4386024691","doi":"10.1097/01.hs9.0000968580.70418.79","title":"P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Myeloid leukemia; Cancer research; Cytarabine; Leukemia; MCL1; Integrated stress response; Biology; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gene; Genetics; Downregulation and upregulation; Translation (biology)","score_opus":0.03089501745174479,"score_gpt":0.2949990361260349,"score_spread":0.2641040186742901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684566,0.0009284686,0.0008077483,0.00006337611,0.000007974341,0.00003836597,0.0004907036,0.000052812564,0.00076483836],"genre_scores_gemma":[0.99852115,0.0002840458,0.00034002736,0.000028635453,0.000005308354,0.00002120994,0.00042780646,0.0000068744885,0.0003648817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988747,0.00001792094,0.0000075387643,0.00003730139,0.000031004944,0.000018825707],"domain_scores_gemma":[0.9998815,0.000017539018,0.00006520415,0.000010673153,0.0000061643354,0.000018823888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001799451,0.00026114177,0.00027983027,0.00022881976,0.00014620024,0.00031873042,0.00017211372,0.00022943997,0.0023069747],"category_scores_gemma":[0.00017099958,0.00010541509,0.00015270921,0.00021461726,0.0001995698,0.00011950281,0.00019106624,0.0003818523,0.00028741307],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040909993,0.00030462744,0.060467944,0.0002188199,0.00007517553,0.0020932697,0.000092309856,0.00090033974,0.8915142,0.0004955768,0.0009937977,0.038753],"study_design_scores_gemma":[0.0005198503,0.0054379166,0.53614277,0.00007907113,0.00035899493,0.02460915,0.00021359256,0.005440676,0.40934047,0.00094730884,0.016873738,0.00003645306],"about_ca_topic_score_codex":0.00015048703,"about_ca_topic_score_gemma":0.00026468668,"teacher_disagreement_score":0.0023069747,"about_ca_system_score_codex":0.00024977562,"about_ca_system_score_gemma":0.00016216499,"threshold_uncertainty_score":0.00771755},"labels":[],"label_agreement":null},{"id":"W4386052241","doi":"10.1097/01.hs9.0000969572.68411.a2","title":"P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Discontinuation; Medicine; Myeloid leukemia; Internal medicine; Observational study; Clinical endpoint; Cohort; Oncology; Pediatrics; Clinical trial","score_opus":0.028180351054470837,"score_gpt":0.33715202625971846,"score_spread":0.3089716752052476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977805,0.00057450496,0.00025596432,0.000029827715,0.0000068917257,0.000032800635,0.00096974627,0.0000047938415,0.00034497067],"genre_scores_gemma":[0.9984444,0.00009383496,0.00011268564,0.000018140254,0.00001616383,0.000022393968,0.0011387137,0.000003099229,0.00015055096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991041,0.00039330538,0.000077379904,0.00018217806,0.00014843933,0.00009462104],"domain_scores_gemma":[0.9967939,0.0009384036,0.0014120578,0.00029107794,0.00019469408,0.00036997854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026651605,0.00037278977,0.0004717858,0.0005133579,0.00018912465,0.00069033843,0.00038509487,0.0004837977,0.0011866699],"category_scores_gemma":[0.003706605,0.00016333912,0.0016100775,0.00065423845,0.00015790368,0.00042754135,0.00061517366,0.0005981823,0.0001590999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008340006,0.00008047091,0.98660976,0.00006318499,0.0005827382,0.000068051035,0.000036742545,0.00026278468,0.0002379393,0.000048290625,0.0001594002,0.003510768],"study_design_scores_gemma":[0.0003224336,0.0022000785,0.9939573,0.000018712644,0.0006196416,0.0003135669,0.0001040669,0.0015096797,0.00013137977,0.00008225299,0.0007309021,0.000009901599],"about_ca_topic_score_codex":0.0008654374,"about_ca_topic_score_gemma":0.00073283294,"teacher_disagreement_score":0.0026651605,"about_ca_system_score_codex":0.00022316216,"about_ca_system_score_gemma":0.0002929089,"threshold_uncertainty_score":0.014094889},"labels":[],"label_agreement":null},{"id":"W4386052329","doi":"10.1097/01.hs9.0000970512.51896.93","title":"P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Carfilzomib; Medicine; Tolerability; Internal medicine; Multiple myeloma; Lenalidomide; Dexamethasone; Adverse effect; Oncology; Gastroenterology","score_opus":0.10469259072811767,"score_gpt":0.41219825223623924,"score_spread":0.3075056615081216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96823525,0.012764789,0.0008144303,0.0019629446,0.00052959286,0.00433276,0.004380482,0.00041676385,0.006563038],"genre_scores_gemma":[0.9693058,0.007040761,0.0021877205,0.002699665,0.0006471307,0.00422015,0.0065433215,0.00006137015,0.007294137],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99968624,0.00013137443,0.000015952215,0.00004113265,0.00003276886,0.00009256613],"domain_scores_gemma":[0.9995696,0.000056068355,0.00010692646,0.000026254336,0.000018925588,0.00022218945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014617395,0.0012776629,0.0014377403,0.00041028083,0.00032649646,0.0009776889,0.0008390329,0.0015179261,0.005880115],"category_scores_gemma":[0.00058466825,0.0004258038,0.0010771151,0.00032740383,0.0004907968,0.000815371,0.00032130082,0.002603906,0.0013466586],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7326664,0.043831885,0.004511614,0.0014761281,0.001550046,0.00065008603,0.00022477665,0.0020825046,0.02150345,0.00031323705,0.016231172,0.17495875],"study_design_scores_gemma":[0.714058,0.26342002,0.012477416,0.00011356158,0.00055453536,0.0005532473,0.000042030973,0.000987775,0.002243353,0.00025247218,0.005268179,0.000029509658],"about_ca_topic_score_codex":0.0009875933,"about_ca_topic_score_gemma":0.0031211267,"teacher_disagreement_score":0.005880115,"about_ca_system_score_codex":0.0006727255,"about_ca_system_score_gemma":0.0010594219,"threshold_uncertainty_score":0.019670963},"labels":[],"label_agreement":null},{"id":"W4386052515","doi":"10.1097/01.hs9.0000970592.64148.2c","title":"P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Population; Logistic regression; Multiple myeloma; Inverse probability weighting; Internal medicine; Relative risk; Propensity score matching; Confidence interval; Environmental health","score_opus":0.12420305222523104,"score_gpt":0.4449858585240313,"score_spread":0.32078280629880024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873487,0.0024643692,0.0016285402,0.00017800974,0.00011512776,0.00013119895,0.007182867,0.00003861979,0.0009124921],"genre_scores_gemma":[0.9938922,0.00014314297,0.0006697568,0.00009023739,0.000049229755,0.00026698413,0.0042378446,0.000022976992,0.00062763185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98619384,0.008417827,0.0010525138,0.00229187,0.0012553253,0.00078860694],"domain_scores_gemma":[0.9785891,0.011337311,0.005760005,0.002850231,0.00058302673,0.000880175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013362314,0.0010682279,0.001448456,0.0010998637,0.00030193044,0.0011883473,0.0019868312,0.001034249,0.0052213217],"category_scores_gemma":[0.02021952,0.0004452377,0.0060666464,0.0019291376,0.00055127614,0.0011080576,0.0016322285,0.0016710787,0.00029438737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071361266,0.00044316365,0.841592,0.0012368659,0.063712806,0.00031160898,0.0003496953,0.0025022458,0.0018969554,0.00062597526,0.0034484114,0.012518951],"study_design_scores_gemma":[0.0026087817,0.0077899327,0.9682514,0.00009382662,0.013707634,0.00020682516,0.000311327,0.0037171592,0.0006672204,0.0003395397,0.002256903,0.00004940931],"about_ca_topic_score_codex":0.005109573,"about_ca_topic_score_gemma":0.0041688285,"teacher_disagreement_score":0.013362314,"about_ca_system_score_codex":0.0005768176,"about_ca_system_score_gemma":0.0005952048,"threshold_uncertainty_score":0.070667565},"labels":[],"label_agreement":null},{"id":"W4386056422","doi":"10.1097/01.hs9.0000972800.74418.67","title":"P1479: COMORBIDITIES AND COMPLICATIONS IN ADULTS WITH PYRUVATE KINASE DEFICIENCY ACCORDING TO HEMOGLOBIN STRATA – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Pyruvate kinase deficiency; Anemia; Internal medicine; Cohort; Hemoglobin; Pediatrics; Pyruvate kinase; Gastroenterology","score_opus":0.031007830066508996,"score_gpt":0.2682154489006635,"score_spread":0.2372076188341545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386056422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981767,0.0006744429,0.00015132311,0.00008850968,0.000010588813,0.000058730293,0.01589551,0.000014928176,0.0013389498],"genre_scores_gemma":[0.98105985,0.0006706366,0.00018921496,0.00011905708,0.000040296873,0.00014669473,0.017461557,0.000010314488,0.0003022986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995296,0.000064495514,0.00010603125,0.00011830762,0.0001096519,0.00007199203],"domain_scores_gemma":[0.99866116,0.00018597009,0.00078264077,0.00008407707,0.00014909182,0.00013713136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004710394,0.0001460999,0.00041433368,0.0012143296,0.000222498,0.000452453,0.00031940086,0.00025731046,0.0017622707],"category_scores_gemma":[0.00154559,0.00017932062,0.00046766916,0.002260019,0.00011982883,0.00050015276,0.000537952,0.00041705967,0.00036733382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018602333,0.000022395456,0.99689615,0.00003413366,0.000062954256,0.00006189366,0.000035126413,0.00003619036,0.00008161101,0.000024771907,0.0009618044,0.0015968896],"study_design_scores_gemma":[0.000019229003,0.000079583595,0.9984372,0.000023082022,0.000043069507,0.0003916414,0.00016938888,0.00016466655,0.000037281694,0.000021634436,0.0006091952,0.000004021817],"about_ca_topic_score_codex":0.002893587,"about_ca_topic_score_gemma":0.0034717973,"teacher_disagreement_score":0.002893587,"about_ca_system_score_codex":0.00020720731,"about_ca_system_score_gemma":0.0003915635,"threshold_uncertainty_score":0.005895376},"labels":[],"label_agreement":null},{"id":"W4386067267","doi":"10.1097/01.hs9.0000971056.91985.c2","title":"P1040: FACTORS ASSOCIATED WITH THROMBOSIS IN MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Polycythemia vera; Internal medicine; Hazard ratio; Thrombosis; Population; Incidence (geometry); Diabetes mellitus; Proportional hazards model; Surgery; Confidence interval; Bone marrow","score_opus":0.06777147028570386,"score_gpt":0.29968683444939304,"score_spread":0.23191536416368919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386067267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041325,0.0048067123,0.00023503395,0.00066766865,0.00005577501,0.00003088763,0.0016258099,0.000016157397,0.0021488338],"genre_scores_gemma":[0.9970829,0.00078486255,0.00024821018,0.00009230209,0.00017886404,0.00002050294,0.0008625206,0.000004669719,0.00072512886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997501,0.00007502161,0.000037513724,0.000034699886,0.00006385336,0.00003874287],"domain_scores_gemma":[0.9987118,0.00026232717,0.000749366,0.000023529967,0.00008561199,0.00016743976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004591203,0.00020386309,0.00020662864,0.00067365356,0.00025235798,0.0004328132,0.00025246918,0.00036101398,0.0054501225],"category_scores_gemma":[0.0021163276,0.000084034335,0.00030762865,0.0012833232,0.00019183164,0.00029501674,0.00027804953,0.00049857626,0.00042877725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018091785,0.000029784378,0.9925809,0.00008177541,0.000029342698,0.00038805202,0.000045709618,0.000043917193,0.00019061683,0.000038928112,0.0008187491,0.0055712676],"study_design_scores_gemma":[0.000015892534,0.00018243318,0.9945785,0.00006538609,0.000069934154,0.0031931836,0.0000760684,0.0002554197,0.000118059885,0.00010346674,0.0013375315,0.0000040399373],"about_ca_topic_score_codex":0.0013657113,"about_ca_topic_score_gemma":0.001330159,"teacher_disagreement_score":0.0054501225,"about_ca_system_score_codex":0.00020387006,"about_ca_system_score_gemma":0.0005565101,"threshold_uncertainty_score":0.018232524},"labels":[],"label_agreement":null},{"id":"W4386067414","doi":"10.1097/01.hs9.0000971928.33191.75","title":"P1260: BIODISTRIBUTION OF LABELED AUTOLOGOUS AND ALLOGENEIC BONE MARROW MESENCHYMAL STROMAL CELLS IN RABBITS AFTER INTRAVENOUS ADMINISTRATION","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Mesenchymal stem cell research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biodistribution; Mesenchymal stem cell; Bone marrow; Spleen; Stromal cell; Transplantation; Chemistry; Pathology; Medicine; Molecular biology; Immunology; Biology; Internal medicine; In vitro","score_opus":0.01974192186846984,"score_gpt":0.28189397711218633,"score_spread":0.2621520552437165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386067414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98095936,0.003662034,0.007253988,0.00019114572,0.00016126799,0.00022754364,0.0007327228,0.0002999114,0.0065119867],"genre_scores_gemma":[0.9674106,0.0043428517,0.007986135,0.00018101066,0.00013498426,0.00037893027,0.0020466186,0.00014165843,0.01737729],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99965525,0.00004321777,0.00003520949,0.00010493894,0.00008450556,0.000076945755],"domain_scores_gemma":[0.99965703,0.00006198503,0.0001245622,0.00004984482,0.000042075542,0.00006453962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005583123,0.00063891616,0.00040887212,0.00086768705,0.00025025665,0.00045069153,0.00034973235,0.0007639883,0.001913375],"category_scores_gemma":[0.00033053852,0.00024647525,0.0005011671,0.00047386088,0.0005413639,0.0006166997,0.00022898737,0.00084969815,0.001199601],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019029877,0.00054299267,0.00072236086,0.00013587768,0.00001678894,0.00033659057,0.00010804133,0.00012286488,0.98647654,0.00034937018,0.0002346451,0.009050875],"study_design_scores_gemma":[0.00009617748,0.0106298085,0.0048083104,0.000027221766,0.000069286725,0.0011202657,0.000055221604,0.0010725163,0.9772003,0.00014334393,0.004758501,0.00001893735],"about_ca_topic_score_codex":0.0005702879,"about_ca_topic_score_gemma":0.00045326632,"teacher_disagreement_score":0.001913375,"about_ca_system_score_codex":0.00033546143,"about_ca_system_score_gemma":0.00038484987,"threshold_uncertainty_score":0.006400883},"labels":[],"label_agreement":null},{"id":"W4386071127","doi":"10.1097/01.hs9.0000971044.20101.d8","title":"P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Internal medicine; Exacerbation; Gastroenterology; Anemia; Bone marrow","score_opus":0.012963645255667799,"score_gpt":0.2547533797614052,"score_spread":0.24178973450573743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386071127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622756,0.02232241,0.00044068389,0.0021469344,0.00014556013,0.00021801083,0.0017690929,0.00006653192,0.0106151],"genre_scores_gemma":[0.99375653,0.0024646271,0.00049135875,0.0007181605,0.0001872669,0.000101352074,0.0014777352,0.000012753629,0.0007901317],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996923,0.000104457555,0.000055031513,0.000055221193,0.00006672837,0.000026236683],"domain_scores_gemma":[0.9992384,0.00025672658,0.00021899257,0.000038634586,0.000118804455,0.00012852871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009190365,0.00016038377,0.0005596768,0.00016950561,0.00014847264,0.00044482303,0.00023837098,0.00023089012,0.0044619995],"category_scores_gemma":[0.0016420668,0.000066332024,0.0004488786,0.00031242036,0.000105253785,0.00032139578,0.00018805618,0.00054105103,0.0005208366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053530395,0.0012657051,0.20485392,0.001981253,0.0013912795,0.00087603636,0.00021173105,0.0007154174,0.017127365,0.00045431007,0.015691025,0.7019017],"study_design_scores_gemma":[0.02912481,0.07125198,0.833255,0.0010304283,0.0029935888,0.0063152043,0.00049281947,0.0027971563,0.012445045,0.00083012384,0.039405175,0.000058773807],"about_ca_topic_score_codex":0.00032033646,"about_ca_topic_score_gemma":0.0008928772,"teacher_disagreement_score":0.0044619995,"about_ca_system_score_codex":0.00037588517,"about_ca_system_score_gemma":0.00046992136,"threshold_uncertainty_score":0.01492691},"labels":[],"label_agreement":null},{"id":"W4386074452","doi":"10.1097/01.hs9.0000970600.40043.b8","title":"P924: TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A REAL-WORLD OBSERVATIONAL CHART REVIEW STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Pediatrics","score_opus":0.0849770091517209,"score_gpt":0.35531216676179295,"score_spread":0.27033515761007204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386074452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806059,0.0023936096,0.00014036016,0.0002526565,0.000013174561,0.00019637014,0.014900424,0.000018172297,0.0014792273],"genre_scores_gemma":[0.99415743,0.0010416517,0.00019428712,0.0001298276,0.000011579466,0.00007773156,0.0042164153,0.000006003637,0.00016505847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981229,0.00029578898,0.00040438506,0.00043039545,0.00050169596,0.00024481717],"domain_scores_gemma":[0.9886531,0.0012451763,0.0067365165,0.00032245804,0.0022118033,0.00083088974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011092178,0.00024925225,0.00042798356,0.0027997964,0.00092667836,0.0013190749,0.00072736526,0.0003721047,0.0014329446],"category_scores_gemma":[0.00521995,0.00026503793,0.00045044892,0.00835843,0.00050726655,0.00062865246,0.00076903275,0.00041600605,0.0001757273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052169984,0.00001542942,0.996849,0.00008095695,0.000049837712,0.00012116935,0.00027886112,0.000026391075,0.000051666142,0.000022279091,0.0009694366,0.0014828257],"study_design_scores_gemma":[0.000008773924,0.000027680468,0.99729997,0.00008022169,0.0000406998,0.0003229369,0.0009574548,0.00011455884,0.000057162993,0.000007490727,0.0010746045,0.000008445907],"about_ca_topic_score_codex":0.39930978,"about_ca_topic_score_gemma":0.43378863,"teacher_disagreement_score":0.60069025,"about_ca_system_score_codex":0.004732848,"about_ca_system_score_gemma":0.006473096,"threshold_uncertainty_score":0.79397106},"labels":[],"label_agreement":null},{"id":"W4386074681","doi":"10.1097/01.hs9.0000970832.89903.8f","title":"P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Medicine; Multiple myeloma; Refractory (planetary science); Bortezomib; Internal medicine; Gastroenterology; Oncology","score_opus":0.029152733148670517,"score_gpt":0.30257578674165714,"score_spread":0.27342305359298663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386074681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723995,0.00078677334,0.000106992484,0.0001582132,0.00004769469,0.00017132738,0.0002791416,0.00007286213,0.0011370316],"genre_scores_gemma":[0.99642307,0.00058282545,0.00029155382,0.0001622633,0.00008509448,0.0001888404,0.00046008086,0.000018321769,0.0017878931],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99982893,0.000051089148,0.000011764037,0.000043396194,0.00002817184,0.00003664272],"domain_scores_gemma":[0.99981827,0.00003111526,0.000043189502,0.000014068122,0.000008989296,0.00008454312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035579733,0.0004915269,0.001047988,0.00028081084,0.00018981133,0.00071959605,0.0005054527,0.00066212704,0.0053306227],"category_scores_gemma":[0.00044126195,0.0002342917,0.0006508884,0.00019668984,0.00042199448,0.0005598742,0.00024849767,0.0016161505,0.00095653534],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6508136,0.043831214,0.0049933325,0.0005573924,0.00063912524,0.00029706425,0.000216124,0.002060737,0.08444821,0.0002459488,0.0038405138,0.20805678],"study_design_scores_gemma":[0.2558713,0.6827497,0.02880392,0.00007646549,0.00066735863,0.0006942725,0.000099585144,0.004188411,0.02120093,0.00028448494,0.0053136623,0.00005004161],"about_ca_topic_score_codex":0.00042158656,"about_ca_topic_score_gemma":0.0008157378,"teacher_disagreement_score":0.0053306227,"about_ca_system_score_codex":0.00041271036,"about_ca_system_score_gemma":0.0004928342,"threshold_uncertainty_score":0.017832696},"labels":[],"label_agreement":null},{"id":"W4386074702","doi":"10.1097/01.hs9.0000971004.26914.cb","title":"P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Discontinuation; Phases of clinical research; Clinical endpoint; Gastroenterology; Oncology; Bone marrow; Clinical trial","score_opus":0.012602810886682003,"score_gpt":0.2505186048097666,"score_spread":0.23791579392308462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386074702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91340107,0.045211535,0.0012826878,0.0032755986,0.000531327,0.0013135053,0.020706618,0.00054672844,0.013730785],"genre_scores_gemma":[0.9480463,0.011483608,0.00154952,0.0036905883,0.0009376492,0.0010024939,0.02906512,0.00008085153,0.0041437517],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99924743,0.0002889455,0.00010331951,0.00009665806,0.00018118983,0.00008253013],"domain_scores_gemma":[0.99786735,0.0004483656,0.000953942,0.00012940555,0.0002996731,0.00030130448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002466868,0.0005721132,0.001686925,0.0005127068,0.0002884403,0.0014664228,0.00064407283,0.0009477255,0.0042745946],"category_scores_gemma":[0.0021108596,0.0002539159,0.0016175545,0.0007328402,0.00025179246,0.00090880226,0.00036112656,0.0018762953,0.0009989333],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31962243,0.0052273152,0.0675997,0.005043425,0.006738796,0.0005406495,0.00026118048,0.0029302384,0.026884576,0.0004999221,0.04626725,0.5183845],"study_design_scores_gemma":[0.18933742,0.22311856,0.46587855,0.0016288927,0.0132888695,0.0034802624,0.0002586448,0.005380167,0.014553584,0.001303132,0.081574686,0.00019722783],"about_ca_topic_score_codex":0.0005543494,"about_ca_topic_score_gemma":0.0017683811,"teacher_disagreement_score":0.0042745946,"about_ca_system_score_codex":0.0009334517,"about_ca_system_score_gemma":0.0007757894,"threshold_uncertainty_score":0.014299989},"labels":[],"label_agreement":null},{"id":"W4386086931","doi":"10.1097/01.hs9.0000973480.97414.1e","title":"P1652: SAFETY OF DOACS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Kidney disease; Internal medicine; Odds ratio; Randomized controlled trial; Atrial fibrillation; Meta-analysis; Regimen; Intensive care medicine","score_opus":0.1055429017719886,"score_gpt":0.3659588355980062,"score_spread":0.2604159338260176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386086931","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045476793,0.9926764,0.0003997903,0.00029450757,0.00017190077,0.00038062438,0.0011735819,0.00002435573,0.00033110988],"genre_scores_gemma":[0.1630976,0.8289763,0.0021582157,0.0012712876,0.00043520244,0.0017597884,0.0016926078,0.00003650709,0.00057248684],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9912607,0.0034305074,0.0030399307,0.00088658836,0.0010894465,0.0002927344],"domain_scores_gemma":[0.9804993,0.013492606,0.0037693148,0.00048510346,0.0015066211,0.0002470875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010543691,0.002171097,0.016401408,0.006348167,0.0006541549,0.0033245175,0.0017121044,0.0022869054,0.0054336293],"category_scores_gemma":[0.029785534,0.0010908663,0.03189516,0.007774119,0.00060419063,0.0015470432,0.0014070106,0.001644545,0.0004213887],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017954579,0.000023623412,0.0036916302,0.5241344,0.45869425,0.000097465956,0.000067401976,0.00029214285,0.00017497237,0.000094044764,0.0009593952,0.009975223],"study_design_scores_gemma":[0.0007999489,0.00018268148,0.004666092,0.037780028,0.95380336,0.000107856926,0.00003884101,0.00016788737,0.00010624918,0.0001696412,0.0021511246,0.000026277834],"about_ca_topic_score_codex":0.0072070034,"about_ca_topic_score_gemma":0.01332664,"teacher_disagreement_score":0.016401408,"about_ca_system_score_codex":0.0023654834,"about_ca_system_score_gemma":0.0036118357,"threshold_uncertainty_score":0.05576104},"labels":[],"label_agreement":null},{"id":"W4386086960","doi":"10.1097/01.hs9.0000974964.49920.9c","title":"PB2039: INFLAMMATORY MARKERS IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS - A SINGLE CENTRE STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Hemophagocytic lymphohistiocytosis; Cytokine storm; Immunology; Macrophage activation syndrome; Pathological; Interleukin 6; Cytokine; Disease; Internal medicine; Coronavirus disease 2019 (COVID-19)","score_opus":0.02510371736495814,"score_gpt":0.285268429296139,"score_spread":0.26016471193118085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386086960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978923,0.0009539582,0.00008344486,0.000040686202,0.000012389765,0.0000788161,0.00023600616,0.0000043184464,0.00069818366],"genre_scores_gemma":[0.99875593,0.00041313856,0.00007039137,0.00008150316,0.00006323522,0.000039739316,0.00028345734,0.0000039771257,0.00028862825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999476,0.00013800699,0.00008330379,0.00013132826,0.00007635016,0.000095019306],"domain_scores_gemma":[0.99897814,0.00018736073,0.00038612407,0.00006635831,0.00010215305,0.00027986747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005555013,0.0004984905,0.0005949436,0.00093135505,0.00057962694,0.0007928681,0.0003937651,0.0006622028,0.004253044],"category_scores_gemma":[0.0013003788,0.00044388502,0.00055777293,0.0011617894,0.00032938688,0.00068007136,0.0006854727,0.00039311568,0.0011853426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088118,0.00033302925,0.98986673,0.0001646666,0.00006238403,0.0033443524,0.0003570195,0.000025808029,0.000908318,0.000027091553,0.00024037166,0.0037889846],"study_design_scores_gemma":[0.0001529859,0.0021237866,0.98590314,0.00007218043,0.00010230458,0.0094497735,0.0008640173,0.00012457372,0.00021054973,0.000028111846,0.0009499216,0.000018626073],"about_ca_topic_score_codex":0.0019997824,"about_ca_topic_score_gemma":0.0017610899,"teacher_disagreement_score":0.004253044,"about_ca_system_score_codex":0.0003532146,"about_ca_system_score_gemma":0.0004607932,"threshold_uncertainty_score":0.0142278075},"labels":[],"label_agreement":null},{"id":"W4386086990","doi":"10.1097/01.hs9.0000973548.20044.8c","title":"P1669: DIRECT ORAL ANTICOAGULANTS VS LOW MOLECULAR WEIGHT HEPARIN IN THE MANAGEMENT OF PATIENTS WITH PRIMARY OR METASTATIC BRAIN TUMOURS: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Meta-analysis; Low molecular weight heparin; Randomized controlled trial; Thrombosis; Malignancy; Internal medicine; Brain metastasis; Heparin; Population; Oncology; Intensive care medicine; Cancer; Metastasis","score_opus":0.06731445474866142,"score_gpt":0.3424315651224318,"score_spread":0.27511711037377035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386086990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004403844,0.9932407,0.00037262065,0.00028685518,0.00018319923,0.00040812689,0.00078832277,0.00002338964,0.00029300008],"genre_scores_gemma":[0.12334564,0.8702396,0.0017828979,0.0010926324,0.00036943806,0.0014200282,0.0011518337,0.000032347303,0.00056557555],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99438417,0.0023397943,0.0018854974,0.00051497563,0.0006619851,0.00021360908],"domain_scores_gemma":[0.9889714,0.007647719,0.0020514182,0.00023474796,0.000896317,0.0001983894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008123299,0.0019406684,0.01700819,0.005662686,0.00056727976,0.0028981944,0.0017751913,0.0020208019,0.0051702247],"category_scores_gemma":[0.01814066,0.00090689625,0.028206129,0.0069750817,0.00058223924,0.0014620188,0.0012087644,0.0015300354,0.0004253097],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002063101,0.000025685184,0.002066027,0.6261757,0.35712916,0.00010534199,0.00007241955,0.00027492462,0.00023089995,0.00011473511,0.0008212743,0.01092079],"study_design_scores_gemma":[0.00091693836,0.0002805169,0.0029345315,0.053220134,0.9395165,0.00010181152,0.000055271514,0.0001616743,0.0001172956,0.00018955526,0.002481537,0.000024275962],"about_ca_topic_score_codex":0.0052532842,"about_ca_topic_score_gemma":0.013587295,"teacher_disagreement_score":0.01700819,"about_ca_system_score_codex":0.0022644515,"about_ca_system_score_gemma":0.0036540402,"threshold_uncertainty_score":0.042960584},"labels":[],"label_agreement":null},{"id":"W4386101054","doi":"10.1097/01.hs9.0000974564.02780.6b","title":"PB1936: IDENTIFYING INEQUITIES IN SUPPORT - GLOBAL SURVEY OF PATIENT ORGANISATIONS DELIVERING SUPPORT SERVICES FOR CLL PATIENTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Service delivery framework; Medicine; Service (business); Business; Health care; Economic growth; Political science; Marketing","score_opus":0.04832421620977106,"score_gpt":0.34331737036039095,"score_spread":0.2949931541506199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386101054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761888,0.00058735546,0.00008140027,0.0014314457,0.000019422892,0.00031307823,0.017618924,0.000017406717,0.0037420937],"genre_scores_gemma":[0.98678315,0.0008175601,0.00041568396,0.00074084284,0.000040186667,0.0009135424,0.0088689225,0.000011679951,0.0014084136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986216,0.0006108466,0.00020353544,0.00011594047,0.00019102887,0.00025705254],"domain_scores_gemma":[0.99577147,0.0009570802,0.001718278,0.00011465302,0.00059559057,0.0008430068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022386208,0.00026083295,0.00029944585,0.0013577511,0.00067750795,0.0008733569,0.00052871794,0.00065074675,0.0063516805],"category_scores_gemma":[0.0067330017,0.00022823231,0.0003846795,0.0025791065,0.00029042628,0.001267778,0.0025275515,0.0006683997,0.0013087664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000172494,0.00016203694,0.96453035,0.0005362496,0.000035366727,0.0001324697,0.008552254,0.00005167812,0.00026769337,0.000085137675,0.010043099,0.01543113],"study_design_scores_gemma":[0.00002738682,0.00020707177,0.98178,0.00018348255,0.000011123701,0.00013182999,0.012253946,0.000067221685,0.0000762494,0.000030561412,0.0052227387,0.000008327423],"about_ca_topic_score_codex":0.012749329,"about_ca_topic_score_gemma":0.013901915,"teacher_disagreement_score":0.012749329,"about_ca_system_score_codex":0.000897312,"about_ca_system_score_gemma":0.001181718,"threshold_uncertainty_score":0.025350213},"labels":[],"label_agreement":null},{"id":"W4386101150","doi":"10.1097/01.hs9.0000975152.94267.34","title":"PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Confidence interval; Observational study; MEDLINE; Oncology; Malignancy; Multivariate analysis; Clinical trial; Refractory (planetary science); Intensive care medicine","score_opus":0.03682725364071148,"score_gpt":0.31982114756770513,"score_spread":0.28299389392699364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386101150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036228981,0.9895348,0.00027833448,0.0006740627,0.00018105612,0.0015746136,0.0033977048,0.000028216367,0.0007082816],"genre_scores_gemma":[0.033677373,0.95625955,0.0016432222,0.0014640887,0.00019505978,0.0041778972,0.0021449858,0.000020056408,0.000417797],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9892898,0.003049436,0.0052815853,0.0007556815,0.0013253588,0.00029809726],"domain_scores_gemma":[0.9618923,0.023832599,0.010024847,0.00059844885,0.003175219,0.00047656297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010488295,0.0014177199,0.0086517,0.016552454,0.00075873005,0.0028508948,0.0021071977,0.0018906461,0.007679038],"category_scores_gemma":[0.042877447,0.0008682834,0.007490969,0.018525753,0.001048752,0.0027937521,0.001946633,0.0010215037,0.00058130216],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015469224,0.000007780896,0.00089114247,0.9813794,0.0043696165,0.000061656734,0.00012074854,0.000049710026,0.00010432748,0.000100146455,0.001289273,0.011471494],"study_design_scores_gemma":[0.00029410372,0.00018463116,0.0054550804,0.9450251,0.03810155,0.00023852229,0.00020064264,0.00006614851,0.00009964797,0.00018506146,0.010121214,0.000028324666],"about_ca_topic_score_codex":0.0086694015,"about_ca_topic_score_gemma":0.028469093,"teacher_disagreement_score":0.016552454,"about_ca_system_score_codex":0.0047494713,"about_ca_system_score_gemma":0.017316576,"threshold_uncertainty_score":0.055468082},"labels":[],"label_agreement":null},{"id":"W4386102508","doi":"10.1097/01.hs9.0000975836.58931.97","title":"PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Obinutuzumab; Medicine; Ibrutinib; Lenalidomide; Rituximab; Internal medicine; Oncology; Follicular lymphoma; Mantle cell lymphoma; Chronic lymphocytic leukemia; Salvage therapy; Phases of clinical research; Idelalisib; Lymphoma; Clinical trial; Chemotherapy; Leukemia; Multiple myeloma","score_opus":0.03128032831111953,"score_gpt":0.3233636286600862,"score_spread":0.2920833003489667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386102508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9549541,0.021532604,0.0005995583,0.0032575433,0.00087412936,0.0024752133,0.003342821,0.0005602511,0.01240374],"genre_scores_gemma":[0.96688545,0.009948394,0.0016388253,0.004145159,0.0005241271,0.001945178,0.00429415,0.0000798285,0.010538951],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99977463,0.00009887092,0.000007951304,0.000033184002,0.000027165168,0.00005818073],"domain_scores_gemma":[0.99973804,0.00003882233,0.00004270428,0.000011981983,0.000014328691,0.00015421919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009087404,0.0011306007,0.0016787482,0.00034454724,0.00038589875,0.0014990289,0.00091304944,0.0011541365,0.0072962204],"category_scores_gemma":[0.00056816015,0.0003629568,0.001345146,0.00031985858,0.0006491622,0.0007222084,0.0003904918,0.0034239192,0.0015068817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7171771,0.020901138,0.002588659,0.002711412,0.002127473,0.00032723544,0.00033439504,0.0027406928,0.021962956,0.0011187263,0.023275182,0.2047351],"study_design_scores_gemma":[0.87549245,0.105061136,0.006436658,0.00016102399,0.00054702384,0.00031110048,0.00006901122,0.0013293409,0.0014320391,0.0005386917,0.008575817,0.000045746237],"about_ca_topic_score_codex":0.001250774,"about_ca_topic_score_gemma":0.0049817995,"teacher_disagreement_score":0.0072962204,"about_ca_system_score_codex":0.0009354171,"about_ca_system_score_gemma":0.001423281,"threshold_uncertainty_score":0.02440834},"labels":[],"label_agreement":null},{"id":"W4386122831","doi":"10.1097/01.hs9.0000977204.63685.a6","title":"PB2629: LATE DIAGNOSIS OF TWO ADULT SIBLINGS WITH BERNARD SOULIER SYNDROME (BSS)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Bernard–Soulier syndrome; Medicine; Tranexamic acid; Ristocetin; Von Willebrand disease; Platelet; Von Willebrand factor; Vaginal bleeding; Coagulation; Pediatrics; Desmopressin; Platelet disorder; Bleeding time; Severe bleeding; Surgery; Internal medicine; Pregnancy; Platelet aggregation; Blood loss","score_opus":0.013356147804806491,"score_gpt":0.2661488682950382,"score_spread":0.2527927204902317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386122831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887475,0.001607192,0.001297782,0.0033265464,0.00031924093,0.00010438473,0.00023874041,0.00009635347,0.0042623184],"genre_scores_gemma":[0.9970016,0.00048496522,0.00055123563,0.000620469,0.00030585003,0.000021417984,0.00012523652,0.00001959273,0.00086963037],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9994248,0.00007470597,0.00006779234,0.00018046537,0.000102931044,0.00014935886],"domain_scores_gemma":[0.99865305,0.0003043247,0.00029025742,0.00007102584,0.00009153969,0.0005898273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032134706,0.002004699,0.00080780877,0.0015894633,0.0017516428,0.0008558309,0.00086959155,0.0042895824,0.0030942939],"category_scores_gemma":[0.002818426,0.00081600295,0.00077094306,0.00073988386,0.0010215188,0.0010423185,0.0011451674,0.0027422155,0.0007508014],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026536243,0.000022911827,0.0067015444,0.00001352907,0.000004203275,0.99149877,0.00012570815,0.000031740678,0.00069380994,0.00009547878,0.00023700719,0.0005488041],"study_design_scores_gemma":[0.000010308032,0.000059547503,0.0055158325,0.000007843613,0.0000057490374,0.9934837,0.00007057603,0.00010765511,0.0002748726,0.00009002413,0.00036778479,0.0000059682784],"about_ca_topic_score_codex":0.0020664413,"about_ca_topic_score_gemma":0.001416458,"teacher_disagreement_score":0.0042895824,"about_ca_system_score_codex":0.0010325222,"about_ca_system_score_gemma":0.00064085575,"threshold_uncertainty_score":0.010351419},"labels":[],"label_agreement":null},{"id":"W4386142904","doi":"10.1097/01.hs9.0000969492.96103.aa","title":"P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Observational study; Clinical trial; IGHV@; Chronic lymphocytic leukemia; Demography; Pediatrics; Oncology; Leukemia","score_opus":0.02100252222309458,"score_gpt":0.306741845796958,"score_spread":0.28573932357386345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386142904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612564,0.0006376932,0.00018746288,0.00047417142,0.0000118581465,0.000017099097,0.0014935542,0.000003948151,0.0010485091],"genre_scores_gemma":[0.99897873,0.00012166586,0.00006669823,0.00012775522,0.00001466565,0.00001993682,0.0005947003,0.0000021155454,0.000073766416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989336,0.0003867601,0.00013575508,0.0002055839,0.0002005339,0.0001377147],"domain_scores_gemma":[0.99715316,0.00046270384,0.0018759925,0.00012537636,0.00018512539,0.00019770817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012614141,0.000100686724,0.00024364344,0.00068223395,0.00040697755,0.0006269066,0.00026418015,0.00032132838,0.002496939],"category_scores_gemma":[0.0043679154,0.0000865211,0.00031098476,0.0013218857,0.00027156365,0.00045084755,0.00054182333,0.00039294764,0.0002454832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018463687,0.00003374772,0.9951185,0.000026651109,0.0000814303,0.000018453344,0.000116453455,0.000048400976,0.000070548704,0.00007403785,0.00039556128,0.0038315721],"study_design_scores_gemma":[0.000026727173,0.00011069678,0.9979025,0.000037351634,0.000059669583,0.00013287313,0.00031777815,0.00024074722,0.00007186339,0.00018451073,0.00091013283,0.0000051454017],"about_ca_topic_score_codex":0.0034914513,"about_ca_topic_score_gemma":0.003862756,"teacher_disagreement_score":0.0034914513,"about_ca_system_score_codex":0.0004087593,"about_ca_system_score_gemma":0.00047579443,"threshold_uncertainty_score":0.0083530545},"labels":[],"label_agreement":null},{"id":"W4386143084","doi":"10.1097/01.hs9.0000977400.14880.93","title":"PB2681: GAPS IN THE ASSESSMENT AND MONITORING OF CARDIOVASCULAR RISK AND PSYCHOLOGICAL BURDEN IN POLYCYTHEMIA VERA: LANDMARK 2.0: A WORLDWIDE HEALTH SURVEY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of British Columbia","funders":"","keywords":"Medicine; Polycythemia vera; Phlebotomy; Quality of life (healthcare); Internal medicine","score_opus":0.05549516958441596,"score_gpt":0.36432288253758044,"score_spread":0.30882771295316447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386143084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772882,0.0032791463,0.0003691864,0.0016571748,0.00004013552,0.00010710851,0.014317076,0.000021384309,0.0029205577],"genre_scores_gemma":[0.98312336,0.0021261603,0.0004102406,0.00045096356,0.00004277501,0.00018272326,0.013098438,0.000009125217,0.0005561929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989236,0.00044621073,0.00015672272,0.00009991729,0.00022552343,0.00014801249],"domain_scores_gemma":[0.99743456,0.0005445614,0.0011100046,0.00011238759,0.00044139716,0.00035722664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023840466,0.0002402142,0.00033633018,0.00069167634,0.00018667892,0.00055514724,0.00033525517,0.00045839787,0.0011180945],"category_scores_gemma":[0.00361817,0.0001711193,0.00044399718,0.0018089405,0.00017163667,0.0005501049,0.00086999853,0.00049404183,0.00039202027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113762704,0.00003738535,0.9831739,0.00017696014,0.00004875792,0.000033882603,0.00024543004,0.000106841435,0.0001348196,0.000031621872,0.0025793898,0.013317178],"study_design_scores_gemma":[0.00000805285,0.000059383514,0.9979024,0.000057720335,0.000014139339,0.000049962415,0.00028233705,0.000086848864,0.000021410486,0.000009762105,0.001504645,0.0000033443184],"about_ca_topic_score_codex":0.014016393,"about_ca_topic_score_gemma":0.014167823,"teacher_disagreement_score":0.014016393,"about_ca_system_score_codex":0.00047085335,"about_ca_system_score_gemma":0.0007123784,"threshold_uncertainty_score":0.027869582},"labels":[],"label_agreement":null},{"id":"W4386170848","doi":"10.1097/01.hs9.0000969780.55126.5b","title":"P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; London Health Sciences Centre","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Regimen; Myelodysplastic syndromes; Dosing; International Prognostic Scoring System; Adverse effect; Oncology; Gastroenterology; Bone marrow","score_opus":0.029238519668841726,"score_gpt":0.35587358611237524,"score_spread":0.3266350664435335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386170848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96411276,0.0033125717,0.0021423711,0.0016953679,0.00061098114,0.01840652,0.0053143976,0.00040404382,0.004001129],"genre_scores_gemma":[0.94051623,0.0034361414,0.005909207,0.0041302512,0.0006403043,0.02320389,0.0077191256,0.0001527262,0.01429221],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999243,0.00037188455,0.000032585653,0.00014290903,0.0000766997,0.00013283128],"domain_scores_gemma":[0.9990657,0.00015641903,0.00024505545,0.00008791969,0.00006712137,0.000377738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026164227,0.002672115,0.0030774348,0.000590586,0.000611391,0.0015761775,0.0012191887,0.0020985503,0.011367806],"category_scores_gemma":[0.0015964563,0.001119036,0.0015661258,0.0005999311,0.0014642809,0.0016324422,0.0005886862,0.0041941265,0.0027353456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9322003,0.028541807,0.0011266845,0.0006359694,0.00070712774,0.00012085674,0.00006903043,0.00081371045,0.008835853,0.00022152605,0.0030296624,0.02369749],"study_design_scores_gemma":[0.83538175,0.1595824,0.0015702143,0.000024949532,0.00028886017,0.00010274437,0.000025656764,0.00048194747,0.00072145177,0.00028799783,0.0015064406,0.000025490117],"about_ca_topic_score_codex":0.00066648755,"about_ca_topic_score_gemma":0.0023759424,"teacher_disagreement_score":0.011367806,"about_ca_system_score_codex":0.0013768997,"about_ca_system_score_gemma":0.0023514256,"threshold_uncertainty_score":0.038029075},"labels":[],"label_agreement":null},{"id":"W4386631797","doi":"10.1097/hs9.0000000000000953","title":"Current and Future Perspective in Hematopoietic Stem Progenitor Cell-gene Therapy for Inborn Errors of Metabolism","year":2023,"lang":"en","type":"editorial","venue":"HemaSphere","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Progenitor cell; Genetic enhancement; Stem cell; Haematopoiesis; Hematopoietic stem cell; Perspective (graphical); Bioinformatics; Cancer research; Progenitor; Biology; Gene; Medicine; Genetics; Computer science","score_opus":0.022033403836206403,"score_gpt":0.32982897794331095,"score_spread":0.30779557410710456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386631797","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000977965,0.9399794,0.0030125296,0.03167446,0.007862829,0.00004138838,0.0002307728,0.00018541876,0.01603533],"genre_scores_gemma":[0.006216629,0.94497764,0.0049336264,0.016428625,0.01493314,0.00009389766,0.00046653626,0.000062135165,0.011887749],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993981,0.00016365219,0.00006317657,0.000094750576,0.00019172936,0.00008864314],"domain_scores_gemma":[0.9977005,0.0009923048,0.0001976353,0.00007459955,0.000584393,0.00045048792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021452112,0.00077770086,0.00090223644,0.000973913,0.00032832185,0.0019096715,0.0011905131,0.003787132,0.028013494],"category_scores_gemma":[0.001918107,0.00015549987,0.00089539593,0.0009347706,0.000795626,0.0028031801,0.00071916176,0.0042130784,0.00808581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046683272,0.00033154912,0.00045342854,0.0035909743,0.000071758725,0.00045588196,0.000060544982,0.0005643986,0.0027562352,0.011065616,0.13449053,0.8456923],"study_design_scores_gemma":[0.000081276354,0.00043772798,0.0007240001,0.0019964431,0.000096268566,0.0014294056,0.00009826931,0.00033780286,0.0008321925,0.006637783,0.9873037,0.000025159397],"about_ca_topic_score_codex":0.0005135491,"about_ca_topic_score_gemma":0.0014184666,"teacher_disagreement_score":0.028013494,"about_ca_system_score_codex":0.0009416595,"about_ca_system_score_gemma":0.0015891993,"threshold_uncertainty_score":0.093714476},"labels":[],"label_agreement":null},{"id":"W4387899802","doi":"10.1097/hs9.0000000000000966","title":"Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"Sierra Oncology; MorphoSys; Cancer Research UK; Galecto; Incyte; Gilead Sciences; CTI Biopharma; Division of Materials Research; Celgene; Pfizer","keywords":"Myelofibrosis; Medicine; Quality of life (healthcare); Anemia; Ruxolitinib; Clinical endpoint; Danazol; Internal medicine; Physical therapy; Myeloproliferative neoplasm; Janus kinase 2; Clinical trial; Bone marrow","score_opus":0.027577465176416873,"score_gpt":0.2802369706173891,"score_spread":0.25265950544097227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387899802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915069,0.0026103249,0.00011752154,0.0002878063,0.000029917974,0.00018250344,0.0037718434,0.000010153656,0.0014830118],"genre_scores_gemma":[0.9914369,0.0008809552,0.00030313464,0.0003309722,0.00009208568,0.0002989329,0.0063084015,0.000005266698,0.00034335212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882346,0.00057622814,0.00016867179,0.00013611525,0.00020892842,0.0000864449],"domain_scores_gemma":[0.9954615,0.0010562876,0.0019266014,0.00024967967,0.0006002272,0.00070567004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033238935,0.0004675551,0.0008362756,0.00046717664,0.0003821886,0.00084536464,0.00039527152,0.0005937022,0.0012146941],"category_scores_gemma":[0.0051944563,0.00019003624,0.0013998303,0.0010720755,0.00027211622,0.00077027996,0.00080726546,0.0007795458,0.0002385292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08999447,0.004761276,0.84087217,0.0008335493,0.0044826665,0.0001564285,0.00039556864,0.0011959894,0.0012397015,0.00022950713,0.0038301547,0.0520085],"study_design_scores_gemma":[0.008095856,0.011163419,0.97585505,0.00010569,0.0012953258,0.00017932137,0.00020075976,0.00070397236,0.00015891617,0.000163956,0.0020315086,0.000046215762],"about_ca_topic_score_codex":0.0014165774,"about_ca_topic_score_gemma":0.0024575863,"teacher_disagreement_score":0.0033238935,"about_ca_system_score_codex":0.0004988553,"about_ca_system_score_gemma":0.00054942345,"threshold_uncertainty_score":0.017578661},"labels":[],"label_agreement":null},{"id":"W4387969051","doi":"10.1097/hs9.0000000000000963","title":"Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Genentech; Italfarmaco; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Jazz Pharmaceuticals; Yuhan; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Constellation Pharmaceuticals","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Post-hoc analysis; Internal medicine; Population; Anemia; Gastroenterology; Bone marrow","score_opus":0.03576256372437367,"score_gpt":0.32653761267776016,"score_spread":0.29077504895338646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387969051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97791046,0.011692084,0.0013996201,0.000750478,0.00032281797,0.0032728724,0.0023698122,0.00013186078,0.0021499086],"genre_scores_gemma":[0.9889992,0.0028834261,0.0013033813,0.00079347024,0.00028623367,0.0022854907,0.0021782082,0.000040158782,0.0012303608],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99620026,0.0027608934,0.00027444755,0.00031043513,0.00018145637,0.0002724622],"domain_scores_gemma":[0.99567634,0.0023865653,0.0008827097,0.00039672607,0.0002538865,0.00040374254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072772005,0.0015254391,0.0038311547,0.00047610502,0.00034885577,0.0013842514,0.00066807616,0.0009903196,0.003477074],"category_scores_gemma":[0.005689294,0.00042685372,0.0070389956,0.0006272323,0.00053915475,0.0008613987,0.00047734848,0.001748305,0.00037199722],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9571123,0.0016930646,0.003039114,0.0011026541,0.017649254,0.000110871515,0.000056649395,0.001064433,0.002282889,0.00009358675,0.0011817444,0.014613478],"study_design_scores_gemma":[0.888999,0.062136166,0.018514384,0.00011551068,0.02404489,0.00016791518,0.00006659042,0.0019274111,0.0014115847,0.0004285755,0.0021372773,0.000050583338],"about_ca_topic_score_codex":0.0005803691,"about_ca_topic_score_gemma":0.0020457678,"teacher_disagreement_score":0.0072772005,"about_ca_system_score_codex":0.0007233042,"about_ca_system_score_gemma":0.0013560026,"threshold_uncertainty_score":0.038486004},"labels":[],"label_agreement":null},{"id":"W4388738295","doi":"10.1097/01.hs9.0000936192.21618.f2","title":"P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Scientific Affairs; Centre Hospitalier Universitaire de Toulouse; Universitätsklinikum Hamburg-Eppendorf; Syddansk Universitet; Université de Toulouse; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; University of Texas MD Anderson Cancer Center; Ankara Universitesi; University of Oxford; Université de Lille; Cancer Research Institute","keywords":"Medicine; Lenalidomide; Daratumumab; Quality of life (healthcare); Internal medicine; Multiple myeloma; Population; Dexamethasone; Subgroup analysis; Randomized controlled trial; Surgery; Confidence interval","score_opus":0.04459092877840427,"score_gpt":0.3177322132499836,"score_spread":0.2731412844715793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388738295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97578764,0.018248126,0.00050847576,0.00067464146,0.00022553469,0.00076686655,0.00265637,0.000030532177,0.0011018883],"genre_scores_gemma":[0.99516356,0.0012011279,0.00031191096,0.00031118808,0.0001747304,0.0007321368,0.0016974752,0.000007885896,0.0003999289],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99842334,0.00077973626,0.00025404248,0.00027189124,0.00012517563,0.00014585636],"domain_scores_gemma":[0.9982462,0.000598706,0.00056453724,0.00025800045,0.00007945598,0.00025311168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037239918,0.0011053513,0.0030715289,0.00046560654,0.00033406226,0.0012034269,0.0007316404,0.0008417392,0.002140135],"category_scores_gemma":[0.0041938177,0.0002950637,0.008325954,0.0006040936,0.0004160092,0.0005814113,0.000724055,0.0014550934,0.00019814678],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8312647,0.000779928,0.070478335,0.0025349767,0.060894735,0.00024902416,0.00018266354,0.0013280421,0.0026810463,0.0002925313,0.0023080455,0.027005997],"study_design_scores_gemma":[0.42899123,0.055148788,0.37575933,0.0011293076,0.120349914,0.0009247546,0.00042563304,0.00537781,0.0019251341,0.003035468,0.006729048,0.00020354024],"about_ca_topic_score_codex":0.0009087382,"about_ca_topic_score_gemma":0.00269476,"teacher_disagreement_score":0.0037239918,"about_ca_system_score_codex":0.00058901816,"about_ca_system_score_gemma":0.0007492661,"threshold_uncertainty_score":0.019694626},"labels":[],"label_agreement":null},{"id":"W4388738310","doi":"10.1097/01.hs9.0000936164.84357.ed","title":"P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Medicine; Daratumumab; Internal medicine; Multiple myeloma; Clinical endpoint; Dexamethasone; Surgery; Phases of clinical research; Minimal residual disease; Progression-free survival; Oncology; Gastroenterology; Chemotherapy; Randomized controlled trial; Bone marrow","score_opus":0.02799922324280263,"score_gpt":0.3080481877675247,"score_spread":0.28004896452472205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388738310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467975,0.0034051144,0.0002391808,0.00019586111,0.000066722525,0.00023877011,0.00064741366,0.000014785664,0.0005123224],"genre_scores_gemma":[0.9966209,0.0008794711,0.00048062252,0.0002905402,0.000102138416,0.00026230875,0.0010493217,0.000005926239,0.00030862106],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990828,0.00053384935,0.00007341356,0.00013243825,0.00008603387,0.00009150662],"domain_scores_gemma":[0.9984005,0.0004835305,0.00053782377,0.00013461929,0.00006635612,0.00037710796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003307183,0.00069977285,0.0018839148,0.0003348639,0.0002889627,0.0010127197,0.0006881547,0.00048337565,0.0014522529],"category_scores_gemma":[0.0016143734,0.00037252047,0.0026697246,0.00043801696,0.0004291017,0.0006501011,0.00047279085,0.0020736528,0.00023467376],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85474026,0.008501855,0.053858552,0.0005325411,0.0060144705,0.00010442524,0.00014481304,0.0019914615,0.008755135,0.00016119881,0.0016095717,0.0635857],"study_design_scores_gemma":[0.33187664,0.42116496,0.22193779,0.00015272351,0.010722239,0.000488846,0.00013568906,0.0041407617,0.003833962,0.00054045697,0.00492232,0.0000836058],"about_ca_topic_score_codex":0.0005119924,"about_ca_topic_score_gemma":0.0016599994,"teacher_disagreement_score":0.003307183,"about_ca_system_score_codex":0.00074680214,"about_ca_system_score_gemma":0.00093999854,"threshold_uncertainty_score":0.017490268},"labels":[],"label_agreement":null},{"id":"W4390458072","doi":"10.1002/j.2572-9241.2019.tb00089.x","title":"PF490 PRESENCE OF BRAFV600E MUTATION IN CHILDHOOD LCH CORRELATES WITH MULTISYSTEM DISEASE AND A POOR SURVIVAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Sanger sequencing; Mutation; Internal medicine; Retrospective cohort study; Disease; Pediatrics; Gastroenterology; Genetics; Biology; Gene","score_opus":0.004188550282559119,"score_gpt":0.21088003522333595,"score_spread":0.20669148494077683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390458072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992512,0.00028781212,0.00006275227,0.000015358904,0.0000030970987,0.0000024340027,0.000100415935,0.000004938183,0.0002719945],"genre_scores_gemma":[0.9997429,0.00006868327,0.000048470705,0.0000049638875,0.0000059292897,0.0000019785864,0.00008143516,0.0000013059897,0.000044190278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996631,0.0000693591,0.000036740137,0.00008586476,0.000080194135,0.00006481424],"domain_scores_gemma":[0.9978136,0.00057620136,0.0011544075,0.00009288925,0.00014115292,0.00022169169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004296606,0.0002467614,0.00029288518,0.0011466596,0.00026435047,0.0004001933,0.00018132039,0.00035840194,0.0027352234],"category_scores_gemma":[0.0017777585,0.00019488021,0.00020956276,0.0006333886,0.00048241313,0.0002918655,0.00022405141,0.00028425737,0.00027560236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005108331,0.000008412954,0.9979096,0.000008158509,0.000010596337,0.00039476404,0.000020413252,0.000021607642,0.0008392732,0.000007175135,0.00003969398,0.0006890357],"study_design_scores_gemma":[0.000002576467,0.0000925646,0.99372524,0.0000051201314,0.000018959174,0.005517632,0.000061422805,0.00008297968,0.0003570142,0.000015735373,0.000118627686,0.0000020298046],"about_ca_topic_score_codex":0.0011594297,"about_ca_topic_score_gemma":0.0011329078,"teacher_disagreement_score":0.0027352234,"about_ca_system_score_codex":0.00023146605,"about_ca_system_score_gemma":0.00019788435,"threshold_uncertainty_score":0.009150267},"labels":[],"label_agreement":null},{"id":"W4398185210","doi":"10.1002/hem3.69","title":"Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)","year":2024,"lang":"en","type":"review","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Myelodysplastic syndromes; Medicine; Drug development; Clinical trial; Drug; Intensive care medicine; Oncology; Medical physics; Internal medicine; Pharmacology; Bone marrow","score_opus":0.27132309223321066,"score_gpt":0.48313530790035203,"score_spread":0.21181221566714137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398185210","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039031205,0.87632114,0.016423725,0.09949234,0.0023387854,0.001372181,0.00014251262,0.00015677571,0.0033622177],"genre_scores_gemma":[0.009781757,0.78185296,0.12999472,0.06732142,0.004138789,0.0050860588,0.00021068954,0.0001376802,0.0014759896],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.90823096,0.073155604,0.008147934,0.002149532,0.007728297,0.00058771664],"domain_scores_gemma":[0.6733712,0.2818648,0.014251066,0.006239533,0.020826899,0.003446524],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.17062892,0.0012643021,0.0056457836,0.0027055268,0.00086646306,0.009126789,0.004102163,0.0074875583,0.0039215307],"category_scores_gemma":[0.1665929,0.0010041455,0.0042437953,0.0033630964,0.0040932954,0.012427145,0.0030075968,0.0163354,0.00195879],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044263067,0.00023582598,0.00034376478,0.04880895,0.00058882753,0.00014167241,0.0006604273,0.001079791,0.00049707014,0.045018528,0.046321675,0.8558608],"study_design_scores_gemma":[0.0020749075,0.0011123299,0.0013765116,0.11041922,0.0015183099,0.0007298045,0.00060236215,0.0016940167,0.00073665095,0.062269356,0.8173015,0.00016502732],"about_ca_topic_score_codex":0.0014134551,"about_ca_topic_score_gemma":0.003062057,"teacher_disagreement_score":0.8293711,"about_ca_system_score_codex":0.003319123,"about_ca_system_score_gemma":0.02536221,"threshold_uncertainty_score":0.90238273},"labels":[],"label_agreement":null},{"id":"W4399045499","doi":"10.1002/hem3.74","title":"First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"Pharmacyclics","keywords":"Ibrutinib; Post-hoc analysis; Chronic lymphocytic leukemia; Medicine; Oncology; Internal medicine; Post hoc; Pooled analysis; Survival analysis; Population; Leukemia; Meta-analysis","score_opus":0.018026519877040136,"score_gpt":0.29915942787016636,"score_spread":0.28113290799312624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399045499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9182631,0.06720386,0.003345353,0.0003497246,0.00084769225,0.0004646468,0.0057635345,0.0001824878,0.0035796124],"genre_scores_gemma":[0.9917504,0.003404369,0.0005343511,0.00028391925,0.0003693151,0.00023959251,0.0024423406,0.000034812845,0.0009408275],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.99644476,0.0018269005,0.0003139933,0.00078052224,0.0003674004,0.00026644074],"domain_scores_gemma":[0.9954834,0.0023445105,0.0010062648,0.0006013916,0.00029193432,0.00027262367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072700316,0.0013128795,0.0039391867,0.001112352,0.00022301072,0.0011876017,0.00063280476,0.000908076,0.0035515404],"category_scores_gemma":[0.005298099,0.0004060144,0.011619689,0.0010142714,0.0002823257,0.0010072346,0.0006116801,0.0011094096,0.00032448163],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34562054,0.00070785545,0.23790784,0.0046796026,0.3491628,0.00051517715,0.00016637187,0.0024702316,0.0032261217,0.00020060998,0.00546098,0.04988186],"study_design_scores_gemma":[0.02282127,0.03814628,0.6384579,0.00047188738,0.2800822,0.00065615994,0.00031517984,0.007496015,0.001523627,0.00049095997,0.009374551,0.00016401058],"about_ca_topic_score_codex":0.0009982274,"about_ca_topic_score_gemma":0.0018936439,"teacher_disagreement_score":0.0072700316,"about_ca_system_score_codex":0.0005338226,"about_ca_system_score_gemma":0.00047799308,"threshold_uncertainty_score":0.038448095},"labels":[],"label_agreement":null},{"id":"W4400982166","doi":"10.1002/hem3.136","title":"Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Pfizer","keywords":"Multiple myeloma; Term (time); Refractory (planetary science); Medicine; Oncology; Internal medicine; Biology; Physics","score_opus":0.016703976176522393,"score_gpt":0.27470621404530243,"score_spread":0.25800223786878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400982166","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37594122,0.58931077,0.0030283271,0.0108999405,0.0008576934,0.00028978448,0.00876103,0.0002461989,0.010665096],"genre_scores_gemma":[0.7792381,0.17429504,0.0043411576,0.01732462,0.003331185,0.0005780876,0.018720359,0.00016634828,0.002005056],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99894613,0.00031453994,0.00018492683,0.00010093457,0.00037220263,0.0000812668],"domain_scores_gemma":[0.99443156,0.0020515223,0.0018168723,0.00024987845,0.0009813713,0.00046887746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005818175,0.00045578333,0.0016871555,0.0005588748,0.00025804996,0.0017363805,0.0008592854,0.0008175506,0.0009984919],"category_scores_gemma":[0.004313811,0.00020976264,0.0013996975,0.001342463,0.00036982016,0.0010570739,0.00047142166,0.0019820451,0.0004522611],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0256646,0.0009715789,0.08209835,0.002960229,0.0034524917,0.00028702948,0.00033844245,0.001858359,0.0054223244,0.00082706794,0.03194026,0.8441792],"study_design_scores_gemma":[0.010211249,0.026152402,0.54869366,0.00283839,0.014150859,0.0024661405,0.00030998362,0.0038306483,0.0064316466,0.0018666292,0.3828201,0.00022831903],"about_ca_topic_score_codex":0.0012404687,"about_ca_topic_score_gemma":0.0030079915,"teacher_disagreement_score":0.005818175,"about_ca_system_score_codex":0.0012189652,"about_ca_system_score_gemma":0.001044361,"threshold_uncertainty_score":0.030769825},"labels":[],"label_agreement":null},{"id":"W4401744308","doi":"10.1002/hem3.116","title":"RNA binding protein‐directed control of leukemic stem cell evolution and function","year":2024,"lang":"en","type":"review","venue":"HemaSphere","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Haematopoiesis; Stem cell; Biology; Myeloid leukemia; RNA-binding protein; Myeloid; Hematopoietic stem cell; Leukemia; Function (biology); Disease; Transcriptome; RNA; Computational biology; Cancer research; Immunology; Gene; Gene expression; Genetics; Medicine; Internal medicine","score_opus":0.01744990871103646,"score_gpt":0.2712963733619915,"score_spread":0.25384646465095506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401744308","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76773757,0.04830521,0.13249211,0.0027322855,0.0005742854,0.00008317212,0.00089422415,0.0017206575,0.045460485],"genre_scores_gemma":[0.97192794,0.00818238,0.011287297,0.00033054856,0.00007006531,0.000026451056,0.00024169659,0.0001256109,0.0078079207],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998254,0.000030889187,0.000008400456,0.000059683673,0.000053553445,0.00002213179],"domain_scores_gemma":[0.99992514,0.000019031704,0.000022302533,0.000011724264,0.000008439035,0.000013353748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034830297,0.00020213946,0.00013210911,0.00012554372,0.00018804379,0.00056514505,0.00024316444,0.0002928109,0.0012419974],"category_scores_gemma":[0.00022419544,0.000093315386,0.00009948516,0.0001133409,0.0004966957,0.0002849341,0.00025557622,0.00045899188,0.00070135714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003746686,0.0000065262993,0.00014011371,0.00004063624,0.0000020466564,0.000040869974,0.00003444585,0.0003165655,0.97857976,0.008815309,0.00031346423,0.011672847],"study_design_scores_gemma":[0.000009985145,0.000090738,0.002039342,0.000015582487,0.0000068846894,0.0002706225,0.000052831594,0.0038877157,0.94568545,0.0037085738,0.044219937,0.000012329515],"about_ca_topic_score_codex":0.00025969004,"about_ca_topic_score_gemma":0.00048722763,"teacher_disagreement_score":0.0012419974,"about_ca_system_score_codex":0.00048183248,"about_ca_system_score_gemma":0.00023990749,"threshold_uncertainty_score":0.0041549206},"labels":[],"label_agreement":null},{"id":"W4401745029","doi":"10.1002/hem3.130","title":"Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma","year":2024,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"University of Toronto","keywords":"Chimeric antigen receptor; Chemoimmunotherapy; Medicine; Oncology; Refractory (planetary science); Lymphoma; Internal medicine; CD19; Disease; Immunotherapy; Antigen; Immunology; Rituximab; Cancer; Biology","score_opus":0.06631002535945682,"score_gpt":0.379980524641565,"score_spread":0.3136704992821082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401745029","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005491593,0.9989436,0.000054959048,0.00012410338,0.00005498081,0.000004747701,0.00003052125,0.0000028907011,0.00023504237],"genre_scores_gemma":[0.0049580047,0.9943558,0.00017766093,0.00015427457,0.00008824789,0.000019302806,0.0000768303,9.731376e-7,0.00016892972],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997677,0.00007742672,0.000041519055,0.00003530098,0.000059103688,0.000018932084],"domain_scores_gemma":[0.99949,0.0002921599,0.00010292795,0.0000075703288,0.00009057694,0.000016731448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079003384,0.0006299957,0.0016215822,0.001109736,0.00009974039,0.000535982,0.00044344476,0.0005413794,0.00085515104],"category_scores_gemma":[0.0013356119,0.00014971814,0.00074720825,0.0011032999,0.0001880205,0.000392119,0.0002826947,0.0007852524,0.00031594557],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004338089,0.000066909786,0.0031035005,0.019290859,0.0007436246,0.00009782501,0.00003987136,0.0002833929,0.0010687133,0.0005209886,0.008298965,0.9660515],"study_design_scores_gemma":[0.00070667407,0.0031214731,0.096123986,0.06481999,0.013228524,0.0066297916,0.00040720133,0.0013865681,0.0053847465,0.0041366625,0.80381465,0.00023967233],"about_ca_topic_score_codex":0.00074794283,"about_ca_topic_score_gemma":0.0012646563,"teacher_disagreement_score":0.0016215822,"about_ca_system_score_codex":0.0003572624,"about_ca_system_score_gemma":0.0005877477,"threshold_uncertainty_score":0.004178107},"labels":[],"label_agreement":null},{"id":"W4401913715","doi":"10.1002/hem3.146","title":"Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Genentech; F. Hoffmann-La Roche; AbbVie","keywords":"Rituximab; Hypogammaglobulinemia; Medicine; Internal medicine; Chronic lymphocytic leukemia; CD20; Gastroenterology; Venetoclax; Refractory (planetary science); Antibody; Immune system; Immunology; Bendamustine; Leukemia","score_opus":0.011910906799896948,"score_gpt":0.264676162737068,"score_spread":0.2527652559371711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401913715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980818,0.0014484396,0.00003490223,0.000034538432,0.000008555957,0.00002065939,0.00007522629,0.000003903729,0.00029193392],"genre_scores_gemma":[0.99938846,0.000165631,0.000045357625,0.000068240224,0.000014944468,0.000024057179,0.00017411083,6.857738e-7,0.000118564225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995937,0.00018770945,0.000034476405,0.00005789718,0.000056764242,0.00006958928],"domain_scores_gemma":[0.9992213,0.00021745797,0.000288771,0.00003666144,0.00004302185,0.00019278942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000976408,0.00019303603,0.0008428772,0.0001963009,0.00023165859,0.00036565762,0.00018313577,0.00036676135,0.0007249933],"category_scores_gemma":[0.0009552854,0.00011350334,0.00050266215,0.0002821551,0.00018581675,0.00032551,0.00018197874,0.00057479687,0.00010761359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15996817,0.003895493,0.67566824,0.00043389428,0.0018998437,0.0012173968,0.00036799622,0.0013954241,0.03338802,0.00011797928,0.0013418689,0.12030562],"study_design_scores_gemma":[0.0059176097,0.07068927,0.9160472,0.000064257096,0.0008378572,0.0012161621,0.00013419945,0.0009234435,0.0020013328,0.00008863928,0.0020501504,0.000029870955],"about_ca_topic_score_codex":0.0004976357,"about_ca_topic_score_gemma":0.0010599116,"teacher_disagreement_score":0.000976408,"about_ca_system_score_codex":0.00042229792,"about_ca_system_score_gemma":0.00020285095,"threshold_uncertainty_score":0.0051638484},"labels":[],"label_agreement":null},{"id":"W4402568580","doi":"10.1002/hem3.70004","title":"Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier; Genesis Pharma; Associazione Italiana per la Ricerca sul Cancro; Ministerstvo Zdravotnictví Ceské Republiky; Incyte; BeiGene; Genentech; Sunesis; Gilead Sciences; AbbVie; European Commission; Sanofi; Cilag; TG Therapeutics; Amgen; Ministero della Salute; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Chronic lymphocytic leukemia; Medicine; Oncology; Internal medicine; Leukemia","score_opus":0.09932132477308753,"score_gpt":0.3667572029476041,"score_spread":0.2674358781745166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402568580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941361,0.003994901,0.0001400902,0.0004936432,0.000012355401,0.000024501403,0.00023569229,0.0000018667212,0.0009608476],"genre_scores_gemma":[0.9975931,0.0014106099,0.00016220489,0.00034659955,0.00004242678,0.00003093282,0.0003197611,0.0000024327833,0.000091812595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986727,0.0006299104,0.00019082033,0.00020360954,0.00013971116,0.00016320653],"domain_scores_gemma":[0.99721575,0.0007209521,0.0013725157,0.00012699283,0.00033393415,0.00022977062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023621349,0.00020123506,0.00027056658,0.0010380232,0.00049554347,0.0010342337,0.00025160218,0.00047423298,0.0006997259],"category_scores_gemma":[0.005384984,0.000131737,0.00034648096,0.0025921983,0.00044332517,0.0008613134,0.0006231234,0.00060797104,0.000118737014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046636938,0.00011309579,0.98752546,0.000041032716,0.00008879716,0.0000908369,0.00046142927,0.00009362282,0.00014469255,0.00012492172,0.00036155124,0.010488179],"study_design_scores_gemma":[0.000108338805,0.0005669552,0.9920912,0.00017796179,0.00014628342,0.00064884865,0.002009567,0.0002844377,0.00014878385,0.00016396187,0.0036343972,0.000019208657],"about_ca_topic_score_codex":0.002769377,"about_ca_topic_score_gemma":0.0029547475,"teacher_disagreement_score":0.002769377,"about_ca_system_score_codex":0.0006972628,"about_ca_system_score_gemma":0.0006569285,"threshold_uncertainty_score":0.012492299},"labels":[],"label_agreement":null},{"id":"W4404813541","doi":"10.1002/hem3.70001","title":"Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Veterinärmedizinische Universität Wien; Universität Wien; Christian Doppler Forschungsgesellschaft; Vienna Science and Technology Fund; Austrian Science Fund; Medizinische Universität Wien; European Commission; Siemens Medical Solutions USA","keywords":"Myeloid leukemia; Dual (grammatical number); Lymphoma; Block (permutation group theory); Cancer research; Acute leukemia; Leukemia; Medicine; Immunology; Mathematics","score_opus":0.011697156603415188,"score_gpt":0.2629680298935974,"score_spread":0.2512708732901822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404813541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362344,0.0016310181,0.0022199717,0.00005466072,0.000023134167,0.00004727361,0.0003014131,0.00014060496,0.0019585018],"genre_scores_gemma":[0.9941981,0.0009902982,0.002269385,0.00004527836,0.0000062254394,0.000045459998,0.000597612,0.000015464477,0.0018321873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998851,0.00001939804,0.000012408022,0.000017761742,0.000032579486,0.00003278191],"domain_scores_gemma":[0.99994767,0.000009403868,0.000012259344,0.00000677033,0.000004993728,0.000018855426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012134861,0.00035711378,0.00023320566,0.0002599593,0.00008096679,0.0001905777,0.00018198499,0.00021056419,0.0010513825],"category_scores_gemma":[0.00007697261,0.00012883145,0.00023512283,0.0001800189,0.00016015548,0.0001407766,0.0001256732,0.00046585253,0.00028876387],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035327536,0.00013610708,0.00021856684,0.000055024648,0.0000152219945,0.000041723677,0.000012819892,0.00034808836,0.9926898,0.00019119217,0.0001492758,0.005788927],"study_design_scores_gemma":[0.0001010239,0.002946575,0.002366215,0.000004440412,0.000034420398,0.00028884562,0.0000137033085,0.0014433633,0.9906342,0.00003544105,0.002125882,0.0000059349786],"about_ca_topic_score_codex":0.0004943381,"about_ca_topic_score_gemma":0.0013978101,"teacher_disagreement_score":0.0010513825,"about_ca_system_score_codex":0.00021163761,"about_ca_system_score_gemma":0.00030596554,"threshold_uncertainty_score":0.00351727},"labels":[],"label_agreement":null},{"id":"W4408845598","doi":"10.1002/hem3.70106","title":"Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; University of British Columbia","funders":"AOP Orphan; Astellas Pharma; Galecto; Sierra Oncology; Incyte; CTI Biopharma; BeiGene; Bristol-Myers Squibb; AstraZeneca; CSL Behring; MPN Research Foundation; Alexion Pharmaceuticals; Gilead Sciences; Sanofi; GlaxoSmithKline; Pfizer; Novartis Pharmaceuticals Corporation; Celgene","keywords":"Medicine; Depression (economics); Myeloproliferative neoplasm; Quality of life (healthcare); Polycythemia vera; Family medicine; Disease; Physical therapy; Emergency medicine; Internal medicine; Myelofibrosis","score_opus":0.01158140979650688,"score_gpt":0.3007316178053178,"score_spread":0.2891502080088109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408845598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649614,0.00040090157,0.00006855227,0.00082606316,0.00001278101,0.000025935868,0.00074988254,0.0000055891187,0.0014141494],"genre_scores_gemma":[0.998879,0.00020790506,0.00010751855,0.00024329036,0.000013697076,0.000017791619,0.00043406372,0.0000015381358,0.00009522465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978478,0.0011945218,0.00023788265,0.00010218284,0.00037648177,0.00024113865],"domain_scores_gemma":[0.9914533,0.0024899056,0.0038006916,0.00013798926,0.00091837026,0.0011998728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031358849,0.0001352987,0.00028195986,0.0005542075,0.00031318024,0.00062709185,0.00020553594,0.0004878327,0.00094731344],"category_scores_gemma":[0.009330328,0.0001243485,0.0005130747,0.00072909635,0.00032441356,0.00045252268,0.00058327767,0.00071807427,0.00016517282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090063986,0.00008200255,0.992569,0.00005560494,0.000051222545,0.000053282834,0.0015913553,0.00010435228,0.00008289016,0.000025559411,0.00078899076,0.0045055686],"study_design_scores_gemma":[0.0000071976706,0.00015146376,0.99656504,0.00002606089,0.0000121653775,0.00007741732,0.00233395,0.00017501652,0.000024362786,0.000018587278,0.0006007153,0.000007975548],"about_ca_topic_score_codex":0.00834824,"about_ca_topic_score_gemma":0.0076513533,"teacher_disagreement_score":0.00834824,"about_ca_system_score_codex":0.0005861028,"about_ca_system_score_gemma":0.0004378763,"threshold_uncertainty_score":0.016599298},"labels":[],"label_agreement":null},{"id":"W4408884237","doi":"10.1002/hem3.70111","title":"Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"European Association for Haemophilia and Allied Disorders; Nemzeti Kutatási Fejlesztési és Innovációs Hivatal; Hungarian Scientific Research Fund; European Hematology Association","keywords":"Haemophilia; Medicine; Clotting factor; Incidence (geometry); Hematology; Internal medicine; Pediatrics; Major bleeding","score_opus":0.11115762673751604,"score_gpt":0.39349760629183156,"score_spread":0.2823399795543155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408884237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3400895,0.25993901,0.12500282,0.19134912,0.017691046,0.00027517692,0.0013900562,0.0005930165,0.06367033],"genre_scores_gemma":[0.88525116,0.062674284,0.017299693,0.018694576,0.011088995,0.00012179912,0.0005845533,0.00015798066,0.0041269213],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996653,0.0014062707,0.00046476693,0.0005189698,0.0008254112,0.00013165682],"domain_scores_gemma":[0.98846906,0.006242447,0.0011511587,0.00084140693,0.0026943616,0.0006015295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005277187,0.00045102293,0.0009170854,0.0031988595,0.0006374846,0.00303319,0.000687323,0.0008552453,0.0009661594],"category_scores_gemma":[0.01704805,0.00017887798,0.00038251592,0.0020439588,0.0047111395,0.0027830733,0.0014529811,0.002537029,0.0005579872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006230239,0.00015254291,0.21677399,0.0022568011,0.00033525136,0.0047345115,0.008668865,0.0006149409,0.007835518,0.124940425,0.06254758,0.5705166],"study_design_scores_gemma":[0.0000962383,0.0007515858,0.34688374,0.005127367,0.00048963225,0.06436657,0.009563351,0.0025512034,0.0025817882,0.1306887,0.43662605,0.00027383107],"about_ca_topic_score_codex":0.001183344,"about_ca_topic_score_gemma":0.0010482745,"teacher_disagreement_score":0.005277187,"about_ca_system_score_codex":0.00078915764,"about_ca_system_score_gemma":0.0009315849,"threshold_uncertainty_score":0.027908742},"labels":[],"label_agreement":null},{"id":"W4410776881","doi":"10.1002/hem3.70145","title":"Characterization of cancer‐associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classic Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; University Health Network","funders":"Academy of Finland; Helsingin ja Uudenmaan Sairaanhoitopiiri; Helsingin Yliopisto","keywords":"Tumor microenvironment; Stromal cell; Cancer-Associated Fibroblasts; Cancer research; Immune system; Lymphoma; Biology; Cancer; Population; Pathology; Fibroblast activation protein, alpha; Fibroblast; Nodular sclerosis; Immunology; Medicine; Internal medicine; Cell culture; Hodgkin lymphoma; Genetics","score_opus":0.009133015429994338,"score_gpt":0.2374523188488286,"score_spread":0.22831930341883425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410776881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986965,0.00028393994,0.0007770578,0.0000049554014,7.619572e-7,0.000002508709,0.00010744224,0.000006651048,0.00012022441],"genre_scores_gemma":[0.99921167,0.00006713041,0.0004981147,0.00000409308,0.000001487681,0.000005035525,0.00008730134,0.0000017340581,0.00012335343],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99993277,0.000011775585,0.000004089562,0.00002436008,0.0000127966705,0.000014337387],"domain_scores_gemma":[0.999923,0.000018330904,0.00002175645,0.000010027853,0.000015090516,0.000011722539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013570867,0.000064389016,0.00009740542,0.00041826683,0.00011310909,0.00021535704,0.000056116427,0.000102719794,0.00039265087],"category_scores_gemma":[0.00015626,0.000077822406,0.00005624404,0.00020536612,0.00011885074,0.000094825235,0.000111796166,0.0000716679,0.00008268374],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024298218,0.000015619042,0.08806993,0.000044183293,0.00001973084,0.0001541472,0.00014834487,0.00021371688,0.90533835,0.00008362634,0.00004353228,0.0056258105],"study_design_scores_gemma":[0.000011819404,0.00013502104,0.8497856,0.0000067737524,0.00003768477,0.0014921476,0.00058043946,0.0032208557,0.14332189,0.00017230399,0.0012272093,0.000008184923],"about_ca_topic_score_codex":0.0006952795,"about_ca_topic_score_gemma":0.0013250735,"teacher_disagreement_score":0.0006952795,"about_ca_system_score_codex":0.00010239628,"about_ca_system_score_gemma":0.000055943474,"threshold_uncertainty_score":0.0013824701},"labels":[],"label_agreement":null},{"id":"W4412008193","doi":"10.1002/hem3.70352","title":"Preclinical Efficacy of Tasquinimod in Myelodysplastic Neoplasms: Restoring Erythropoiesis and Mitigating Bone Loss","year":2025,"lang":"en","type":"preprint","venue":"HemaSphere","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"Active Biotech","keywords":"Erythropoiesis; Medicine; Myelodysplastic syndromes; Bone marrow; Cancer research; Anemia; Pharmacology; Oncology; Internal medicine","score_opus":0.03090296219618452,"score_gpt":0.342556286757576,"score_spread":0.3116533245613915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412008193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860951,0.00533572,0.0024245523,0.00039523983,0.0002208911,0.00069929834,0.0018279321,0.00026176963,0.0027396947],"genre_scores_gemma":[0.982382,0.006381401,0.0032263862,0.0002361908,0.00007485779,0.0008729468,0.0023148032,0.0000320206,0.004479413],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983704,0.000036626243,0.000015443899,0.000031118638,0.000035646506,0.000044023185],"domain_scores_gemma":[0.9998136,0.000020078971,0.000037006823,0.0000135476075,0.000026108393,0.000089749024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043517235,0.0007033736,0.00063516217,0.0006308877,0.0002376729,0.00033013007,0.00052085303,0.00065867294,0.0019994427],"category_scores_gemma":[0.00017318295,0.00026412902,0.0005394483,0.00021636204,0.0003907355,0.0003236913,0.00020176012,0.0019274133,0.00036562068],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0138616925,0.012330068,0.00044063164,0.0006986298,0.00015047328,0.00023822559,0.000097174714,0.00173242,0.9458085,0.00070910965,0.0010852669,0.02284787],"study_design_scores_gemma":[0.007236405,0.17366539,0.0061598606,0.00013489086,0.00052719616,0.0005278502,0.00013600121,0.0029888868,0.7920409,0.00062656536,0.015904209,0.00005181348],"about_ca_topic_score_codex":0.000561269,"about_ca_topic_score_gemma":0.0011998843,"teacher_disagreement_score":0.0019994427,"about_ca_system_score_codex":0.00025937974,"about_ca_system_score_gemma":0.0005684391,"threshold_uncertainty_score":0.0066887736},"labels":[],"label_agreement":null},{"id":"W4412371428","doi":"10.1002/hem3.70165","title":"Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?","year":2025,"lang":"en","type":"editorial","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; University of Toronto","funders":"","keywords":"Thalassemia; Medicine; Blood transfusion; Internal medicine","score_opus":0.011179993153500262,"score_gpt":0.291936137157545,"score_spread":0.28075614400404475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412371428","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1723585,0.70933294,0.0020970148,0.04870959,0.021723699,0.0022646766,0.004297712,0.00029866418,0.038917314],"genre_scores_gemma":[0.66983473,0.21311462,0.0041603036,0.06409006,0.018660447,0.0024366137,0.004696615,0.0002427451,0.022763867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864656,0.00073123834,0.00014331794,0.00013315176,0.00016464565,0.00018103854],"domain_scores_gemma":[0.9982401,0.0007046813,0.00039001132,0.00007869596,0.00017774128,0.0004087874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033102385,0.0010516138,0.0044358284,0.00083427824,0.0005160979,0.003215648,0.0012128061,0.00253131,0.020963732],"category_scores_gemma":[0.0046646222,0.00027764158,0.0037117023,0.00086032454,0.0008096544,0.003512825,0.0007589336,0.005859464,0.003123825],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39128375,0.0027895153,0.004008804,0.01073388,0.006591876,0.0002788401,0.0003431727,0.0013036426,0.0016552466,0.005696581,0.039031558,0.53628314],"study_design_scores_gemma":[0.4647298,0.13108963,0.02666269,0.0136422785,0.019012563,0.0022457852,0.0017822956,0.0042221607,0.0022354047,0.025528554,0.30839485,0.00045409],"about_ca_topic_score_codex":0.0008083339,"about_ca_topic_score_gemma":0.0027937084,"teacher_disagreement_score":0.020963732,"about_ca_system_score_codex":0.0012394282,"about_ca_system_score_gemma":0.0008932001,"threshold_uncertainty_score":0.070130646},"labels":[],"label_agreement":null},{"id":"W4413910826","doi":"10.1002/hem3.70206","title":"Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia","funders":"Ministero della Salute","keywords":"Medicine; Minimal residual disease; Cumulative incidence; Hazard ratio; Internal medicine; Proportional hazards model; Context (archaeology); Prednisone; Incidence (geometry); Oncology; Cohort; Confidence interval; Leukemia","score_opus":0.029965557484606452,"score_gpt":0.30139748465011884,"score_spread":0.2714319271655124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413910826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99850154,0.0004329306,0.00011973837,0.000091103786,0.00000775481,0.000016814542,0.000333718,0.0000044364947,0.00049198983],"genre_scores_gemma":[0.9988669,0.000094613286,0.00007750376,0.000049740152,0.000011518631,0.000013020095,0.0007770403,0.0000029902183,0.000106605185],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994355,0.00024872302,0.000048144233,0.00008184074,0.000089303714,0.00009640189],"domain_scores_gemma":[0.99875116,0.0003362318,0.0005393412,0.00006209351,0.00011554807,0.00019572298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013237938,0.00014989113,0.0004555883,0.00017947149,0.00021296348,0.0006028661,0.0001885866,0.00027259372,0.0006592504],"category_scores_gemma":[0.0021731993,0.00007492585,0.00041344576,0.00035099447,0.00017186921,0.00045317083,0.00030248187,0.00062666077,0.0001444848],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007769834,0.00019779432,0.9770208,0.000025830046,0.0001254512,0.00014313102,0.000102827515,0.00079716207,0.00087341596,0.00008765769,0.00072541606,0.012130697],"study_design_scores_gemma":[0.00029928656,0.004730116,0.9902442,0.00001647012,0.00019020692,0.00054171967,0.00015784867,0.0015387832,0.0007067004,0.00010745226,0.0014548776,0.000012377017],"about_ca_topic_score_codex":0.0009817315,"about_ca_topic_score_gemma":0.0010655437,"teacher_disagreement_score":0.0013237938,"about_ca_system_score_codex":0.0005750251,"about_ca_system_score_gemma":0.00047438737,"threshold_uncertainty_score":0.007000923},"labels":[],"label_agreement":null},{"id":"W4414420388","doi":"10.1002/hem3.70224","title":"The impact of reduced dosing frequency of elranatamab on patient‐reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM‐3","year":2025,"lang":"en","type":"letter","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Pfizer","keywords":"Dosing; Refractory (planetary science); Incidence (geometry); Multiple myeloma; Clinical trial; Quality of life (healthcare)","score_opus":0.021111578107003495,"score_gpt":0.29165523703766494,"score_spread":0.27054365893066146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414420388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745592,0.01927604,0.0002892437,0.0011425287,0.00019304184,0.0002728559,0.0018907954,0.000044937045,0.002331362],"genre_scores_gemma":[0.9911466,0.003924925,0.00046642078,0.0011018752,0.0003233829,0.00036139126,0.002110992,0.000013461919,0.000550925],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99898106,0.0004990015,0.00010847826,0.00012103149,0.00018351496,0.00010690398],"domain_scores_gemma":[0.9980919,0.0005132716,0.00077104225,0.000131554,0.00015942068,0.00033281336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029490425,0.0005427258,0.0013116254,0.00020314495,0.00028919315,0.00092746934,0.00045976893,0.00053297204,0.0022424604],"category_scores_gemma":[0.0030489971,0.0001332377,0.0029890253,0.0005008185,0.00028558192,0.00072118366,0.00046529688,0.0020187304,0.0003785823],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41451755,0.012977202,0.13019252,0.002372238,0.011311282,0.000109274355,0.00037957777,0.0031302136,0.005037137,0.00032704102,0.0069865123,0.41265947],"study_design_scores_gemma":[0.087600194,0.25415802,0.62782335,0.0005969547,0.011804052,0.00037460076,0.00029298788,0.0036504928,0.002435525,0.0007285586,0.010402838,0.00013245642],"about_ca_topic_score_codex":0.001163797,"about_ca_topic_score_gemma":0.0020660413,"teacher_disagreement_score":0.0029490425,"about_ca_system_score_codex":0.0007051599,"about_ca_system_score_gemma":0.000659731,"threshold_uncertainty_score":0.015596211},"labels":[],"label_agreement":null},{"id":"W4415132558","doi":"10.1002/hem3.70216","title":"European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Pharmaceuticals; Kite Pharma; EUSA Pharma; Servier; Adaptive Biotechnologies; Regeneron Pharmaceuticals; BeiGene; European Commission; Sanofi; PharmaMar; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Ministero della Salute; Pfizer; GlaxoSmithKline","keywords":"Multiple myeloma; Risk stratification; Workflow; Genetic testing; DNA sequencing; Statement (logic); MEDLINE","score_opus":0.17092217404667132,"score_gpt":0.3226412180158104,"score_spread":0.1517190439691391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415132558","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006518208,0.30036202,0.09628339,0.4677795,0.04689299,0.0024427597,0.00627375,0.0015530605,0.071894355],"genre_scores_gemma":[0.071492314,0.3051134,0.26133442,0.2760891,0.018409042,0.0056098523,0.020096334,0.0012547163,0.040600765],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9665218,0.016073024,0.0048907255,0.0015956986,0.009469081,0.0014497306],"domain_scores_gemma":[0.93669105,0.021769652,0.0043305433,0.0023529248,0.032012824,0.002842938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07582785,0.0011506611,0.0019846503,0.0042169373,0.0015597815,0.004337981,0.0042630676,0.006379416,0.0034456437],"category_scores_gemma":[0.057826493,0.0007307436,0.0030493638,0.0033418362,0.0020824624,0.002451008,0.004160495,0.0077608298,0.0033803454],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004142281,0.00011765021,0.0045014275,0.005419298,0.00034145638,0.00049393054,0.00074086187,0.002144612,0.0020973587,0.014593489,0.5344625,0.43467313],"study_design_scores_gemma":[0.00010608832,0.00010851551,0.0035351126,0.009624308,0.0003096577,0.00068132504,0.00030784187,0.00079737767,0.0018772567,0.010781552,0.9717914,0.000079709294],"about_ca_topic_score_codex":0.0121741835,"about_ca_topic_score_gemma":0.009766738,"teacher_disagreement_score":0.07582785,"about_ca_system_score_codex":0.003989236,"about_ca_system_score_gemma":0.021082584,"threshold_uncertainty_score":0.40102082},"labels":[],"label_agreement":null},{"id":"W4415619271","doi":"10.1002/hem3.70232","title":"Choosing words wisely: Language, metaphor, and psychological challenges after pulmonary embolism","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Clinical Reasoning and Diagnostic Skills","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University","funders":"Wellcome Trust","keywords":"Hypervigilance; Anxiety; Depression (economics); Mental health; Normative; Population; Cohort; Perspective (graphical)","score_opus":0.03149613265867566,"score_gpt":0.35911287236921224,"score_spread":0.32761673971053656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415619271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640704,0.011525993,0.00088143366,0.012793268,0.0003295232,0.000049381622,0.000047074413,0.000023398681,0.010279612],"genre_scores_gemma":[0.99314606,0.0029168113,0.00038660545,0.0022765228,0.00010908749,0.000022595208,0.000030027884,0.000013306646,0.0010990497],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99830925,0.0009419518,0.00007898449,0.0000959874,0.00030786966,0.00026589833],"domain_scores_gemma":[0.9966515,0.0018654672,0.0009003062,0.00007847014,0.00019359893,0.00031075586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016287953,0.0004481673,0.0003961656,0.0007422921,0.0022519352,0.0032259475,0.0006689382,0.0015677887,0.0026657218],"category_scores_gemma":[0.013398502,0.0001999231,0.00030131763,0.00074845296,0.0032488576,0.003914805,0.0024276415,0.0024445087,0.00042063373],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032183278,0.0009552178,0.12143727,0.00097230275,0.00010823649,0.02489769,0.71517724,0.00025376966,0.0035863875,0.01110672,0.022653494,0.09852974],"study_design_scores_gemma":[0.000057773967,0.0005455569,0.12390744,0.001320101,0.00010197453,0.04463889,0.77461267,0.0008391993,0.0005283358,0.015569092,0.037715975,0.00016304919],"about_ca_topic_score_codex":0.0019525199,"about_ca_topic_score_gemma":0.0034561355,"teacher_disagreement_score":0.0032259475,"about_ca_system_score_codex":0.0013134042,"about_ca_system_score_gemma":0.0015562597,"threshold_uncertainty_score":0.009529471},"labels":[],"label_agreement":null},{"id":"W4416734638","doi":"10.1002/hem3.70248","title":"Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Corticosteroid; Hazard ratio; Cumulative dose; Lymphoma; Cytokine release syndrome; Cumulative incidence; Toxicity; Methylprednisolone; Prednisone","score_opus":0.022807049954925034,"score_gpt":0.3072871860336976,"score_spread":0.28448013607877254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416734638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856573,0.0009619482,0.0000792041,0.00002101147,0.0000023362804,0.000006321561,0.00012265757,0.00000309032,0.00023765412],"genre_scores_gemma":[0.9995165,0.00018611446,0.000039750084,0.000016461292,0.000006911094,0.0000033365918,0.00019580274,0.0000017574827,0.000033369502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860245,0.00034166756,0.00028932354,0.00025593463,0.00034806412,0.00016258021],"domain_scores_gemma":[0.9941446,0.0010942302,0.0038247097,0.00021332823,0.00033988178,0.0003832898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095709006,0.000113680544,0.00037775873,0.00048151912,0.00015397514,0.0006245117,0.00021765896,0.00030871193,0.0004992069],"category_scores_gemma":[0.004017371,0.000118876356,0.00039681702,0.0007729385,0.00037072715,0.00037919127,0.0003005493,0.00043282373,0.00015868993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062920223,0.000023647368,0.99299157,0.00001907389,0.0000667858,0.00016533537,0.00005916205,0.00016492433,0.00074403366,0.000015570296,0.000045123383,0.0050755264],"study_design_scores_gemma":[0.000013880281,0.0004627577,0.9975988,0.000012284319,0.000048472957,0.00079292315,0.000113184156,0.0002469728,0.00043217986,0.0000207928,0.00025137886,0.0000063092752],"about_ca_topic_score_codex":0.0011720998,"about_ca_topic_score_gemma":0.0015849876,"teacher_disagreement_score":0.0011720998,"about_ca_system_score_codex":0.0005612385,"about_ca_system_score_gemma":0.00045182827,"threshold_uncertainty_score":0.0050616264},"labels":[],"label_agreement":null}]}